Term,NES,FDR q-val,Perturbation
GPCR_LIGAND_BINDING,-2.763458405,0,swainsonine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.644414641,0,swainsonine
SIGNALING_BY_GPCR,-2.480495256,0.000859419,swainsonine
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.430542484,0.000966846,swainsonine
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.366691076,0.001804779,swainsonine
G_ALPHA_I_SIGNALLING_EVENTS,-2.11623495,0.015469533,swainsonine
ADAPTIVE_IMMUNE_SYSTEM,-2.084370638,0.020257722,swainsonine
SUMOYLATION_OF_CHROMATIN_ORGANIZATION_PROTEINS,-1.920723399,0.075091691,swainsonine
NEURONAL_SYSTEM,-1.9162466,0.069183189,swainsonine
RHO_GTPASES_ACTIVATE_FORMINS,-1.893329345,0.07386702,swainsonine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.063676759,0,nicardipine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.971066908,0,nicardipine
NONSENSE_MEDIATED_DECAY_NMD,-2.951055812,0,nicardipine
CELLULAR_RESPONSE_TO_STARVATION,-2.92586316,0,nicardipine
SELENOAMINO_ACID_METABOLISM,-2.92578653,0,nicardipine
EUKARYOTIC_TRANSLATION_INITIATION,-2.79274051,9.52E-05,nicardipine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.728161262,0.000244882,nicardipine
ADAPTIVE_IMMUNE_SYSTEM,2.481290035,0.005041102,nicardipine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.446653291,0.005881286,nicardipine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.421187322,0.00448098,nicardipine
MITOTIC_METAPHASE_AND_ANAPHASE,3.137380108,0,bambuterol
CELL_CYCLE_MITOTIC,3.048718523,0,bambuterol
M_PHASE,2.806677982,0,bambuterol
CELL_CYCLE_CHECKPOINTS,2.757178804,0,bambuterol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.686944846,0,bambuterol
NONSENSE_MEDIATED_DECAY_NMD,-2.675816037,0,bambuterol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.673654264,0,bambuterol
EUKARYOTIC_TRANSLATION_INITIATION,-2.613702601,0,bambuterol
SELENOAMINO_ACID_METABOLISM,-2.603872405,0,bambuterol
CELLULAR_RESPONSE_TO_STARVATION,-2.602378726,0,bambuterol
EUKARYOTIC_TRANSLATION_ELONGATION,3.882710993,0,neratinib
CELLULAR_RESPONSES_TO_STIMULI,2.452187644,0,neratinib
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.533290283,0,neratinib
SARS_COV_INFECTIONS,2.601200551,0,neratinib
INFECTIOUS_DISEASE,2.605670789,0,neratinib
VIRAL_INFECTION_PATHWAYS,2.781020655,0,neratinib
METABOLISM_OF_RNA,2.789173041,0,neratinib
SARS_COV_2_INFECTION,2.836477895,0,neratinib
NERVOUS_SYSTEM_DEVELOPMENT,2.950873984,0,neratinib
SARS_COV_2_HOST_INTERACTIONS,3.20086096,0,neratinib
EUKARYOTIC_TRANSLATION_ELONGATION,4.802149866,0,enalapril
CELLULAR_RESPONSES_TO_STIMULI,2.556346807,0,enalapril
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.710973228,0,enalapril
NERVOUS_SYSTEM_DEVELOPMENT,2.800361294,0,enalapril
SARS_COV_1_HOST_INTERACTIONS,2.924305363,0,enalapril
SARS_COV_1_INFECTION,2.976185877,0,enalapril
METABOLISM_OF_RNA,3.054897014,0,enalapril
RRNA_PROCESSING,3.970241386,0,enalapril
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,4.094289451,0,enalapril
SIGNALING_BY_ROBO_RECEPTORS,4.242705174,0,enalapril
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.878744458,0,trimipramine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.873389355,0,trimipramine
NONSENSE_MEDIATED_DECAY_NMD,-2.869920683,0,trimipramine
EUKARYOTIC_TRANSLATION_INITIATION,-2.817955519,0,trimipramine
SELENOAMINO_ACID_METABOLISM,-2.809801319,0,trimipramine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.772903359,0,trimipramine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.770037116,0,trimipramine
CELLULAR_RESPONSE_TO_STARVATION,-2.751741349,0,trimipramine
RRNA_PROCESSING,-2.743477904,0,trimipramine
SIGNALING_BY_ROBO_RECEPTORS,-2.691994614,0,trimipramine
SELENOAMINO_ACID_METABOLISM,-3.06085262,0,fluorouracil
EUKARYOTIC_TRANSLATION_ELONGATION,-3.058333217,0,fluorouracil
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.053871217,0,fluorouracil
NONSENSE_MEDIATED_DECAY_NMD,-3.032184372,0,fluorouracil
EUKARYOTIC_TRANSLATION_INITIATION,-3.022810719,0,fluorouracil
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.912545826,0,fluorouracil
CELLULAR_RESPONSE_TO_STARVATION,-2.899178037,0,fluorouracil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.862977437,0,fluorouracil
SIGNALING_BY_ROBO_RECEPTORS,-2.855444428,0,fluorouracil
INFLUENZA_INFECTION,-2.749317996,0,fluorouracil
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.968901547,0,aripiprazole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.726456956,0,aripiprazole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.734615439,0,aripiprazole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.785547675,0,aripiprazole
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.88547885,0,aripiprazole
SARS_COV_1_HOST_INTERACTIONS,2.899506283,0,aripiprazole
TRANSLATION,2.91166349,0,aripiprazole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.117734386,0,aripiprazole
RRNA_PROCESSING,3.141179163,0,aripiprazole
INFLUENZA_INFECTION,3.171291684,0,aripiprazole
MITOTIC_METAPHASE_AND_ANAPHASE,3.38660397,0,ibudilast
CELL_CYCLE_CHECKPOINTS,3.177608065,0,ibudilast
CELL_CYCLE_MITOTIC,3.063280981,0,ibudilast
M_PHASE,2.968437174,0,ibudilast
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.78608049,0,ibudilast
MITOTIC_SPINDLE_CHECKPOINT,2.774384526,0,ibudilast
SEPARATION_OF_SISTER_CHROMATIDS,2.743531314,0,ibudilast
EUKARYOTIC_TRANSLATION_ELONGATION,-2.383575543,0,ibudilast
MAPK6_MAPK4_SIGNALING,2.608793557,0.000552855,ibudilast
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.588663152,0.000491427,ibudilast
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,3.174296658,0,gimeracil
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.666250428,0,gimeracil
C_TYPE_LECTIN_RECEPTORS_CLRS,2.686358717,0,gimeracil
ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS,2.707997678,0,gimeracil
S_PHASE,2.716952309,0,gimeracil
APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1,2.729720267,0,gimeracil
DNA_REPLICATION,2.729929909,0,gimeracil
CELL_CYCLE_CHECKPOINTS,2.751098002,0,gimeracil
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.752570763,0,gimeracil
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,2.695713989,0,gimeracil
GPCR_LIGAND_BINDING,3.075155446,0,relcovaptan
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,3.006899967,0,relcovaptan
SIGNALING_BY_GPCR,2.875394328,0,relcovaptan
CELL_CYCLE_MITOTIC,-2.867456193,0,relcovaptan
M_PHASE,-2.865507273,0,relcovaptan
MITOTIC_PROMETAPHASE,-2.827745351,0,relcovaptan
CELL_CYCLE_CHECKPOINTS,-2.761059821,0,relcovaptan
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.755438925,0,relcovaptan
G_ALPHA_I_SIGNALLING_EVENTS,2.542317583,0,relcovaptan
G_ALPHA_Q_SIGNALLING_EVENTS,2.479415925,0.000108325,relcovaptan
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.506532459,0,omeprazole
SARS_COV_1_INFECTION,2.739740833,0,omeprazole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.759673143,0,omeprazole
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.8707721,0,omeprazole
NERVOUS_SYSTEM_DEVELOPMENT,2.873600987,0,omeprazole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.89932496,0,omeprazole
SARS_COV_1_HOST_INTERACTIONS,2.902911305,0,omeprazole
RRNA_PROCESSING,2.998336482,0,omeprazole
TRANSLATION,3.036016252,0,omeprazole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.728049424,0,omeprazole
EUKARYOTIC_TRANSLATION_ELONGATION,4.575208357,0,dacomitinib
SARS_COV_INFECTIONS,2.569024592,0,dacomitinib
SARS_COV_2_INFECTION,2.670504641,0,dacomitinib
SARS_COV_2_HOST_INTERACTIONS,3.061989423,0,dacomitinib
INFECTIOUS_DISEASE,3.265836828,0,dacomitinib
CELLULAR_RESPONSES_TO_STIMULI,3.42396615,0,dacomitinib
VIRAL_INFECTION_PATHWAYS,3.435007809,0,dacomitinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.485498868,0,dacomitinib
SARS_COV_1_HOST_INTERACTIONS,3.530620414,0,dacomitinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.547198376,0,dacomitinib
METABOLISM_OF_RNA,-3.513149832,0,brequinar
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.658367973,0,brequinar
G_ALPHA_Q_SIGNALLING_EVENTS,2.687602452,0,brequinar
CELL_CYCLE_CHECKPOINTS,-2.73324357,0,brequinar
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-2.759264391,0,brequinar
M_PHASE,-2.776295406,0,brequinar
RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL,-2.720819559,0,brequinar
RRNA_PROCESSING,-2.890172465,0,brequinar
SIGNALING_BY_GPCR,2.960699735,0,brequinar
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,3.10586644,0,brequinar
RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY,2.814474632,0,alectinib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.711663423,0,alectinib
SELENOAMINO_ACID_METABOLISM,-2.706515112,0,alectinib
NONSENSE_MEDIATED_DECAY_NMD,-2.673670642,0,alectinib
SIGNALING_BY_ROBO_RECEPTORS,-2.647413676,0,alectinib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.632903258,0,alectinib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.553447578,0,alectinib
EUKARYOTIC_TRANSLATION_INITIATION,-2.460037561,0,alectinib
INTERFERON_SIGNALING,2.575236212,0.003222476,alectinib
CELLULAR_RESPONSE_TO_STARVATION,-2.375916049,0.000493178,alectinib
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.995787861,0,vanoxerine
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.793699132,0.001485677,vanoxerine
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.781365216,0.000990451,vanoxerine
C_TYPE_LECTIN_RECEPTORS_CLRS,2.77407052,0.000742838,vanoxerine
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,2.758989283,0.000594271,vanoxerine
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.710124172,0.000495226,vanoxerine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.529287525,0.001273437,vanoxerine
MITOTIC_METAPHASE_AND_ANAPHASE,2.528867026,0.001114257,vanoxerine
NONSENSE_MEDIATED_DECAY_NMD,-2.379307256,0.002396397,vanoxerine
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.501551465,0.001650752,vanoxerine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.220954539,0,levocabastine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.460457502,0,levocabastine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.617228944,0,levocabastine
CELLULAR_RESPONSE_TO_STARVATION,-2.667557412,0,levocabastine
SELENOAMINO_ACID_METABOLISM,-2.80124762,0,levocabastine
EUKARYOTIC_TRANSLATION_INITIATION,-2.678386537,0,levocabastine
CELL_CYCLE_MITOTIC,2.8115719,0,levocabastine
NONSENSE_MEDIATED_DECAY_NMD,-2.92409811,0,levocabastine
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.939327686,0,levocabastine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.963610009,0,levocabastine
NONSENSE_MEDIATED_DECAY_NMD,-2.981923061,0,glasdegib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.97010571,0,glasdegib
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.941563106,0,glasdegib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.863753611,0,glasdegib
SELENOAMINO_ACID_METABOLISM,-2.858928259,0,glasdegib
CELLULAR_RESPONSE_TO_STARVATION,-2.775598842,0,glasdegib
EUKARYOTIC_TRANSLATION_INITIATION,-2.758217854,0,glasdegib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.675052938,0,glasdegib
GASTRULATION,2.751989778,0.003178745,glasdegib
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.623676321,0.003178745,glasdegib
EUKARYOTIC_TRANSLATION_ELONGATION,-3.249165355,0,lapatinib
SARS_COV_1_INFECTION,-2.526803963,0,lapatinib
SARS_COV_1_HOST_INTERACTIONS,-2.587684549,0,lapatinib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.633350644,0,lapatinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.683523619,0,lapatinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.683943382,0,lapatinib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.777495076,0,lapatinib
RRNA_PROCESSING,-2.80389912,0,lapatinib
INFLUENZA_INFECTION,-2.926547949,0,lapatinib
TRANSLATION,-2.909814752,0,lapatinib
METABOLISM_OF_RNA,-2.848467668,0,betrixaban
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.813991495,0,betrixaban
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.616689472,0,betrixaban
GPCR_LIGAND_BINDING,2.535989546,0,betrixaban
SIGNALING_BY_GPCR,2.522942245,0,betrixaban
MRNA_SPLICING,-2.278107418,0.005769,betrixaban
G_ALPHA_Q_SIGNALLING_EVENTS,2.254221076,0.001415806,betrixaban
SUMOYLATION,-2.272878892,0.005769,betrixaban
G_ALPHA_S_SIGNALLING_EVENTS,2.223216601,0.001698967,betrixaban
CELL_CYCLE_CHECKPOINTS,-2.23179147,0.008076599,betrixaban
FATTY_ACID_METABOLISM,2.535717435,0.002394691,phenazone
SIGNALING_BY_FGFR,-2.207898482,0.030782386,phenazone
SIGNALING_BY_FGFR2,-2.10206672,0.049593844,phenazone
MAPK_FAMILY_SIGNALING_CASCADES,-2.081223587,0.043323358,phenazone
INTERFERON_SIGNALING,-2.036033453,0.049878866,phenazone
METABOLISM_OF_VITAMINS_AND_COFACTORS,2.105400983,0.0766301,phenazone
SIGNALING_BY_FGFR1,-1.969342172,0.072965655,phenazone
POTENTIAL_THERAPEUTICS_FOR_SARS,-1.943429547,0.076195905,phenazone
MAPK1_MAPK3_SIGNALING,-1.934729908,0.070359739,phenazone
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-1.934054196,0.061992304,phenazone
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.154020602,0,VX-809
SIGNALING_BY_ROBO_RECEPTORS,2.593365899,0,VX-809
CELLULAR_RESPONSE_TO_STARVATION,2.629135178,0,VX-809
INFLUENZA_INFECTION,2.709718851,0,VX-809
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.727351818,0,VX-809
TRANSLATION,2.743850755,0,VX-809
EUKARYOTIC_TRANSLATION_INITIATION,2.664165122,0,VX-809
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.808048998,0,VX-809
SELENOAMINO_ACID_METABOLISM,2.808048998,0,VX-809
MRNA_SPLICING,-2.865114588,0,VX-809
EUKARYOTIC_TRANSLATION_ELONGATION,-3.230436617,0,naringenin
TRANSLATION,-2.726222288,0,naringenin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.743674222,0,naringenin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.762171487,0,naringenin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.769921457,0,naringenin
INFLUENZA_INFECTION,-2.915975162,0,naringenin
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.919858039,0,naringenin
SIGNALING_BY_ROBO_RECEPTORS,-3.010522947,0,naringenin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-3.001011307,0,naringenin
EUKARYOTIC_TRANSLATION_INITIATION,-3.047422604,0,naringenin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.920209836,0,oxybenzone
VIRAL_INFECTION_PATHWAYS,2.872406808,0,oxybenzone
SARS_COV_1_HOST_INTERACTIONS,2.931186227,0,oxybenzone
SARS_COV_1_INFECTION,2.941088751,0,oxybenzone
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.346224051,0,oxybenzone
METABOLISM_OF_RNA,3.373954931,0,oxybenzone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,4.051381156,0,oxybenzone
SIGNALING_BY_ROBO_RECEPTORS,4.39021209,0,oxybenzone
RRNA_PROCESSING,4.394683633,0,oxybenzone
TRANSLATION,4.531336126,0,oxybenzone
GPCR_LIGAND_BINDING,-2.401694987,0,histamine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.252085432,0.007303834,histamine
SIGNALING_BY_GPCR,-2.246130058,0.005217024,histamine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.179658106,0.007825537,histamine
EUKARYOTIC_TRANSLATION_INITIATION,-2.142155692,0.010851411,histamine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.13701942,0.009912346,histamine
G_ALPHA_Q_SIGNALLING_EVENTS,-2.09909453,0.012818974,histamine
NONSENSE_MEDIATED_DECAY_NMD,-2.097226679,0.011347028,histamine
SELENOAMINO_ACID_METABOLISM,-2.077859176,0.014143933,histamine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.025791744,0.024206993,histamine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.357304238,0,oxaprozin
NONSENSE_MEDIATED_DECAY_NMD,-3.303128261,0,oxaprozin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.27457435,0,oxaprozin
SELENOAMINO_ACID_METABOLISM,-3.239359533,0,oxaprozin
CELLULAR_RESPONSE_TO_STARVATION,-3.154257035,0,oxaprozin
EUKARYOTIC_TRANSLATION_INITIATION,-3.089849245,0,oxaprozin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.079259721,0,oxaprozin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.858525716,0,oxaprozin
TRANSLATION,-2.825619883,0,oxaprozin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.744955173,0,oxaprozin
CELL_CYCLE_MITOTIC,3.071101887,0,ibuprofen
CELL_CYCLE,2.855017471,0,ibuprofen
CELL_CYCLE_CHECKPOINTS,2.79077315,0,ibuprofen
MITOTIC_METAPHASE_AND_ANAPHASE,2.687358355,0,ibuprofen
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.615804073,0,ibuprofen
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.601162777,0,ibuprofen
EUKARYOTIC_TRANSLATION_ELONGATION,-2.59827207,0,ibuprofen
NONSENSE_MEDIATED_DECAY_NMD,-2.58003012,0,ibuprofen
EUKARYOTIC_TRANSLATION_INITIATION,-2.518274175,0.000240638,ibuprofen
SELENOAMINO_ACID_METABOLISM,-2.494770899,0.000180479,ibuprofen
C_TYPE_LECTIN_RECEPTORS_CLRS,3.079764064,0,oxypurinol
NONSENSE_MEDIATED_DECAY_NMD,-2.669761075,0,oxypurinol
CELL_CYCLE_MITOTIC,3.04835191,0,oxypurinol
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.941664444,0.00127036,oxypurinol
SELENOAMINO_ACID_METABOLISM,-2.527264512,0.000324613,oxypurinol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.64058159,0.00024346,oxypurinol
ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS,2.648118572,0.000508144,oxypurinol
CELL_CYCLE,2.702626024,0.00058632,oxypurinol
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.705018211,0.00063518,oxypurinol
GASTRULATION,2.741384478,0.000692924,oxypurinol
CELL_CYCLE_MITOTIC,3.49762707,0,regorafenib
NUCLEAR_PORE_COMPLEX_NPC_DISASSEMBLY,2.696933801,0,regorafenib
RESOLUTION_OF_SISTER_CHROMATID_COHESION,2.706306914,0,regorafenib
MITOTIC_SPINDLE_CHECKPOINT,2.712387095,0,regorafenib
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.715878494,0,regorafenib
G1_S_DNA_DAMAGE_CHECKPOINTS,2.754745618,0,regorafenib
ANTIGEN_PROCESSING_CROSS_PRESENTATION,2.765126086,0,regorafenib
SNRNP_ASSEMBLY,2.771087528,0,regorafenib
INTERACTIONS_OF_REV_WITH_HOST_CELLULAR_PROTEINS,2.773877906,0,regorafenib
SCF_SKP2_MEDIATED_DEGRADATION_OF_P27_P21,2.793452204,0,regorafenib
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.884664789,0,dacarbazine
GASTRULATION,2.881388032,0,dacarbazine
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.714597201,0,dacarbazine
NONSENSE_MEDIATED_DECAY_NMD,-2.678721035,0,dacarbazine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.662074459,0,dacarbazine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.651803871,0,dacarbazine
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.641752532,0,dacarbazine
SELENOAMINO_ACID_METABOLISM,-2.560495517,0,dacarbazine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.510320526,0,dacarbazine
EUKARYOTIC_TRANSLATION_INITIATION,-2.463124332,0,dacarbazine
METABOLISM_OF_RNA,-3.273359976,0,reserpine
GPCR_LIGAND_BINDING,2.951303652,0,reserpine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.805550625,0,reserpine
SIGNALING_BY_GPCR,2.751923424,0,reserpine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.696865008,0,reserpine
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.593454066,0,reserpine
G_ALPHA_Q_SIGNALLING_EVENTS,2.51114932,0,reserpine
MRNA_SPLICING,-2.508917639,0.000960102,reserpine
G_ALPHA_I_SIGNALLING_EVENTS,2.368778575,0.000215482,reserpine
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.545590075,0.001600171,reserpine
EUKARYOTIC_TRANSLATION_ELONGATION,4.078248839,0,azacitidine
SARS_COV_1_INFECTION,2.901467996,0,azacitidine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.047055088,0,azacitidine
SARS_COV_1_HOST_INTERACTIONS,3.054689863,0,azacitidine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.141908687,0,azacitidine
RRNA_PROCESSING,3.177752891,0,azacitidine
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,-3.187345821,0,azacitidine
TRANSLATION,3.287387221,0,azacitidine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.300009543,0,azacitidine
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,-3.325193826,0,azacitidine
EUKARYOTIC_TRANSLATION_ELONGATION,3.895366582,0,vandetanib
INFECTIOUS_DISEASE,2.391143192,0,vandetanib
SARS_COV_2_INFECTION,2.531519567,0,vandetanib
VIRAL_INFECTION_PATHWAYS,2.550552079,0,vandetanib
SARS_COV_2_HOST_INTERACTIONS,2.69077523,0,vandetanib
METABOLISM_OF_RNA,2.704475782,0,vandetanib
CELLULAR_RESPONSES_TO_STIMULI,2.73460489,0,vandetanib
SARS_COV_1_INFECTION,3.237081417,0,vandetanib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.243004344,0,vandetanib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.258831154,0,vandetanib
EUKARYOTIC_TRANSLATION_ELONGATION,-3.267757144,0,clofarabine
SARS_COV_1_HOST_INTERACTIONS,-2.555882802,0,clofarabine
RRNA_PROCESSING,-2.783992641,0,clofarabine
INFLUENZA_INFECTION,-2.796378202,0,clofarabine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.517167383,0,clofarabine
SIGNALING_BY_ROBO_RECEPTORS,-2.838636103,0,clofarabine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.849776542,0,clofarabine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.861305372,0,clofarabine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.89504702,0,clofarabine
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,2.917459683,0,clofarabine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.369227765,0,verapamil
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.738043186,0,verapamil
SARS_COV_1_INFECTION,-2.767938101,0,verapamil
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.813977918,0,verapamil
TRANSLATION,-2.845744628,0,verapamil
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.861670131,0,verapamil
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.875529983,0,verapamil
SARS_COV_1_HOST_INTERACTIONS,-2.877201902,0,verapamil
INFLUENZA_INFECTION,-3.032767887,0,verapamil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.08718132,0,verapamil
SELENOAMINO_ACID_METABOLISM,-3.178603832,0,nitrendipine
SARS_COV_1_HOST_INTERACTIONS,-2.680862706,0,nitrendipine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.755913742,0,nitrendipine
RRNA_PROCESSING,-2.796474259,0,nitrendipine
INFLUENZA_INFECTION,-2.797138317,0,nitrendipine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.818197351,0,nitrendipine
TRANSLATION,-2.83969189,0,nitrendipine
SIGNALING_BY_ROBO_RECEPTORS,-2.882966949,0,nitrendipine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.793325258,0,nitrendipine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.996545972,0,nitrendipine
EUKARYOTIC_TRANSLATION_ELONGATION,3.3596621,0,tipifarnib-P2
RRNA_PROCESSING,2.586891194,0,tipifarnib-P2
SARS_COV_1_HOST_INTERACTIONS,2.640418342,0,tipifarnib-P2
TRANSLATION,2.745526854,0,tipifarnib-P2
INFLUENZA_INFECTION,3.032681323,0,tipifarnib-P2
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.041963288,0,tipifarnib-P2
CELLULAR_RESPONSE_TO_STARVATION,3.055723226,0,tipifarnib-P2
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.482119356,0,tipifarnib-P2
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.106798658,0,tipifarnib-P2
EUKARYOTIC_TRANSLATION_INITIATION,3.193006025,0,tipifarnib-P2
EUKARYOTIC_TRANSLATION_ELONGATION,4.13642684,0,tivozanib
VIRAL_INFECTION_PATHWAYS,2.973175923,0,tivozanib
CELLULAR_RESPONSES_TO_STIMULI,3.003910714,0,tivozanib
SARS_COV_2_HOST_INTERACTIONS,3.050684645,0,tivozanib
METABOLISM_OF_RNA,3.077791075,0,tivozanib
SARS_COV_1_INFECTION,3.265180072,0,tivozanib
NERVOUS_SYSTEM_DEVELOPMENT,3.342109219,0,tivozanib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.380146039,0,tivozanib
SARS_COV_1_HOST_INTERACTIONS,3.403770162,0,tivozanib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.5619377,0,tivozanib
GPCR_LIGAND_BINDING,2.443054636,0,metamizole
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.237857163,0.005797303,metamizole
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.26337642,0.047058824,metamizole
SIGNALING_BY_GPCR,2.207984322,0.005410816,metamizole
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.105729006,0.056470588,metamizole
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.100251145,0.037647059,metamizole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.047162726,0.024155429,metamizole
KERATINIZATION,2.046973793,0.019324343,metamizole
SUMOYLATION,-1.847234515,0.138235294,metamizole
INTERFERON_SIGNALING,-1.785501461,0.154352941,metamizole
EUKARYOTIC_TRANSLATION_ELONGATION,3.83055454,0,repaglinide
CELLULAR_RESPONSES_TO_STIMULI,2.420695417,0,repaglinide
VIRAL_INFECTION_PATHWAYS,2.546982486,0,repaglinide
SARS_COV_2_HOST_INTERACTIONS,2.61294606,0,repaglinide
METABOLISM_OF_RNA,2.677838095,0,repaglinide
NERVOUS_SYSTEM_DEVELOPMENT,2.895542181,0,repaglinide
SARS_COV_1_INFECTION,3.105607159,0,repaglinide
SARS_COV_1_HOST_INTERACTIONS,3.299822693,0,repaglinide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.305200952,0,repaglinide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.335165751,0,repaglinide
EUKARYOTIC_TRANSLATION_ELONGATION,3.500289067,0,almitrine
SARS_COV_1_HOST_INTERACTIONS,2.643846766,0,almitrine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.745970255,0,almitrine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.789337571,0,almitrine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.794718608,0,almitrine
TRANSLATION,3.304599478,0,almitrine
SIGNALING_BY_ROBO_RECEPTORS,3.332184962,0,almitrine
RRNA_PROCESSING,3.333999637,0,almitrine
INFLUENZA_INFECTION,3.314125235,0,almitrine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.369708019,0,almitrine
MITOTIC_METAPHASE_AND_ANAPHASE,3.126119833,0,setiptiline
CELL_CYCLE_MITOTIC,3.117718051,0,setiptiline
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.978933576,0,setiptiline
EUKARYOTIC_TRANSLATION_ELONGATION,-2.90391183,0,setiptiline
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.795412007,0,setiptiline
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.791412961,0,setiptiline
NONSENSE_MEDIATED_DECAY_NMD,-2.783463747,0,setiptiline
CELLULAR_RESPONSE_TO_STARVATION,-2.766560079,0,setiptiline
EUKARYOTIC_TRANSLATION_INITIATION,-2.698910546,0,setiptiline
SELENOAMINO_ACID_METABOLISM,-2.689663211,0,setiptiline
EUKARYOTIC_TRANSLATION_ELONGATION,-2.287459809,0.002022399,lacidipine
EUKARYOTIC_TRANSLATION_INITIATION,-2.277272787,0.0010112,lacidipine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.209537782,0.003707732,lacidipine
NONSENSE_MEDIATED_DECAY_NMD,-2.186189954,0.003539199,lacidipine
SELENOAMINO_ACID_METABOLISM,-2.153316308,0.004651518,lacidipine
CELLULAR_RESPONSE_TO_STARVATION,-2.145080558,0.005224531,lacidipine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.106202521,0.008089597,lacidipine
RAB_REGULATION_OF_TRAFFICKING,1.981698532,0.034684359,lacidipine
TRANSLATION,-1.915199241,0.076345573,lacidipine
RRNA_PROCESSING,-1.885726796,0.090670901,lacidipine
NONSENSE_MEDIATED_DECAY_NMD,-3.208142918,0,solifenacin-succinate
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.722141175,0,solifenacin-succinate
SARS_COV_1_HOST_INTERACTIONS,-2.722394007,0,solifenacin-succinate
TRANSLATION,-2.735371654,0,solifenacin-succinate
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.760799607,0,solifenacin-succinate
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.80408105,0,solifenacin-succinate
INFLUENZA_INFECTION,-2.842846967,0,solifenacin-succinate
RRNA_PROCESSING,-2.858351353,0,solifenacin-succinate
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.977081328,0,solifenacin-succinate
SIGNALING_BY_ROBO_RECEPTORS,-2.977893427,0,solifenacin-succinate
EUKARYOTIC_TRANSLATION_ELONGATION,3.008124872,0,aclidinium
NONSENSE_MEDIATED_DECAY_NMD,2.97697012,0,aclidinium
SELENOAMINO_ACID_METABOLISM,2.966438541,0,aclidinium
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.878421568,0,aclidinium
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.860777568,0,aclidinium
EUKARYOTIC_TRANSLATION_INITIATION,2.852522348,0,aclidinium
CELLULAR_RESPONSE_TO_STARVATION,2.844472642,0,aclidinium
INFLUENZA_INFECTION,2.821009254,0,aclidinium
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.798537671,0,aclidinium
TRANSLATION,2.720166841,0,aclidinium
EUKARYOTIC_TRANSLATION_ELONGATION,3.824194282,0,radezolid
SARS_COV_2_HOST_INTERACTIONS,2.515516027,0,radezolid
METABOLISM_OF_RNA,2.572415286,0,radezolid
NERVOUS_SYSTEM_DEVELOPMENT,2.722114219,0,radezolid
SARS_COV_1_INFECTION,2.977582903,0,radezolid
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.154125742,0,radezolid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.165356114,0,radezolid
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.284190362,0,radezolid
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.346703556,0,radezolid
RRNA_PROCESSING,3.44124205,0,radezolid
EUKARYOTIC_TRANSLATION_ELONGATION,-3.347567624,0,procaine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.679402556,0,procaine
SARS_COV_1_INFECTION,-2.694479902,0,procaine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.734073234,0,procaine
SARS_COV_1_HOST_INTERACTIONS,-2.836732066,0,procaine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.915295665,0,procaine
RRNA_PROCESSING,-2.972161841,0,procaine
TRANSLATION,-2.98200975,0,procaine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.987906691,0,procaine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.985906747,0,procaine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.950816612,0,tamibarotene
RRNA_PROCESSING,-2.608733824,0,tamibarotene
CELLULAR_RESPONSE_TO_STARVATION,-2.648695308,0,tamibarotene
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.655624257,0,tamibarotene
EUKARYOTIC_TRANSLATION_INITIATION,-2.658114095,0,tamibarotene
TRANSLATION,-2.449666121,0,tamibarotene
SELENOAMINO_ACID_METABOLISM,-2.688480988,0,tamibarotene
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.742209325,0,tamibarotene
EUKARYOTIC_TRANSLATION_ELONGATION,-2.842483998,0,tamibarotene
NONSENSE_MEDIATED_DECAY_NMD,-2.678649501,0,tamibarotene
CELL_CYCLE_MITOTIC,-3.269624186,0,gestrinone
M_PHASE,-3.113066134,0,gestrinone
CELL_CYCLE,-2.940396034,0,gestrinone
MITOTIC_PROMETAPHASE,-2.894840236,0,gestrinone
RHO_GTPASE_EFFECTORS,-2.868364009,0,gestrinone
G2_M_DNA_DAMAGE_CHECKPOINT,-2.853111554,0,gestrinone
CELL_CYCLE_CHECKPOINTS,-2.850455869,0,gestrinone
NEUTROPHIL_DEGRANULATION,-2.745937709,0,gestrinone
MITOTIC_METAPHASE_AND_ANAPHASE,-2.722972782,0,gestrinone
GPCR_LIGAND_BINDING,2.655978167,0,gestrinone
EUKARYOTIC_TRANSLATION_ELONGATION,4.353737534,0,amuvatinib
INFECTIOUS_DISEASE,2.586393636,0,amuvatinib
SARS_COV_INFECTIONS,2.704849072,0,amuvatinib
METABOLISM_OF_RNA,2.764435146,0,amuvatinib
VIRAL_INFECTION_PATHWAYS,2.772799955,0,amuvatinib
CELLULAR_RESPONSES_TO_STIMULI,2.839990156,0,amuvatinib
SARS_COV_2_HOST_INTERACTIONS,3.21931388,0,amuvatinib
NERVOUS_SYSTEM_DEVELOPMENT,3.28763182,0,amuvatinib
SARS_COV_1_INFECTION,3.373053157,0,amuvatinib
SARS_COV_1_HOST_INTERACTIONS,3.582764152,0,amuvatinib
EUKARYOTIC_TRANSLATION_ELONGATION,4.30315536,0,cabozantinib
SARS_COV_INFECTIONS,2.710111781,0,cabozantinib
INFECTIOUS_DISEASE,2.905680832,0,cabozantinib
SARS_COV_2_INFECTION,2.925097839,0,cabozantinib
VIRAL_INFECTION_PATHWAYS,3.12620065,0,cabozantinib
METABOLISM_OF_RNA,3.143704639,0,cabozantinib
SARS_COV_2_HOST_INTERACTIONS,3.147624657,0,cabozantinib
CELLULAR_RESPONSES_TO_STIMULI,3.157737125,0,cabozantinib
SARS_COV_1_INFECTION,3.30623936,0,cabozantinib
SARS_COV_1_HOST_INTERACTIONS,3.367828534,0,cabozantinib
EUKARYOTIC_TRANSLATION_ELONGATION,3.104300336,0,BRD-A04553218
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.962390227,0,BRD-A04553218
SELENOAMINO_ACID_METABOLISM,2.957769653,0,BRD-A04553218
CELLULAR_RESPONSE_TO_STARVATION,2.915357705,0,BRD-A04553218
NONSENSE_MEDIATED_DECAY_NMD,2.909132797,0,BRD-A04553218
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.811018785,0,BRD-A04553218
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.801833178,0,BRD-A04553218
EUKARYOTIC_TRANSLATION_INITIATION,2.627692355,0,BRD-A04553218
SIGNALING_BY_ROBO_RECEPTORS,2.579493924,0,BRD-A04553218
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.464211626,0,BRD-A04553218
EUKARYOTIC_TRANSLATION_ELONGATION,3.87872459,0,pazopanib
VIRAL_INFECTION_PATHWAYS,2.591251475,0,pazopanib
CELLULAR_RESPONSES_TO_STIMULI,2.751787369,0,pazopanib
METABOLISM_OF_RNA,2.782992684,0,pazopanib
CHROMATIN_ORGANIZATION,-2.794622268,0,pazopanib
SARS_COV_1_INFECTION,2.937550493,0,pazopanib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.074473487,0,pazopanib
NERVOUS_SYSTEM_DEVELOPMENT,3.111977592,0,pazopanib
SARS_COV_1_HOST_INTERACTIONS,3.131111179,0,pazopanib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.27807348,0,pazopanib
EUKARYOTIC_TRANSLATION_ELONGATION,3.881451603,0,VX-745
SARS_COV_1_INFECTION,2.568711295,0,VX-745
NERVOUS_SYSTEM_DEVELOPMENT,2.646456185,0,VX-745
SARS_COV_1_HOST_INTERACTIONS,2.720491081,0,VX-745
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.85557276,0,VX-745
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.990499388,0,VX-745
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.184060024,0,VX-745
SIGNALING_BY_ROBO_RECEPTORS,3.246883726,0,VX-745
TRANSLATION,3.29726973,0,VX-745
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.184924989,0,VX-745
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.283321204,0,levobunolol
EUKARYOTIC_TRANSLATION_INITIATION,-2.420696615,0,levobunolol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.480922669,0,levobunolol
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.5150188,0,levobunolol
M_PHASE,2.523694778,0,levobunolol
SELENOAMINO_ACID_METABOLISM,-2.53078165,0,levobunolol
APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1,2.535854673,0,levobunolol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.543012778,0,levobunolol
NONSENSE_MEDIATED_DECAY_NMD,-2.549107265,0,levobunolol
REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS,2.566222008,0,levobunolol
EUKARYOTIC_TRANSLATION_ELONGATION,-3.566253396,0,mibefradil
SARS_COV_2_INFECTION,-2.393329222,0,mibefradil
NERVOUS_SYSTEM_DEVELOPMENT,-2.46083435,0,mibefradil
SARS_COV_2_HOST_INTERACTIONS,-2.68252016,0,mibefradil
SARS_COV_1_INFECTION,-2.733878363,0,mibefradil
SARS_COV_1_HOST_INTERACTIONS,-2.938884609,0,mibefradil
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-3.002207168,0,mibefradil
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-3.063230254,0,mibefradil
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-3.068274531,0,mibefradil
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-3.138885538,0,mibefradil
EUKARYOTIC_TRANSLATION_ELONGATION,-3.122467253,0,ondansetron
SELENOAMINO_ACID_METABOLISM,-3.054364588,0,ondansetron
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.042103968,0,ondansetron
NONSENSE_MEDIATED_DECAY_NMD,-3.028871658,0,ondansetron
EUKARYOTIC_TRANSLATION_INITIATION,-3.012235523,0,ondansetron
CELLULAR_RESPONSE_TO_STARVATION,-2.921109238,0,ondansetron
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.9198986,0,ondansetron
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.84305932,0,ondansetron
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.753492805,0,ondansetron
SIGNALING_BY_ROBO_RECEPTORS,-2.752150874,0,ondansetron
METABOLISM_OF_RNA,-2.769432354,0,metformin
RRNA_PROCESSING,-2.676397504,0,metformin
GPCR_LIGAND_BINDING,2.585469994,0,metformin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.656040926,0.000744643,metformin
SIGNALING_BY_GPCR,2.523822993,0.000406335,metformin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.520736113,0.00027089,metformin
MRNA_SPLICING,-2.288039863,0.005584826,metformin
G_ALPHA_S_SIGNALLING_EVENTS,2.169834721,0.00731403,metformin
SENSORY_PERCEPTION,2.131072429,0.008289234,metformin
G_ALPHA_I_SIGNALLING_EVENTS,2.035744634,0.016253399,metformin
EUKARYOTIC_TRANSLATION_ELONGATION,-3.516163136,0,flecainide
SARS_COV_1_INFECTION,-2.770352691,0,flecainide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.831673127,0,flecainide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.840652744,0,flecainide
SARS_COV_1_HOST_INTERACTIONS,-2.913742921,0,flecainide
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.976389993,0,flecainide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-3.004289923,0,flecainide
TRANSLATION,-3.051827206,0,flecainide
SIGNALING_BY_ROBO_RECEPTORS,-3.196522642,0,flecainide
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.885095259,0,flecainide
EUKARYOTIC_TRANSLATION_ELONGATION,4.837296252,0,pentoxifylline
METABOLISM_OF_RNA,2.732022215,0,pentoxifylline
SARS_COV_1_INFECTION,2.738603266,0,pentoxifylline
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.909125898,0,pentoxifylline
SIGNALING_BY_ROBO_RECEPTORS,4.009084086,0,pentoxifylline
TRANSLATION,4.149182808,0,pentoxifylline
RRNA_PROCESSING,4.181799163,0,pentoxifylline
SARS_COV_1_HOST_INTERACTIONS,2.731635407,0,pentoxifylline
INFLUENZA_INFECTION,4.473454248,0,pentoxifylline
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.543888666,0,pentoxifylline
EUKARYOTIC_TRANSLATION_ELONGATION,3.603878734,0,vismodegib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.644892047,0,vismodegib
RRNA_PROCESSING,2.812789687,0,vismodegib
INFLUENZA_INFECTION,3.022918732,0,vismodegib
CELLULAR_RESPONSE_TO_STARVATION,3.192017231,0,vismodegib
SIGNALING_BY_ROBO_RECEPTORS,3.258688556,0,vismodegib
TRANSLATION,2.836657058,0,vismodegib
EUKARYOTIC_TRANSLATION_INITIATION,3.399039723,0,vismodegib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.416660242,0,vismodegib
NONSENSE_MEDIATED_DECAY_NMD,3.45927102,0,vismodegib
EUKARYOTIC_TRANSLATION_ELONGATION,3.441862791,0,etacrynic-acid
NERVOUS_SYSTEM_DEVELOPMENT,2.678677352,0,etacrynic-acid
RRNA_PROCESSING,2.7043135,0,etacrynic-acid
SARS_COV_1_HOST_INTERACTIONS,2.715419185,0,etacrynic-acid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.802553094,0,etacrynic-acid
TRANSLATION,2.870479348,0,etacrynic-acid
INFLUENZA_INFECTION,2.931162711,0,etacrynic-acid
SIGNALING_BY_ROBO_RECEPTORS,3.06411758,0,etacrynic-acid
SARS_COV_1_INFECTION,2.412131972,0,etacrynic-acid
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.128936722,0,etacrynic-acid
EUKARYOTIC_TRANSLATION_ELONGATION,-3.156916828,0,physostigmine
NONSENSE_MEDIATED_DECAY_NMD,-3.146547095,0,physostigmine
SELENOAMINO_ACID_METABOLISM,-3.037676369,0,physostigmine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.991875499,0,physostigmine
GPCR_LIGAND_BINDING,2.775036547,0,physostigmine
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.701551349,0,physostigmine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.616988408,0,physostigmine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.881892255,0.00022195,physostigmine
INTERFERON_SIGNALING,2.472208727,0.000865009,physostigmine
EUKARYOTIC_TRANSLATION_INITIATION,-2.837929728,0.000277437,physostigmine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.253401674,0,sulfasalazine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.662426825,0,sulfasalazine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.700655693,0,sulfasalazine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.709180122,0,sulfasalazine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.765198367,0,sulfasalazine
SARS_COV_1_INFECTION,-2.778883664,0,sulfasalazine
TRANSLATION,-2.81433607,0,sulfasalazine
SARS_COV_1_HOST_INTERACTIONS,-2.838474976,0,sulfasalazine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.957855336,0,sulfasalazine
INFLUENZA_INFECTION,-2.871332976,0,sulfasalazine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.005335648,0,levalbuterol
MITOTIC_METAPHASE_AND_ANAPHASE,3.002149719,0,levalbuterol
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.988300448,0,levalbuterol
CELL_CYCLE_MITOTIC,2.931072729,0,levalbuterol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.58671787,0,levalbuterol
NONSENSE_MEDIATED_DECAY_NMD,-2.559620711,0,levalbuterol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.374853717,0,levalbuterol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.368048499,0,levalbuterol
SELENOAMINO_ACID_METABOLISM,-2.500174195,0,levalbuterol
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.756036361,0.000699706,levalbuterol
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.928194956,0.005092003,alvimopan
METABOLISM_OF_RNA,-2.924259779,0.002546002,alvimopan
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.760307815,0.001697334,alvimopan
RRNA_PROCESSING,-2.748547755,0.001273001,alvimopan
MRNA_SPLICING,-2.623549751,0.002036801,alvimopan
MITOTIC_METAPHASE_AND_ANAPHASE,-2.515754504,0.001697334,alvimopan
M_PHASE,-2.410603213,0.002546002,alvimopan
CHROMATIN_ORGANIZATION,-2.248436293,0.006683254,alvimopan
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.073807505,0.040076882,alvimopan
GPCR_LIGAND_BINDING,2.05716529,0.024536867,alvimopan
EUKARYOTIC_TRANSLATION_ELONGATION,4.020276805,0,levonorgestrel
VIRAL_INFECTION_PATHWAYS,2.627907705,0,levonorgestrel
METABOLISM_OF_RNA,2.707590475,0,levonorgestrel
SARS_COV_2_HOST_INTERACTIONS,2.711286535,0,levonorgestrel
SARS_COV_1_INFECTION,3.017742909,0,levonorgestrel
NERVOUS_SYSTEM_DEVELOPMENT,3.145862232,0,levonorgestrel
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.206391874,0,levonorgestrel
SARS_COV_1_HOST_INTERACTIONS,3.229814313,0,levonorgestrel
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.300901715,0,levonorgestrel
TRANSLATION,3.485776149,0,levonorgestrel
SELENOAMINO_ACID_METABOLISM,4.117095931,0,mazindol
CELLULAR_RESPONSES_TO_STIMULI,2.425177954,0,mazindol
METABOLISM_OF_RNA,2.457517973,0,mazindol
SARS_COV_INFECTIONS,2.458338039,0,mazindol
INFECTIOUS_DISEASE,2.469700403,0,mazindol
VIRAL_INFECTION_PATHWAYS,2.780346175,0,mazindol
SARS_COV_2_HOST_INTERACTIONS,2.794514627,0,mazindol
NERVOUS_SYSTEM_DEVELOPMENT,3.087267526,0,mazindol
SARS_COV_1_INFECTION,3.14660832,0,mazindol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.3128361,0,mazindol
RESPIRATORY_ELECTRON_TRANSPORT,2.776209538,0,sacubitril
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.636333612,0,sacubitril
CELLULAR_RESPONSE_TO_STARVATION,2.474394287,0.002480838,sacubitril
NONSENSE_MEDIATED_DECAY_NMD,2.310043837,0.005271781,sacubitril
EUKARYOTIC_TRANSLATION_INITIATION,2.305937167,0.004713593,sacubitril
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.260649614,0.007029042,sacubitril
TRANSLATION,2.225509321,0.008860137,sacubitril
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.15007475,0.01426482,sacubitril
SELENOAMINO_ACID_METABOLISM,2.108591168,0.01805499,sacubitril
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,1.955420034,0.055942904,sacubitril
PROTEASOME_ASSEMBLY,2.459537878,0.015295455,dabrafenib
HOST_INTERACTIONS_OF_HIV_FACTORS,2.401396297,0.012746213,dabrafenib
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,2.372283163,0.008497475,dabrafenib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.435807789,0.019277653,dabrafenib
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.288414813,0.013383523,dabrafenib
ANTIGEN_PROCESSING_CROSS_PRESENTATION,2.285294436,0.011216667,dabrafenib
SELENOAMINO_ACID_METABOLISM,-2.352222134,0.023494639,dabrafenib
NONSENSE_MEDIATED_DECAY_NMD,-2.294194423,0.025301919,dabrafenib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.27655486,0.022139179,dabrafenib
SEPARATION_OF_SISTER_CHROMATIDS,2.081362682,0.048435609,dabrafenib
NONSENSE_MEDIATED_DECAY_NMD,3.810832756,0,RAF-265
VIRAL_INFECTION_PATHWAYS,2.464883728,0,RAF-265
SARS_COV_2_INFECTION,2.708647425,0,RAF-265
METABOLISM_OF_RNA,2.746101574,0,RAF-265
NERVOUS_SYSTEM_DEVELOPMENT,2.795279796,0,RAF-265
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.840849986,0,RAF-265
SARS_COV_2_HOST_INTERACTIONS,2.914885121,0,RAF-265
SARS_COV_1_HOST_INTERACTIONS,3.004490416,0,RAF-265
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.185582949,0,RAF-265
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.239126165,0,RAF-265
EUKARYOTIC_TRANSLATION_ELONGATION,4.056967415,0,ponatinib
NERVOUS_SYSTEM_DEVELOPMENT,2.625106235,0,ponatinib
SARS_COV_1_HOST_INTERACTIONS,2.797838771,0,ponatinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.880928429,0,ponatinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.019467827,0,ponatinib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.128015964,0,ponatinib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.331065916,0,ponatinib
TRANSLATION,3.478777868,0,ponatinib
CELLULAR_RESPONSE_TO_STARVATION,3.659709833,0,ponatinib
SIGNALING_BY_ROBO_RECEPTORS,3.493898654,0,ponatinib
GLYCEROPHOSPHOLIPID_BIOSYNTHESIS,-2.359411826,0.935239744,miglustat
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.314001168,0.8327886,miglustat
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.235185875,0.593933848,miglustat
PHOSPHOLIPID_METABOLISM,-2.279401191,1,miglustat
EUKARYOTIC_TRANSLATION_ELONGATION,-2.243308205,0.938246946,miglustat
SELENOAMINO_ACID_METABOLISM,-2.20151667,0.895644921,miglustat
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.200985377,0.718320258,miglustat
MRNA_SPLICING,1.064431425,0.829127991,miglustat
NONSENSE_MEDIATED_DECAY_NMD,-2.171643627,0.696835472,miglustat
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.152204443,0.65313558,miglustat
EUKARYOTIC_TRANSLATION_ELONGATION,3.859139995,0,olaparib
NERVOUS_SYSTEM_DEVELOPMENT,2.428490361,0,olaparib
SARS_COV_1_INFECTION,2.616528271,0,olaparib
SARS_COV_1_HOST_INTERACTIONS,2.766216751,0,olaparib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.998793003,0,olaparib
TRANSLATION,3.089949764,0,olaparib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.10327474,0,olaparib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.170686912,0,olaparib
SIGNALING_BY_ROBO_RECEPTORS,3.221594762,0,olaparib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.860069513,0,olaparib
EUKARYOTIC_TRANSLATION_INITIATION,-3.283894886,0,perhexiline
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.697337814,0,perhexiline
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.755706412,0,perhexiline
TRANSLATION,-2.850585936,0,perhexiline
INFLUENZA_INFECTION,-2.890315811,0,perhexiline
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.906363102,0,perhexiline
RRNA_PROCESSING,-2.938833918,0,perhexiline
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.94661646,0,perhexiline
SIGNALING_BY_ROBO_RECEPTORS,-2.950137527,0,perhexiline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.066467562,0,perhexiline
EUKARYOTIC_TRANSLATION_ELONGATION,-2.912258108,0,topiramate
NONSENSE_MEDIATED_DECAY_NMD,-2.869726175,0,topiramate
SELENOAMINO_ACID_METABOLISM,-2.771602195,0,topiramate
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.75844081,0,topiramate
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.738167225,0,topiramate
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,2.713510355,0,topiramate
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.618628207,0.000461754,topiramate
C_TYPE_LECTIN_RECEPTORS_CLRS,2.492516021,0.000461754,topiramate
G1_S_DNA_DAMAGE_CHECKPOINTS,2.521124082,0.000527719,topiramate
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,2.553784272,0.000738806,topiramate
EUKARYOTIC_TRANSLATION_ELONGATION,-2.417654428,0,itraconazole
SELENOAMINO_ACID_METABOLISM,-2.37338811,0,itraconazole
NONSENSE_MEDIATED_DECAY_NMD,-2.304372134,0.000312007,itraconazole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.269721348,0.00046801,itraconazole
RRNA_PROCESSING,-2.268754499,0.000374408,itraconazole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.227222674,0.00046801,itraconazole
EUKARYOTIC_TRANSLATION_INITIATION,-2.214686839,0.000534869,itraconazole
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.149213861,0.001521034,itraconazole
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.986647018,0.103350558,itraconazole
CELLULAR_RESPONSE_TO_STARVATION,-2.059567297,0.005200115,itraconazole
EUKARYOTIC_TRANSLATION_ELONGATION,3.726014329,0,dazoxiben
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.3788805,0,dazoxiben
NERVOUS_SYSTEM_DEVELOPMENT,2.642398421,0,dazoxiben
SARS_COV_1_INFECTION,2.902329927,0,dazoxiben
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.094943693,0,dazoxiben
SARS_COV_1_HOST_INTERACTIONS,3.186446934,0,dazoxiben
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.189952394,0,dazoxiben
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.224984543,0,dazoxiben
RRNA_PROCESSING,3.327805592,0,dazoxiben
SIGNALING_BY_ROBO_RECEPTORS,3.405037417,0,dazoxiben
EUKARYOTIC_TRANSLATION_ELONGATION,3.900394549,0,aminosalicylic-acid
CELLULAR_RESPONSES_TO_STIMULI,2.425694647,0,aminosalicylic-acid
VIRAL_INFECTION_PATHWAYS,2.569625825,0,aminosalicylic-acid
SARS_COV_2_HOST_INTERACTIONS,2.621432934,0,aminosalicylic-acid
NERVOUS_SYSTEM_DEVELOPMENT,3.051928456,0,aminosalicylic-acid
SARS_COV_1_INFECTION,3.096513368,0,aminosalicylic-acid
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.230308817,0,aminosalicylic-acid
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.278147032,0,aminosalicylic-acid
SARS_COV_1_HOST_INTERACTIONS,3.301950773,0,aminosalicylic-acid
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.306886339,0,aminosalicylic-acid
EUKARYOTIC_TRANSLATION_ELONGATION,3.588296899,0,quinapril
METABOLISM_OF_RNA,2.553077949,0,quinapril
NERVOUS_SYSTEM_DEVELOPMENT,2.635205802,0,quinapril
SARS_COV_1_INFECTION,2.85889602,0,quinapril
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.859199768,0,quinapril
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.98918081,0,quinapril
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.004145317,0,quinapril
SARS_COV_1_HOST_INTERACTIONS,3.015341672,0,quinapril
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.137513633,0,quinapril
TRANSLATION,3.27798611,0,quinapril
EUKARYOTIC_TRANSLATION_ELONGATION,4.155887688,0,acrivastine
SARS_COV_1_INFECTION,3.081762242,0,acrivastine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.198869418,0,acrivastine
NERVOUS_SYSTEM_DEVELOPMENT,3.203885584,0,acrivastine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.266097066,0,acrivastine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.288442595,0,acrivastine
SARS_COV_1_HOST_INTERACTIONS,3.290534958,0,acrivastine
RRNA_PROCESSING,3.689629688,0,acrivastine
TRANSLATION,3.716981031,0,acrivastine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.700616041,0,acrivastine
CELL_CYCLE_MITOTIC,4.339757579,0,atrasentan
CELL_CYCLE,3.876949562,0,atrasentan
CELL_CYCLE_CHECKPOINTS,3.473923153,0,atrasentan
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.294296247,0,atrasentan
MITOTIC_METAPHASE_AND_ANAPHASE,3.29252395,0,atrasentan
M_PHASE,3.276028737,0,atrasentan
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.921340241,0,atrasentan
SEPARATION_OF_SISTER_CHROMATIDS,2.601532661,0.000384949,atrasentan
MITOTIC_SPINDLE_CHECKPOINT,2.67983195,0.000419944,atrasentan
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.745941815,0.000513265,atrasentan
REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS,2.386572684,0.018370272,iniparib
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,-2.598015208,0.01053179,iniparib
HOST_INTERACTIONS_OF_HIV_FACTORS,2.308492177,0.019390842,iniparib
MAPK1_MAPK3_SIGNALING,2.259263353,0.018370272,iniparib
MAPK_FAMILY_SIGNALING_CASCADES,2.236691159,0.018880557,iniparib
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.221662825,0.017145587,iniparib
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.155599748,0.023132935,iniparib
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.150616392,0.020411413,iniparib
SIGNALING_BY_INTERLEUKINS,2.120885703,0.024238553,iniparib
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.103556229,0.024493696,iniparib
EUKARYOTIC_TRANSLATION_ELONGATION,-3.418700296,0,mianserin
NERVOUS_SYSTEM_DEVELOPMENT,-2.452871729,0,mianserin
SARS_COV_2_HOST_INTERACTIONS,-2.459148845,0,mianserin
SARS_COV_1_INFECTION,-2.757678856,0,mianserin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.855257585,0,mianserin
SARS_COV_1_HOST_INTERACTIONS,-2.896585144,0,mianserin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.918077709,0,mianserin
TRANSLATION,-3.00125488,0,mianserin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-3.016470104,0,mianserin
RRNA_PROCESSING,-3.0492906,0,mianserin
MRNA_SPLICING,1.712172204,0.204358585,cyclobenzaprine
COLLAGEN_FORMATION,1.658550262,0.091535616,cyclobenzaprine
ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES,1.658550262,0.091535616,cyclobenzaprine
PROTEIN_LOCALIZATION,1.448808283,0.234693063,cyclobenzaprine
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.472740506,1,cyclobenzaprine
NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH,1.383138397,0.269753333,cyclobenzaprine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.322891119,0.305047763,cyclobenzaprine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.310383218,0.278073647,cyclobenzaprine
GLYCOSAMINOGLYCAN_METABOLISM,1.20637231,0.405045103,cyclobenzaprine
TRNA_PROCESSING,1.177406531,0.411413569,cyclobenzaprine
NONSENSE_MEDIATED_DECAY_NMD,2.920011687,0,enzalutamide
TRANSLATION,2.403260487,0,enzalutamide
CELLULAR_RESPONSE_TO_STARVATION,2.549810012,0,enzalutamide
SIGNALING_BY_ROBO_RECEPTORS,2.641176452,0,enzalutamide
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-2.644404848,0,enzalutamide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.790735763,0,enzalutamide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.585539886,0,enzalutamide
EUKARYOTIC_TRANSLATION_ELONGATION,2.826671878,0,enzalutamide
SELENOAMINO_ACID_METABOLISM,2.885792691,0,enzalutamide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.885792691,0,enzalutamide
EUKARYOTIC_TRANSLATION_INITIATION,3.073085432,0,ORE-1001
EUKARYOTIC_TRANSLATION_ELONGATION,3.059137897,0,ORE-1001
NONSENSE_MEDIATED_DECAY_NMD,3.003336764,0,ORE-1001
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.991178275,0,ORE-1001
SELENOAMINO_ACID_METABOLISM,2.973588689,0,ORE-1001
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.928720763,0,ORE-1001
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.895375785,0,ORE-1001
TRANSLATION,2.812672658,0,ORE-1001
INFLUENZA_INFECTION,2.796222659,0,ORE-1001
CELLULAR_RESPONSE_TO_STARVATION,2.710097697,0,ORE-1001
EUKARYOTIC_TRANSLATION_ELONGATION,4.10755953,0,dasatinib
INFECTIOUS_DISEASE,2.49110092,0,dasatinib
VIRAL_INFECTION_PATHWAYS,2.605147536,0,dasatinib
SARS_COV_2_INFECTION,2.660683341,0,dasatinib
CELLULAR_RESPONSES_TO_STIMULI,2.770481471,0,dasatinib
SARS_COV_2_HOST_INTERACTIONS,2.862617477,0,dasatinib
SARS_COV_1_INFECTION,3.020618064,0,dasatinib
NERVOUS_SYSTEM_DEVELOPMENT,3.025944168,0,dasatinib
SARS_COV_1_HOST_INTERACTIONS,3.254743757,0,dasatinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.281098492,0,dasatinib
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.858366221,0,rotundine
NONSENSE_MEDIATED_DECAY_NMD,-2.485945967,0,rotundine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.577165266,0,rotundine
SELENOAMINO_ACID_METABOLISM,-2.471626937,0,rotundine
ADAPTIVE_IMMUNE_SYSTEM,2.823731836,0,rotundine
S_PHASE,2.688441887,0.001461018,rotundine
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.683545188,0.001826273,rotundine
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.676008604,0.001565377,rotundine
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.670282253,0.001369704,rotundine
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.644925805,0.001217515,rotundine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.861639246,0,carvedilol
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.392409808,0,carvedilol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.400523913,0,carvedilol
SARS_COV_1_HOST_INTERACTIONS,-2.407942158,0,carvedilol
TRANSLATION,-2.449990038,0,carvedilol
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.455900797,0,carvedilol
INFLUENZA_INFECTION,-2.550610161,0,carvedilol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.641156455,0,carvedilol
RRNA_PROCESSING,-2.582268942,0,carvedilol
EUKARYOTIC_TRANSLATION_INITIATION,-2.679269036,0,carvedilol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.381942546,0.000983868,SU-11652
NONSENSE_MEDIATED_DECAY_NMD,-2.350535018,0.000491934,SU-11652
SELENOAMINO_ACID_METABOLISM,-2.311984107,0.000655912,SU-11652
EUKARYOTIC_TRANSLATION_INITIATION,-2.306272024,0.000491934,SU-11652
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.291952955,0.000393547,SU-11652
CELLULAR_RESPONSE_TO_STARVATION,-2.230944976,0.000983868,SU-11652
MRNA_SPLICING,2.374374591,0.008274519,SU-11652
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.211972732,0.001405526,SU-11652
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.257416447,0.007584976,SU-11652
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.170885993,0.001844753,SU-11652
EUKARYOTIC_TRANSLATION_ELONGATION,-3.245887929,0,blonanserin
SELENOAMINO_ACID_METABOLISM,-3.096941101,0,blonanserin
NONSENSE_MEDIATED_DECAY_NMD,-3.065950799,0,blonanserin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.003768583,0,blonanserin
CELLULAR_RESPONSE_TO_STARVATION,-2.798810611,0,blonanserin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.777733553,0,blonanserin
GPCR_LIGAND_BINDING,2.557391515,0.000914183,blonanserin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.533093271,0.000609455,blonanserin
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.599275327,0.001828366,blonanserin
EUKARYOTIC_TRANSLATION_INITIATION,-2.528424244,0.000831144,blonanserin
EUKARYOTIC_TRANSLATION_ELONGATION,3.883630717,0,cabergoline
SARS_COV_2_INFECTION,2.518260704,0,cabergoline
INFECTIOUS_DISEASE,2.530820679,0,cabergoline
METABOLISM_OF_RNA,2.547621555,0,cabergoline
VIRAL_INFECTION_PATHWAYS,2.652608021,0,cabergoline
SARS_COV_2_HOST_INTERACTIONS,2.723226345,0,cabergoline
NERVOUS_SYSTEM_DEVELOPMENT,3.250861275,0,cabergoline
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.265311548,0,cabergoline
SARS_COV_1_INFECTION,3.307083366,0,cabergoline
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.338929975,0,cabergoline
SELENOAMINO_ACID_METABOLISM,4.148959931,0,quetiapine
SARS_COV_2_HOST_INTERACTIONS,2.649039294,0,quetiapine
METABOLISM_OF_RNA,2.67185417,0,quetiapine
NERVOUS_SYSTEM_DEVELOPMENT,3.299659536,0,quetiapine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.321819718,0,quetiapine
SARS_COV_1_INFECTION,3.324701332,0,quetiapine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.384597363,0,quetiapine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.432527554,0,quetiapine
SARS_COV_1_HOST_INTERACTIONS,3.482044443,0,quetiapine
RRNA_PROCESSING,3.613184988,0,quetiapine
EUKARYOTIC_TRANSLATION_ELONGATION,3.093496335,0,prazosin
EUKARYOTIC_TRANSLATION_INITIATION,2.974037521,0,prazosin
SELENOAMINO_ACID_METABOLISM,2.966213235,0,prazosin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.897720161,0,prazosin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.864419157,0,prazosin
NONSENSE_MEDIATED_DECAY_NMD,2.860684153,0,prazosin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.815989899,0,prazosin
SIGNALING_BY_ROBO_RECEPTORS,2.7525795,0,prazosin
SARS_COV_1_HOST_INTERACTIONS,2.715983603,0,prazosin
CELLULAR_RESPONSE_TO_STARVATION,2.601927562,0,prazosin
EUKARYOTIC_TRANSLATION_ELONGATION,-3.179637586,0,amlodipine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.437725492,0,amlodipine
SARS_COV_1_HOST_INTERACTIONS,-2.462023141,0,amlodipine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.468214468,0,amlodipine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.590750077,0,amlodipine
RRNA_PROCESSING,-2.674618808,0,amlodipine
TRANSLATION,-2.690706317,0,amlodipine
SIGNALING_BY_ROBO_RECEPTORS,-2.74481522,0,amlodipine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.620652784,0,amlodipine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.910377671,0,amlodipine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.417655518,0,torasemide
TRANSLATION,-2.782343562,0,torasemide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.783007851,0,torasemide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.794621861,0,torasemide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.874834159,0,torasemide
CELLULAR_RESPONSE_TO_STARVATION,-3.130984033,0,torasemide
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.831688801,0,torasemide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.145924769,0,torasemide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.268053916,0,torasemide
SELENOAMINO_ACID_METABOLISM,-3.313125648,0,torasemide
KERATINIZATION,2.506370097,0.000458495,mepivacaine
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.506370097,0.000458495,mepivacaine
S_PHASE,-2.339418222,0.022934796,mepivacaine
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-2.333615246,0.012013464,mepivacaine
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,-2.149992895,0.057519012,mepivacaine
G1_S_DNA_DAMAGE_CHECKPOINTS,-2.13943326,0.050511157,mepivacaine
DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS,-2.130075421,0.044340605,mepivacaine
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,-2.127298714,0.03822466,mepivacaine
TCR_SIGNALING,-2.119483957,0.03494826,mepivacaine
PROGRAMMED_CELL_DEATH,-2.118804248,0.030716244,mepivacaine
EUKARYOTIC_TRANSLATION_ELONGATION,3.094190121,0,zosuquidar
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.497842613,0,zosuquidar
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.516283455,0,zosuquidar
SARS_COV_1_HOST_INTERACTIONS,2.545726416,0,zosuquidar
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.558890942,0,zosuquidar
MRNA_SPLICING,-2.670583919,0,zosuquidar
TRANSLATION,2.742874808,0,zosuquidar
RRNA_PROCESSING,2.830888874,0,zosuquidar
SIGNALING_BY_ROBO_RECEPTORS,2.927024599,0,zosuquidar
CELLULAR_RESPONSE_TO_STARVATION,2.913430283,0,zosuquidar
EUKARYOTIC_TRANSLATION_ELONGATION,3.596321982,0,haloperidol
SIGNALING_BY_ROBO_RECEPTORS,3.219241156,0,haloperidol
TRANSLATION,3.254247294,0,haloperidol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.341481685,0,haloperidol
CELLULAR_RESPONSE_TO_STARVATION,3.369082419,0,haloperidol
INFLUENZA_INFECTION,3.43367535,0,haloperidol
SARS_COV_1_HOST_INTERACTIONS,3.225965773,0,haloperidol
NONSENSE_MEDIATED_DECAY_NMD,3.516915863,0,haloperidol
EUKARYOTIC_TRANSLATION_INITIATION,3.575504385,0,haloperidol
SELENOAMINO_ACID_METABOLISM,3.580558546,0,haloperidol
SELENOAMINO_ACID_METABOLISM,4.364857303,0,resatorvid
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.944796265,0,resatorvid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.537537753,0,resatorvid
TRANSLATION,3.563817952,0,resatorvid
SIGNALING_BY_ROBO_RECEPTORS,3.586012327,0,resatorvid
RRNA_PROCESSING,3.658399652,0,resatorvid
EUKARYOTIC_TRANSLATION_INITIATION,3.970839305,0,resatorvid
CELLULAR_RESPONSE_TO_STARVATION,3.937124756,0,resatorvid
NONSENSE_MEDIATED_DECAY_NMD,4.001042918,0,resatorvid
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.020989026,0,resatorvid
EUKARYOTIC_TRANSLATION_ELONGATION,-3.554093468,0,phenylbutazone
SARS_COV_2_HOST_INTERACTIONS,-2.546808651,0,phenylbutazone
NERVOUS_SYSTEM_DEVELOPMENT,-2.666728979,0,phenylbutazone
SARS_COV_1_INFECTION,-2.708376679,0,phenylbutazone
SARS_COV_1_HOST_INTERACTIONS,-2.898884795,0,phenylbutazone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.996423202,0,phenylbutazone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-3.022812919,0,phenylbutazone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-3.09172043,0,phenylbutazone
TRANSLATION,-3.19070159,0,phenylbutazone
INFLUENZA_INFECTION,-3.238663656,0,phenylbutazone
SELENOAMINO_ACID_METABOLISM,-3.24874508,0,diflunisal
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.486038384,0,diflunisal
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.70874721,0,diflunisal
SARS_COV_1_HOST_INTERACTIONS,-2.716866355,0,diflunisal
TRANSLATION,-2.722406842,0,diflunisal
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.794347915,0,diflunisal
RRNA_PROCESSING,-2.805109967,0,diflunisal
INFLUENZA_INFECTION,-2.850882408,0,diflunisal
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.820693502,0,diflunisal
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-3.042046471,0,diflunisal
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.030284641,0.0723722,pantoprazole
EUKARYOTIC_TRANSLATION_ELONGATION,-2.105325707,0.038452827,pantoprazole
NONSENSE_MEDIATED_DECAY_NMD,-2.067126141,0.028136215,pantoprazole
SELENOAMINO_ACID_METABOLISM,-2.059651239,0.020633224,pantoprazole
MRNA_SPLICING,1.945276941,0.06567107,pantoprazole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.042795978,0.018991945,pantoprazole
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.004024631,0.026072892,pantoprazole
EUKARYOTIC_TRANSLATION_INITIATION,-1.9884578,0.02579153,pantoprazole
RRNA_PROCESSING,-1.964848676,0.028136215,pantoprazole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.960893165,0.025557062,pantoprazole
EUKARYOTIC_TRANSLATION_ELONGATION,-3.425179503,0,azelaic-acid
SARS_COV_1_HOST_INTERACTIONS,-2.679792734,0,azelaic-acid
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.789168332,0,azelaic-acid
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.819350332,0,azelaic-acid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.874728299,0,azelaic-acid
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.886469806,0,azelaic-acid
TRANSLATION,-2.988210337,0,azelaic-acid
INFLUENZA_INFECTION,-3.019855668,0,azelaic-acid
NERVOUS_SYSTEM_DEVELOPMENT,-2.648674935,0,azelaic-acid
RRNA_PROCESSING,-3.126486264,0,azelaic-acid
M_PHASE,-3.377132775,0,BRD-K97440753
GPCR_LIGAND_BINDING,3.015738838,0,BRD-K97440753
CELL_CYCLE_MITOTIC,-3.006634985,0,BRD-K97440753
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.929622981,0,BRD-K97440753
CELL_CYCLE_CHECKPOINTS,-2.808653871,0,BRD-K97440753
MITOTIC_METAPHASE_AND_ANAPHASE,-2.774984135,0,BRD-K97440753
SIGNALING_BY_GPCR,2.745957272,0,BRD-K97440753
CELL_CYCLE,-2.650321122,0,BRD-K97440753
KERATINIZATION,2.628544939,0,BRD-K97440753
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.579936259,0,BRD-K97440753
METABOLISM_OF_RNA,-3.57548486,0,ranolazine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.528495203,0,ranolazine
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.77330604,0.001182369,ranolazine
MITOTIC_METAPHASE_AND_ANAPHASE,-2.533837778,0.001773553,ranolazine
RRNA_PROCESSING,-2.451777139,0.001418842,ranolazine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.321108488,0.008255504,ranolazine
GPCR_LIGAND_BINDING,2.231688789,0.006754503,ranolazine
G_ALPHA_S_SIGNALLING_EVENTS,2.186643002,0.006254169,ranolazine
SUMOYLATION,-2.054159385,0.023056186,ranolazine
G_ALPHA_Q_SIGNALLING_EVENTS,2.110437119,0.008818379,ranolazine
METABOLISM_OF_RNA,-3.191010342,0,indoramin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.685129151,0,indoramin
RRNA_PROCESSING,-2.681084279,0,indoramin
GPCR_LIGAND_BINDING,2.628870084,0,indoramin
SIGNALING_BY_GPCR,2.559883622,0,indoramin
G_ALPHA_Q_SIGNALLING_EVENTS,2.537801177,0,indoramin
SUMOYLATION,-2.377072244,0.005524179,indoramin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.27182567,0.00897679,indoramin
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.164820624,0.005285456,indoramin
MITOTIC_SPINDLE_CHECKPOINT,-2.023104026,0.040326504,indoramin
KERATINIZATION,1.875616357,0.08417124,caffeine
FORMATION_OF_THE_CORNIFIED_ENVELOPE,1.875616357,0.08417124,caffeine
GLYCOSAMINOGLYCAN_METABOLISM,1.670246774,0.172341707,caffeine
G_ALPHA_I_SIGNALLING_EVENTS,-2.718897391,1,caffeine
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.71107561,1,caffeine
SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT,1.615734753,0.174903712,caffeine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.680474753,1,caffeine
GPCR_LIGAND_BINDING,-2.679816933,1,caffeine
CHROMATIN_ORGANIZATION,1.535999042,0.211084222,caffeine
SIGNALING_BY_GPCR,-2.435281096,1,caffeine
EUKARYOTIC_TRANSLATION_ELONGATION,3.928294734,0,pyrazolanthrone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.778732529,0,pyrazolanthrone
SARS_COV_1_HOST_INTERACTIONS,2.805161481,0,pyrazolanthrone
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.820018575,0,pyrazolanthrone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.013119278,0,pyrazolanthrone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.083564675,0,pyrazolanthrone
TRANSLATION,3.276680722,0,pyrazolanthrone
SIGNALING_BY_ROBO_RECEPTORS,3.429577634,0,pyrazolanthrone
SARS_COV_1_INFECTION,2.643564949,0,pyrazolanthrone
RRNA_PROCESSING,3.576404579,0,pyrazolanthrone
EUKARYOTIC_TRANSLATION_ELONGATION,4.069116409,0,BRD-K55591206
NERVOUS_SYSTEM_DEVELOPMENT,2.763632776,0,BRD-K55591206
SARS_COV_1_INFECTION,2.971210848,0,BRD-K55591206
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.131741509,0,BRD-K55591206
SARS_COV_1_HOST_INTERACTIONS,3.161857409,0,BRD-K55591206
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.197019459,0,BRD-K55591206
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.367087122,0,BRD-K55591206
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.484262873,0,BRD-K55591206
RRNA_PROCESSING,3.531795906,0,BRD-K55591206
TRANSLATION,3.519072434,0,BRD-K55591206
EUKARYOTIC_TRANSLATION_ELONGATION,-2.869911216,0,BRD-K33211335
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.618513137,0,BRD-K33211335
EUKARYOTIC_TRANSLATION_INITIATION,-2.646770819,0,BRD-K33211335
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.668350588,0,BRD-K33211335
SELENOAMINO_ACID_METABOLISM,-2.73239085,0,BRD-K33211335
CELLULAR_RESPONSE_TO_STARVATION,-2.619395608,0,BRD-K33211335
NONSENSE_MEDIATED_DECAY_NMD,-2.816661521,0,BRD-K33211335
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.531733351,0.000266279,BRD-K33211335
MITOTIC_METAPHASE_AND_ANAPHASE,2.572654678,0.000292906,BRD-K33211335
C_TYPE_LECTIN_RECEPTORS_CLRS,2.751593115,0.000732266,BRD-K33211335
EUKARYOTIC_TRANSLATION_ELONGATION,-3.386029725,0,KPT-330
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.692401383,0,KPT-330
SARS_COV_1_HOST_INTERACTIONS,-2.713324868,0,KPT-330
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.733610126,0,KPT-330
TRANSLATION,-2.768637853,0,KPT-330
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.781415573,0,KPT-330
RRNA_PROCESSING,-3.00950767,0,KPT-330
INFLUENZA_INFECTION,-3.088049966,0,KPT-330
SIGNALING_BY_ROBO_RECEPTORS,-3.096573562,0,KPT-330
CELLULAR_RESPONSE_TO_STARVATION,-3.162815452,0,KPT-330
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.011771531,0,dimethyl-fumarate
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.916451875,0,dimethyl-fumarate
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.59351032,0,dimethyl-fumarate
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.542602303,0.000679474,dimethyl-fumarate
EUKARYOTIC_TRANSLATION_ELONGATION,-2.532937207,0.001130572,dimethyl-fumarate
SELENOAMINO_ACID_METABOLISM,-2.443292593,0.000847929,dimethyl-fumarate
GASTRULATION,2.463728411,0.002174318,dimethyl-fumarate
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.417062577,0.000942143,dimethyl-fumarate
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.390289037,0.002717897,dimethyl-fumarate
NONSENSE_MEDIATED_DECAY_NMD,-2.333669381,0.001271893,dimethyl-fumarate
MITOTIC_METAPHASE_AND_ANAPHASE,2.862543643,0,suprofen
SELENOAMINO_ACID_METABOLISM,-2.50440213,0,suprofen
EUKARYOTIC_TRANSLATION_ELONGATION,-2.571972023,0,suprofen
SEPARATION_OF_SISTER_CHROMATIDS,2.576080572,0,suprofen
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.578090643,0,suprofen
CELL_CYCLE_CHECKPOINTS,2.641626803,0,suprofen
ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS,2.643621261,0,suprofen
NONSENSE_MEDIATED_DECAY_NMD,-2.52458881,0,suprofen
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,2.69857534,0,suprofen
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.713062478,0,suprofen
EUKARYOTIC_TRANSLATION_ELONGATION,-3.40313704,0,acebutolol
SELENOAMINO_ACID_METABOLISM,-3.322272579,0,acebutolol
NONSENSE_MEDIATED_DECAY_NMD,-3.291338735,0,acebutolol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.204426503,0,acebutolol
EUKARYOTIC_TRANSLATION_INITIATION,-3.01537856,0,acebutolol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.012711601,0,acebutolol
CELLULAR_RESPONSE_TO_STARVATION,-3.00910063,0,acebutolol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.630577367,7.34E-05,acebutolol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.515583961,6.52E-05,acebutolol
SARS_COV_1_HOST_INTERACTIONS,-2.50531292,0.000117361,acebutolol
ANTIGEN_PROCESSING_CROSS_PRESENTATION,3.186421613,0,resveratrol
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,3.010277607,0,resveratrol
PROTEASOME_ASSEMBLY,2.935117743,0,resveratrol
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.819255979,0.000639085,resveratrol
HOST_INTERACTIONS_OF_HIV_FACTORS,2.70622195,0.000511268,resveratrol
CELLULAR_RESPONSE_TO_HYPOXIA,2.563535994,0.002130283,resveratrol
REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS,2.552805613,0.001825957,resveratrol
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.547174725,0.001597712,resveratrol
SWITCHING_OF_ORIGINS_TO_A_POST_REPLICATIVE_STATE,2.509785553,0.001704226,resveratrol
APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1,2.496058527,0.001789437,resveratrol
EUKARYOTIC_TRANSLATION_ELONGATION,-3.15702564,0,atomoxetine
SARS_COV_1_HOST_INTERACTIONS,-2.473245375,0,atomoxetine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.48884828,0,atomoxetine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.591460801,0,atomoxetine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.650770624,0,atomoxetine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.677878218,0,atomoxetine
TRANSLATION,-2.699203968,0,atomoxetine
RRNA_PROCESSING,-2.710693447,0,atomoxetine
INFLUENZA_INFECTION,-2.842929482,0,atomoxetine
SIGNALING_BY_ROBO_RECEPTORS,-2.91503858,0,atomoxetine
EUKARYOTIC_TRANSLATION_ELONGATION,5.190709833,0,dabigatran-etexilate
VIRAL_INFECTION_PATHWAYS,2.689205625,0,dabigatran-etexilate
CELLULAR_RESPONSES_TO_STIMULI,2.874349633,0,dabigatran-etexilate
NERVOUS_SYSTEM_DEVELOPMENT,2.951361432,0,dabigatran-etexilate
SARS_COV_1_INFECTION,2.988138444,0,dabigatran-etexilate
METABOLISM_OF_RNA,3.24456514,0,dabigatran-etexilate
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.314128634,0,dabigatran-etexilate
TRANSLATION,4.407887964,0,dabigatran-etexilate
SIGNALING_BY_ROBO_RECEPTORS,4.559756621,0,dabigatran-etexilate
RRNA_PROCESSING,4.611872912,0,dabigatran-etexilate
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.447068801,0,dipyridamole
SIGNALING_BY_ROBO_RECEPTORS,2.784708087,0,dipyridamole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.851400709,0,dipyridamole
INFLUENZA_INFECTION,2.967081327,0,dipyridamole
RRNA_PROCESSING,3.002539981,0,dipyridamole
TRANSLATION,3.031417088,0,dipyridamole
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.009627035,0,dipyridamole
NONSENSE_MEDIATED_DECAY_NMD,3.345900049,0,dipyridamole
SELENOAMINO_ACID_METABOLISM,3.349392915,0,dipyridamole
EUKARYOTIC_TRANSLATION_INITIATION,3.369220059,0,dipyridamole
EUKARYOTIC_TRANSLATION_ELONGATION,3.505011415,0,indometacin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.464696305,0,indometacin
SARS_COV_1_INFECTION,2.551026756,0,indometacin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.740393927,0,indometacin
NERVOUS_SYSTEM_DEVELOPMENT,2.74723519,0,indometacin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.757248645,0,indometacin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.878629046,0,indometacin
RRNA_PROCESSING,3.018193632,0,indometacin
TRANSLATION,3.129678866,0,indometacin
SARS_COV_1_HOST_INTERACTIONS,2.858770163,0,indometacin
NONSENSE_MEDIATED_DECAY_NMD,3.939164545,0,lisinopril
METABOLISM_OF_RNA,2.402421525,0,lisinopril
VIRAL_INFECTION_PATHWAYS,2.551666674,0,lisinopril
SARS_COV_2_HOST_INTERACTIONS,2.744091128,0,lisinopril
NERVOUS_SYSTEM_DEVELOPMENT,2.953000954,0,lisinopril
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.074420231,0,lisinopril
SARS_COV_1_INFECTION,3.095390268,0,lisinopril
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.202086558,0,lisinopril
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.226200567,0,lisinopril
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.342246691,0,lisinopril
EUKARYOTIC_TRANSLATION_ELONGATION,2.546535468,0.000822774,carbachol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.545094816,0.000411387,carbachol
EUKARYOTIC_TRANSLATION_INITIATION,2.516287662,0.000274258,carbachol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.508954906,0.000205694,carbachol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.495282993,0.000164555,carbachol
SELENOAMINO_ACID_METABOLISM,2.486128528,0.000137129,carbachol
NONSENSE_MEDIATED_DECAY_NMD,2.482476837,0.000117539,carbachol
SIGNALING_BY_ROBO_RECEPTORS,2.470196755,0.000102847,carbachol
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.446478449,0.000182839,carbachol
GPCR_LIGAND_BINDING,2.371386177,0.000164555,carbachol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.40608687,0,genistein
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.360293022,0,genistein
SELENOAMINO_ACID_METABOLISM,-2.356742655,0,genistein
NONSENSE_MEDIATED_DECAY_NMD,-2.330039578,0,genistein
EUKARYOTIC_TRANSLATION_INITIATION,-2.304670001,0,genistein
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.257704048,0,genistein
TRANSLATION,-2.257687738,0,genistein
RRNA_PROCESSING,-2.254679802,0.000122952,genistein
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.237062713,0.000327872,genistein
INFLUENZA_INFECTION,-2.203862951,0.000491807,genistein
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.409218798,0,pelitinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.68706704,0,pelitinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.830147149,0,pelitinib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.865978594,0,pelitinib
TRANSLATION,-2.874309918,0,pelitinib
SARS_COV_1_INFECTION,-2.933440871,0,pelitinib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.936032078,0,pelitinib
SARS_COV_1_HOST_INTERACTIONS,-3.003295866,0,pelitinib
INFLUENZA_INFECTION,-3.148810171,0,pelitinib
CELLULAR_RESPONSE_TO_STARVATION,-3.186839083,0,pelitinib
CELL_CYCLE_CHECKPOINTS,-3.207611202,0,diminazene-aceturate
GPCR_LIGAND_BINDING,2.806929754,0,diminazene-aceturate
METABOLISM_OF_RNA,-2.792308535,0,diminazene-aceturate
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.790334754,0,diminazene-aceturate
CELL_CYCLE_MITOTIC,-2.678224718,0,diminazene-aceturate
SIGNALING_BY_GPCR,2.580981907,0,diminazene-aceturate
SEPARATION_OF_SISTER_CHROMATIDS,-2.558600895,0,diminazene-aceturate
CELL_CYCLE,-2.547576536,0,diminazene-aceturate
M_PHASE,-2.53570797,0.000918009,diminazene-aceturate
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.263850229,0.000468194,diminazene-aceturate
EUKARYOTIC_TRANSLATION_ELONGATION,3.439680103,0,palbociclib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.754495239,0,palbociclib
SIGNALING_BY_ROBO_RECEPTORS,2.807422525,0,palbociclib
INFLUENZA_INFECTION,2.870390339,0,palbociclib
TRANSLATION,2.935680269,0,palbociclib
CELLULAR_RESPONSE_TO_STARVATION,2.993023294,0,palbociclib
RRNA_PROCESSING,2.675044528,0,palbociclib
NONSENSE_MEDIATED_DECAY_NMD,3.079022986,0,palbociclib
EUKARYOTIC_TRANSLATION_INITIATION,3.224658397,0,palbociclib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.269767326,0,palbociclib
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.8091552,0,melatonin
DNA_REPAIR,-2.661413193,0,melatonin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.652035506,0,melatonin
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.61636216,0.000660319,melatonin
CHROMATIN_ORGANIZATION,-2.546893999,0.001584767,melatonin
METABOLISM_OF_RNA,-2.534671897,0.001320639,melatonin
RRNA_PROCESSING,-2.451574914,0.001886627,melatonin
PKR_MEDIATED_SIGNALING,-2.39220964,0.001650799,melatonin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.22101189,0.013794807,melatonin
GPCR_LIGAND_BINDING,2.220447778,0.006897403,melatonin
CELL_CYCLE_MITOTIC,-2.898483938,0,quercetin
CELL_CYCLE,-2.813622671,0,quercetin
CELL_CYCLE_CHECKPOINTS,-2.742831381,0,quercetin
M_PHASE,-2.654992244,0,quercetin
GPCR_LIGAND_BINDING,2.646811456,0,quercetin
SIGNALING_BY_GPCR,2.536883306,0,quercetin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.397288147,0,quercetin
MITOTIC_PROMETAPHASE,-2.403502245,0.002493105,quercetin
MITOTIC_SPINDLE_CHECKPOINT,-2.400626338,0.002077588,quercetin
G_ALPHA_S_SIGNALLING_EVENTS,2.215391927,0.001577011,quercetin
EUKARYOTIC_TRANSLATION_ELONGATION,-3.832041422,0,imiquimod
ADAPTIVE_IMMUNE_SYSTEM,2.663467791,0,imiquimod
SARS_COV_1_HOST_INTERACTIONS,-2.846428016,0,imiquimod
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.921075877,0,imiquimod
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-3.000635969,0,imiquimod
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-3.023241136,0,imiquimod
SIGNALING_BY_ROBO_RECEPTORS,-3.132932413,0,imiquimod
INFLUENZA_INFECTION,-3.151280469,0,imiquimod
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-3.16488325,0,imiquimod
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-3.087497738,0,imiquimod
EUKARYOTIC_TRANSLATION_ELONGATION,-3.350961264,0,tiludronate
SARS_COV_1_INFECTION,-2.713222268,0,tiludronate
SARS_COV_1_HOST_INTERACTIONS,-2.763483929,0,tiludronate
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.805972194,0,tiludronate
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.810848523,0,tiludronate
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.830375428,0,tiludronate
TRANSLATION,-2.936560668,0,tiludronate
INFLUENZA_INFECTION,-3.000674701,0,tiludronate
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.136597208,0,tiludronate
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.66984964,0,tiludronate
EUKARYOTIC_TRANSLATION_ELONGATION,-3.006635531,0,norfloxacin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.500571715,0,norfloxacin
TRANSLATION,-2.513932286,0,norfloxacin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.572870218,0,norfloxacin
SARS_COV_1_INFECTION,-2.593348193,0,norfloxacin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.704304389,0,norfloxacin
INFLUENZA_INFECTION,-2.721950769,0,norfloxacin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.747556215,0,norfloxacin
RRNA_PROCESSING,-2.751537597,0,norfloxacin
SARS_COV_2_HOST_INTERACTIONS,-2.459676362,0,norfloxacin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.268701897,0,vortioxetine
CELLULAR_RESPONSE_TO_STARVATION,2.848090079,0,vortioxetine
EUKARYOTIC_TRANSLATION_INITIATION,3.053425259,0,vortioxetine
NONSENSE_MEDIATED_DECAY_NMD,3.060927154,0,vortioxetine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.751409972,0,vortioxetine
SELENOAMINO_ACID_METABOLISM,3.163584089,0,vortioxetine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.070661207,0,vortioxetine
EUKARYOTIC_TRANSLATION_ELONGATION,3.256478935,0,vortioxetine
TRANSLATION,2.648202791,6.90E-05,vortioxetine
INFLUENZA_INFECTION,2.694686088,7.66E-05,vortioxetine
EUKARYOTIC_TRANSLATION_ELONGATION,3.592706921,0,etoricoxib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.488869065,0,etoricoxib
RRNA_PROCESSING,2.85721463,0,etoricoxib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.936172045,0,etoricoxib
SIGNALING_BY_ROBO_RECEPTORS,3.061015836,0,etoricoxib
TRANSLATION,3.207120442,0,etoricoxib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.255512003,0,etoricoxib
INFLUENZA_INFECTION,3.191354975,0,etoricoxib
CELLULAR_RESPONSE_TO_STARVATION,3.308843542,0,etoricoxib
NONSENSE_MEDIATED_DECAY_NMD,3.387273108,0,etoricoxib
EUKARYOTIC_TRANSLATION_INITIATION,2.809610093,0,levomequitazine
EUKARYOTIC_TRANSLATION_ELONGATION,2.798609554,0,levomequitazine
NONSENSE_MEDIATED_DECAY_NMD,2.749766055,0,levomequitazine
SELENOAMINO_ACID_METABOLISM,2.737007147,0,levomequitazine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.707954947,0,levomequitazine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.66478469,0,levomequitazine
INFLUENZA_INFECTION,2.513860857,0.000110584,levomequitazine
SIGNALING_BY_ROBO_RECEPTORS,2.501389334,9.95E-05,levomequitazine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.551562407,0.000142179,levomequitazine
SARS_COV_1_HOST_INTERACTIONS,2.54823268,0.000124407,levomequitazine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.201236916,0,gemfibrozil
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.583475302,0,gemfibrozil
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.676197461,0,gemfibrozil
TRANSLATION,-2.709529968,0,gemfibrozil
INFLUENZA_INFECTION,-2.798403068,0,gemfibrozil
SIGNALING_BY_ROBO_RECEPTORS,-2.910959191,0,gemfibrozil
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.932853143,0,gemfibrozil
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.627095539,0,gemfibrozil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.969430517,0,gemfibrozil
EUKARYOTIC_TRANSLATION_INITIATION,-2.99755896,0,gemfibrozil
EUKARYOTIC_TRANSLATION_ELONGATION,4.213008346,0,SB-939
CELLULAR_RESPONSES_TO_STIMULI,2.511782083,0,SB-939
INFECTIOUS_DISEASE,2.578371988,0,SB-939
VIRAL_INFECTION_PATHWAYS,2.713640853,0,SB-939
SARS_COV_2_HOST_INTERACTIONS,2.7679127,0,SB-939
METABOLISM_OF_RNA,2.792348323,0,SB-939
SARS_COV_1_INFECTION,3.121210406,0,SB-939
NERVOUS_SYSTEM_DEVELOPMENT,3.179317696,0,SB-939
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.314554379,0,SB-939
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.328541403,0,SB-939
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.5588911,0,mebendazole
SARS_COV_1_HOST_INTERACTIONS,2.735724576,0,mebendazole
SARS_COV_1_INFECTION,2.766468055,0,mebendazole
METABOLISM_OF_RNA,3.382221843,0,mebendazole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.781257855,0,mebendazole
SIGNALING_BY_ROBO_RECEPTORS,3.90211332,0,mebendazole
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.114687477,0,mebendazole
RRNA_PROCESSING,4.200691539,0,mebendazole
TRANSLATION,4.163000744,0,mebendazole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.335002991,0,mebendazole
EUKARYOTIC_TRANSLATION_ELONGATION,-2.835884841,0.000554862,ellagic-acid
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.4907598,0.001764031,ellagic-acid
NONSENSE_MEDIATED_DECAY_NMD,-2.80231917,0.000832293,ellagic-acid
SELENOAMINO_ACID_METABOLISM,-2.781630705,0.00092477,ellagic-acid
MAPK_FAMILY_SIGNALING_CASCADES,2.41366201,0.004410078,ellagic-acid
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.312689732,0.008232145,ellagic-acid
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,-2.6921593,0.002358163,ellagic-acid
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.288239965,0.007056124,ellagic-acid
MAPK1_MAPK3_SIGNALING,2.272486517,0.007056124,ellagic-acid
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.660063482,0.003218199,ellagic-acid
GPCR_LIGAND_BINDING,-2.846322071,0,doxazosin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.767530471,0,doxazosin
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.451609826,0.0004224,doxazosin
SIGNALING_BY_GPCR,-2.436147181,0.0003168,doxazosin
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.382435395,0.00025344,doxazosin
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.378513028,0.0002112,doxazosin
ANTIGEN_PROCESSING_CROSS_PRESENTATION,-2.247096514,0.003258511,doxazosin
ADAPTIVE_IMMUNE_SYSTEM,-2.199563497,0.004276796,doxazosin
G_ALPHA_Q_SIGNALLING_EVENTS,-2.11232452,0.009855991,doxazosin
PROTEIN_LOCALIZATION,2.227167098,0.070296809,doxazosin
EUKARYOTIC_TRANSLATION_ELONGATION,-3.30854345,0,methocarbamol
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.579862482,0,methocarbamol
TRANSLATION,-2.643350329,0,methocarbamol
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.647478345,0,methocarbamol
SIGNALING_BY_ROBO_RECEPTORS,-2.721167892,0,methocarbamol
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.730299098,0,methocarbamol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.733420639,0,methocarbamol
APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1,2.738210649,0,methocarbamol
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.739198947,0,methocarbamol
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,2.821225946,0,methocarbamol
EUKARYOTIC_TRANSLATION_ELONGATION,-3.174437823,0,propranolol
NERVOUS_SYSTEM_DEVELOPMENT,-2.404813441,0,propranolol
SARS_COV_1_INFECTION,-2.452735569,0,propranolol
SARS_COV_2_HOST_INTERACTIONS,-2.560977657,0,propranolol
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.564284944,0,propranolol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.635012231,0,propranolol
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.64253363,0,propranolol
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.688914584,0,propranolol
SARS_COV_1_HOST_INTERACTIONS,-2.713668964,0,propranolol
TRANSLATION,-2.738934851,0,propranolol
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.932853448,0,bosutinib
HOST_INTERACTIONS_OF_HIV_FACTORS,2.90995461,0.001481921,bosutinib
GASTRULATION,2.893184469,0.000987947,bosutinib
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.803795591,0.00074096,bosutinib
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,2.789342684,0.000592768,bosutinib
ANTIGEN_PROCESSING_CROSS_PRESENTATION,2.782936071,0.000493974,bosutinib
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,2.782211996,0.000423406,bosutinib
G1_S_DNA_DAMAGE_CHECKPOINTS,2.756160027,0.00037048,bosutinib
SEPARATION_OF_SISTER_CHROMATIDS,2.752849727,0.000329316,bosutinib
MITOTIC_METAPHASE_AND_ANAPHASE,2.751245953,0.000296384,bosutinib
EUKARYOTIC_TRANSLATION_ELONGATION,4.424181249,0,oxiconazole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.354521256,0,oxiconazole
TRANSLATION,4.352606483,0,oxiconazole
SELENOAMINO_ACID_METABOLISM,4.351570337,0,oxiconazole
EUKARYOTIC_TRANSLATION_INITIATION,4.209345321,0,oxiconazole
NONSENSE_MEDIATED_DECAY_NMD,4.190187535,0,oxiconazole
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.083429412,0,oxiconazole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.077941704,0,oxiconazole
CELLULAR_RESPONSE_TO_STARVATION,4.051676154,0,oxiconazole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.905072002,0,oxiconazole
EUKARYOTIC_TRANSLATION_ELONGATION,3.748513017,0,lomerizine
SARS_COV_1_INFECTION,2.705929008,0,lomerizine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.722262029,0,lomerizine
NERVOUS_SYSTEM_DEVELOPMENT,2.775578662,0,lomerizine
RRNA_PROCESSING,3.043119339,0,lomerizine
SARS_COV_1_HOST_INTERACTIONS,3.14128909,0,lomerizine
TRANSLATION,3.253484287,0,lomerizine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.265067658,0,lomerizine
INFLUENZA_INFECTION,3.342163623,0,lomerizine
EUKARYOTIC_TRANSLATION_INITIATION,3.495808463,0,lomerizine
METABOLISM_OF_RNA,-3.030685575,0,furosemide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.485375466,0,furosemide
GPCR_LIGAND_BINDING,2.371149239,0,furosemide
RRNA_PROCESSING,-2.521561082,0.004127883,furosemide
SUMOYLATION,-2.482987355,0.002751922,furosemide
NEURONAL_SYSTEM,2.179636258,0.00629646,furosemide
MRNA_SPLICING,-2.124079528,0.025455281,furosemide
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.109988228,0.022015378,furosemide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.069985096,0.022932686,furosemide
SENSORY_PERCEPTION,2.10422112,0.010897719,furosemide
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-3.263988062,0,clofazimine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.37275283,0,clofazimine
SARS_COV_1_HOST_INTERACTIONS,2.487707033,0,clofazimine
RRNA_PROCESSING,2.554978886,0,clofazimine
INFLUENZA_INFECTION,2.556682896,0,clofazimine
NUCLEAR_ENVELOPE_BREAKDOWN,-2.669584655,0,clofazimine
TRANSLATION,2.687169988,0,clofazimine
SIGNALING_BY_ROBO_RECEPTORS,2.690922678,0,clofazimine
CELLULAR_RESPONSE_TO_STARVATION,2.748795974,0,clofazimine
MITOTIC_PROPHASE,-2.751883789,0,clofazimine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.21470227,0,amonafide
EUKARYOTIC_TRANSLATION_ELONGATION,4.20706246,0,amonafide
EUKARYOTIC_TRANSLATION_INITIATION,4.081119845,0,amonafide
SELENOAMINO_ACID_METABOLISM,4.064348174,0,amonafide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.008767292,0,amonafide
NONSENSE_MEDIATED_DECAY_NMD,3.994547577,0,amonafide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.955566439,0,amonafide
CELLULAR_RESPONSE_TO_STARVATION,3.947523071,0,amonafide
TRANSLATION,3.881389527,0,amonafide
INFLUENZA_INFECTION,3.784520689,0,amonafide
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,2.352711971,0.016409082,dalfampridine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.318537531,0.012306812,dalfampridine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.160156432,0.01494127,dalfampridine
SELENOAMINO_ACID_METABOLISM,-2.116239989,0.012304575,dalfampridine
RAB_REGULATION_OF_TRAFFICKING,1.923981908,0.053329517,dalfampridine
MRNA_SPLICING,1.884908928,0.058457355,dalfampridine
NONSENSE_MEDIATED_DECAY_NMD,-2.071923066,0.016406101,dalfampridine
EUKARYOTIC_TRANSLATION_INITIATION,-2.04907832,0.015160995,dalfampridine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.037727236,0.013886592,dalfampridine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.037332455,0.01157216,dalfampridine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.165950983,0,simvastatin
SELENOAMINO_ACID_METABOLISM,-3.107205965,0,simvastatin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.094274536,0,simvastatin
NONSENSE_MEDIATED_DECAY_NMD,-3.058070039,0,simvastatin
EUKARYOTIC_TRANSLATION_INITIATION,-2.986682404,0,simvastatin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.949669738,0,simvastatin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.946647044,0,simvastatin
CELLULAR_RESPONSE_TO_STARVATION,-2.934467369,0,simvastatin
SIGNALING_BY_ROBO_RECEPTORS,-2.866937465,0,simvastatin
CELL_CYCLE,2.856929332,0,simvastatin
EUKARYOTIC_TRANSLATION_ELONGATION,4.033058366,0,rucaparib
SARS_COV_1_INFECTION,2.981055856,0,rucaparib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.100168771,0,rucaparib
SARS_COV_1_HOST_INTERACTIONS,3.156885675,0,rucaparib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.227582941,0,rucaparib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.348958482,0,rucaparib
TRANSLATION,3.384124572,0,rucaparib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.449772492,0,rucaparib
SIGNALING_BY_ROBO_RECEPTORS,3.505933168,0,rucaparib
RRNA_PROCESSING,3.537044952,0,rucaparib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.355791298,0,BVD-523
GPCR_LIGAND_BINDING,-2.158953338,0.013821998,BVD-523
EUKARYOTIC_TRANSLATION_ELONGATION,-2.108598191,0.013376127,BVD-523
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.076149502,0.014490804,BVD-523
RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_DIFFERENTIATION_OF_HSCS,1.904552668,0.205620461,BVD-523
EUKARYOTIC_TRANSLATION_INITIATION,-2.04198058,0.018904926,BVD-523
G_ALPHA_Q_SIGNALLING_EVENTS,-2.032950141,0.017537588,BVD-523
SIGNALING_BY_GPCR,-2.022854193,0.016433527,BVD-523
MRNA_SPLICING,1.834693184,0.116703505,BVD-523
HEDGEHOG_ON_STATE,1.835761977,0.17366593,BVD-523
EUKARYOTIC_TRANSLATION_ELONGATION,-3.315895128,0,cyproheptadine
NONSENSE_MEDIATED_DECAY_NMD,-3.156028554,0,cyproheptadine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.125462993,0,cyproheptadine
SELENOAMINO_ACID_METABOLISM,-3.118353247,0,cyproheptadine
CELLULAR_RESPONSE_TO_STARVATION,-2.953814938,0,cyproheptadine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.915952896,0,cyproheptadine
EUKARYOTIC_TRANSLATION_INITIATION,-2.815196561,0,cyproheptadine
ADAPTIVE_IMMUNE_SYSTEM,2.596531626,0,cyproheptadine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.438352416,0.007886055,cyproheptadine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.563579287,0.001103732,cyproheptadine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.219300953,0,proguanil
SELENOAMINO_ACID_METABOLISM,-3.199437295,0,proguanil
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.132831161,0,proguanil
NONSENSE_MEDIATED_DECAY_NMD,-3.105469462,0,proguanil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.017442486,0,proguanil
CELLULAR_RESPONSE_TO_STARVATION,-3.015021602,0,proguanil
EUKARYOTIC_TRANSLATION_INITIATION,-2.914064488,0,proguanil
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.664208514,0.005098071,proguanil
GPCR_LIGAND_BINDING,2.55722395,0.003398714,proguanil
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.518063105,0.002265809,proguanil
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,3.025929914,0,SR-27897
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.774714183,0.003151907,SR-27897
C_TYPE_LECTIN_RECEPTORS_CLRS,2.746785439,0.002101271,SR-27897
INNATE_IMMUNE_SYSTEM,2.745412723,0.001575953,SR-27897
ADAPTIVE_IMMUNE_SYSTEM,2.714700581,0.001891144,SR-27897
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,2.712803077,0.001575953,SR-27897
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.641088235,0.001801089,SR-27897
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,2.582901584,0.001575953,SR-27897
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.47578663,0.002521525,SR-27897
TCR_SIGNALING,2.478926022,0.002801695,SR-27897
EUKARYOTIC_TRANSLATION_ELONGATION,-2.78462127,0,lenalidomide
NONSENSE_MEDIATED_DECAY_NMD,-2.731907088,0,lenalidomide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.710774837,0,lenalidomide
EUKARYOTIC_TRANSLATION_INITIATION,-2.68961166,0,lenalidomide
SELENOAMINO_ACID_METABOLISM,-2.673953756,0,lenalidomide
CELLULAR_RESPONSE_TO_STARVATION,-2.631007433,0,lenalidomide
RRNA_PROCESSING,-2.584254121,0,lenalidomide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.516784269,0.000448715,lenalidomide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.508119395,0.000478629,lenalidomide
ANTIGEN_PROCESSING_CROSS_PRESENTATION,2.255225828,0.046526656,lenalidomide
EUKARYOTIC_TRANSLATION_ELONGATION,-3.313974053,0,aminoguanidine
ADAPTIVE_IMMUNE_SYSTEM,2.662581238,0,aminoguanidine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.682288151,0,aminoguanidine
CELLULAR_RESPONSE_TO_STARVATION,-2.899725545,0,aminoguanidine
EUKARYOTIC_TRANSLATION_INITIATION,-2.927325708,0,aminoguanidine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.663394703,0,aminoguanidine
NONSENSE_MEDIATED_DECAY_NMD,-3.109383134,0,aminoguanidine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.181398232,0,aminoguanidine
SELENOAMINO_ACID_METABOLISM,-3.22824957,0,aminoguanidine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.954069841,0,aminoguanidine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.146091966,0,fluoxetine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.81391505,0,fluoxetine
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.723375215,0,fluoxetine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.722244923,0,fluoxetine
SELENOAMINO_ACID_METABOLISM,-2.693397323,0,fluoxetine
NONSENSE_MEDIATED_DECAY_NMD,-2.686269944,0,fluoxetine
EUKARYOTIC_TRANSLATION_INITIATION,-2.590814633,0,fluoxetine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.427482263,0,fluoxetine
CELLULAR_RESPONSE_TO_STARVATION,-2.452353239,0,fluoxetine
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.6363609,0.001806926,fluoxetine
RESPIRATORY_ELECTRON_TRANSPORT,2.347312012,0.019120459,naphazoline
TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES,2.342864766,0.009560229,naphazoline
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,2.327259552,0.008073083,naphazoline
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.219658999,0.015933716,naphazoline
NEURONAL_SYSTEM,2.173100312,0.018865519,naphazoline
PI3K_AKT_SIGNALING_IN_CANCER,2.13091291,0.021669853,naphazoline
MUSCLE_CONTRACTION,2.005195611,0.053173086,naphazoline
INTERFERON_ALPHA_BETA_SIGNALING,-1.981299551,0.25965405,naphazoline
PEPTIDE_LIGAND_BINDING_RECEPTORS,1.958907029,0.065168897,naphazoline
COPI_MEDIATED_ANTEROGRADE_TRANSPORT,1.897743238,0.088803909,naphazoline
EUKARYOTIC_TRANSLATION_ELONGATION,4.0984695,0,sertindole
CELLULAR_RESPONSES_TO_STIMULI,2.465063902,0,sertindole
INFECTIOUS_DISEASE,2.538836859,0,sertindole
METABOLISM_OF_RNA,2.634151097,0,sertindole
SARS_COV_2_HOST_INTERACTIONS,2.885800448,0,sertindole
VIRAL_INFECTION_PATHWAYS,2.890542657,0,sertindole
NERVOUS_SYSTEM_DEVELOPMENT,3.078813458,0,sertindole
SARS_COV_1_INFECTION,3.193488092,0,sertindole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.267862417,0,sertindole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.317240901,0,sertindole
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.497515676,0.004678382,brexpiprazole
TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT,-2.460381485,0.002923989,brexpiprazole
SIGNALING_BY_WNT,-2.398605906,0.004288517,brexpiprazole
HOST_INTERACTIONS_OF_HIV_FACTORS,-2.3606949,0.007017573,brexpiprazole
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,-2.351847518,0.006081897,brexpiprazole
INFECTIOUS_DISEASE,-2.320557917,0.007602371,brexpiprazole
REGULATION_OF_RUNX2_EXPRESSION_AND_ACTIVITY,-2.290585578,0.008354254,brexpiprazole
VIRAL_INFECTION_PATHWAYS,-2.280752822,0.008187169,brexpiprazole
G1_S_DNA_DAMAGE_CHECKPOINTS,-2.277762869,0.007407439,brexpiprazole
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.218902718,0.013462753,brexpiprazole
EUKARYOTIC_TRANSLATION_ELONGATION,-2.54403368,0.005351297,propafenone
TRANSCRIPTIONAL_REGULATION_BY_RUNX1,2.351594329,0.024425171,propafenone
GASTRULATION,2.329080686,0.013957241,propafenone
SELENOAMINO_ACID_METABOLISM,-2.502232782,0.004548602,propafenone
NONSENSE_MEDIATED_DECAY_NMD,-2.400355836,0.008740452,propafenone
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.335843477,0.011505288,propafenone
RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY,2.143905459,0.044779481,propafenone
GPCR_LIGAND_BINDING,2.14388587,0.033584611,propafenone
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.134877943,0.029310206,propafenone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.312654788,0.011237723,propafenone
EUKARYOTIC_TRANSLATION_ELONGATION,-2.874315056,0,hypericin
TRANSCRIPTIONAL_REGULATION_BY_RUNX1,2.61678998,0,hypericin
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.623895324,0,hypericin
ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS,2.655981361,0,hypericin
CLEC7A_DECTIN_1_SIGNALING,2.661516663,0,hypericin
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.675840252,0,hypericin
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,2.689833353,0,hypericin
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.699595387,0,hypericin
PROTEASOME_ASSEMBLY,2.652260137,0,hypericin
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,2.721398097,0,hypericin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.271708741,0,phenformin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.695228478,0,phenformin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.739464347,0,phenformin
TRANSLATION,-2.813661028,0,phenformin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.863809778,0,phenformin
SARS_COV_1_HOST_INTERACTIONS,-2.87570569,0,phenformin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.95239293,0,phenformin
SIGNALING_BY_ROBO_RECEPTORS,-2.972942133,0,phenformin
RRNA_PROCESSING,-3.020566166,0,phenformin
SARS_COV_1_INFECTION,-2.731266977,0,phenformin
GPCR_LIGAND_BINDING,-2.598684843,0,pentamidine
ANTIGEN_PROCESSING_CROSS_PRESENTATION,-2.528901982,0,pentamidine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.492101307,0.000400469,pentamidine
SIGNALING_BY_GPCR,-2.40694503,0.001501758,pentamidine
MAPK1_MAPK3_SIGNALING,-2.26718392,0.00360422,pentamidine
RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY,-2.211535794,0.006207268,pentamidine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.205321857,0.006007033,pentamidine
MAPK_FAMILY_SIGNALING_CASCADES,-2.176096861,0.007358616,pentamidine
TOLL_LIKE_RECEPTOR_CASCADES,-2.158611557,0.00720844,pentamidine
SIGNALING_BY_INTERLEUKINS,-2.148720131,0.007088299,pentamidine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.865969307,0,trazodone
SARS_COV_1_INFECTION,2.543669794,0,trazodone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.613692762,0,trazodone
SARS_COV_1_HOST_INTERACTIONS,2.757453127,0,trazodone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.821919623,0,trazodone
RRNA_PROCESSING,2.894327968,0,trazodone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.903404301,0,trazodone
CELLULAR_RESPONSE_TO_STARVATION,3.001379546,0,trazodone
SIGNALING_BY_ROBO_RECEPTORS,3.057338847,0,trazodone
INFLUENZA_INFECTION,3.097457691,0,trazodone
NONSENSE_MEDIATED_DECAY_NMD,3.224307736,0,navitoclax
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.487360396,0,navitoclax
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.509564155,0,navitoclax
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.692554807,0,navitoclax
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.706587105,0,navitoclax
RRNA_PROCESSING,2.774495576,0,navitoclax
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.819747723,0,navitoclax
TRANSLATION,2.878619441,0,navitoclax
SIGNALING_BY_ROBO_RECEPTORS,2.87938562,0,navitoclax
SARS_COV_1_HOST_INTERACTIONS,2.571971062,0,navitoclax
NONSENSE_MEDIATED_DECAY_NMD,-3.117038012,0,talmapimod
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.451840259,0,talmapimod
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.493748751,0,talmapimod
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.514776253,0,talmapimod
TRANSLATION,-2.563303323,0,talmapimod
SARS_COV_1_HOST_INTERACTIONS,-2.570261586,0,talmapimod
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.66780394,0,talmapimod
RRNA_PROCESSING,-2.697366963,0,talmapimod
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.785516873,0,talmapimod
INFLUENZA_INFECTION,-2.679735657,0,talmapimod
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.163037661,0.390273451,roflumilast
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.836192707,0.083136835,roflumilast
SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT,1.780744163,0.063629868,roflumilast
GPCR_LIGAND_BINDING,-2.044654689,0.438925426,roflumilast
G_ALPHA_Q_SIGNALLING_EVENTS,-1.986061874,0.438925426,roflumilast
SARS_COV_1_INFECTION,-1.981957454,0.336862044,roflumilast
PEPTIDE_LIGAND_BINDING_RECEPTORS,-1.953097906,0.326602823,roflumilast
GLYCOSAMINOGLYCAN_METABOLISM,1.547092151,0.165499583,roflumilast
SIGNALING_BY_GPCR,-1.912896195,0.355723498,roflumilast
C_TYPE_LECTIN_RECEPTORS_CLRS,-1.872120731,0.392388754,roflumilast
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.694476094,0,alisertib
GPCR_LIGAND_BINDING,2.535421703,0,alisertib
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.454437258,0.01314486,alisertib
SUMOYLATION,-2.439782926,0.00657243,alisertib
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.318058917,0.000999489,alisertib
SIGNALING_BY_GPCR,2.317829121,0.000749616,alisertib
G_ALPHA_Q_SIGNALLING_EVENTS,2.303910036,0.001049463,alisertib
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.309783543,0.009639564,alisertib
SENSORY_PERCEPTION,2.246811231,0.002123913,alisertib
MRNA_SPLICING,-2.169587998,0.021689019,alisertib
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.441123317,0,baricitinib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.343048788,0.000979181,baricitinib
NONSENSE_MEDIATED_DECAY_NMD,-2.298593954,0.000979181,baricitinib
SELENOAMINO_ACID_METABOLISM,-2.267846934,0.000652787,baricitinib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.205606229,0.001468771,baricitinib
EUKARYOTIC_TRANSLATION_INITIATION,-2.159414563,0.002545871,baricitinib
RAB_REGULATION_OF_TRAFFICKING,2.052913999,0.008740564,baricitinib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.149827662,0.002284756,baricitinib
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,2.026044849,0.007416236,baricitinib
MRNA_SPLICING,2.013478913,0.006754072,baricitinib
KERATINIZATION,2.295678739,0.007783013,alizapride
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,-2.215513835,0.025470719,alizapride
GLYCOSAMINOGLYCAN_METABOLISM,2.189938623,0.009878439,alizapride
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.176602286,0.007383884,alizapride
NONSENSE_MEDIATED_DECAY_NMD,-2.125258477,0.041920559,alizapride
DISEASES_OF_GLYCOSYLATION,2.048783212,0.012572559,alizapride
ASYMMETRIC_LOCALIZATION_OF_PCP_PROTEINS,-2.091739953,0.042097439,alizapride
PROGRAMMED_CELL_DEATH,-2.07726775,0.036348839,alizapride
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.074315246,0.029291327,alizapride
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.916936089,0.021313481,alizapride
EUKARYOTIC_TRANSLATION_ELONGATION,3.376068689,0,lidocaine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.530628296,0,lidocaine
RRNA_PROCESSING,2.591002342,0,lidocaine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.807688837,0,lidocaine
INFLUENZA_INFECTION,2.845997566,0,lidocaine
TRANSLATION,2.846767392,0,lidocaine
SIGNALING_BY_ROBO_RECEPTORS,2.713313184,0,lidocaine
NONSENSE_MEDIATED_DECAY_NMD,3.091390092,0,lidocaine
EUKARYOTIC_TRANSLATION_INITIATION,3.140072746,0,lidocaine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.227429456,0,lidocaine
EUKARYOTIC_TRANSLATION_ELONGATION,3.53041208,0,benzylpenicillin
SIGNALING_BY_ROBO_RECEPTORS,2.871172189,0,benzylpenicillin
TRANSLATION,2.88669671,0,benzylpenicillin
RRNA_PROCESSING,2.933908719,0,benzylpenicillin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.945164427,0,benzylpenicillin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.999137783,0,benzylpenicillin
INFLUENZA_INFECTION,2.991356269,0,benzylpenicillin
EUKARYOTIC_TRANSLATION_INITIATION,3.182042612,0,benzylpenicillin
NONSENSE_MEDIATED_DECAY_NMD,3.329094166,0,benzylpenicillin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.358127483,0,benzylpenicillin
EUKARYOTIC_TRANSLATION_ELONGATION,-3.201091611,0,rimexolone
INFLUENZA_INFECTION,-2.609526507,0,rimexolone
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.674085183,0,rimexolone
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,2.769183522,0,rimexolone
TOLL_LIKE_RECEPTOR_CASCADES,2.799127767,0,rimexolone
SIGNALING_BY_ROBO_RECEPTORS,-2.864616069,0,rimexolone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.888688705,0,rimexolone
RRNA_PROCESSING,-2.932857397,0,rimexolone
TRANSLATION,-2.612461895,0,rimexolone
CELLULAR_RESPONSE_TO_STARVATION,-2.968999494,0,rimexolone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.909814471,0,ARN-509
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.68893811,0,ARN-509
RESPIRATORY_ELECTRON_TRANSPORT,2.691896359,0,ARN-509
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.113670158,0,ARN-509
SARS_COV_1_INFECTION,3.159128619,0,ARN-509
INFLUENZA_INFECTION,3.205725515,0,ARN-509
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.259375786,0,ARN-509
RRNA_PROCESSING,3.308064051,0,ARN-509
SARS_COV_1_HOST_INTERACTIONS,3.36976821,0,ARN-509
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.447998755,0,ARN-509
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.630111951,0,cyclizine
METABOLISM_OF_RNA,-2.627669947,0,cyclizine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.396902903,0,cyclizine
RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL,-2.481411532,0.001828747,cyclizine
SUMOYLATION,-2.435775715,0.00205734,cyclizine
GPCR_LIGAND_BINDING,2.329096858,0.001157206,cyclizine
SENSORY_PERCEPTION,2.310030468,0.000771471,cyclizine
SIGNALING_BY_GPCR,2.297675782,0.000771471,cyclizine
HOST_INTERACTIONS_OF_HIV_FACTORS,-2.192783709,0.00822936,cyclizine
MRNA_SPLICING,-2.120053314,0.008686547,cyclizine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.628536763,0,ganaxolone
SIGNALING_BY_ROBO_RECEPTORS,-2.857450112,0,ganaxolone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.906722591,0,ganaxolone
RRNA_PROCESSING,-2.96198469,0,ganaxolone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-3.006363023,0,ganaxolone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-3.02150349,0,ganaxolone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-3.077262137,0,ganaxolone
INFLUENZA_INFECTION,-2.928096754,0,ganaxolone
EUKARYOTIC_TRANSLATION_INITIATION,-3.321761041,0,ganaxolone
CELLULAR_RESPONSE_TO_STARVATION,-3.371413369,0,ganaxolone
EUKARYOTIC_TRANSLATION_ELONGATION,-3.638090365,0,ramelteon
ADAPTIVE_IMMUNE_SYSTEM,2.668151064,0,ramelteon
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.701363923,0,ramelteon
SARS_COV_1_HOST_INTERACTIONS,-2.786432056,0,ramelteon
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.866651587,0,ramelteon
SIGNALING_BY_ROBO_RECEPTORS,-2.896448465,0,ramelteon
RRNA_PROCESSING,-2.936685042,0,ramelteon
INFLUENZA_INFECTION,-2.96186934,0,ramelteon
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-3.018656641,0,ramelteon
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.919472909,0,ramelteon
MITOTIC_METAPHASE_AND_ANAPHASE,3.320157859,0,diazepam
NEUTROPHIL_DEGRANULATION,2.623787878,0,diazepam
SEPARATION_OF_SISTER_CHROMATIDS,2.671441672,0,diazepam
MITOTIC_SPINDLE_CHECKPOINT,2.712297902,0,diazepam
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.741307015,0,diazepam
EUKARYOTIC_TRANSLATION_ELONGATION,-2.496765733,0,diazepam
CELL_CYCLE,2.937995091,0,diazepam
M_PHASE,3.027889365,0,diazepam
CELL_CYCLE_MITOTIC,3.173608815,0,diazepam
CELL_CYCLE_CHECKPOINTS,3.210227968,0,diazepam
SELENOAMINO_ACID_METABOLISM,3.602664252,0,rabeprazole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.780044465,0,rabeprazole
NERVOUS_SYSTEM_DEVELOPMENT,2.792203741,0,rabeprazole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.816563059,0,rabeprazole
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.919026041,0,rabeprazole
TRANSLATION,3.176704813,0,rabeprazole
SIGNALING_BY_ROBO_RECEPTORS,3.188514164,0,rabeprazole
RRNA_PROCESSING,3.189535181,0,rabeprazole
SARS_COV_1_HOST_INTERACTIONS,2.690243123,0,rabeprazole
INFLUENZA_INFECTION,3.258509852,0,rabeprazole
RESPIRATORY_ELECTRON_TRANSPORT,2.36018359,0.011090065,etodolac
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.242809161,0.018298607,etodolac
TOLL_LIKE_RECEPTOR_CASCADES,-2.145284835,0.07612578,etodolac
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,-2.009460619,0.110978547,etodolac
DISEASES_OF_METABOLISM,1.970841168,0.131232437,etodolac
CHROMATIN_ORGANIZATION,-1.956423042,0.113730081,etodolac
SUMOYLATION,-1.885459326,0.154544506,etodolac
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,1.854226646,0.214592759,etodolac
MYD88_INDEPENDENT_TLR4_CASCADE,-1.857780348,0.153168738,etodolac
SENSORY_PERCEPTION,1.805145965,0.240654412,etodolac
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.841480708,0,metoclopramide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.626315799,0,metoclopramide
EUKARYOTIC_TRANSLATION_INITIATION,2.610642637,0.000362588,metoclopramide
SELENOAMINO_ACID_METABOLISM,2.537272164,0.000543882,metoclopramide
CELLULAR_RESPONSE_TO_STARVATION,2.513519293,0.000652659,metoclopramide
NONSENSE_MEDIATED_DECAY_NMD,2.427254321,0.001269058,metoclopramide
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,2.355801724,0.002330923,metoclopramide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.3184481,0.002855381,metoclopramide
TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES,2.25821119,0.004109332,metoclopramide
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.192768922,0.006417809,metoclopramide
MRNA_SPLICING,2.52396334,0.001685346,sulpiride
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.279043839,0.011797421,sulpiride
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.885003485,0.056739979,sulpiride
SYNTHESIS_OF_DNA,1.595296599,0.176539985,sulpiride
AMYLOID_FIBER_FORMATION,-2.404578991,0.467905642,sulpiride
REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA,1.381799924,0.387629561,sulpiride
EUKARYOTIC_TRANSLATION_ELONGATION,-2.185528122,0.996969076,sulpiride
SELENOAMINO_ACID_METABOLISM,-2.11412068,0.763339841,sulpiride
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.112175576,0.574446398,sulpiride
EUKARYOTIC_TRANSLATION_INITIATION,-2.083368442,0.483243628,sulpiride
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.984023887,0,ofloxacin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.749117828,0.000711018,ofloxacin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.745010511,0.000355509,ofloxacin
NONSENSE_MEDIATED_DECAY_NMD,-2.742419201,0.000237006,ofloxacin
SELENOAMINO_ACID_METABOLISM,-2.716893124,0.000177755,ofloxacin
CELLULAR_RESPONSE_TO_STARVATION,-2.673596325,0.000142204,ofloxacin
EUKARYOTIC_TRANSLATION_INITIATION,-2.640024556,0.000355509,ofloxacin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.536625086,0.001828333,ofloxacin
RRNA_PROCESSING,-2.529145582,0.001688668,ofloxacin
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.148418686,0.042823093,ofloxacin
M_PHASE,-4.225327739,0,tanaproget
GPCR_LIGAND_BINDING,2.357236152,0,tanaproget
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.666211313,0,tanaproget
MITOTIC_SPINDLE_CHECKPOINT,-2.676314287,0,tanaproget
MHC_CLASS_II_ANTIGEN_PRESENTATION,-2.680658228,0,tanaproget
MITOTIC_G2_G2_M_PHASES,-2.685453821,0,tanaproget
G2_M_CHECKPOINTS,-3.02238968,0,tanaproget
GOLGI_TO_ER_RETROGRADE_TRANSPORT,-2.677642997,0,tanaproget
SEPARATION_OF_SISTER_CHROMATIDS,-3.195689477,0,tanaproget
CELL_CYCLE_CHECKPOINTS,-3.572924074,0,tanaproget
EUKARYOTIC_TRANSLATION_ELONGATION,3.921025794,0,sobetirome
SARS_COV_2_HOST_INTERACTIONS,2.469972127,0,sobetirome
METABOLISM_OF_RNA,2.563252683,0,sobetirome
NERVOUS_SYSTEM_DEVELOPMENT,2.996549886,0,sobetirome
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.101635373,0,sobetirome
SARS_COV_1_INFECTION,3.125880007,0,sobetirome
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.274690262,0,sobetirome
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.291274816,0,sobetirome
SARS_COV_1_HOST_INTERACTIONS,3.345314628,0,sobetirome
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.3568391,0,sobetirome
EUKARYOTIC_TRANSLATION_ELONGATION,3.945129277,0,venlafaxine
SARS_COV_1_HOST_INTERACTIONS,2.631048233,0,venlafaxine
NERVOUS_SYSTEM_DEVELOPMENT,2.667215037,0,venlafaxine
TRANSLATION,3.342597254,0,venlafaxine
SIGNALING_BY_ROBO_RECEPTORS,3.403705792,0,venlafaxine
RRNA_PROCESSING,3.434866745,0,venlafaxine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.439837779,0,venlafaxine
INFLUENZA_INFECTION,3.544058889,0,venlafaxine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.817979388,0,venlafaxine
NONSENSE_MEDIATED_DECAY_NMD,3.701660221,0,venlafaxine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.763253583,0,dequalinium
RESPIRATORY_ELECTRON_TRANSPORT,2.490490479,0,dequalinium
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.623372917,0,dequalinium
DISEASES_OF_METABOLISM,2.68226978,0,dequalinium
RRNA_PROCESSING,2.921910999,0,dequalinium
SIGNALING_BY_ROBO_RECEPTORS,2.989860875,0,dequalinium
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.322480669,0,dequalinium
TRANSLATION,3.323441656,0,dequalinium
INFLUENZA_INFECTION,2.854062711,0,dequalinium
CELLULAR_RESPONSE_TO_STARVATION,3.422625453,0,dequalinium
EUKARYOTIC_TRANSLATION_ELONGATION,4.245393189,0,PD-0325901
VIRAL_INFECTION_PATHWAYS,2.474230979,0,PD-0325901
CELLULAR_RESPONSES_TO_STIMULI,2.561791241,0,PD-0325901
METABOLISM_OF_RNA,2.583500576,0,PD-0325901
SARS_COV_2_HOST_INTERACTIONS,2.670276924,0,PD-0325901
SARS_COV_1_INFECTION,2.724347905,0,PD-0325901
NERVOUS_SYSTEM_DEVELOPMENT,2.991011902,0,PD-0325901
SARS_COV_1_HOST_INTERACTIONS,3.006657443,0,PD-0325901
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.126284884,0,PD-0325901
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.403569281,0,PD-0325901
EUKARYOTIC_TRANSLATION_ELONGATION,4.067776338,0,AT-7867
SARS_COV_1_HOST_INTERACTIONS,2.846317951,0,AT-7867
SARS_COV_1_INFECTION,2.898256916,0,AT-7867
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.95458315,0,AT-7867
NERVOUS_SYSTEM_DEVELOPMENT,3.048682313,0,AT-7867
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.115423178,0,AT-7867
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.333951586,0,AT-7867
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.336143499,0,AT-7867
SIGNALING_BY_ROBO_RECEPTORS,3.463905946,0,AT-7867
RRNA_PROCESSING,3.466595811,0,AT-7867
EUKARYOTIC_TRANSLATION_ELONGATION,4.077733638,0,MK-1775
CELLULAR_RESPONSES_TO_STIMULI,2.457403421,0,MK-1775
SARS_COV_2_INFECTION,2.557668557,0,MK-1775
INFECTIOUS_DISEASE,2.62109082,0,MK-1775
METABOLISM_OF_RNA,2.720951579,0,MK-1775
VIRAL_INFECTION_PATHWAYS,2.767404367,0,MK-1775
SARS_COV_2_HOST_INTERACTIONS,2.813953504,0,MK-1775
NERVOUS_SYSTEM_DEVELOPMENT,2.980968625,0,MK-1775
SARS_COV_1_INFECTION,3.093523783,0,MK-1775
SARS_COV_1_HOST_INTERACTIONS,3.188242352,0,MK-1775
RESPIRATORY_ELECTRON_TRANSPORT,2.537642162,0.003317083,phentolamine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.53447831,0.001658541,phentolamine
TRANSLATION,2.28551698,0.009951249,phentolamine
DISEASES_OF_METABOLISM,2.235395176,0.009951249,phentolamine
SELENOAMINO_ACID_METABOLISM,2.228724735,0.007960999,phentolamine
CELLULAR_RESPONSE_TO_STARVATION,2.148343288,0.014189744,phentolamine
INTERFERON_ALPHA_BETA_SIGNALING,-2.105610432,0.113456075,phentolamine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.064660862,0.024325275,phentolamine
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.028106034,0.028333417,phentolamine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.01329087,0.028133778,phentolamine
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.721073082,0,chlorpropamide
RESPIRATORY_ELECTRON_TRANSPORT,2.627996315,0.000571904,chlorpropamide
DISEASES_OF_METABOLISM,2.308648878,0.007244123,chlorpropamide
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.226715071,0.013725707,chlorpropamide
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,-2.137049348,0.081432962,chlorpropamide
TP53_REGULATES_METABOLIC_GENES,2.075535722,0.039347026,chlorpropamide
TRANSLATION,2.040150874,0.043655372,chlorpropamide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.036440409,0.037745693,chlorpropamide
ANTIGEN_PROCESSING_CROSS_PRESENTATION,2.034059119,0.033742362,chlorpropamide
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,1.973231209,0.047658703,chlorpropamide
EUKARYOTIC_TRANSLATION_ELONGATION,3.90998818,0,primaquine
SELENOAMINO_ACID_METABOLISM,3.875071457,0,primaquine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.782376097,0,primaquine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.763253724,0,primaquine
NONSENSE_MEDIATED_DECAY_NMD,3.748084215,0,primaquine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.681408593,0,primaquine
EUKARYOTIC_TRANSLATION_INITIATION,3.529734306,0,primaquine
INFLUENZA_INFECTION,3.366839303,0,primaquine
SIGNALING_BY_ROBO_RECEPTORS,3.364239774,0,primaquine
CELLULAR_RESPONSE_TO_STARVATION,3.333870563,0,primaquine
GPCR_LIGAND_BINDING,2.568130781,0.000777895,bosentan
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.527068675,0.000388947,bosentan
SIGNALING_BY_GPCR,2.448502781,0.000259298,bosentan
G_ALPHA_Q_SIGNALLING_EVENTS,2.224849568,0.002917105,bosentan
METABOLISM_OF_RNA,-2.327789915,0.028762088,bosentan
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.195296729,0.030974557,bosentan
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.144353276,0.027287109,bosentan
CELL_CYCLE_CHECKPOINTS,-2.116663085,0.027102737,bosentan
SENSORY_PERCEPTION,2.099683225,0.011201684,bosentan
G2_M_CHECKPOINTS,-2.04871772,0.033187025,bosentan
EUKARYOTIC_TRANSLATION_ELONGATION,4.08669842,0,curcumin
SARS_COV_1_HOST_INTERACTIONS,2.549214901,0,curcumin
NERVOUS_SYSTEM_DEVELOPMENT,2.748534719,0,curcumin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.344495128,0,curcumin
TRANSLATION,3.484365865,0,curcumin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.6394122,0,curcumin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.649616696,0,curcumin
CELLULAR_RESPONSE_TO_STARVATION,3.688583228,0,curcumin
SIGNALING_BY_ROBO_RECEPTORS,3.543880107,0,curcumin
EUKARYOTIC_TRANSLATION_INITIATION,3.76926279,0,curcumin
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.853754944,0.431898114,levosimendan
GLYCOSAMINOGLYCAN_METABOLISM,1.836860746,0.153232109,levosimendan
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.793417387,0.101736072,levosimendan
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.790227474,0.620586276,levosimendan
GPCR_LIGAND_BINDING,-2.749059231,0.62254621,levosimendan
G_ALPHA_I_SIGNALLING_EVENTS,-2.721030035,0.555106673,levosimendan
SIGNALING_BY_GPCR,-2.532996209,0.630956107,levosimendan
PROGRAMMED_CELL_DEATH,-2.222506072,0.619160869,levosimendan
SARS_COV_1_INFECTION,-2.15906006,0.549952302,levosimendan
G_ALPHA_Q_SIGNALLING_EVENTS,-2.053398676,0.516219807,levosimendan
EUKARYOTIC_TRANSLATION_ELONGATION,-3.335769603,0,palonosetron
SARS_COV_2_HOST_INTERACTIONS,-2.599658245,0,palonosetron
SARS_COV_1_INFECTION,-2.769535339,0,palonosetron
TRANSLATION,-2.801460554,0,palonosetron
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.829009906,0,palonosetron
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.846227319,0,palonosetron
SARS_COV_1_HOST_INTERACTIONS,-2.9220758,0,palonosetron
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.955060452,0,palonosetron
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.997164315,0,palonosetron
RRNA_PROCESSING,-3.005214577,0,palonosetron
EUKARYOTIC_TRANSLATION_ELONGATION,3.815445431,0,ARRY-334543
SARS_COV_1_INFECTION,2.743240624,0,ARRY-334543
NERVOUS_SYSTEM_DEVELOPMENT,2.778666494,0,ARRY-334543
SARS_COV_1_HOST_INTERACTIONS,3.039105625,0,ARRY-334543
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.047946469,0,ARRY-334543
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.093502248,0,ARRY-334543
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.10129987,0,ARRY-334543
RRNA_PROCESSING,3.184456473,0,ARRY-334543
TRANSLATION,3.331729266,0,ARRY-334543
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.044750135,0,ARRY-334543
EUKARYOTIC_TRANSLATION_ELONGATION,2.700606678,0,glipizide
SELENOAMINO_ACID_METABOLISM,2.587699024,0,glipizide
NONSENSE_MEDIATED_DECAY_NMD,2.494667977,0.000195612,glipizide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.409221961,0.001320379,glipizide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.385004516,0.001408404,glipizide
CELLULAR_RESPONSE_TO_STARVATION,2.355953828,0.001662699,glipizide
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.340610239,0.026058089,glipizide
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.313548717,0.014766251,glipizide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.328774835,0.001928172,glipizide
ADAPTIVE_IMMUNE_SYSTEM,-2.288266686,0.01273951,glipizide
EUKARYOTIC_TRANSLATION_ELONGATION,-3.621251576,0,disopyramide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.778243848,0,disopyramide
SIGNALING_BY_ROBO_RECEPTORS,-2.804933741,0,disopyramide
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.816424259,0,disopyramide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.878347357,0,disopyramide
INFLUENZA_INFECTION,-2.883757522,0,disopyramide
TRANSLATION,-3.010064955,0,disopyramide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.801216432,0,disopyramide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.333834731,0,disopyramide
EUKARYOTIC_TRANSLATION_INITIATION,-3.343234599,0,disopyramide
NONSENSE_MEDIATED_DECAY_NMD,-2.818374429,0,travoprost
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.576065091,0,travoprost
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.652262099,0,travoprost
EUKARYOTIC_TRANSLATION_INITIATION,-2.68972594,0,travoprost
RRNA_PROCESSING,-2.691667505,0,travoprost
SIGNALING_BY_ROBO_RECEPTORS,-2.568871509,0,travoprost
SELENOAMINO_ACID_METABOLISM,-2.737745555,0,travoprost
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.760423746,0,travoprost
EUKARYOTIC_TRANSLATION_ELONGATION,-2.78521218,0,travoprost
CELLULAR_RESPONSE_TO_STARVATION,-2.691707649,0,travoprost
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.23991934,0,phenytoin
RRNA_PROCESSING,3.34501353,0,phenytoin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.455183708,0,phenytoin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.940060448,0,phenytoin
TRANSLATION,3.951664654,0,phenytoin
INFLUENZA_INFECTION,3.986255491,0,phenytoin
SIGNALING_BY_ROBO_RECEPTORS,3.69261114,0,phenytoin
NONSENSE_MEDIATED_DECAY_NMD,4.039124503,0,phenytoin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.089733314,0,phenytoin
EUKARYOTIC_TRANSLATION_INITIATION,4.118641468,0,phenytoin
EUKARYOTIC_TRANSLATION_ELONGATION,2.911511846,0,PX-12
NONSENSE_MEDIATED_DECAY_NMD,2.861320763,0,PX-12
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.839203264,0,PX-12
SELENOAMINO_ACID_METABOLISM,2.813948993,0,PX-12
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.766735032,0,PX-12
EUKARYOTIC_TRANSLATION_INITIATION,2.728424785,0,PX-12
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.663366933,0,PX-12
CELLULAR_RESPONSE_TO_STARVATION,2.64752239,0,PX-12
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-2.584099881,0,PX-12
SIGNALING_BY_ROBO_RECEPTORS,2.549766294,0,PX-12
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.113374347,0,prochlorperazine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.699491344,0,prochlorperazine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.716160629,0,prochlorperazine
SARS_COV_1_HOST_INTERACTIONS,-2.781745611,0,prochlorperazine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.806860808,0,prochlorperazine
SIGNALING_BY_ROBO_RECEPTORS,-2.81351564,0,prochlorperazine
INFLUENZA_INFECTION,-2.837942479,0,prochlorperazine
CELLULAR_RESPONSE_TO_STARVATION,-2.907302775,0,prochlorperazine
TRANSLATION,-2.684107388,0,prochlorperazine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.964437899,0,prochlorperazine
EUKARYOTIC_TRANSLATION_ELONGATION,3.052206535,0,lurasidone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.989358854,0,lurasidone
EUKARYOTIC_TRANSLATION_INITIATION,2.902167662,0,lurasidone
SELENOAMINO_ACID_METABOLISM,2.886154353,0,lurasidone
NONSENSE_MEDIATED_DECAY_NMD,2.856027938,0,lurasidone
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.808010396,0,lurasidone
TRANSLATION,2.659478488,0,lurasidone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.620266258,0,lurasidone
CELLULAR_RESPONSE_TO_STARVATION,2.497952616,0.000159207,lurasidone
INFLUENZA_INFECTION,2.432259325,0.000286572,lurasidone
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.235195225,0,primidone
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.521947507,0,primidone
SELENOAMINO_ACID_METABOLISM,-2.555504015,0,primidone
NONSENSE_MEDIATED_DECAY_NMD,-2.596264043,0,primidone
CLEC7A_DECTIN_1_SIGNALING,2.64486561,0,primidone
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.66089715,0,primidone
EUKARYOTIC_TRANSLATION_ELONGATION,-2.675826102,0,primidone
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.683924988,0,primidone
CELLULAR_RESPONSE_TO_HEAT_STRESS,2.716741944,0,primidone
ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS,2.766826555,0,primidone
INTERFERON_SIGNALING,-2.125031826,0.083864104,otamixaban
CIRCADIAN_CLOCK,2.098624758,0.250099057,otamixaban
PKR_MEDIATED_SIGNALING,-1.979434635,0.177046441,otamixaban
FLT3_SIGNALING,-1.975923572,0.122517518,otamixaban
PHOSPHOLIPID_METABOLISM,-1.973608173,0.092923498,otamixaban
CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL,-1.940353755,0.095045984,otamixaban
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-1.904420811,0.10422617,otamixaban
METABOLISM_OF_VITAMINS_AND_COFACTORS,1.905563076,0.45883192,otamixaban
NEURONAL_SYSTEM,-1.840211039,0.149683374,otamixaban
SIGNALING_BY_FGFR,-1.827367922,0.143914943,otamixaban
EUKARYOTIC_TRANSLATION_ELONGATION,3.432943247,0,erythromycin
NERVOUS_SYSTEM_DEVELOPMENT,2.439555376,0,erythromycin
RRNA_PROCESSING,2.786207454,0,erythromycin
SARS_COV_1_HOST_INTERACTIONS,2.80823542,0,erythromycin
TRANSLATION,2.82197115,0,erythromycin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.909483147,0,erythromycin
SIGNALING_BY_ROBO_RECEPTORS,3.050151162,0,erythromycin
INFLUENZA_INFECTION,2.976613064,0,erythromycin
CELLULAR_RESPONSE_TO_STARVATION,3.162826229,0,erythromycin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.293026505,0,erythromycin
METABOLISM_OF_RNA,-2.67479254,0,rosiglitazone
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.57187154,0,rosiglitazone
GPCR_LIGAND_BINDING,2.551540619,0,rosiglitazone
SIGNALING_BY_GPCR,2.448220947,0.00020654,rosiglitazone
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.571848287,0.002546873,rosiglitazone
ISG15_ANTIVIRAL_MECHANISM,-2.43571884,0.004244789,rosiglitazone
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.297539978,0.000867468,rosiglitazone
G_ALPHA_I_SIGNALLING_EVENTS,2.311038979,0.001084335,rosiglitazone
M_PHASE,-2.359363802,0.004244789,rosiglitazone
MITOTIC_PROMETAPHASE,-2.366084469,0.005093747,rosiglitazone
EUKARYOTIC_TRANSLATION_ELONGATION,-3.238621496,0,ziprasidone
NONSENSE_MEDIATED_DECAY_NMD,-3.215492112,0,ziprasidone
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.083558911,0,ziprasidone
SELENOAMINO_ACID_METABOLISM,-3.08192137,0,ziprasidone
CELLULAR_RESPONSE_TO_STARVATION,-2.983124114,0,ziprasidone
EUKARYOTIC_TRANSLATION_INITIATION,-2.917160703,0,ziprasidone
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.650413285,0.001766424,ziprasidone
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.642871862,0.001766424,ziprasidone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.805185263,0.000239821,ziprasidone
GPCR_LIGAND_BINDING,2.518111619,0.001766424,ziprasidone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.704541542,0,dexfenfluramine
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.755893526,0,dexfenfluramine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.80550385,0,dexfenfluramine
RRNA_PROCESSING,3.829187483,0,dexfenfluramine
CELLULAR_RESPONSE_TO_STARVATION,4.066006147,0,dexfenfluramine
SIGNALING_BY_ROBO_RECEPTORS,4.068844173,0,dexfenfluramine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.272004494,0,dexfenfluramine
METABOLISM_OF_RNA,2.807895498,0,dexfenfluramine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.344959725,0,dexfenfluramine
NONSENSE_MEDIATED_DECAY_NMD,4.394631969,0,dexfenfluramine
MITF_M_DEPENDENT_GENE_EXPRESSION,1.871794436,0.118238878,BRD-K44408410
PEPTIDE_HORMONE_METABOLISM,1.723890528,0.159913236,BRD-K44408410
MRNA_SPLICING,1.545283353,0.270721802,BRD-K44408410
REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA,1.519768238,0.225332287,BRD-K44408410
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.474087852,0.233376408,BRD-K44408410
GLUCOSE_METABOLISM,1.410637939,0.264906775,BRD-K44408410
SYNTHESIS_OF_DNA,1.359954104,0.303489016,BRD-K44408410
EUKARYOTIC_TRANSLATION_ELONGATION,-2.237835744,1,BRD-K44408410
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.334960947,0.300685342,BRD-K44408410
NONSENSE_MEDIATED_DECAY_NMD,-2.183487324,1,BRD-K44408410
EUKARYOTIC_TRANSLATION_ELONGATION,-2.352938284,0.000980801,riluzole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.298276283,0.001961602,riluzole
NONSENSE_MEDIATED_DECAY_NMD,-2.285611907,0.001961602,riluzole
SELENOAMINO_ACID_METABOLISM,-2.269552173,0.001471201,riluzole
EUKARYOTIC_TRANSLATION_INITIATION,-2.262110312,0.001373121,riluzole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.234303146,0.001471201,riluzole
RRNA_PROCESSING,-2.209714052,0.001961602,riluzole
CELLULAR_RESPONSE_TO_STARVATION,-2.16855691,0.002329402,riluzole
TRANSLATION,-2.163043445,0.00207058,riluzole
RAB_REGULATION_OF_TRAFFICKING,1.99157315,0.049426587,riluzole
EUKARYOTIC_TRANSLATION_ELONGATION,-2.367852112,0,amitriptyline
SELENOAMINO_ACID_METABOLISM,-2.270840699,0.001933721,amitriptyline
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.214609049,0.003545155,amitriptyline
NONSENSE_MEDIATED_DECAY_NMD,-2.146045036,0.00991032,amitriptyline
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.110927966,0.011408954,amitriptyline
RAB_REGULATION_OF_TRAFFICKING,1.885164022,0.101906412,amitriptyline
EUKARYOTIC_TRANSLATION_INITIATION,-2.095457524,0.012408043,amitriptyline
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.844856756,0.062781629,amitriptyline
RRNA_PROCESSING,-2.082430946,0.01270731,amitriptyline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.045345024,0.017766062,amitriptyline
EUKARYOTIC_TRANSLATION_ELONGATION,-3.320051081,0,cromoglicic-acid
SARS_COV_1_INFECTION,-2.530033969,0,cromoglicic-acid
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.654089353,0,cromoglicic-acid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.65989221,0,cromoglicic-acid
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.684697211,0,cromoglicic-acid
MITOTIC_METAPHASE_AND_ANAPHASE,2.72128503,0,cromoglicic-acid
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.784771675,0,cromoglicic-acid
INFLUENZA_INFECTION,-2.823098751,0,cromoglicic-acid
TRANSLATION,-2.851662554,0,cromoglicic-acid
SARS_COV_1_HOST_INTERACTIONS,-2.635215512,0,cromoglicic-acid
EUKARYOTIC_TRANSLATION_ELONGATION,3.7749652,0,D-serine
SARS_COV_2_HOST_INTERACTIONS,2.617029932,0,D-serine
SARS_COV_1_INFECTION,2.846650943,0,D-serine
NERVOUS_SYSTEM_DEVELOPMENT,2.901858629,0,D-serine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.938633289,0,D-serine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.972960047,0,D-serine
SARS_COV_1_HOST_INTERACTIONS,3.00192437,0,D-serine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.050644491,0,D-serine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.25390234,0,D-serine
RRNA_PROCESSING,3.288259581,0,D-serine
EUKARYOTIC_TRANSLATION_ELONGATION,3.484643306,0,triflupromazine
SARS_COV_1_INFECTION,2.538830914,0,triflupromazine
RRNA_PROCESSING,2.71772648,0,triflupromazine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.740057316,0,triflupromazine
SARS_COV_1_HOST_INTERACTIONS,2.941257622,0,triflupromazine
SIGNALING_BY_ROBO_RECEPTORS,2.953421541,0,triflupromazine
INFLUENZA_INFECTION,3.016154115,0,triflupromazine
TRANSLATION,2.957213523,0,triflupromazine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.154962992,0,triflupromazine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.264172707,0,triflupromazine
DNA_STRAND_ELONGATION,-2.414365394,0.001235761,BRD-K47869605
DOWNSTREAM_TCR_SIGNALING,2.343221442,0.02072501,BRD-K47869605
TCR_SIGNALING,2.312905262,0.011842863,BRD-K47869605
ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS,-2.219623828,0.012357615,BRD-K47869605
RESPIRATORY_ELECTRON_TRANSPORT,-2.099589145,0.030276156,BRD-K47869605
DNA_REPAIR,-2.06890672,0.030430627,BRD-K47869605
TNFR2_NON_CANONICAL_NF_KB_PATHWAY,2.074200061,0.092769092,BRD-K47869605
CLEC7A_DECTIN_1_SIGNALING,2.059319402,0.079569234,BRD-K47869605
INTERLEUKIN_1_FAMILY_SIGNALING,2.047816273,0.070168962,BRD-K47869605
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,-2.000527341,0.040285824,BRD-K47869605
EUKARYOTIC_TRANSLATION_ELONGATION,3.942782648,0,NVP-TAE226
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.476278566,0,NVP-TAE226
NERVOUS_SYSTEM_DEVELOPMENT,2.554628006,0,NVP-TAE226
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.642923458,0,NVP-TAE226
SARS_COV_1_INFECTION,2.718615568,0,NVP-TAE226
SARS_COV_1_HOST_INTERACTIONS,2.88756978,0,NVP-TAE226
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.949385908,0,NVP-TAE226
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.118944453,0,NVP-TAE226
TRANSLATION,3.250511467,0,NVP-TAE226
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.397443771,0,NVP-TAE226
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.576008664,0,cilostazol
SARS_COV_1_HOST_INTERACTIONS,2.774432427,0,cilostazol
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.811246176,0,cilostazol
TRANSLATION,2.978151077,0,cilostazol
RRNA_PROCESSING,3.045617547,0,cilostazol
SIGNALING_BY_ROBO_RECEPTORS,3.105370208,0,cilostazol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.274244947,0,cilostazol
INFLUENZA_INFECTION,3.199792635,0,cilostazol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.448410816,0,cilostazol
EUKARYOTIC_TRANSLATION_INITIATION,3.456479103,0,cilostazol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.519582676,0,BRD-K76022557
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.483732974,0,BRD-K76022557
SIGNALING_BY_ROBO_RECEPTORS,2.45744244,0,BRD-K76022557
EUKARYOTIC_TRANSLATION_ELONGATION,2.419169807,0.000224875,BRD-K76022557
NONSENSE_MEDIATED_DECAY_NMD,2.354374615,0.0001799,BRD-K76022557
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.340293726,0.000149917,BRD-K76022557
SELENOAMINO_ACID_METABOLISM,2.300411446,0.000257,BRD-K76022557
EUKARYOTIC_TRANSLATION_INITIATION,2.266318626,0.000674626,BRD-K76022557
SARS_COV_1_HOST_INTERACTIONS,2.254994927,0.000699612,BRD-K76022557
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.218414185,0.000809551,BRD-K76022557
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.98452363,0,pitavastatin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.730876328,0,pitavastatin
METABOLISM_OF_RNA,-2.496077619,0.002484544,pitavastatin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.36898642,0.005112469,pitavastatin
GPCR_LIGAND_BINDING,2.264290707,0.006390586,pitavastatin
MRNA_SPLICING,-1.967929952,0.047827469,pitavastatin
DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA,2.068460222,0.029254681,pitavastatin
PEPTIDE_LIGAND_BINDING_RECEPTORS,1.935183478,0.082438555,pitavastatin
TRANSLATION,1.912856566,0.081458666,pitavastatin
SIGNALING_BY_GPCR,1.903469904,0.074272807,pitavastatin
CELL_CYCLE_MITOTIC,3.46329991,0,folic-acid
NONSENSE_MEDIATED_DECAY_NMD,-2.526379807,0,folic-acid
EUKARYOTIC_TRANSLATION_ELONGATION,-2.551517605,0,folic-acid
MITOTIC_PROMETAPHASE,2.623121659,0,folic-acid
CELL_CYCLE,2.693498632,0,folic-acid
EUKARYOTIC_TRANSLATION_INITIATION,-2.546888504,0,folic-acid
RESOLUTION_OF_SISTER_CHROMATID_COHESION,2.783664205,0,folic-acid
MITOTIC_METAPHASE_AND_ANAPHASE,2.884217314,0,folic-acid
M_PHASE,2.963959377,0,folic-acid
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.726357284,0,folic-acid
RESPIRATORY_ELECTRON_TRANSPORT,2.181780918,0.088859863,pindolol
DISEASES_OF_GLYCOSYLATION,2.126401545,0.073075546,pindolol
CELLULAR_SENESCENCE,-2.05153505,0.154638429,pindolol
INTRACELLULAR_SIGNALING_BY_SECOND_MESSENGERS,1.948647981,0.143812674,pindolol
DISEASES_OF_METABOLISM,1.918994869,0.135043608,pindolol
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,1.859938367,0.163689222,pindolol
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,1.791815469,0.210457571,pindolol
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-1.824530016,0.505888573,pindolol
PI3K_AKT_SIGNALING_IN_CANCER,1.769953907,0.208119154,pindolol
MITOCHONDRIAL_BIOGENESIS,1.740894907,0.217034371,pindolol
EUKARYOTIC_TRANSLATION_ELONGATION,-3.157273373,0,CP-945598
SARS_COV_1_INFECTION,-2.51156235,0,CP-945598
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.530524152,0,CP-945598
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.667801514,0,CP-945598
TRANSLATION,-2.679861946,0,CP-945598
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.699169802,0,CP-945598
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.720139342,0,CP-945598
INFLUENZA_INFECTION,-2.756656342,0,CP-945598
SIGNALING_BY_ROBO_RECEPTORS,-2.915289275,0,CP-945598
SARS_COV_1_HOST_INTERACTIONS,-2.677489904,0,CP-945598
MRNA_SPLICING,2.442217023,0.003317645,PF-02545920
EUKARYOTIC_TRANSLATION_ELONGATION,-2.270473435,0.000891961,PF-02545920
SELENOAMINO_ACID_METABOLISM,-2.194666206,0.002675884,PF-02545920
EUKARYOTIC_TRANSLATION_INITIATION,-2.189310078,0.001783922,PF-02545920
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.168307026,0.001560932,PF-02545920
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.19770178,0.011611758,PF-02545920
NONSENSE_MEDIATED_DECAY_NMD,-2.160486429,0.00160553,PF-02545920
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.155961498,0.001337942,PF-02545920
SARS_COV_2_HOST_INTERACTIONS,-2.078145694,0.005861459,PF-02545920
CELLULAR_RESPONSE_TO_STARVATION,-2.047065966,0.008362136,PF-02545920
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.137443808,0,chlormezanone
SARS_COV_1_INFECTION,2.436846342,0,chlormezanone
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.447124458,0,chlormezanone
INFLUENZA_INFECTION,2.453989184,0,chlormezanone
TP53_REGULATES_METABOLIC_GENES,2.473747317,0,chlormezanone
CELLULAR_RESPONSE_TO_STARVATION,2.568708947,0,chlormezanone
NONSENSE_MEDIATED_DECAY_NMD,2.719063143,0,chlormezanone
RESPIRATORY_ELECTRON_TRANSPORT,2.517383732,0,chlormezanone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.752288007,0,chlormezanone
SELENOAMINO_ACID_METABOLISM,2.765993175,0,chlormezanone
NONSENSE_MEDIATED_DECAY_NMD,3.221051647,0,erlotinib
SIGNALING_BY_ROBO_RECEPTORS,2.824733238,0,erlotinib
RRNA_PROCESSING,2.895094163,0,erlotinib
TRANSLATION,2.910416822,0,erlotinib
INFLUENZA_INFECTION,2.921374133,0,erlotinib
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.978932436,0,erlotinib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.925444298,0,erlotinib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.092844547,0,erlotinib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.105085561,0,erlotinib
CELLULAR_RESPONSE_TO_STARVATION,3.120212572,0,erlotinib
EUKARYOTIC_TRANSLATION_ELONGATION,3.766658688,0,erteberel
VIRAL_INFECTION_PATHWAYS,2.529439755,0,erteberel
NERVOUS_SYSTEM_DEVELOPMENT,3.068586728,0,erteberel
SARS_COV_1_INFECTION,3.211959897,0,erteberel
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.213005033,0,erteberel
SARS_COV_1_HOST_INTERACTIONS,3.285373207,0,erteberel
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.30849062,0,erteberel
TRANSLATION,3.321297241,0,erteberel
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.359738756,0,erteberel
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.381440141,0,erteberel
EUKARYOTIC_TRANSLATION_ELONGATION,2.982325768,0,dronedarone
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.922969425,0,dronedarone
NONSENSE_MEDIATED_DECAY_NMD,2.898061478,0,dronedarone
SELENOAMINO_ACID_METABOLISM,2.889381981,0,dronedarone
CELLULAR_RESPONSE_TO_STARVATION,2.851114186,0,dronedarone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.840508569,0,dronedarone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.806499448,0,dronedarone
SIGNALING_BY_ROBO_RECEPTORS,2.801694654,0,dronedarone
EUKARYOTIC_TRANSLATION_INITIATION,2.696433552,0,dronedarone
TRANSLATION,2.41634531,8.71E-05,dronedarone
EUKARYOTIC_TRANSLATION_ELONGATION,4.256082248,0,vorinostat
METABOLISM_OF_RNA,2.633264895,0,vorinostat
NERVOUS_SYSTEM_DEVELOPMENT,2.818615342,0,vorinostat
SARS_COV_1_INFECTION,2.842391005,0,vorinostat
SARS_COV_1_HOST_INTERACTIONS,3.000677653,0,vorinostat
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.120681779,0,vorinostat
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.173623105,0,vorinostat
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.278388206,0,vorinostat
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.411072486,0,vorinostat
TRANSLATION,3.492446417,0,vorinostat
EUKARYOTIC_TRANSLATION_ELONGATION,-3.397090126,0,diclofenac
SARS_COV_1_INFECTION,-2.812225195,0,diclofenac
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.82090941,0,diclofenac
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.826112183,0,diclofenac
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.908886325,0,diclofenac
SARS_COV_1_HOST_INTERACTIONS,-2.93036949,0,diclofenac
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.968333047,0,diclofenac
TRANSLATION,-3.013624565,0,diclofenac
INFLUENZA_INFECTION,-3.122492229,0,diclofenac
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.179545716,0,diclofenac
RAB_REGULATION_OF_TRAFFICKING,2.838639756,0,ifenprodil
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,2.414911079,0,ifenprodil
EUKARYOTIC_TRANSLATION_ELONGATION,-2.247346146,0.001956189,ifenprodil
SELENOAMINO_ACID_METABOLISM,-2.205827045,0.003912378,ifenprodil
EUKARYOTIC_TRANSLATION_INITIATION,-2.183525477,0.002934284,ifenprodil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.169866785,0.00268976,ifenprodil
NONSENSE_MEDIATED_DECAY_NMD,-2.152886056,0.002151808,ifenprodil
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.118183756,0.002771268,ifenprodil
TRANSLATION,-2.109509019,0.002654828,ifenprodil
RRNA_PROCESSING,-2.030815041,0.006479877,ifenprodil
EUKARYOTIC_TRANSLATION_ELONGATION,-3.176676491,0,fostamatinib
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.488853163,0,fostamatinib
TRANSLATION,-2.641448465,0,fostamatinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.645416988,0,fostamatinib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.658466105,0,fostamatinib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.696220817,0,fostamatinib
SARS_COV_1_INFECTION,-2.698709438,0,fostamatinib
SARS_COV_1_HOST_INTERACTIONS,-2.728017617,0,fostamatinib
INFLUENZA_INFECTION,-2.918029976,0,fostamatinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.673110331,0,fostamatinib
EUKARYOTIC_TRANSLATION_ELONGATION,3.181992121,0,afatinib
SARS_COV_1_HOST_INTERACTIONS,2.589483679,0,afatinib
SIGNALING_BY_ROBO_RECEPTORS,2.59367106,0,afatinib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.599883275,0,afatinib
INFLUENZA_INFECTION,2.75750439,0,afatinib
CELLULAR_RESPONSE_TO_STARVATION,2.818282506,0,afatinib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.704252066,0,afatinib
RRNA_PROCESSING,2.858349577,0,afatinib
EUKARYOTIC_TRANSLATION_INITIATION,2.897866203,0,afatinib
SELENOAMINO_ACID_METABOLISM,2.971324337,0,afatinib
TRANSLATION,3.284387117,0,ripasudil
EUKARYOTIC_TRANSLATION_ELONGATION,3.568250687,0,ripasudil
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.547407594,0,ripasudil
NONSENSE_MEDIATED_DECAY_NMD,3.541859184,0,ripasudil
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.861011306,0,ripasudil
EUKARYOTIC_TRANSLATION_INITIATION,3.507062779,0,ripasudil
RRNA_PROCESSING,2.932075008,0,ripasudil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.474521496,0,ripasudil
INFLUENZA_INFECTION,3.045971989,0,ripasudil
SIGNALING_BY_ROBO_RECEPTORS,3.097476268,0,ripasudil
GPCR_LIGAND_BINDING,2.59026177,0,nicergoline
SIGNALING_BY_GPCR,2.529760279,0,nicergoline
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.435066487,0.000258133,nicergoline
G_ALPHA_Q_SIGNALLING_EVENTS,2.241759973,0.002323194,nicergoline
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.31732118,0.032169772,nicergoline
RRNA_PROCESSING,-2.145378223,0.048254659,nicergoline
METABOLISM_OF_RNA,-2.127152436,0.03464437,nicergoline
TRNA_PROCESSING,-2.111205337,0.029695175,nicergoline
G_ALPHA_I_SIGNALLING_EVENTS,2.124163909,0.008053737,nicergoline
HCMV_INFECTION,-2.019095517,0.038108807,nicergoline
EUKARYOTIC_TRANSLATION_ELONGATION,-3.032536991,0,chlortalidone
SARS_COV_1_HOST_INTERACTIONS,-2.539847531,0,chlortalidone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.554969282,0,chlortalidone
TRANSLATION,-2.659993036,0,chlortalidone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.662530886,0,chlortalidone
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.673586086,0,chlortalidone
INFLUENZA_INFECTION,-2.747849488,0,chlortalidone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.853434242,0,chlortalidone
RRNA_PROCESSING,-2.678701683,0,chlortalidone
CELLULAR_RESPONSE_TO_STARVATION,-2.880656493,0,chlortalidone
MRNA_SPLICING,2.185947746,0.037574722,toremifene
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.043340747,0.040990606,toremifene
RAB_REGULATION_OF_TRAFFICKING,1.871184334,0.075149445,toremifene
UNFOLDED_PROTEIN_RESPONSE_UPR,1.509220053,0.387702818,toremifene
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.466679985,0.372331341,toremifene
C_TYPE_LECTIN_RECEPTORS_CLRS,1.452215299,0.335895246,toremifene
DISORDERS_OF_TRANSMEMBRANE_TRANSPORTERS,1.438526692,0.306453581,toremifene
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.42999346,0.280102477,toremifene
REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA,1.418267091,0.267577569,toremifene
SYNTHESIS_OF_DNA,1.390205138,0.273953886,toremifene
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.35920933,0.015693272,isradipine
SEMAPHORIN_INTERACTIONS,-2.276659878,0.013962869,isradipine
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.315729287,0.014385499,isradipine
RESPIRATORY_ELECTRON_TRANSPORT,2.299986801,0.009590333,isradipine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.169888082,0.026482396,isradipine
TRANSLATION,1.981045274,0.089451648,isradipine
BETA_CATENIN_INDEPENDENT_WNT_SIGNALING,1.923516457,0.108109204,isradipine
DISEASES_OF_METABOLISM,1.848684026,0.150207028,isradipine
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,-1.875301966,0.302916688,isradipine
CELLULAR_RESPONSE_TO_STARVATION,1.817575721,0.165269766,isradipine
SELENOAMINO_ACID_METABOLISM,3.553595288,0,resiquimod
RRNA_PROCESSING,2.667772688,0,resiquimod
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.982828428,0,resiquimod
SIGNALING_BY_ROBO_RECEPTORS,3.02919286,0,resiquimod
TRANSLATION,3.061156564,0,resiquimod
CELLULAR_RESPONSE_TO_STARVATION,3.329474493,0,resiquimod
INFLUENZA_INFECTION,2.740435194,0,resiquimod
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.420973861,0,resiquimod
EUKARYOTIC_TRANSLATION_INITIATION,3.44667195,0,resiquimod
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.533239836,0,resiquimod
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.615593771,0,mCPP
GPCR_LIGAND_BINDING,2.609424076,0,mCPP
SIGNALING_BY_GPCR,2.548268813,0,mCPP
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.585338142,0.005821389,mCPP
MITOTIC_PROMETAPHASE,-2.25368452,0.021830209,mCPP
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.192821938,0.019404631,mCPP
MITOTIC_SPINDLE_CHECKPOINT,-2.178951889,0.015281147,mCPP
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.145726405,0.004233988,mCPP
RHO_GTPASES_ACTIVATE_FORMINS,-2.157137916,0.015135612,mCPP
G_ALPHA_Q_SIGNALLING_EVENTS,2.130791404,0.003828997,mCPP
SELENOAMINO_ACID_METABOLISM,3.471604323,0,lorcaserin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.755717305,0,lorcaserin
SIGNALING_BY_ROBO_RECEPTORS,2.75603487,0,lorcaserin
RRNA_PROCESSING,2.847298752,0,lorcaserin
INFLUENZA_INFECTION,2.961326801,0,lorcaserin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.045810807,0,lorcaserin
TRANSLATION,2.775915726,0,lorcaserin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.279607701,0,lorcaserin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.305429282,0,lorcaserin
NONSENSE_MEDIATED_DECAY_NMD,3.334473628,0,lorcaserin
MITOTIC_METAPHASE_AND_ANAPHASE,3.35289195,0,clotrimazole
CELL_CYCLE_MITOTIC,3.212274778,0,clotrimazole
M_PHASE,2.900915338,0,clotrimazole
CELL_CYCLE_CHECKPOINTS,2.891067558,0,clotrimazole
SEPARATION_OF_SISTER_CHROMATIDS,2.802812316,0,clotrimazole
INTERFERON_SIGNALING,2.61323226,0.000627989,clotrimazole
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.515923314,0.00161483,clotrimazole
CELL_CYCLE,2.479003654,0.001883968,clotrimazole
RESOLUTION_OF_SISTER_CHROMATID_COHESION,2.454074025,0.001674638,clotrimazole
MITOTIC_SPINDLE_CHECKPOINT,2.441870939,0.001507175,clotrimazole
SELENOAMINO_ACID_METABOLISM,4.342102419,0,doxofylline
SARS_COV_2_INFECTION,2.469232878,0,doxofylline
SARS_COV_INFECTIONS,2.558948939,0,doxofylline
CELLULAR_RESPONSES_TO_STIMULI,2.648889817,0,doxofylline
INFECTIOUS_DISEASE,2.720312967,0,doxofylline
METABOLISM_OF_RNA,2.919451762,0,doxofylline
VIRAL_INFECTION_PATHWAYS,2.997694122,0,doxofylline
SARS_COV_2_HOST_INTERACTIONS,3.031056573,0,doxofylline
SARS_COV_1_INFECTION,3.371430108,0,doxofylline
NERVOUS_SYSTEM_DEVELOPMENT,3.458562169,0,doxofylline
EUKARYOTIC_TRANSLATION_ELONGATION,3.820935115,0,idelalisib
INFECTIOUS_DISEASE,2.486766011,0,idelalisib
G_ALPHA_S_SIGNALLING_EVENTS,2.567279745,0,idelalisib
METABOLISM_OF_RNA,2.608774666,0,idelalisib
SARS_COV_2_HOST_INTERACTIONS,2.652028377,0,idelalisib
VIRAL_INFECTION_PATHWAYS,2.653183309,0,idelalisib
CELLULAR_RESPONSES_TO_STIMULI,2.664113763,0,idelalisib
NERVOUS_SYSTEM_DEVELOPMENT,2.85229385,0,idelalisib
SARS_COV_1_INFECTION,3.008817534,0,idelalisib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.058545692,0,idelalisib
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.561737953,0,disulfiram
CELLULAR_RESPONSE_TO_HEAT_STRESS,3.346730371,0,disulfiram
C_TYPE_LECTIN_RECEPTORS_CLRS,2.89705202,0,disulfiram
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.79179464,0,disulfiram
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.761424065,0,disulfiram
EUKARYOTIC_TRANSLATION_ELONGATION,-2.698700376,0,disulfiram
NONSENSE_MEDIATED_DECAY_NMD,-2.623787815,0,disulfiram
SELENOAMINO_ACID_METABOLISM,-2.615360175,0,disulfiram
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.567400625,0,disulfiram
GASTRULATION,2.643042429,0.000527282,disulfiram
CELL_CYCLE_MITOTIC,3.291129454,0,carprofen
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.419150703,0,carprofen
M_PHASE,2.439492288,0,carprofen
EUKARYOTIC_TRANSLATION_INITIATION,-2.468792941,0,carprofen
C_TYPE_LECTIN_RECEPTORS_CLRS,2.480915475,0,carprofen
SELENOAMINO_ACID_METABOLISM,-2.483423857,0,carprofen
CELLULAR_RESPONSE_TO_STARVATION,-2.532442496,0,carprofen
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.583865912,0,carprofen
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.414371322,0,carprofen
NONSENSE_MEDIATED_DECAY_NMD,-2.636430775,0,carprofen
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-2.393154385,0.004879203,macitentan
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.407745125,0.006029446,macitentan
CELL_CYCLE,-2.346918481,0.004879203,macitentan
S_PHASE,-2.337317372,0.003252802,macitentan
HIV_INFECTION,-2.330071477,0.002439602,macitentan
CELL_CYCLE_MITOTIC,-2.299084858,0.002439602,macitentan
HIV_LIFE_CYCLE,-2.259691156,0.003659402,macitentan
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,-2.235738555,0.004182174,macitentan
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.232070522,0.003659402,macitentan
MITOTIC_G2_G2_M_PHASES,-2.137639689,0.009351806,macitentan
RRNA_PROCESSING,3.308771746,0,ALW-II-49-7
SARS_COV_1_HOST_INTERACTIONS,2.724147326,0,ALW-II-49-7
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.860843129,0,ALW-II-49-7
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.996883868,0,ALW-II-49-7
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.036490497,0,ALW-II-49-7
SIGNALING_BY_ROBO_RECEPTORS,3.176787259,0,ALW-II-49-7
TRANSLATION,3.184185722,0,ALW-II-49-7
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.258309135,0,ALW-II-49-7
SARS_COV_1_INFECTION,2.653196385,0,ALW-II-49-7
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.32096612,0,ALW-II-49-7
EUKARYOTIC_TRANSLATION_ELONGATION,3.196802974,0,quizartinib
SARS_COV_1_HOST_INTERACTIONS,2.601741879,0,quizartinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.696401221,0,quizartinib
RRNA_PROCESSING,2.730454407,0,quizartinib
TRANSLATION,2.813401087,0,quizartinib
SIGNALING_BY_ROBO_RECEPTORS,2.876011648,0,quizartinib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.893304855,0,quizartinib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.906042544,0,quizartinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.678596196,0,quizartinib
INFLUENZA_INFECTION,2.989602342,0,quizartinib
EUKARYOTIC_TRANSLATION_ELONGATION,-3.013384392,0,atracurium
TRANSLATION,-2.616217531,0,atracurium
SIGNALING_BY_ROBO_RECEPTORS,-2.662648762,0,atracurium
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.734677869,0,atracurium
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.745244495,0,atracurium
CELL_CYCLE_CHECKPOINTS,2.769547906,0,atracurium
SELENOAMINO_ACID_METABOLISM,-2.852053057,0,atracurium
SARS_COV_1_HOST_INTERACTIONS,-2.537420555,0,atracurium
EUKARYOTIC_TRANSLATION_INITIATION,-2.879621018,0,atracurium
NONSENSE_MEDIATED_DECAY_NMD,-2.896888344,0,atracurium
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,3.343107122,0,sotalol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.528160838,0,sotalol
SELENOAMINO_ACID_METABOLISM,-2.379134792,0,sotalol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.348282347,0,sotalol
TCR_SIGNALING,2.799725571,0,sotalol
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,2.801912688,0,sotalol
NONSENSE_MEDIATED_DECAY_NMD,-2.50772996,0,sotalol
ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS,2.94859689,0,sotalol
APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1,2.956453348,0,sotalol
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,3.09653624,0,sotalol
EUKARYOTIC_TRANSLATION_ELONGATION,4.067665444,0,lacosamide
CELLULAR_RESPONSES_TO_STIMULI,2.590171343,0,lacosamide
INFECTIOUS_DISEASE,2.665954701,0,lacosamide
METABOLISM_OF_RNA,2.68788956,0,lacosamide
SARS_COV_2_HOST_INTERACTIONS,2.710283141,0,lacosamide
VIRAL_INFECTION_PATHWAYS,2.840692356,0,lacosamide
NERVOUS_SYSTEM_DEVELOPMENT,3.115612386,0,lacosamide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.247154742,0,lacosamide
SARS_COV_1_INFECTION,3.277893356,0,lacosamide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.345255342,0,lacosamide
S_PHASE,-2.468239027,0.018943534,doxapram
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,-2.094821957,0.092612831,doxapram
SYNTHESIS_OF_DNA,-2.051007523,0.089806382,doxapram
TNFR2_NON_CANONICAL_NF_KB_PATHWAY,-1.974236131,0.111030156,doxapram
HIV_INFECTION,-1.933543777,0.11408217,doxapram
CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL,-1.912150003,0.110503947,doxapram
TRANSCRIPTIONAL_REGULATION_BY_RUNX1,-1.860311746,0.127192298,doxapram
DNA_REPLICATION,-1.82511354,0.136288201,doxapram
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-1.783935631,0.154822461,doxapram
SARS_COV_1_INFECTION,1.888476257,0.499839321,doxapram
MITOTIC_METAPHASE_AND_ANAPHASE,2.848617071,0,cefdinir
RESOLUTION_OF_SISTER_CHROMATID_COHESION,2.47615225,0,cefdinir
SARS_COV_1_HOST_INTERACTIONS,-2.485617984,0,cefdinir
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.496474552,0,cefdinir
SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS,2.517159021,0,cefdinir
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.531163297,0,cefdinir
SELENOAMINO_ACID_METABOLISM,-2.547284567,0,cefdinir
CELLULAR_RESPONSE_TO_STARVATION,-2.550508288,0,cefdinir
CELL_CYCLE,2.420899197,0,cefdinir
NONSENSE_MEDIATED_DECAY_NMD,-2.595567493,0,cefdinir
GPCR_LIGAND_BINDING,2.711762369,0,tadalafil
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.5152274,0,tadalafil
SIGNALING_BY_GPCR,2.38465554,0,tadalafil
SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS,-2.602667668,0.0023966,tadalafil
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.519784722,0.0011983,tadalafil
ISG15_ANTIVIRAL_MECHANISM,-2.506912119,0.000798867,tadalafil
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.342558997,0.000166146,tadalafil
KERATINIZATION,2.32168905,0.000531669,tadalafil
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.451905436,0.00299575,tadalafil
MRNA_SPLICING,-2.442967209,0.00287592,tadalafil
EUKARYOTIC_TRANSLATION_ELONGATION,3.76772864,0,aminocaproic-acid
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.629788581,0,aminocaproic-acid
SARS_COV_1_INFECTION,2.680086556,0,aminocaproic-acid
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.777389008,0,aminocaproic-acid
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.87466676,0,aminocaproic-acid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.908842116,0,aminocaproic-acid
NERVOUS_SYSTEM_DEVELOPMENT,2.977396427,0,aminocaproic-acid
RRNA_PROCESSING,3.142577739,0,aminocaproic-acid
INFLUENZA_INFECTION,3.366294031,0,aminocaproic-acid
SARS_COV_1_HOST_INTERACTIONS,2.988945894,0,aminocaproic-acid
EUKARYOTIC_TRANSLATION_ELONGATION,3.762937164,0,pioglitazone
NERVOUS_SYSTEM_DEVELOPMENT,2.793158429,0,pioglitazone
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.158691959,0,pioglitazone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.198809596,0,pioglitazone
RRNA_PROCESSING,3.211827546,0,pioglitazone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.268313664,0,pioglitazone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.273303968,0,pioglitazone
SARS_COV_1_HOST_INTERACTIONS,3.323104481,0,pioglitazone
TRANSLATION,3.353813464,0,pioglitazone
SARS_COV_1_INFECTION,2.985175679,0,pioglitazone
GPCR_LIGAND_BINDING,3.101231089,0,talazoparib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.972791597,0,talazoparib
SIGNALING_BY_GPCR,2.932751756,0,talazoparib
METABOLISM_OF_RNA,-2.893629259,0,talazoparib
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.775944989,0,talazoparib
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.468443873,0,talazoparib
TRNA_PROCESSING,-2.562839884,0.000863469,talazoparib
M_PHASE,-2.490174521,0.001295204,talazoparib
CELL_CYCLE_MITOTIC,-2.450548667,0.002072326,talazoparib
CELL_CYCLE_CHECKPOINTS,-2.409333199,0.002158673,talazoparib
EUKARYOTIC_TRANSLATION_ELONGATION,3.951095038,0,diethylcarbamazine
NERVOUS_SYSTEM_DEVELOPMENT,3.030370349,0,diethylcarbamazine
SARS_COV_1_INFECTION,3.117391726,0,diethylcarbamazine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.13705106,0,diethylcarbamazine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.145710806,0,diethylcarbamazine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.16950485,0,diethylcarbamazine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.21791631,0,diethylcarbamazine
RRNA_PROCESSING,3.304045015,0,diethylcarbamazine
SARS_COV_1_HOST_INTERACTIONS,3.367725617,0,diethylcarbamazine
TRANSLATION,3.578255969,0,diethylcarbamazine
EUKARYOTIC_TRANSLATION_ELONGATION,3.865149073,0,dapsone
NERVOUS_SYSTEM_DEVELOPMENT,2.740229981,0,dapsone
SARS_COV_1_INFECTION,3.066535671,0,dapsone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.130307042,0,dapsone
RRNA_PROCESSING,3.252632685,0,dapsone
TRANSLATION,3.337706855,0,dapsone
SARS_COV_1_HOST_INTERACTIONS,3.382410575,0,dapsone
SIGNALING_BY_ROBO_RECEPTORS,3.497095138,0,dapsone
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.14333918,0,dapsone
CELLULAR_RESPONSE_TO_STARVATION,3.619974784,0,dapsone
RAB_REGULATION_OF_TRAFFICKING,2.461076765,0,neostigmine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.335475715,0.001341382,neostigmine
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,2.190261701,0.003577018,neostigmine
MRNA_SPLICING,1.993660506,0.012743125,neostigmine
PEPTIDE_HORMONE_METABOLISM,1.736434244,0.048021462,neostigmine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.421015748,0.976610246,neostigmine
GLUCOSE_METABOLISM,1.478725966,0.143751397,neostigmine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.445609841,0.145252467,neostigmine
EUKARYOTIC_TRANSLATION_INITIATION,-2.371203344,0.751693947,neostigmine
SELENOAMINO_ACID_METABOLISM,-2.368844476,0.512638173,neostigmine
EUKARYOTIC_TRANSLATION_ELONGATION,3.278634201,0,etizolam
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.532571004,0,etizolam
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.586512098,0,etizolam
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.631691727,0,etizolam
SARS_COV_1_HOST_INTERACTIONS,2.739795329,0,etizolam
MRNA_SPLICING,-2.758908375,0,etizolam
SIGNALING_BY_ROBO_RECEPTORS,2.971019307,0,etizolam
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.002009138,0,etizolam
RRNA_PROCESSING,3.023532547,0,etizolam
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.691127807,0,etizolam
CELLULAR_RESPONSE_TO_HEAT_STRESS,3.388553202,0,oxymetazoline
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,3.317160478,0,oxymetazoline
CELL_CYCLE_MITOTIC,3.255016366,0,oxymetazoline
MITOTIC_METAPHASE_AND_ANAPHASE,2.923147249,0,oxymetazoline
CELL_CYCLE,2.686463526,0.000764307,oxymetazoline
M_PHASE,2.664306214,0.000636922,oxymetazoline
EUKARYOTIC_TRANSLATION_ELONGATION,-2.376795248,0.000670144,oxymetazoline
EUKARYOTIC_TRANSLATION_INITIATION,-2.374003026,0.000335072,oxymetazoline
MITOTIC_PROPHASE,2.413199495,0.0016378,oxymetazoline
RESPIRATORY_ELECTRON_TRANSPORT,2.401419883,0.001433075,oxymetazoline
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.314487387,0.002552655,enzastaurin
EUKARYOTIC_TRANSLATION_ELONGATION,2.297968604,0.00170177,enzastaurin
GPCR_LIGAND_BINDING,2.270496311,0.001418142,enzastaurin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.257386521,0.001063606,enzastaurin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.254673075,0.000850885,enzastaurin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.351348904,0.013036677,enzastaurin
NONSENSE_MEDIATED_DECAY_NMD,2.245675354,0.000850885,enzastaurin
SIGNALING_BY_GPCR,2.222166742,0.00121555,enzastaurin
CELL_CYCLE_CHECKPOINTS,-2.267888017,0.014123066,enzastaurin
SELENOAMINO_ACID_METABOLISM,2.135444341,0.003509901,enzastaurin
EUKARYOTIC_TRANSLATION_ELONGATION,3.847335256,0,dantrolene
SARS_COV_2_HOST_INTERACTIONS,2.556797898,0,dantrolene
METABOLISM_OF_RNA,2.706102674,0,dantrolene
SARS_COV_1_INFECTION,2.847149587,0,dantrolene
NERVOUS_SYSTEM_DEVELOPMENT,2.936602993,0,dantrolene
SARS_COV_1_HOST_INTERACTIONS,3.184963548,0,dantrolene
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.271992121,0,dantrolene
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.298980481,0,dantrolene
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.363333614,0,dantrolene
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.394350678,0,dantrolene
EUKARYOTIC_TRANSLATION_ELONGATION,3.736899867,0,BRD-K82225283
METABOLISM_OF_RNA,2.656920349,0,BRD-K82225283
NERVOUS_SYSTEM_DEVELOPMENT,2.811387591,0,BRD-K82225283
SARS_COV_1_INFECTION,2.91042458,0,BRD-K82225283
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.115780767,0,BRD-K82225283
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.127391195,0,BRD-K82225283
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.138975207,0,BRD-K82225283
SARS_COV_1_HOST_INTERACTIONS,3.188596215,0,BRD-K82225283
RRNA_PROCESSING,3.468617084,0,BRD-K82225283
INFLUENZA_INFECTION,3.470223746,0,BRD-K82225283
EUKARYOTIC_TRANSLATION_ELONGATION,3.801319943,0,citalopram
SARS_COV_1_INFECTION,2.820775006,0,citalopram
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.004155467,0,citalopram
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.032154237,0,citalopram
SARS_COV_1_HOST_INTERACTIONS,3.072250498,0,citalopram
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.142327724,0,citalopram
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.223202255,0,citalopram
TRANSLATION,3.293171939,0,citalopram
RRNA_PROCESSING,3.297189874,0,citalopram
INFLUENZA_INFECTION,3.489906398,0,citalopram
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,1.948587005,0.050903647,isoniazid
EUKARYOTIC_TRANSLATION_ELONGATION,-2.445550051,0.105476888,isoniazid
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.435613693,0.064350578,isoniazid
SELENOAMINO_ACID_METABOLISM,-2.382681683,0.124507886,isoniazid
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.314138152,0.222082071,isoniazid
NONSENSE_MEDIATED_DECAY_NMD,-2.312606774,0.18056869,isoniazid
SARS_COV_1_HOST_INTERACTIONS,-2.301274127,0.167246992,isoniazid
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.279037597,0.168237709,isoniazid
CELLULAR_RESPONSE_TO_STARVATION,-2.237636101,0.180955761,isoniazid
EUKARYOTIC_TRANSLATION_INITIATION,-2.21165991,0.177945208,isoniazid
EUKARYOTIC_TRANSLATION_ELONGATION,-3.114700481,0,benzthiazide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.555136923,0,benzthiazide
TRANSLATION,-2.572445987,0,benzthiazide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.581784792,0,benzthiazide
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.632967379,0,benzthiazide
SARS_COV_1_INFECTION,-2.643784208,0,benzthiazide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.661327328,0,benzthiazide
INFLUENZA_INFECTION,-2.775190162,0,benzthiazide
RRNA_PROCESSING,-2.804176159,0,benzthiazide
SARS_COV_1_HOST_INTERACTIONS,-2.636566775,0,benzthiazide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,5.114174074,0,vemurafenib
NERVOUS_SYSTEM_DEVELOPMENT,2.916004567,0,vemurafenib
SARS_COV_1_INFECTION,2.98515157,0,vemurafenib
SARS_COV_1_HOST_INTERACTIONS,3.156118228,0,vemurafenib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.477820234,0,vemurafenib
METABOLISM_OF_RNA,3.562834643,0,vemurafenib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,4.144962838,0,vemurafenib
RRNA_PROCESSING,4.574878443,0,vemurafenib
CELLULAR_RESPONSE_TO_STARVATION,4.691000382,0,vemurafenib
SIGNALING_BY_ROBO_RECEPTORS,4.525002998,0,vemurafenib
EUKARYOTIC_TRANSLATION_ELONGATION,-3.185348183,0,levocetirizine
SARS_COV_1_INFECTION,-2.633639885,0,levocetirizine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.720722716,0,levocetirizine
INFLUENZA_INFECTION,-2.781467615,0,levocetirizine
SARS_COV_1_HOST_INTERACTIONS,-2.819705447,0,levocetirizine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.849295349,0,levocetirizine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.867633091,0,levocetirizine
RRNA_PROCESSING,-2.887623695,0,levocetirizine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.895765618,0,levocetirizine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.741904972,0,levocetirizine
CELL_CYCLE_MITOTIC,2.799325785,0,tesaglitazar
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.693641498,0,tesaglitazar
MITOTIC_METAPHASE_AND_ANAPHASE,2.650300288,0,tesaglitazar
EUKARYOTIC_TRANSLATION_ELONGATION,-2.630045788,0,tesaglitazar
M_PHASE,2.484831681,0.001832208,tesaglitazar
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.539406132,0.001073304,tesaglitazar
RESOLUTION_OF_SISTER_CHROMATID_COHESION,2.404433974,0.0043973,tesaglitazar
NONSENSE_MEDIATED_DECAY_NMD,-2.5117161,0.001669584,tesaglitazar
CELLULAR_RESPONSE_TO_STARVATION,-2.499923053,0.001431072,tesaglitazar
SELENOAMINO_ACID_METABOLISM,-2.497165927,0.001287965,tesaglitazar
MRNA_SPLICING,2.088288833,0.033019192,tolazamide
ONCOGENIC_MAPK_SIGNALING,-2.670146681,0.040702957,tolazamide
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,2.046752316,0.026828094,tolazamide
RAB_REGULATION_OF_TRAFFICKING,1.792356284,0.070853684,tolazamide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.781302087,0.059331361,tolazamide
REGULATION_OF_TP53_ACTIVITY,1.699234338,0.092040999,tolazamide
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,1.544839008,0.186076907,tolazamide
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,1.530503138,0.172466317,tolazamide
REGULATION_OF_TP53_ACTIVITY_THROUGH_PHOSPHORYLATION,1.365625986,0.33612506,tolazamide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.188992922,1,tolazamide
KERATINIZATION,2.36955049,0.001147505,diphenidol
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.36955049,0.001147505,diphenidol
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,-2.907211135,0.270554004,diphenidol
RAB_REGULATION_OF_TRAFFICKING,1.629556809,0.169575692,diphenidol
EXTRACELLULAR_MATRIX_ORGANIZATION,-2.504276728,1,diphenidol
KEAP1_NFE2L2_PATHWAY,-2.321926153,1,diphenidol
NUCLEAR_EVENTS_MEDIATED_BY_NFE2L2,-2.219524613,1,diphenidol
HOST_INTERACTIONS_OF_HIV_FACTORS,-2.142786069,0.972862388,diphenidol
GPCR_LIGAND_BINDING,-2.132218934,0.816756124,diphenidol
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,-2.129481427,0.702017292,diphenidol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.767706825,0,riociguat
CELLULAR_RESPONSES_TO_STIMULI,2.440207248,0,riociguat
INFECTIOUS_DISEASE,2.462056142,0,riociguat
METABOLISM_OF_RNA,2.547863104,0,riociguat
VIRAL_INFECTION_PATHWAYS,2.605232983,0,riociguat
SARS_COV_2_HOST_INTERACTIONS,2.630907524,0,riociguat
SARS_COV_1_INFECTION,3.061922701,0,riociguat
NERVOUS_SYSTEM_DEVELOPMENT,3.133541291,0,riociguat
SARS_COV_1_HOST_INTERACTIONS,3.346591869,0,riociguat
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.394712025,0,riociguat
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.495867644,0,diazoxide
EUKARYOTIC_TRANSLATION_INITIATION,2.444541237,0,diazoxide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.438038494,0,diazoxide
SARS_COV_1_INFECTION,2.388907911,0.000239909,diazoxide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.381935079,0.000191927,diazoxide
SIGNALING_BY_ROBO_RECEPTORS,2.378021028,0.00015994,diazoxide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.257058853,0.001782184,diazoxide
INFLUENZA_INFECTION,2.162249403,0.005278006,diazoxide
GPCR_LIGAND_BINDING,2.158157629,0.004904813,diazoxide
SARS_COV_2_HOST_INTERACTIONS,2.137445948,0.00537397,diazoxide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.883916465,0,mephentermine
SIGNALING_BY_ROBO_RECEPTORS,-2.47842251,0,mephentermine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.4839152,0,mephentermine
MITOTIC_METAPHASE_AND_ANAPHASE,2.488600822,0,mephentermine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.501042114,0,mephentermine
CELLULAR_RESPONSE_TO_STARVATION,-2.538540613,0,mephentermine
NEUTROPHIL_DEGRANULATION,2.552186929,0,mephentermine
SARS_COV_1_HOST_INTERACTIONS,-2.564215267,0,mephentermine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.578606189,0,mephentermine
RRNA_PROCESSING,-2.56538776,0,mephentermine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,3.066390566,0,ciclesonide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.953412523,0,ciclesonide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.912105415,0,ciclesonide
INNATE_IMMUNE_SYSTEM,2.873755485,0,ciclesonide
SELENOAMINO_ACID_METABOLISM,-2.857642732,0,ciclesonide
SIGNALING_BY_INTERLEUKINS,2.799577241,0,ciclesonide
NONSENSE_MEDIATED_DECAY_NMD,-2.760847937,0,ciclesonide
EUKARYOTIC_TRANSLATION_INITIATION,-2.731092779,0,ciclesonide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.720994119,0,ciclesonide
CELLULAR_RESPONSE_TO_STARVATION,-2.705999856,0,ciclesonide
EUKARYOTIC_TRANSLATION_ELONGATION,3.526864789,0,agomelatine
NERVOUS_SYSTEM_DEVELOPMENT,2.625687854,0,agomelatine
METABOLISM_OF_RNA,2.654705099,0,agomelatine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.928586003,0,agomelatine
SARS_COV_1_HOST_INTERACTIONS,2.929554455,0,agomelatine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.980802761,0,agomelatine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.016590673,0,agomelatine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.04989865,0,agomelatine
TRANSLATION,3.257027893,0,agomelatine
SARS_COV_1_INFECTION,2.582973499,0,agomelatine
EUKARYOTIC_TRANSLATION_ELONGATION,3.64405849,0,tolbutamide
NERVOUS_SYSTEM_DEVELOPMENT,2.473225754,0,tolbutamide
SARS_COV_1_INFECTION,2.716181866,0,tolbutamide
METABOLISM_OF_RNA,2.733486344,0,tolbutamide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.96924629,0,tolbutamide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.990980256,0,tolbutamide
SARS_COV_1_HOST_INTERACTIONS,3.048261189,0,tolbutamide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.139291041,0,tolbutamide
TRANSLATION,3.275584895,0,tolbutamide
RRNA_PROCESSING,3.395613716,0,tolbutamide
EUKARYOTIC_TRANSLATION_ELONGATION,4.075253736,0,allopurinol
SARS_COV_2_INFECTION,2.486616598,0,allopurinol
INFECTIOUS_DISEASE,2.588105867,0,allopurinol
CELLULAR_RESPONSES_TO_STIMULI,2.61100284,0,allopurinol
VIRAL_INFECTION_PATHWAYS,2.774464694,0,allopurinol
SARS_COV_2_HOST_INTERACTIONS,2.878294769,0,allopurinol
METABOLISM_OF_RNA,3.043298143,0,allopurinol
NERVOUS_SYSTEM_DEVELOPMENT,3.326836192,0,allopurinol
SARS_COV_1_INFECTION,3.327460143,0,allopurinol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.485081865,0,allopurinol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.89031387,0,latanoprost
INFLUENZA_INFECTION,-2.575169331,0,latanoprost
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.702587432,0,latanoprost
SIGNALING_BY_ROBO_RECEPTORS,-2.72051306,0,latanoprost
RRNA_PROCESSING,-2.725582035,0,latanoprost
EUKARYOTIC_TRANSLATION_INITIATION,-2.712936325,0,latanoprost
CELLULAR_RESPONSE_TO_STARVATION,-2.733435292,0,latanoprost
NONSENSE_MEDIATED_DECAY_NMD,-2.742933701,0,latanoprost
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.81451233,0,latanoprost
SELENOAMINO_ACID_METABOLISM,-2.840827468,0,latanoprost
EUKARYOTIC_TRANSLATION_ELONGATION,4.108239809,0,carbamazepine
METABOLISM_OF_RNA,2.784402662,0,carbamazepine
NERVOUS_SYSTEM_DEVELOPMENT,3.163085101,0,carbamazepine
SARS_COV_1_INFECTION,3.169257078,0,carbamazepine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.231376065,0,carbamazepine
SARS_COV_1_HOST_INTERACTIONS,3.44555746,0,carbamazepine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.497370026,0,carbamazepine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.563486838,0,carbamazepine
RRNA_PROCESSING,3.583339468,0,carbamazepine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.617909717,0,carbamazepine
EUKARYOTIC_TRANSLATION_ELONGATION,4.567608227,0,BMS-927711
SARS_COV_1_HOST_INTERACTIONS,2.850796587,0,BMS-927711
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,3.040378949,0,BMS-927711
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.260645758,0,BMS-927711
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.659965765,0,BMS-927711
RRNA_PROCESSING,3.9180752,0,BMS-927711
CELLULAR_RESPONSE_TO_STARVATION,4.149630432,0,BMS-927711
INFLUENZA_INFECTION,4.159858115,0,BMS-927711
SIGNALING_BY_ROBO_RECEPTORS,3.878834549,0,BMS-927711
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.245921227,0,BMS-927711
EUKARYOTIC_TRANSLATION_ELONGATION,2.845901283,0,lonafarnib
SELENOAMINO_ACID_METABOLISM,2.837728841,0,lonafarnib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.82026262,0,lonafarnib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.807916831,0,lonafarnib
EUKARYOTIC_TRANSLATION_INITIATION,2.802608841,0,lonafarnib
NONSENSE_MEDIATED_DECAY_NMD,2.721011359,0,lonafarnib
CELLULAR_RESPONSE_TO_STARVATION,2.649579622,0,lonafarnib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.507811812,0,lonafarnib
TRANSLATION,2.47985938,0,lonafarnib
INFLUENZA_INFECTION,2.313635278,5.18E-05,lonafarnib
EUKARYOTIC_TRANSLATION_ELONGATION,4.091484546,0,selumetinib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.84160054,0,selumetinib
RRNA_PROCESSING,2.863354397,0,selumetinib
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.882240196,0,selumetinib
TRANSLATION,3.328253456,0,selumetinib
INFLUENZA_INFECTION,3.502663569,0,selumetinib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.740511339,0,selumetinib
SIGNALING_BY_ROBO_RECEPTORS,3.360669518,0,selumetinib
NONSENSE_MEDIATED_DECAY_NMD,3.773831149,0,selumetinib
EUKARYOTIC_TRANSLATION_INITIATION,3.824625631,0,selumetinib
EUKARYOTIC_TRANSLATION_ELONGATION,3.654928972,0,valrubicin
NERVOUS_SYSTEM_DEVELOPMENT,2.610940115,0,valrubicin
SARS_COV_2_HOST_INTERACTIONS,2.652276108,0,valrubicin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.749889161,0,valrubicin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.75773676,0,valrubicin
SARS_COV_1_INFECTION,2.871879747,0,valrubicin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.874791741,0,valrubicin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.908428347,0,valrubicin
TRANSLATION,3.07747758,0,valrubicin
SARS_COV_1_HOST_INTERACTIONS,3.230972127,0,valrubicin
INTERFERON_SIGNALING,-2.309457222,0.020027635,albendazole
REGULATION_OF_T_CELL_ACTIVATION_BY_CD28_FAMILY,2.271011384,0.035944136,albendazole
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.220432431,0.020981332,albendazole
DNA_STRAND_ELONGATION,-2.096623548,0.048002743,albendazole
INTERFERON_ALPHA_BETA_SIGNALING,-2.069270591,0.045539026,albendazole
DNA_REPAIR,-2.049023823,0.042344142,albendazole
BETA_CATENIN_INDEPENDENT_WNT_SIGNALING,1.995665373,0.204564423,albendazole
DNA_DOUBLE_STRAND_BREAK_REPAIR,-1.984949288,0.0613545,albendazole
DISEASES_OF_DNA_REPAIR,-1.978405432,0.055041935,albendazole
ISG15_ANTIVIRAL_MECHANISM,-1.936484305,0.06604351,albendazole
EUKARYOTIC_TRANSLATION_ELONGATION,4.030422936,0,decitabine
SARS_COV_INFECTIONS,2.606379042,0,decitabine
VIRAL_INFECTION_PATHWAYS,2.639262762,0,decitabine
SARS_COV_2_INFECTION,2.663022941,0,decitabine
CELLULAR_RESPONSES_TO_STIMULI,2.686986386,0,decitabine
METABOLISM_OF_RNA,2.69620235,0,decitabine
MRNA_SPLICING,-2.781301175,0,decitabine
SARS_COV_2_HOST_INTERACTIONS,2.867864092,0,decitabine
SARS_COV_1_INFECTION,3.063823563,0,decitabine
NERVOUS_SYSTEM_DEVELOPMENT,3.07306375,0,decitabine
EUKARYOTIC_TRANSLATION_INITIATION,4.182335762,0,xaliproden
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.721718816,0,xaliproden
RESPIRATORY_ELECTRON_TRANSPORT,2.73992936,0,xaliproden
VIRAL_INFECTION_PATHWAYS,2.843890873,0,xaliproden
CELLULAR_RESPONSES_TO_STIMULI,2.916861121,0,xaliproden
NERVOUS_SYSTEM_DEVELOPMENT,2.958781661,0,xaliproden
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.211705769,0,xaliproden
SARS_COV_1_HOST_INTERACTIONS,3.217064914,0,xaliproden
SARS_COV_1_INFECTION,3.310259775,0,xaliproden
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.343224123,0,xaliproden
EUKARYOTIC_TRANSLATION_ELONGATION,-3.476978076,0,forskolin
METABOLISM_OF_RNA,-2.41418241,0,forskolin
NERVOUS_SYSTEM_DEVELOPMENT,-2.54674053,0,forskolin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.644421994,0,forskolin
SARS_COV_1_INFECTION,-2.648257643,0,forskolin
SARS_COV_2_HOST_INTERACTIONS,-2.668003838,0,forskolin
SARS_COV_1_HOST_INTERACTIONS,-2.865184162,0,forskolin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.872877731,0,forskolin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.896865324,0,forskolin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.899670432,0,forskolin
EUKARYOTIC_TRANSLATION_ELONGATION,4.814544957,0,aminolevulinic-acid
METABOLISM_OF_RNA,2.856853956,0,aminolevulinic-acid
RRNA_PROCESSING,3.867463106,0,aminolevulinic-acid
SIGNALING_BY_ROBO_RECEPTORS,3.920454089,0,aminolevulinic-acid
TRANSLATION,4.14401152,0,aminolevulinic-acid
CELLULAR_RESPONSE_TO_STARVATION,4.196942559,0,aminolevulinic-acid
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.285783622,0,aminolevulinic-acid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.852411427,0,aminolevulinic-acid
NONSENSE_MEDIATED_DECAY_NMD,4.368102738,0,aminolevulinic-acid
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.552805768,0,aminolevulinic-acid
GPCR_LIGAND_BINDING,-2.693622066,0,pomalidomide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.472097611,0.000581356,pomalidomide
SIGNALING_BY_GPCR,-2.412980514,0.001162712,pomalidomide
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.367827009,0.00145339,pomalidomide
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.340611298,0.001627796,pomalidomide
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-2.231688866,0.004650847,pomalidomide
ADAPTIVE_IMMUNE_SYSTEM,-2.15973864,0.007308473,pomalidomide
GASTRULATION,-2.127373654,0.009301693,pomalidomide
G_ALPHA_I_SIGNALLING_EVENTS,-2.071133132,0.015115251,pomalidomide
SIGNALING_BY_INTERLEUKINS,-2.064212707,0.014650167,pomalidomide
HIV_INFECTION,-2.257763091,0.028367624,mepacrine
FATTY_ACID_METABOLISM,2.189373445,0.094868486,mepacrine
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.164724399,0.05757286,mepacrine
MITOTIC_METAPHASE_AND_ANAPHASE,-2.061393686,0.10545356,mepacrine
METABOLISM_OF_VITAMINS_AND_COFACTORS,2.095970655,0.059866118,mepacrine
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,-2.035522576,0.089625248,mepacrine
HIV_LIFE_CYCLE,-2.023908886,0.073694154,mepacrine
SEPARATION_OF_SISTER_CHROMATIDS,-2.020022134,0.060682049,mepacrine
NEURONAL_SYSTEM,-1.999017773,0.061668748,mepacrine
LATE_SARS_COV_2_INFECTION_EVENTS,2.056167377,0.05865914,mepacrine
CELL_CYCLE_CHECKPOINTS,-2.654696676,0,PCI-24781
CELL_CYCLE_MITOTIC,-2.617101697,0,PCI-24781
MITOTIC_METAPHASE_AND_ANAPHASE,-2.544816887,0,PCI-24781
SEPARATION_OF_SISTER_CHROMATIDS,-2.507622538,0,PCI-24781
ANTIGEN_PROCESSING_CROSS_PRESENTATION,-2.450924875,0.000586955,PCI-24781
CELL_CYCLE,-2.398776038,0.000978259,PCI-24781
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-2.398526118,0.000838508,PCI-24781
MITOTIC_SPINDLE_CHECKPOINT,-2.395341538,0.000917118,PCI-24781
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.365741669,0.000978259,PCI-24781
APOPTOSIS,-2.360755173,0.000880433,PCI-24781
EUKARYOTIC_TRANSLATION_ELONGATION,4.53168387,0,fomepizole
RRNA_PROCESSING,3.536707177,0,fomepizole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.585829825,0,fomepizole
TRANSLATION,3.790510858,0,fomepizole
SIGNALING_BY_ROBO_RECEPTORS,3.825175427,0,fomepizole
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.993674316,0,fomepizole
NONSENSE_MEDIATED_DECAY_NMD,3.905072554,0,fomepizole
CELLULAR_RESPONSE_TO_STARVATION,4.090549596,0,fomepizole
EUKARYOTIC_TRANSLATION_INITIATION,4.17056323,0,fomepizole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.259855555,0,fomepizole
CELL_CYCLE_MITOTIC,3.360253138,0,glimepiride
TRANSLATION,-2.618367031,0,glimepiride
CELLULAR_RESPONSE_TO_STARVATION,-2.732046203,0,glimepiride
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.533153985,0,glimepiride
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.488134058,0,glimepiride
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.830597502,0,glimepiride
SIGNALING_BY_ROBO_RECEPTORS,-2.575870584,0,glimepiride
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.911310388,0,glimepiride
EUKARYOTIC_TRANSLATION_INITIATION,-2.973687669,0,glimepiride
SELENOAMINO_ACID_METABOLISM,-2.975533615,0,glimepiride
EUKARYOTIC_TRANSLATION_ELONGATION,3.734644906,0,miconazole
SARS_COV_2_HOST_INTERACTIONS,2.556873641,0,miconazole
SARS_COV_1_INFECTION,3.03126465,0,miconazole
NERVOUS_SYSTEM_DEVELOPMENT,3.079226386,0,miconazole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.172447228,0,miconazole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.212990542,0,miconazole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.269854555,0,miconazole
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.326550286,0,miconazole
SARS_COV_1_HOST_INTERACTIONS,3.34128539,0,miconazole
RRNA_PROCESSING,3.494088206,0,miconazole
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.86092542,0,nimesulide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.7823624,0,nimesulide
GPCR_LIGAND_BINDING,2.679371742,0,nimesulide
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-2.66401586,0,nimesulide
SIGNALING_BY_GPCR,2.604753413,0,nimesulide
TRNA_PROCESSING,-2.559056218,0,nimesulide
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.273290348,0.000906553,nimesulide
MRNA_SPLICING,-2.390945173,0.005705436,nimesulide
G_ALPHA_Q_SIGNALLING_EVENTS,2.240488638,0.001305436,nimesulide
G_ALPHA_S_SIGNALLING_EVENTS,2.236916528,0.001087863,nimesulide
METABOLISM_OF_RNA,-4.253091575,0,bexarotene
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.549758979,0,bexarotene
MITOTIC_PROMETAPHASE,-2.559093955,0,bexarotene
G2_M_CHECKPOINTS,-2.5713534,0,bexarotene
TRNA_PROCESSING,-2.571455098,0,bexarotene
MITOTIC_SPINDLE_CHECKPOINT,-2.581473515,0,bexarotene
DNA_REPLICATION_PRE_INITIATION,-2.793937213,0,bexarotene
MRNA_SPLICING,-2.810683279,0,bexarotene
SEPARATION_OF_SISTER_CHROMATIDS,-2.830850838,0,bexarotene
SIGNALING_BY_GPCR,2.852035956,0,bexarotene
EUKARYOTIC_TRANSLATION_ELONGATION,4.288730047,0,sunitinib
SARS_COV_1_INFECTION,2.87802766,0,sunitinib
NERVOUS_SYSTEM_DEVELOPMENT,2.938815764,0,sunitinib
SARS_COV_1_HOST_INTERACTIONS,3.063351373,0,sunitinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.262128921,0,sunitinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.367706459,0,sunitinib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.53287158,0,sunitinib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.541095693,0,sunitinib
SIGNALING_BY_ROBO_RECEPTORS,3.618651855,0,sunitinib
RRNA_PROCESSING,3.713692818,0,sunitinib
EUKARYOTIC_TRANSLATION_ELONGATION,-3.126442569,0,marimastat
NONSENSE_MEDIATED_DECAY_NMD,-3.109200105,0,marimastat
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.088475441,0,marimastat
SELENOAMINO_ACID_METABOLISM,-3.082910763,0,marimastat
EUKARYOTIC_TRANSLATION_INITIATION,-3.064037511,0,marimastat
CELLULAR_RESPONSE_TO_STARVATION,-3.006176974,0,marimastat
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.938188993,0,marimastat
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.879221788,0,marimastat
SIGNALING_BY_ROBO_RECEPTORS,-2.701189982,0,marimastat
RRNA_PROCESSING,-2.691549487,0,marimastat
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.349387975,0.025503607,AZD-9291
MAPK1_MAPK3_SIGNALING,-2.272121226,0.031575895,AZD-9291
TCR_SIGNALING,-2.26155543,0.025908426,AZD-9291
MAPK_FAMILY_SIGNALING_CASCADES,-2.261235677,0.01943132,AZD-9291
ANTIGEN_PROCESSING_CROSS_PRESENTATION,-2.244683127,0.018702645,AZD-9291
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,-2.195124044,0.029349389,AZD-9291
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.189772233,0.026024089,AZD-9291
PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION,-2.185179921,0.023226499,AZD-9291
GPCR_LIGAND_BINDING,-2.181441277,0.021860235,AZD-9291
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.169347667,0.02198168,AZD-9291
SELENOAMINO_ACID_METABOLISM,3.13562552,0,cariprazine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.46554403,0,cariprazine
SARS_COV_1_INFECTION,2.465956111,0,cariprazine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.529769802,0,cariprazine
RRNA_PROCESSING,2.686636479,0,cariprazine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.696297744,0,cariprazine
TRANSLATION,2.701290444,0,cariprazine
INFLUENZA_INFECTION,2.717413891,0,cariprazine
SARS_COV_1_HOST_INTERACTIONS,2.722620387,0,cariprazine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.650298127,0,cariprazine
EUKARYOTIC_TRANSLATION_ELONGATION,4.24603923,0,pasireotide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.2108573,0,pasireotide
SIGNALING_BY_ROBO_RECEPTORS,3.474316925,0,pasireotide
CELLULAR_RESPONSE_TO_STARVATION,3.544694341,0,pasireotide
RRNA_PROCESSING,3.590874404,0,pasireotide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.73486054,0,pasireotide
TRANSLATION,3.741913769,0,pasireotide
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.852367497,0,pasireotide
EUKARYOTIC_TRANSLATION_INITIATION,3.995637112,0,pasireotide
SELENOAMINO_ACID_METABOLISM,4.010578604,0,pasireotide
EUKARYOTIC_TRANSLATION_INITIATION,3.474018884,0,gabapentin
NERVOUS_SYSTEM_DEVELOPMENT,2.664102695,0,gabapentin
SARS_COV_1_INFECTION,2.812868619,0,gabapentin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.922729569,0,gabapentin
RRNA_PROCESSING,2.948116418,0,gabapentin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.06853319,0,gabapentin
SARS_COV_1_HOST_INTERACTIONS,3.104301152,0,gabapentin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.107336778,0,gabapentin
CELLULAR_RESPONSE_TO_STARVATION,3.14220651,0,gabapentin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.889596576,0,gabapentin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.387801056,0,zileuton
NONSENSE_MEDIATED_DECAY_NMD,-2.325150199,0,zileuton
SELENOAMINO_ACID_METABOLISM,-2.311404544,0,zileuton
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.296398131,0,zileuton
EUKARYOTIC_TRANSLATION_INITIATION,-2.249953184,0,zileuton
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.229889849,0,zileuton
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.211975553,0,zileuton
CELLULAR_RESPONSE_TO_STARVATION,-2.183029491,0.00060877,zileuton
RAB_REGULATION_OF_TRAFFICKING,2.285189695,0.018202404,zileuton
SIGNALING_BY_ROBO_RECEPTORS,-2.173782367,0.000865807,zileuton
EUKARYOTIC_TRANSLATION_ELONGATION,-3.331730763,0,linagliptin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.457474706,0,linagliptin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.46045171,0,linagliptin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.550634355,0,linagliptin
SARS_COV_1_HOST_INTERACTIONS,-2.433600115,0,linagliptin
TRANSLATION,-2.644200631,0,linagliptin
RRNA_PROCESSING,-2.722260365,0,linagliptin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.744982957,0,linagliptin
INFLUENZA_INFECTION,-2.757932795,0,linagliptin
SIGNALING_BY_ROBO_RECEPTORS,-2.621588655,0,linagliptin
METABOLISM_OF_RNA,-3.750599284,0,mycophenolate-mofetil
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.543130604,0,mycophenolate-mofetil
TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM,-2.549972535,0,mycophenolate-mofetil
ISG15_ANTIVIRAL_MECHANISM,-2.595507462,0,mycophenolate-mofetil
SIGNALING_BY_GPCR,2.601501845,0,mycophenolate-mofetil
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.714855478,0,mycophenolate-mofetil
SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS,-2.718305625,0,mycophenolate-mofetil
CELL_CYCLE_MITOTIC,-2.562570123,0,mycophenolate-mofetil
TRANSPORT_OF_MATURE_MRNAS_DERIVED_FROM_INTRONLESS_TRANSCRIPTS,-2.768671486,0,mycophenolate-mofetil
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.833831859,0,mycophenolate-mofetil
EUKARYOTIC_TRANSLATION_ELONGATION,3.527910859,0,doramapimod
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.577074545,0,doramapimod
SARS_COV_1_HOST_INTERACTIONS,2.580923641,0,doramapimod
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.629746748,0,doramapimod
SARS_COV_1_INFECTION,2.652415032,0,doramapimod
TRANSLATION,2.798539721,0,doramapimod
SIGNALING_BY_ROBO_RECEPTORS,2.79888916,0,doramapimod
RRNA_PROCESSING,2.946754632,0,doramapimod
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.954422891,0,doramapimod
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.184621928,0,doramapimod
EUKARYOTIC_TRANSLATION_ELONGATION,-2.885058961,0,benzbromarone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.543515786,0,benzbromarone
INFLUENZA_INFECTION,-2.551342948,0,benzbromarone
RRNA_PROCESSING,-2.621818096,0,benzbromarone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.675664946,0,benzbromarone
SIGNALING_BY_ROBO_RECEPTORS,-2.687272748,0,benzbromarone
SARS_COV_1_INFECTION,-2.688130686,0,benzbromarone
SARS_COV_1_HOST_INTERACTIONS,-2.616699907,0,benzbromarone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.720663127,0,benzbromarone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.769739769,0,benzbromarone
EUKARYOTIC_TRANSLATION_ELONGATION,-3.029211107,0,mecamylamine
TRANSLATION,-2.632972867,0,mecamylamine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.674461398,0,mecamylamine
INFLUENZA_INFECTION,-2.675078823,0,mecamylamine
SIGNALING_BY_ROBO_RECEPTORS,-2.751377843,0,mecamylamine
RRNA_PROCESSING,-2.753741083,0,mecamylamine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.803989274,0,mecamylamine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.597002383,0,mecamylamine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.845833514,0,mecamylamine
SELENOAMINO_ACID_METABOLISM,-2.964825985,0,mecamylamine
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.192276784,0.006764904,camptothecin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.142953305,0.007731319,camptothecin
G_ALPHA_Q_SIGNALLING_EVENTS,-2.069266363,0.018684021,camptothecin
SIGNALING_BY_INSULIN_RECEPTOR,-2.061374734,0.016187449,camptothecin
EXTRA_NUCLEAR_ESTROGEN_SIGNALING,-2.017023959,0.019908146,camptothecin
PI3K_AKT_SIGNALING_IN_CANCER,-2.015993307,0.016590122,camptothecin
SIGNALING_BY_ALK_IN_CANCER,-2.012886322,0.014772342,camptothecin
CONSTITUTIVE_SIGNALING_BY_ABERRANT_PI3K_IN_CANCER,-1.961788174,0.023435561,camptothecin
SIGNALING_BY_GPCR,-1.940999088,0.025878443,camptothecin
GPCR_LIGAND_BINDING,-1.925832062,0.028122673,camptothecin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.196149967,0.005125852,urea
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.125884724,0.006407315,urea
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.116836222,0.004841083,urea
SELENOAMINO_ACID_METABOLISM,-2.103523024,0.004485121,urea
NONSENSE_MEDIATED_DECAY_NMD,-2.070209815,0.004613267,urea
G_ALPHA_Q_SIGNALLING_EVENTS,-2.067293129,0.003844389,urea
CELLULAR_RESPONSE_TO_STARVATION,-2.018449201,0.005491985,urea
EUKARYOTIC_TRANSLATION_INITIATION,-1.994248963,0.006727681,urea
DISORDERS_OF_TRANSMEMBRANE_TRANSPORTERS,1.74117907,0.947953562,urea
SARS_COV_2_HOST_INTERACTIONS,-1.914353331,0.02439526,urea
EUKARYOTIC_TRANSLATION_ELONGATION,4.095734391,0,MLN-8054
SARS_COV_2_INFECTION,2.461639583,0,MLN-8054
VIRAL_INFECTION_PATHWAYS,2.46198311,0,MLN-8054
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.506470076,0,MLN-8054
SARS_COV_2_HOST_INTERACTIONS,2.700512763,0,MLN-8054
NERVOUS_SYSTEM_DEVELOPMENT,2.895376667,0,MLN-8054
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.055580623,0,MLN-8054
SARS_COV_1_INFECTION,3.072053105,0,MLN-8054
SARS_COV_1_HOST_INTERACTIONS,3.2509846,0,MLN-8054
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.390869122,0,MLN-8054
RAB_REGULATION_OF_TRAFFICKING,2.138002384,0.038830055,camostat-mesilate
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.927798097,0.06841486,camostat-mesilate
MRNA_SPLICING,1.582155998,0.249621785,camostat-mesilate
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.497786168,0.275970751,camostat-mesilate
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.449014829,0.278836779,camostat-mesilate
EUKARYOTIC_TRANSLATION_ELONGATION,-2.117466693,1,camostat-mesilate
NONSENSE_MEDIATED_DECAY_NMD,-2.066973016,1,camostat-mesilate
SELENOAMINO_ACID_METABOLISM,-2.045963854,1,camostat-mesilate
DISEASES_OF_METABOLISM,1.31112186,0.471199641,camostat-mesilate
SIGNALING_BY_VEGF,1.299240875,0.421319309,camostat-mesilate
EUKARYOTIC_TRANSLATION_ELONGATION,4.10644037,0,molindone
SARS_COV_1_INFECTION,2.82137053,0,molindone
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.895286197,0,molindone
NERVOUS_SYSTEM_DEVELOPMENT,2.92457117,0,molindone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.966284035,0,molindone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.077049439,0,molindone
RRNA_PROCESSING,3.398620598,0,molindone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.652579449,0,molindone
TRANSLATION,3.731344491,0,molindone
SARS_COV_1_HOST_INTERACTIONS,3.124828212,0,molindone
EUKARYOTIC_TRANSLATION_ELONGATION,4.070269765,0,benazepril
SARS_COV_1_INFECTION,3.058975218,0,benazepril
NERVOUS_SYSTEM_DEVELOPMENT,3.096804924,0,benazepril
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.142367875,0,benazepril
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.232990916,0,benazepril
SARS_COV_1_HOST_INTERACTIONS,3.257804024,0,benazepril
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.331316055,0,benazepril
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.370870467,0,benazepril
TRANSLATION,3.384985676,0,benazepril
SARS_COV_2_HOST_INTERACTIONS,2.663581125,0,benazepril
EUKARYOTIC_TRANSLATION_ELONGATION,-3.00538115,0,aspirin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.510616576,0,aspirin
SARS_COV_1_HOST_INTERACTIONS,-2.561242232,0,aspirin
TRANSLATION,-2.562966043,0,aspirin
INFLUENZA_INFECTION,-2.695730569,0,aspirin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.703169344,0,aspirin
SIGNALING_BY_ROBO_RECEPTORS,-2.739896268,0,aspirin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.788309243,0,aspirin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.746761823,0,aspirin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.80912652,0,aspirin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.797287344,0,tranilast
SELENOAMINO_ACID_METABOLISM,-2.748620758,0,tranilast
NONSENSE_MEDIATED_DECAY_NMD,-2.708380691,0,tranilast
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.704260196,0,tranilast
CELLULAR_RESPONSE_TO_STARVATION,-2.645353103,0.000127534,tranilast
EUKARYOTIC_TRANSLATION_INITIATION,-2.622840951,0.000106278,tranilast
CELL_CYCLE_MITOTIC,2.593990349,0.004804743,tranilast
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.528460122,0.002402372,tranilast
INNATE_IMMUNE_SYSTEM,2.52747236,0.001601581,tranilast
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.612397492,0.000182191,tranilast
M_PHASE,-2.886452961,0,probenecid
GPCR_LIGAND_BINDING,2.828120775,0,probenecid
MITOTIC_PROMETAPHASE,-2.687429051,0,probenecid
SIGNALING_BY_GPCR,2.58644389,0,probenecid
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.573193222,0,probenecid
ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION,-2.63193246,0.000868012,probenecid
MYD88_INDEPENDENT_TLR4_CASCADE,-2.602199844,0.000651009,probenecid
CELL_CYCLE_CHECKPOINTS,-2.534832666,0.000868012,probenecid
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.53064242,0.00074401,probenecid
CELL_CYCLE_MITOTIC,-2.53850117,0.001041615,probenecid
METABOLISM_OF_RNA,-3.154781012,0,lamotrigine
M_PHASE,-3.151653693,0,lamotrigine
GPCR_LIGAND_BINDING,2.967652665,0,lamotrigine
CELL_CYCLE_MITOTIC,-2.924713205,0,lamotrigine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.873848985,0,lamotrigine
CELL_CYCLE,-2.860744651,0,lamotrigine
MITOTIC_PROMETAPHASE,-2.834348347,0,lamotrigine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.825663543,0,lamotrigine
SIGNALING_BY_GPCR,2.822919934,0,lamotrigine
CELL_CYCLE_CHECKPOINTS,-2.806375546,0,lamotrigine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.051996662,0,BRD-K72166146
CELLULAR_RESPONSES_TO_STIMULI,2.415656841,0,BRD-K72166146
SARS_COV_2_INFECTION,2.434995542,0,BRD-K72166146
SARS_COV_INFECTIONS,2.461810063,0,BRD-K72166146
METABOLISM_OF_RNA,2.533096103,0,BRD-K72166146
INFECTIOUS_DISEASE,2.67330984,0,BRD-K72166146
VIRAL_INFECTION_PATHWAYS,2.906666225,0,BRD-K72166146
SARS_COV_1_INFECTION,3.114569617,0,BRD-K72166146
NERVOUS_SYSTEM_DEVELOPMENT,3.132884063,0,BRD-K72166146
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.153375881,0,BRD-K72166146
EUKARYOTIC_TRANSLATION_ELONGATION,4.930211731,0,nimodipine
SARS_COV_1_INFECTION,2.810999906,0,nimodipine
SARS_COV_1_HOST_INTERACTIONS,2.916706626,0,nimodipine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.275557183,0,nimodipine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,4.054264492,0,nimodipine
SIGNALING_BY_ROBO_RECEPTORS,4.156463626,0,nimodipine
RRNA_PROCESSING,4.177589088,0,nimodipine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.532426761,0,nimodipine
METABOLISM_OF_RNA,3.068355174,0,nimodipine
TRANSLATION,4.632032802,0,nimodipine
EUKARYOTIC_TRANSLATION_ELONGATION,3.931388153,0,equol
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.883760688,0,equol
SIGNALING_BY_ROBO_RECEPTORS,3.37477702,0,equol
RRNA_PROCESSING,3.431519743,0,equol
INFLUENZA_INFECTION,3.501501368,0,equol
TRANSLATION,3.510211538,0,equol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.525970265,0,equol
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.189723749,0,equol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.723530519,0,equol
NONSENSE_MEDIATED_DECAY_NMD,3.746484432,0,equol
MITOTIC_METAPHASE_AND_ANAPHASE,-2.303508612,0.040568969,gefitinib
SEPARATION_OF_SISTER_CHROMATIDS,-2.219482446,0.042742306,gefitinib
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,-2.145575516,0.042500824,gefitinib
CELL_CYCLE_MITOTIC,-2.134728795,0.034411179,gefitinib
S_PHASE,-2.071191827,0.042887195,gefitinib
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.037522905,0.0468475,gefitinib
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,2.029689927,0.167313491,gefitinib
RHO_GTPASES_ACTIVATE_FORMINS,-1.957041761,0.06664902,gefitinib
HOST_INTERACTIONS_OF_HIV_FACTORS,-1.91989804,0.071176807,gefitinib
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-1.915388651,0.05781078,gefitinib
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.189426071,0.051658326,lomitapide
RESPIRATORY_ELECTRON_TRANSPORT,2.187165736,0.026649136,lomitapide
TP53_REGULATES_METABOLIC_GENES,1.931315325,0.129009152,lomitapide
ISG15_ANTIVIRAL_MECHANISM,-1.948050851,0.59276503,lomitapide
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,1.894592428,0.126685894,lomitapide
MUSCLE_CONTRACTION,1.877958652,0.112664348,lomitapide
SUMOYLATION,-1.896777829,0.431514773,lomitapide
ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION,-1.879775185,0.329692427,lomitapide
INTERLEUKIN_1_FAMILY_SIGNALING,-1.803993881,0.419023556,lomitapide
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,-1.749105913,0.477845833,lomitapide
REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA,1.627831491,0.754867698,letrozole
HOST_INTERACTIONS_OF_HIV_FACTORS,1.533540538,0.627309036,letrozole
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.533502913,0.418206024,letrozole
ASPARAGINE_N_LINKED_GLYCOSYLATION,1.470622395,0.460434348,letrozole
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.449507768,0.411682476,letrozole
KEAP1_NFE2L2_PATHWAY,1.442930306,0.352970544,letrozole
RAB_REGULATION_OF_TRAFFICKING,1.437790363,0.31103345,letrozole
DISEASES_OF_METABOLISM,1.427503469,0.284385921,letrozole
C_TYPE_LECTIN_RECEPTORS_CLRS,1.384428242,0.321129417,letrozole
SYNTHESIS_OF_DNA,1.353503841,0.34423365,letrozole
EUKARYOTIC_TRANSLATION_ELONGATION,3.996182893,0,candesartan
INFECTIOUS_DISEASE,2.569025356,0,candesartan
SARS_COV_2_INFECTION,2.5746229,0,candesartan
CELLULAR_RESPONSES_TO_STIMULI,2.702312078,0,candesartan
METABOLISM_OF_RNA,2.72355664,0,candesartan
VIRAL_INFECTION_PATHWAYS,2.729352826,0,candesartan
SARS_COV_2_HOST_INTERACTIONS,2.918851889,0,candesartan
NERVOUS_SYSTEM_DEVELOPMENT,3.214721035,0,candesartan
SARS_COV_1_INFECTION,3.250414675,0,candesartan
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.440839775,0,candesartan
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.735672378,0,rosuvastatin
KERATINIZATION,2.367357299,0,rosuvastatin
SARS_COV_2_INFECTION,2.462049278,0,rosuvastatin
METABOLISM_OF_RNA,2.500723581,0,rosuvastatin
VIRAL_INFECTION_PATHWAYS,2.541602651,0,rosuvastatin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.608746497,0,rosuvastatin
SARS_COV_2_HOST_INTERACTIONS,2.776199438,0,rosuvastatin
NERVOUS_SYSTEM_DEVELOPMENT,2.904792315,0,rosuvastatin
SARS_COV_1_INFECTION,3.149851819,0,rosuvastatin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.275428154,0,rosuvastatin
EUKARYOTIC_TRANSLATION_ELONGATION,-3.314417632,0,arbutin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.821203396,0,arbutin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.822846972,0,arbutin
TRANSLATION,-2.825415305,0,arbutin
SARS_COV_1_INFECTION,-2.907847255,0,arbutin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-3.002139822,0,arbutin
SARS_COV_1_HOST_INTERACTIONS,-3.019876371,0,arbutin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.031998306,0,arbutin
INFLUENZA_INFECTION,-3.034729443,0,arbutin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.851624411,0,arbutin
EUKARYOTIC_TRANSLATION_ELONGATION,-3.268064763,0,tafamidis-meglumine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.621173299,0,tafamidis-meglumine
SARS_COV_1_HOST_INTERACTIONS,-2.638009056,0,tafamidis-meglumine
RRNA_PROCESSING,-2.662374631,0,tafamidis-meglumine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.724785982,0,tafamidis-meglumine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.751572042,0,tafamidis-meglumine
TRANSLATION,-2.848054595,0,tafamidis-meglumine
INFLUENZA_INFECTION,-2.894695578,0,tafamidis-meglumine
SIGNALING_BY_ROBO_RECEPTORS,-2.928016766,0,tafamidis-meglumine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-3.032952472,0,tafamidis-meglumine
NONSENSE_MEDIATED_DECAY_NMD,-2.91050962,0,amiodarone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.383593032,0,amiodarone
SARS_COV_1_HOST_INTERACTIONS,-2.448710845,0,amiodarone
INFLUENZA_INFECTION,-2.495909507,0,amiodarone
RRNA_PROCESSING,-2.540883896,0,amiodarone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.564950203,0,amiodarone
SIGNALING_BY_ROBO_RECEPTORS,-2.583742773,0,amiodarone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.617099914,0,amiodarone
TRANSLATION,-2.476554508,0,amiodarone
EUKARYOTIC_TRANSLATION_INITIATION,-2.769894848,0,amiodarone
VIRAL_INFECTION_PATHWAYS,-2.655440758,0,foretinib
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,-2.428265613,0,foretinib
PCP_CE_PATHWAY,-2.4378963,0,foretinib
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,-2.437900515,0,foretinib
BETA_CATENIN_INDEPENDENT_WNT_SIGNALING,-2.444503785,0,foretinib
TNFR2_NON_CANONICAL_NF_KB_PATHWAY,-2.444808229,0,foretinib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.447411967,0,foretinib
G1_S_DNA_DAMAGE_CHECKPOINTS,-2.449010027,0,foretinib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.454460537,0,foretinib
SIGNALING_BY_WNT,-2.466984561,0,foretinib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.254306481,0,linifanib
VIRAL_INFECTION_PATHWAYS,2.565961488,0,linifanib
METABOLISM_OF_RNA,2.740686828,0,linifanib
CELLULAR_RESPONSES_TO_STIMULI,2.819820619,0,linifanib
SARS_COV_1_INFECTION,2.992739136,0,linifanib
NERVOUS_SYSTEM_DEVELOPMENT,3.153760471,0,linifanib
SARS_COV_1_HOST_INTERACTIONS,3.18633112,0,linifanib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.230855525,0,linifanib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.402082798,0,linifanib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.542102953,0,linifanib
EUKARYOTIC_TRANSLATION_ELONGATION,4.421081039,0,quinidine
SELENOAMINO_ACID_METABOLISM,4.383870765,0,quinidine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.352820139,0,quinidine
EUKARYOTIC_TRANSLATION_INITIATION,4.286102985,0,quinidine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.244914196,0,quinidine
NONSENSE_MEDIATED_DECAY_NMD,4.187259777,0,quinidine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.136871399,0,quinidine
TRANSLATION,4.039592053,0,quinidine
CELLULAR_RESPONSE_TO_STARVATION,4.020757783,0,quinidine
INFLUENZA_INFECTION,4.006235091,0,quinidine
SELENOAMINO_ACID_METABOLISM,3.554840321,0,bumetanide
GPCR_LIGAND_BINDING,2.33978277,0,bumetanide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.368117068,0,bumetanide
NERVOUS_SYSTEM_DEVELOPMENT,2.764209129,0,bumetanide
SARS_COV_1_INFECTION,2.862431019,0,bumetanide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.873420578,0,bumetanide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.002260521,0,bumetanide
RRNA_PROCESSING,3.058005484,0,bumetanide
SARS_COV_1_HOST_INTERACTIONS,3.068711255,0,bumetanide
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.088637687,0,bumetanide
EUKARYOTIC_TRANSLATION_ELONGATION,3.955787636,0,FR-180204
NERVOUS_SYSTEM_DEVELOPMENT,2.72595069,0,FR-180204
SARS_COV_1_HOST_INTERACTIONS,2.775480286,0,FR-180204
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.874789027,0,FR-180204
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.162771162,0,FR-180204
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.166428991,0,FR-180204
TRANSLATION,3.261038597,0,FR-180204
RRNA_PROCESSING,3.278774986,0,FR-180204
SIGNALING_BY_ROBO_RECEPTORS,3.330423752,0,FR-180204
SARS_COV_1_INFECTION,2.753010319,0,FR-180204
EUKARYOTIC_TRANSLATION_ELONGATION,-2.832817958,0,azathioprine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.772255842,0,azathioprine
NONSENSE_MEDIATED_DECAY_NMD,-2.766396225,0,azathioprine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.727461754,0,azathioprine
SELENOAMINO_ACID_METABOLISM,-2.673840864,0,azathioprine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.529091804,0,azathioprine
CELLULAR_RESPONSE_TO_STARVATION,-2.526820094,0,azathioprine
EUKARYOTIC_TRANSLATION_INITIATION,-2.490452079,0,azathioprine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.328793454,0.000228441,azathioprine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,2.50393419,0.006108826,azathioprine
EUKARYOTIC_TRANSLATION_ELONGATION,4.287001837,0,propentofylline
RRNA_PROCESSING,3.405515988,0,propentofylline
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.553161629,0,propentofylline
INFLUENZA_INFECTION,3.811069259,0,propentofylline
SIGNALING_BY_ROBO_RECEPTORS,3.965398833,0,propentofylline
CELLULAR_RESPONSE_TO_STARVATION,4.091796358,0,propentofylline
TRANSLATION,3.908192736,0,propentofylline
NONSENSE_MEDIATED_DECAY_NMD,4.131664373,0,propentofylline
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.185490235,0,propentofylline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.18724603,0,propentofylline
EUKARYOTIC_TRANSLATION_ELONGATION,4.164833992,0,tiagabine
SIGNALING_BY_ROBO_RECEPTORS,3.198936968,0,tiagabine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.543694951,0,tiagabine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.586634795,0,tiagabine
CELLULAR_RESPONSE_TO_STARVATION,3.617514701,0,tiagabine
TRANSLATION,3.62742016,0,tiagabine
RRNA_PROCESSING,3.268975549,0,tiagabine
NONSENSE_MEDIATED_DECAY_NMD,3.727561741,0,tiagabine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.975160113,0,tiagabine
EUKARYOTIC_TRANSLATION_INITIATION,4.045883947,0,tiagabine
EUKARYOTIC_TRANSLATION_ELONGATION,4.150537086,0,meclizine
SARS_COV_1_INFECTION,3.075847474,0,meclizine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.118575284,0,meclizine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.133484705,0,meclizine
NERVOUS_SYSTEM_DEVELOPMENT,3.158611023,0,meclizine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.221943684,0,meclizine
SARS_COV_1_HOST_INTERACTIONS,3.35042184,0,meclizine
TRANSLATION,3.55680635,0,meclizine
RRNA_PROCESSING,3.627321818,0,meclizine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.480661398,0,meclizine
GPCR_LIGAND_BINDING,2.397562487,0.006589786,lestaurtinib
NONSENSE_MEDIATED_DECAY_NMD,-2.523241361,0.013975702,lestaurtinib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.504263617,0.007919565,lestaurtinib
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,-2.498052622,0.005900852,lestaurtinib
SIGNALING_BY_GPCR,2.28437198,0.010982976,lestaurtinib
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,-2.466724468,0.005590281,lestaurtinib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.402116342,0.010248848,lestaurtinib
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.151590021,0.026359143,lestaurtinib
PHOSPHOLIPID_METABOLISM,2.096894895,0.020867655,lestaurtinib
CDC42_GTPASE_CYCLE,2.096958346,0.025041186,lestaurtinib
EUKARYOTIC_TRANSLATION_INITIATION,4.188865895,0,felbinac
VIRAL_INFECTION_PATHWAYS,2.583635177,0,felbinac
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.634082676,0,felbinac
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.669933638,0,felbinac
METABOLISM_OF_RNA,2.678875919,0,felbinac
CELLULAR_RESPONSES_TO_STIMULI,2.872470225,0,felbinac
SARS_COV_1_INFECTION,2.87278748,0,felbinac
SARS_COV_1_HOST_INTERACTIONS,2.937691937,0,felbinac
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.143692486,0,felbinac
RRNA_PROCESSING,3.311394264,0,felbinac
EUKARYOTIC_TRANSLATION_INITIATION,2.478521223,0.000854927,sildenafil
SARS_COV_1_INFECTION,2.335960556,0.002137317,sildenafil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.335304692,0.001424878,sildenafil
CELL_CYCLE_CHECKPOINTS,-2.330996068,0.017857824,sildenafil
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.291435387,0.012897318,sildenafil
METABOLISM_OF_RNA,-2.098000852,0.025794635,sildenafil
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.043061532,0.024306483,sildenafil
MRNA_SPLICING,-2.019576004,0.023810432,sildenafil
GPCR_LIGAND_BINDING,2.10716404,0.013251365,sildenafil
CELLULAR_RESPONSE_TO_STARVATION,2.105518628,0.010943063,sildenafil
EUKARYOTIC_TRANSLATION_ELONGATION,3.916660362,0,tacrine
SARS_COV_2_INFECTION,2.421128761,0,tacrine
SARS_COV_INFECTIONS,2.42143334,0,tacrine
VIRAL_INFECTION_PATHWAYS,2.429674662,0,tacrine
CELLULAR_RESPONSES_TO_STIMULI,2.452887424,0,tacrine
METABOLISM_OF_RNA,2.580493169,0,tacrine
SARS_COV_2_HOST_INTERACTIONS,2.783641123,0,tacrine
NERVOUS_SYSTEM_DEVELOPMENT,2.896311948,0,tacrine
SARS_COV_1_INFECTION,3.099217714,0,tacrine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.349757127,0,tacrine
EUKARYOTIC_TRANSLATION_ELONGATION,-3.110486269,0,maprotiline
NONSENSE_MEDIATED_DECAY_NMD,-3.066852629,0,maprotiline
SELENOAMINO_ACID_METABOLISM,-3.031102468,0,maprotiline
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.016508287,0,maprotiline
CELLULAR_RESPONSE_TO_STARVATION,-2.950275384,0,maprotiline
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.943753147,0,maprotiline
EUKARYOTIC_TRANSLATION_INITIATION,-2.872932878,0,maprotiline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.800631778,0,maprotiline
SIGNALING_BY_ROBO_RECEPTORS,-2.755877256,0,maprotiline
RRNA_PROCESSING,-2.666459471,6.85E-05,maprotiline
EUKARYOTIC_TRANSLATION_ELONGATION,4.25144743,0,probucol
INFECTIOUS_DISEASE,2.683439837,0,probucol
VIRAL_INFECTION_PATHWAYS,2.891311744,0,probucol
SARS_COV_2_HOST_INTERACTIONS,2.943123127,0,probucol
SARS_COV_1_INFECTION,3.278279204,0,probucol
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.380671026,0,probucol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.419376389,0,probucol
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.520902928,0,probucol
SARS_COV_1_HOST_INTERACTIONS,3.529503608,0,probucol
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.700873721,0,probucol
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.545468838,0,celecoxib
KERATINIZATION,2.545468838,0,celecoxib
RAB_REGULATION_OF_TRAFFICKING,1.606121885,0.173243651,celecoxib
GLYCOSAMINOGLYCAN_METABOLISM,1.549709056,0.172860029,celecoxib
SENSORY_PERCEPTION,1.534304432,0.15108565,celecoxib
GPCR_LIGAND_BINDING,-2.046196033,1,celecoxib
SIGNALING_BY_GPCR,-2.035331461,1,celecoxib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.025626102,1,celecoxib
PEPTIDE_LIGAND_BINDING_RECEPTORS,-1.960114525,1,celecoxib
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,-1.928894967,1,celecoxib
RRNA_PROCESSING,-2.747506725,0,zaleplon
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.581987825,0.001351177,zaleplon
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.503815303,0.00180157,zaleplon
METABOLISM_OF_RNA,-2.479807955,0.002026766,zaleplon
MHC_CLASS_II_ANTIGEN_PRESENTATION,-2.434477362,0.002702355,zaleplon
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.427236884,0.002251962,zaleplon
MRNA_SPLICING,-2.298028289,0.004246558,zaleplon
GOLGI_TO_ER_RETROGRADE_TRANSPORT,-2.165206024,0.00776927,zaleplon
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.063987383,0.067286956,zaleplon
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,-1.905680126,0.029725904,zaleplon
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.718198138,0,fexofenadine
NERVOUS_SYSTEM_DEVELOPMENT,2.587776398,0,fexofenadine
SARS_COV_1_INFECTION,2.815043245,0,fexofenadine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.91112907,0,fexofenadine
SARS_COV_1_HOST_INTERACTIONS,3.034609381,0,fexofenadine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.077226763,0,fexofenadine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.13900286,0,fexofenadine
TRANSLATION,3.153731,0,fexofenadine
SIGNALING_BY_ROBO_RECEPTORS,3.193966735,0,fexofenadine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.27162895,0,fexofenadine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,3.045162343,0,naftifine
METABOLISM_OF_RNA,-2.89279457,0,naftifine
GPCR_LIGAND_BINDING,2.886984568,0,naftifine
SIGNALING_BY_GPCR,2.845325217,0,naftifine
SUMOYLATION,-2.735568771,0,naftifine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-2.69054012,0,naftifine
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.690109618,0,naftifine
G_ALPHA_I_SIGNALLING_EVENTS,2.557303892,0.000154786,naftifine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.416043852,0.002454228,naftifine
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.366253418,0.000619143,naftifine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.757217539,0,olanzapine
RAB_REGULATION_OF_TRAFFICKING,2.432270696,0.002508161,olanzapine
RNA_POLYMERASE_II_TRANSCRIPTION_TERMINATION,2.340756977,0.004458954,olanzapine
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,2.093390655,0.017139103,olanzapine
MRNA_SPLICING,2.039548448,0.016052233,olanzapine
PEPTIDE_HORMONE_METABOLISM,1.731027432,0.052950076,olanzapine
GLUCOSE_METABOLISM,1.535602953,0.122302731,olanzapine
REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA,1.496083566,0.127707222,olanzapine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.457587888,0.141014412,olanzapine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.415649143,1,olanzapine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.061436114,0,clonidine
EUKARYOTIC_TRANSLATION_INITIATION,2.67695581,0.000553459,clonidine
SELENOAMINO_ACID_METABOLISM,2.674282379,0.000368973,clonidine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.653655324,0.00027673,clonidine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.625822816,0.000442767,clonidine
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,2.490413537,0.000737945,clonidine
TRANSLATION,2.45160457,0.000790656,clonidine
NONSENSE_MEDIATED_DECAY_NMD,2.431129723,0.001106918,clonidine
MUSCLE_CONTRACTION,2.39731804,0.00090566,clonidine
RESPIRATORY_ELECTRON_TRANSPORT,2.372051334,0.000830189,clonidine
EUKARYOTIC_TRANSLATION_ELONGATION,2.700293725,0,bupropion
SELENOAMINO_ACID_METABOLISM,2.527015688,0,bupropion
EUKARYOTIC_TRANSLATION_INITIATION,2.408247805,0,bupropion
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.390347414,0,bupropion
MHC_CLASS_II_ANTIGEN_PRESENTATION,-2.64412324,0.001772499,bupropion
NONSENSE_MEDIATED_DECAY_NMD,2.358126045,0.000304611,bupropion
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.312434616,0.000634607,bupropion
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.302585603,0.000761529,bupropion
SARS_COV_1_HOST_INTERACTIONS,2.212244849,0.001999013,bupropion
CELLULAR_RESPONSE_TO_STARVATION,2.18633977,0.002115357,bupropion
SIGNALING_BY_ROBO_RECEPTORS,2.362315277,0,buspirone
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.410931934,0.005289164,buspirone
DNA_REPAIR,-2.143375557,0.027768112,buspirone
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.141069007,0.018512075,buspirone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.170765535,0.009671603,buspirone
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.080052014,0.015698834,buspirone
CELL_CYCLE_CHECKPOINTS,-1.968900757,0.042313313,buspirone
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-1.880649309,0.052362725,buspirone
SENSORY_PERCEPTION,2.019626461,0.024179007,buspirone
SARS_COV_2_HOST_INTERACTIONS,2.003137513,0.021866232,buspirone
SELENOAMINO_ACID_METABOLISM,4.292419231,0,diacerein
METABOLISM_OF_RNA,2.725734428,0,diacerein
INFECTIOUS_DISEASE,2.750003934,0,diacerein
SARS_COV_2_HOST_INTERACTIONS,2.872478742,0,diacerein
VIRAL_INFECTION_PATHWAYS,2.916324144,0,diacerein
SARS_COV_1_INFECTION,3.162793371,0,diacerein
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.264757468,0,diacerein
NERVOUS_SYSTEM_DEVELOPMENT,3.41815195,0,diacerein
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.434634434,0,diacerein
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.492122024,0,diacerein
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.558674786,0,tazarotene
REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF,-2.612979188,0.002140534,tazarotene
NONSENSE_MEDIATED_DECAY_NMD,2.203342118,0.006260919,tazarotene
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.182125069,0.023545877,tazarotene
EUKARYOTIC_TRANSLATION_INITIATION,2.165803833,0.007791366,tazarotene
MRNA_SPLICING,-2.098144121,0.027113435,tazarotene
SUMOYLATION,-2.005919572,0.035318816,tazarotene
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.027074558,0.026087164,tazarotene
CELLULAR_RESPONSE_TO_STARVATION,1.896409063,0.074797116,tazarotene
METABOLISM_OF_STEROIDS,-1.680032925,0.21148479,tazarotene
EUKARYOTIC_TRANSLATION_ELONGATION,3.678714322,0,hydroxyurea
RRNA_PROCESSING,3.075179074,0,hydroxyurea
SIGNALING_BY_ROBO_RECEPTORS,3.146431302,0,hydroxyurea
TRANSLATION,3.179741744,0,hydroxyurea
INFLUENZA_INFECTION,3.331346174,0,hydroxyurea
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.354194233,0,hydroxyurea
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.144532004,0,hydroxyurea
SELENOAMINO_ACID_METABOLISM,3.479320709,0,hydroxyurea
EUKARYOTIC_TRANSLATION_INITIATION,3.480825605,0,hydroxyurea
NONSENSE_MEDIATED_DECAY_NMD,3.581299625,0,hydroxyurea
EUKARYOTIC_TRANSLATION_ELONGATION,3.910772175,0,MEK-162
SARS_COV_INFECTIONS,2.360885006,0,MEK-162
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.390524557,0,MEK-162
SARS_COV_2_INFECTION,2.390555679,0,MEK-162
KERATINIZATION,2.581827601,0,MEK-162
SARS_COV_2_HOST_INTERACTIONS,2.7628159,0,MEK-162
METABOLISM_OF_RNA,2.952106239,0,MEK-162
NERVOUS_SYSTEM_DEVELOPMENT,2.954995281,0,MEK-162
SARS_COV_1_INFECTION,3.313911183,0,MEK-162
SARS_COV_1_HOST_INTERACTIONS,3.524875963,0,MEK-162
KERATINIZATION,2.276981611,0.00443996,amoxapine
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.276981611,0.00443996,amoxapine
G_ALPHA_Q_SIGNALLING_EVENTS,-1.927647471,0.544384241,amoxapine
SARS_COV_2_ACTIVATES_MODULATES_INNATE_AND_ADAPTIVE_IMMUNE_RESPONSES,-1.92712315,0.275244742,amoxapine
GPCR_LIGAND_BINDING,-1.917102556,0.205204029,amoxapine
ECM_PROTEOGLYCANS,1.642048272,0.146653212,amoxapine
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,-1.884116015,0.205034438,amoxapine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.868502879,0.190483607,amoxapine
GLYCOSAMINOGLYCAN_METABOLISM,1.579350295,0.157013118,amoxapine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.566485416,0.135297679,amoxapine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.481962569,0,BRD-K31342827
SELENOAMINO_ACID_METABOLISM,-2.417246755,0,BRD-K31342827
NONSENSE_MEDIATED_DECAY_NMD,-2.395350194,0,BRD-K31342827
EUKARYOTIC_TRANSLATION_INITIATION,-2.3579355,0,BRD-K31342827
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.345141965,0,BRD-K31342827
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.31862115,0,BRD-K31342827
CELLULAR_RESPONSE_TO_STARVATION,-2.277637947,0.00013582,BRD-K31342827
RRNA_PROCESSING,-2.175425408,0.00047537,BRD-K31342827
MRNA_SPLICING,2.143026667,0.064113102,BRD-K31342827
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.14745361,0.001056377,BRD-K31342827
MRNA_SPLICING,1.976360562,0.109038462,anastrozole
EUKARYOTIC_TRANSLATION_ELONGATION,-2.040464329,0.033877841,anastrozole
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.946528046,0.062307692,anastrozole
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.83069805,0.089134615,anastrozole
SELENOAMINO_ACID_METABOLISM,-1.980128198,0.051287287,anastrozole
NONSENSE_MEDIATED_DECAY_NMD,-1.97294802,0.037014678,anastrozole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.957133763,0.03293679,anastrozole
SARS_COV_2_HOST_INTERACTIONS,-1.924506742,0.038959517,anastrozole
EUKARYOTIC_TRANSLATION_INITIATION,-1.898764102,0.04391572,anastrozole
DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA,-1.888878962,0.041540686,anastrozole
INTRINSIC_PATHWAY_FOR_APOPTOSIS,-2.32133584,0.017298141,cobimetinib
PROGRAMMED_CELL_DEATH,-2.259769328,0.018919842,cobimetinib
APOPTOSIS,-2.21522124,0.020901921,cobimetinib
S_PHASE,-2.167011233,0.025947212,cobimetinib
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-2.11878836,0.034380056,cobimetinib
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,-2.108247953,0.032974582,cobimetinib
DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS,-2.09363656,0.033824044,cobimetinib
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,-2.075723592,0.034596283,cobimetinib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.074045372,0.031232755,cobimetinib
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,-2.073567801,0.028217593,cobimetinib
EUKARYOTIC_TRANSLATION_ELONGATION,4.298830348,0,ibrutinib
CELLULAR_RESPONSES_TO_STIMULI,2.605958523,0,ibrutinib
INFECTIOUS_DISEASE,2.701006427,0,ibrutinib
METABOLISM_OF_RNA,2.869298292,0,ibrutinib
VIRAL_INFECTION_PATHWAYS,2.912608651,0,ibrutinib
SARS_COV_2_HOST_INTERACTIONS,2.915791651,0,ibrutinib
SARS_COV_1_INFECTION,3.396585436,0,ibrutinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.473358341,0,ibrutinib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.534527771,0,ibrutinib
NERVOUS_SYSTEM_DEVELOPMENT,3.579983749,0,ibrutinib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.732189504,0,clenbuterol
GPCR_LIGAND_BINDING,2.654298556,0,clenbuterol
SIGNALING_BY_GPCR,2.542371916,0,clenbuterol
G_ALPHA_Q_SIGNALLING_EVENTS,2.383416912,0.000193784,clenbuterol
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.650139182,0.004931684,clenbuterol
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.432287404,0.004931684,clenbuterol
METABOLISM_OF_RNA,-2.411291742,0.003287789,clenbuterol
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.299270046,0.000620109,clenbuterol
SUMOYLATION,-2.213433126,0.008013987,clenbuterol
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.196366425,0.008383863,clenbuterol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.389968867,0.000983038,amfepramone
SELENOAMINO_ACID_METABOLISM,-2.324716018,0.000491519,amfepramone
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.305917619,0.000327679,amfepramone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.270408152,0.000491519,amfepramone
NONSENSE_MEDIATED_DECAY_NMD,-2.229145954,0.000589823,amfepramone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.228495018,0.000491519,amfepramone
CELLULAR_RESPONSE_TO_STARVATION,-2.215469679,0.00070217,amfepramone
EUKARYOTIC_TRANSLATION_INITIATION,-2.192676021,0.000614399,amfepramone
INFLUENZA_INFECTION,-2.167295094,0.000764585,amfepramone
SIGNALING_BY_ROBO_RECEPTORS,-2.154587306,0.000714937,amfepramone
EUKARYOTIC_TRANSLATION_ELONGATION,-2.725779349,0,rolipram
SELENOAMINO_ACID_METABOLISM,-2.672538352,0,rolipram
NONSENSE_MEDIATED_DECAY_NMD,-2.626328554,0,rolipram
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.580097107,0,rolipram
EUKARYOTIC_TRANSLATION_INITIATION,-2.559103357,0,rolipram
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.509052678,0,rolipram
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.505818174,0,rolipram
CELLULAR_RESPONSE_TO_STARVATION,-2.454846695,0,rolipram
RRNA_PROCESSING,-2.436849989,0,rolipram
SIGNALING_BY_ROBO_RECEPTORS,-2.384353953,0,rolipram
M_PHASE,-2.920608023,0,itopride
GPCR_LIGAND_BINDING,2.831166758,0,itopride
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.706468779,0,itopride
SIGNALING_BY_GPCR,2.567575185,0,itopride
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.566275396,0,itopride
CELL_CYCLE_MITOTIC,-2.683450353,0.002429094,itopride
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.609415897,0.002429094,itopride
CELL_CYCLE,-2.58552719,0.002429094,itopride
METABOLISM_OF_RNA,-2.582024591,0.001943275,itopride
CHROMATIN_ORGANIZATION,-2.455593429,0.002024245,itopride
EUKARYOTIC_TRANSLATION_ELONGATION,4.018449578,0,OSI-930
SARS_COV_1_INFECTION,2.899879488,0,OSI-930
SARS_COV_1_HOST_INTERACTIONS,2.919281296,0,OSI-930
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.088690617,0,OSI-930
TRANSLATION,3.198689327,0,OSI-930
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.201054768,0,OSI-930
RRNA_PROCESSING,3.358928456,0,OSI-930
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.371689791,0,OSI-930
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.855680287,0,OSI-930
SIGNALING_BY_ROBO_RECEPTORS,3.415277288,0,OSI-930
EUKARYOTIC_TRANSLATION_ELONGATION,4.201885877,0,NVP-BGJ398
NERVOUS_SYSTEM_DEVELOPMENT,2.766734164,0,NVP-BGJ398
SARS_COV_1_INFECTION,2.802994708,0,NVP-BGJ398
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.175292404,0,NVP-BGJ398
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.416554037,0,NVP-BGJ398
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.443312538,0,NVP-BGJ398
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.489655734,0,NVP-BGJ398
SIGNALING_BY_ROBO_RECEPTORS,3.574004491,0,NVP-BGJ398
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.781169682,0,NVP-BGJ398
SARS_COV_1_HOST_INTERACTIONS,2.977131019,0,NVP-BGJ398
EUKARYOTIC_TRANSLATION_ELONGATION,3.879683273,0,veliparib
NERVOUS_SYSTEM_DEVELOPMENT,2.617287584,0,veliparib
SARS_COV_1_HOST_INTERACTIONS,2.707394634,0,veliparib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.794890398,0,veliparib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.108977511,0,veliparib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.198245607,0,veliparib
TRANSLATION,3.227196723,0,veliparib
SIGNALING_BY_ROBO_RECEPTORS,3.258283281,0,veliparib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.267303993,0,veliparib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.428132517,0,veliparib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.290167827,0.000991845,propylthiouracil
SELENOAMINO_ACID_METABOLISM,-2.210256257,0.002479612,propylthiouracil
NONSENSE_MEDIATED_DECAY_NMD,-2.197355084,0.001653075,propylthiouracil
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.164322687,0.002231651,propylthiouracil
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.163827673,0.001785321,propylthiouracil
EUKARYOTIC_TRANSLATION_INITIATION,-2.143863767,0.002479612,propylthiouracil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.117725485,0.003117227,propylthiouracil
RRNA_PROCESSING,-2.101272944,0.003843399,propylthiouracil
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.973884189,0.043680151,propylthiouracil
MRNA_SPLICING,1.966126588,0.022430348,propylthiouracil
EUKARYOTIC_TRANSLATION_ELONGATION,3.854198624,0,fluphenazine
SARS_COV_1_HOST_INTERACTIONS,2.756791339,0,fluphenazine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.8222318,0,fluphenazine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.916025583,0,fluphenazine
RRNA_PROCESSING,3.382438712,0,fluphenazine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.443595172,0,fluphenazine
TRANSLATION,3.518905862,0,fluphenazine
INFLUENZA_INFECTION,3.565503654,0,fluphenazine
SIGNALING_BY_ROBO_RECEPTORS,3.521052492,0,fluphenazine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.646372703,0,fluphenazine
BIOLOGICAL_OXIDATIONS,2.218274862,0.011943041,nateglinide
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.75124255,0.126255004,nateglinide
ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES,1.66479281,0.101942385,nateglinide
COLLAGEN_FORMATION,1.66479281,0.101942385,nateglinide
GLYCOSAMINOGLYCAN_METABOLISM,1.448219731,0.312225212,nateglinide
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,1.440455216,0.271277643,nateglinide
COLLAGEN_BIOSYNTHESIS_AND_MODIFYING_ENZYMES,1.439659063,0.234229843,nateglinide
GLUCOSE_METABOLISM,1.349180855,0.340376665,nateglinide
SIGNALING_BY_INSULIN_RECEPTOR,-1.953046256,1,nateglinide
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-1.881948995,1,nateglinide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.350889873,0,zafirlukast
RRNA_PROCESSING,2.961113268,0,zafirlukast
INFLUENZA_INFECTION,3.043520224,0,zafirlukast
TRANSLATION,3.064939887,0,zafirlukast
MRNA_SPLICING,-3.078923897,0,zafirlukast
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.10243394,0,zafirlukast
EUKARYOTIC_TRANSLATION_INITIATION,3.139887809,0,zafirlukast
SIGNALING_BY_ROBO_RECEPTORS,3.039750052,0,zafirlukast
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.217908898,0,zafirlukast
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.220248284,0,zafirlukast
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-3.216853056,0,rupatadine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.375753287,0.002636826,rupatadine
INTERFERON_SIGNALING,-2.315646931,0.006152593,rupatadine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.223185685,0.010610252,rupatadine
NONSENSE_MEDIATED_DECAY_NMD,2.213830993,0.005305126,rupatadine
EUKARYOTIC_TRANSLATION_INITIATION,2.17900006,0.005441155,rupatadine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.174250414,0.004080866,rupatadine
SIGNALING_BY_ROBO_RECEPTORS,2.1485328,0.00367278,rupatadine
SELENOAMINO_ACID_METABOLISM,2.15076427,0.004407335,rupatadine
EUKARYOTIC_TRANSLATION_ELONGATION,2.140637158,0.003381289,rupatadine
KERATINIZATION,2.114344416,0.016216692,minaprine
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.114344416,0.016216692,minaprine
PROGRAMMED_CELL_DEATH,-2.077361171,0.284622155,minaprine
TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES,-2.034387512,0.205319035,minaprine
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,-2.031755617,0.140862619,minaprine
APOPTOSIS,-2.006564302,0.128731776,minaprine
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,-2.00162515,0.107548066,minaprine
HSP90_CHAPERONE_CYCLE_FOR_STEROID_HORMONE_RECEPTORS_SHR_IN_THE_PRESENCE_OF_LIGAND,-1.982322721,0.101573174,minaprine
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,-1.977750736,0.091097713,minaprine
SIGNALING_BY_WNT,-1.964135297,0.079182415,minaprine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.279880251,0,irbesartan
SELENOAMINO_ACID_METABOLISM,-2.236803276,0,irbesartan
NONSENSE_MEDIATED_DECAY_NMD,-2.178126059,0.000650147,irbesartan
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.16478756,0.000731415,irbesartan
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.148954999,0.000585132,irbesartan
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.141736739,0.000650147,irbesartan
EUKARYOTIC_TRANSLATION_INITIATION,-2.097940644,0.00195044,irbesartan
INFLUENZA_INFECTION,-2.031161634,0.005851321,irbesartan
CELLULAR_RESPONSE_TO_STARVATION,-1.990549798,0.008993697,irbesartan
SARS_COV_1_HOST_INTERACTIONS,-1.98798789,0.008386894,irbesartan
GPCR_LIGAND_BINDING,2.695092992,0,eflornithine
SIGNALING_BY_GPCR,2.601454256,0,eflornithine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.580504112,0,eflornithine
TRNA_PROCESSING_IN_THE_NUCLEUS,-2.658603436,0.007386868,eflornithine
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.558816845,0.003693434,eflornithine
INTERFERON_SIGNALING,-2.506757216,0.003283052,eflornithine
SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS,-2.395867297,0.008618012,eflornithine
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,2.281271604,0.001540822,eflornithine
G_ALPHA_I_SIGNALLING_EVENTS,2.253289863,0.001568837,eflornithine
ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION,-2.337384357,0.008371783,eflornithine
GPCR_LIGAND_BINDING,2.628522035,0,temazepam
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.58372605,0,temazepam
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.374958338,0.001045319,temazepam
SIGNALING_BY_GPCR,2.248687983,0.00450794,temazepam
MITOTIC_SPINDLE_CHECKPOINT,-2.023411093,0.211737463,temazepam
KERATINIZATION,2.040515521,0.020070134,temazepam
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-1.925169641,0.196878694,temazepam
POTASSIUM_CHANNELS,1.979595724,0.030444929,temazepam
MITOTIC_PROMETAPHASE,-1.839827199,0.218547732,temazepam
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,-1.795605297,0.21080879,temazepam
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.109642919,0,torcitabine
NONSENSE_MEDIATED_DECAY_NMD,2.707780982,0,torcitabine
CELLULAR_RESPONSE_TO_STARVATION,2.532947807,0.000366167,torcitabine
RESPIRATORY_ELECTRON_TRANSPORT,2.393466501,0.003295506,torcitabine
TRANSLATION,2.314000373,0.00527281,torcitabine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.228585963,0.009154184,torcitabine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.147736898,0.014594385,torcitabine
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.101157714,0.018811849,torcitabine
DISEASES_OF_GLYCOSYLATION,2.089317703,0.018674536,torcitabine
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,2.064792032,0.019553338,torcitabine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.866126854,0,bendroflumethiazide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.709655776,0,bendroflumethiazide
RESPIRATORY_ELECTRON_TRANSPORT,2.562574323,0,bendroflumethiazide
SELENOAMINO_ACID_METABOLISM,2.548479092,0.000183898,bendroflumethiazide
EUKARYOTIC_TRANSLATION_INITIATION,2.501204304,0.000147118,bendroflumethiazide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.495531457,0.000122599,bendroflumethiazide
DISEASES_OF_METABOLISM,2.436172319,0.000315254,bendroflumethiazide
TRANSLATION,2.43287622,0.000275847,bendroflumethiazide
NONSENSE_MEDIATED_DECAY_NMD,2.352694549,0.001389452,bendroflumethiazide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.28184319,0.002574572,bendroflumethiazide
EUKARYOTIC_TRANSLATION_ELONGATION,3.734098017,0,oxybutynin
SARS_COV_1_INFECTION,2.570486118,0,oxybutynin
NERVOUS_SYSTEM_DEVELOPMENT,2.616944055,0,oxybutynin
SARS_COV_1_HOST_INTERACTIONS,2.896754433,0,oxybutynin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.034534079,0,oxybutynin
TRANSLATION,3.045802365,0,oxybutynin
RRNA_PROCESSING,3.092861009,0,oxybutynin
SIGNALING_BY_ROBO_RECEPTORS,3.337357114,0,oxybutynin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.67536046,0,oxybutynin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.380974476,0,oxybutynin
EUKARYOTIC_TRANSLATION_ELONGATION,3.834963631,0,sumatriptan
NERVOUS_SYSTEM_DEVELOPMENT,2.816844264,0,sumatriptan
SARS_COV_1_INFECTION,2.89916719,0,sumatriptan
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.123365061,0,sumatriptan
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.184705228,0,sumatriptan
SARS_COV_1_HOST_INTERACTIONS,3.186723278,0,sumatriptan
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.214085096,0,sumatriptan
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.30146417,0,sumatriptan
TRANSLATION,3.443753919,0,sumatriptan
RRNA_PROCESSING,3.088205904,0,sumatriptan
RAB_REGULATION_OF_TRAFFICKING,2.387678203,0.001442757,warfarin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.050339288,0.021641348,warfarin
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,1.97327082,0.023084104,warfarin
MRNA_SPLICING,1.720377782,0.065645421,warfarin
GLUCOSE_METABOLISM,1.494496897,0.171110923,warfarin
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,1.409716517,0.228436448,warfarin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.287681276,1,warfarin
NONSENSE_MEDIATED_DECAY_NMD,-2.245237541,1,warfarin
SELENOAMINO_ACID_METABOLISM,-2.222031668,0.911056007,warfarin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.16578936,0.752063307,warfarin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.315540317,0.000723641,PH-797804
MHC_CLASS_II_ANTIGEN_PRESENTATION,-2.637482438,0.007604563,PH-797804
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.423770352,0.005703422,PH-797804
RRNA_PROCESSING,-2.336330087,0.011406844,PH-797804
METABOLISM_OF_RNA,-2.310113522,0.009505703,PH-797804
VISUAL_PHOTOTRANSDUCTION,2.14431728,0.008683696,PH-797804
SEPARATION_OF_SISTER_CHROMATIDS,-2.035726808,0.039543726,PH-797804
GPCR_LIGAND_BINDING,2.087174622,0.012060689,PH-797804
G_ALPHA_Q_SIGNALLING_EVENTS,2.070312624,0.011035531,PH-797804
HCMV_INFECTION,-1.991864021,0.043726236,PH-797804
EUKARYOTIC_TRANSLATION_ELONGATION,4.071925107,0,levamisole
METABOLISM_OF_RNA,2.579989859,0,levamisole
SARS_COV_2_HOST_INTERACTIONS,2.619710838,0,levamisole
VIRAL_INFECTION_PATHWAYS,2.678720424,0,levamisole
SARS_COV_1_INFECTION,2.940752353,0,levamisole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.042790173,0,levamisole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.11208487,0,levamisole
SARS_COV_1_HOST_INTERACTIONS,3.186571551,0,levamisole
NERVOUS_SYSTEM_DEVELOPMENT,3.199429254,0,levamisole
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.204138863,0,levamisole
EUKARYOTIC_TRANSLATION_ELONGATION,-3.824972061,0,aminoglutethimide
SARS_COV_1_HOST_INTERACTIONS,-2.753553147,0,aminoglutethimide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.994651269,0,aminoglutethimide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-3.032875221,0,aminoglutethimide
SIGNALING_BY_ROBO_RECEPTORS,-3.045579324,0,aminoglutethimide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-3.081089585,0,aminoglutethimide
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-3.127814031,0,aminoglutethimide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-3.208605628,0,aminoglutethimide
INFLUENZA_INFECTION,-3.038311512,0,aminoglutethimide
TRANSLATION,-3.298523211,0,aminoglutethimide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.245847158,0.000980234,mitiglinide
RAB_REGULATION_OF_TRAFFICKING,2.336173243,0.004483911,mitiglinide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.194513079,0.003920935,mitiglinide
SELENOAMINO_ACID_METABOLISM,-2.187291017,0.002613957,mitiglinide
CELLULAR_RESPONSE_TO_STARVATION,-2.179693428,0.001960467,mitiglinide
NONSENSE_MEDIATED_DECAY_NMD,-2.178031698,0.001764421,mitiglinide
EUKARYOTIC_TRANSLATION_INITIATION,-2.118372735,0.004084307,mitiglinide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.005183112,0.029145419,mitiglinide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.071593173,0.006441536,mitiglinide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.047502648,0.007229224,mitiglinide
MRNA_SPLICING,2.154531701,0.010645638,cariporide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.033772585,0.030162642,cariporide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.103893246,0.027167662,cariporide
SELENOAMINO_ACID_METABOLISM,-2.098188371,0.014036625,cariporide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.029065014,0.023243444,cariporide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.025591775,0.018111774,cariporide
EUKARYOTIC_TRANSLATION_INITIATION,-2.00464743,0.020466305,cariporide
G_ALPHA_Q_SIGNALLING_EVENTS,-1.976236316,0.024601827,cariporide
NONSENSE_MEDIATED_DECAY_NMD,-1.974479376,0.02121665,cariporide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.964803778,0.020602143,cariporide
SELENOAMINO_ACID_METABOLISM,4.642756227,0,niacin
SARS_COV_1_INFECTION,2.804623775,0,niacin
METABOLISM_OF_RNA,2.914187567,0,niacin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.236496996,0,niacin
RRNA_PROCESSING,3.876290326,0,niacin
SIGNALING_BY_ROBO_RECEPTORS,3.889133747,0,niacin
TRANSLATION,4.09598006,0,niacin
CELLULAR_RESPONSE_TO_STARVATION,4.167362278,0,niacin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.942132983,0,niacin
NONSENSE_MEDIATED_DECAY_NMD,4.372401506,0,niacin
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,3.293560057,0,papaverine
CELL_CYCLE_MITOTIC,3.090325286,0,papaverine
MITOTIC_METAPHASE_AND_ANAPHASE,2.719334416,0,papaverine
M_PHASE,2.60862753,0.00091529,papaverine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.440948659,0.004393392,papaverine
CELL_CYCLE,2.403483162,0.00366116,papaverine
TRANSCRIPTIONAL_REGULATION_BY_RUNX1,2.398245946,0.003138137,papaverine
ANTIGEN_PROCESSING_CROSS_PRESENTATION,2.314806512,0.00457645,papaverine
INTERFERON_SIGNALING,2.289576915,0.004881546,papaverine
SEPARATION_OF_SISTER_CHROMATIDS,2.187787816,0.006989487,papaverine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.355872923,0,glycopyrrolate
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.584518455,0,glycopyrrolate
NERVOUS_SYSTEM_DEVELOPMENT,2.615922578,0,glycopyrrolate
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.705454335,0,glycopyrrolate
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.779765528,0,glycopyrrolate
SARS_COV_1_INFECTION,2.779993411,0,glycopyrrolate
MRNA_SPLICING,-2.865210281,0,glycopyrrolate
SARS_COV_1_HOST_INTERACTIONS,2.934369179,0,glycopyrrolate
CELLULAR_RESPONSE_TO_STARVATION,3.095426984,0,glycopyrrolate
INFLUENZA_INFECTION,3.110095278,0,glycopyrrolate
NONSENSE_MEDIATED_DECAY_NMD,3.372795591,0,naproxen
SARS_COV_1_INFECTION,2.498398136,0,naproxen
SUMOYLATION,-2.547447428,0,naproxen
NERVOUS_SYSTEM_DEVELOPMENT,2.58091261,0,naproxen
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.597317,0,naproxen
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.661195665,0,naproxen
SARS_COV_1_HOST_INTERACTIONS,2.709910351,0,naproxen
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.732105262,0,naproxen
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.77877726,0,naproxen
RRNA_PROCESSING,2.81839864,0,naproxen
EUKARYOTIC_TRANSLATION_ELONGATION,4.546926147,0,rasagiline
EUKARYOTIC_TRANSLATION_INITIATION,4.39403542,0,rasagiline
SELENOAMINO_ACID_METABOLISM,4.382203635,0,rasagiline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.357750057,0,rasagiline
NONSENSE_MEDIATED_DECAY_NMD,4.356265564,0,rasagiline
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.310024596,0,rasagiline
INFLUENZA_INFECTION,4.289376525,0,rasagiline
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.271220362,0,rasagiline
CELLULAR_RESPONSE_TO_STARVATION,4.096462819,0,rasagiline
SIGNALING_BY_ROBO_RECEPTORS,3.844247069,0,rasagiline
METABOLISM_OF_RNA,-4.016100594,0,leflunomide
RRNA_PROCESSING,-3.451092981,0,leflunomide
SIGNALING_BY_GPCR,2.704627679,0,leflunomide
GPCR_LIGAND_BINDING,2.651387658,0,leflunomide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.646327422,0,leflunomide
SUMOYLATION,-2.652049831,0.000780704,leflunomide
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.6408763,0.000585528,leflunomide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.590588443,0.000468423,leflunomide
MRNA_SPLICING,-2.3905426,0.000390352,leflunomide
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.328416682,0.000669175,leflunomide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.377608671,0,trifluoperazine
SELENOAMINO_ACID_METABOLISM,-2.304704662,0,trifluoperazine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.286854246,0,trifluoperazine
RAB_REGULATION_OF_TRAFFICKING,2.343009709,0.001009545,trifluoperazine
EUKARYOTIC_TRANSLATION_INITIATION,-2.242549068,0.00049982,trifluoperazine
NONSENSE_MEDIATED_DECAY_NMD,-2.231151533,0.000399856,trifluoperazine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.223016799,0.000333213,trifluoperazine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.183742339,0.000428417,trifluoperazine
CELLULAR_RESPONSE_TO_STARVATION,-2.168090695,0.000624774,trifluoperazine
TRANSLATION,-2.119123036,0.002332491,trifluoperazine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.573450622,0,EX-527
EUKARYOTIC_TRANSLATION_ELONGATION,3.378680283,0,EX-527
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.309673134,0,EX-527
SELENOAMINO_ACID_METABOLISM,3.307477804,0,EX-527
CELLULAR_RESPONSE_TO_STARVATION,3.300816467,0,EX-527
NONSENSE_MEDIATED_DECAY_NMD,3.176248011,0,EX-527
EUKARYOTIC_TRANSLATION_INITIATION,3.105069073,0,EX-527
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.760221629,0,EX-527
TRANSLATION,2.686863744,0,EX-527
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.675046534,0,EX-527
EUKARYOTIC_TRANSLATION_ELONGATION,-2.325834966,0.002115715,pimozide
G_ALPHA_Q_SIGNALLING_EVENTS,-2.261971016,0.003702501,pimozide
NONSENSE_MEDIATED_DECAY_NMD,-2.166342378,0.011283813,pimozide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.136178185,0.011636433,pimozide
SELENOAMINO_ACID_METABOLISM,-2.129572662,0.009309146,pimozide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.08140119,0.017278339,pimozide
EUKARYOTIC_TRANSLATION_INITIATION,-2.071535179,0.016170108,pimozide
PROGRAMMED_CELL_DEATH,-2.043468982,0.016220482,pimozide
INTERLEUKIN_12_SIGNALING,-2.044742204,0.018248042,pimozide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.03277711,0.016608363,pimozide
SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT,1.499995958,1,trovafloxacin
INTRINSIC_PATHWAY_FOR_APOPTOSIS,-2.236471073,1,trovafloxacin
MITOTIC_G2_G2_M_PHASES,-2.15340813,1,trovafloxacin
RECRUITMENT_OF_NUMA_TO_MITOTIC_CENTROSOMES,-2.087785594,1,trovafloxacin
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,-2.07765954,1,trovafloxacin
GENE_AND_PROTEIN_EXPRESSION_BY_JAK_STAT_SIGNALING_AFTER_INTERLEUKIN_12_STIMULATION,-2.065367305,0.987613916,trovafloxacin
SARS_COV_1_INFECTION,-2.053832537,0.828420407,trovafloxacin
INTERLEUKIN_12_SIGNALING,-2.031187409,0.632961696,trovafloxacin
INTERLEUKIN_12_FAMILY_SIGNALING,-2.031187409,0.632961696,trovafloxacin
CIRCADIAN_CLOCK,-2.01788395,0.568099588,trovafloxacin
EUKARYOTIC_TRANSLATION_ELONGATION,2.990787655,0,esmolol
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.952510488,0,esmolol
GPCR_LIGAND_BINDING,-2.887379605,0,esmolol
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.773074546,0,esmolol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.771360631,0,esmolol
SELENOAMINO_ACID_METABOLISM,2.734891349,0,esmolol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.682062492,0,esmolol
SIGNALING_BY_GPCR,-2.533491431,0,esmolol
CELLULAR_RESPONSE_TO_STARVATION,2.571810579,0.000161864,esmolol
NONSENSE_MEDIATED_DECAY_NMD,2.522669764,0.000269773,esmolol
RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL,-3.458328187,0,AZD-8330
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.499200534,0,AZD-8330
CELLULAR_RESPONSE_TO_STARVATION,2.517504145,0,AZD-8330
SELENOAMINO_ACID_METABOLISM,2.684754032,0,AZD-8330
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.747126846,0,AZD-8330
EUKARYOTIC_TRANSLATION_INITIATION,2.637627315,0,AZD-8330
EUKARYOTIC_TRANSLATION_ELONGATION,2.795970706,0,AZD-8330
METABOLISM_OF_RNA,-2.854881991,0,AZD-8330
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.952219533,0,AZD-8330
NONSENSE_MEDIATED_DECAY_NMD,2.783502244,0,AZD-8330
EUKARYOTIC_TRANSLATION_ELONGATION,-2.91703744,0,filgotinib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.80674516,0,filgotinib
NONSENSE_MEDIATED_DECAY_NMD,-2.773683674,0,filgotinib
SELENOAMINO_ACID_METABOLISM,-2.765342673,0,filgotinib
CELLULAR_RESPONSE_TO_STARVATION,-2.738681236,0,filgotinib
EUKARYOTIC_TRANSLATION_INITIATION,-2.669133226,0,filgotinib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.57562277,0,filgotinib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.555585483,0,filgotinib
RRNA_PROCESSING,-2.532483846,0,filgotinib
SIGNALING_BY_ROBO_RECEPTORS,-2.434698248,0,filgotinib
EUKARYOTIC_TRANSLATION_ELONGATION,-3.309319229,0,BRD-K26619122
SELENOAMINO_ACID_METABOLISM,-3.233218057,0,BRD-K26619122
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-3.191091959,0,BRD-K26619122
NONSENSE_MEDIATED_DECAY_NMD,-3.10235175,0,BRD-K26619122
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-3.09851833,0,BRD-K26619122
CELLULAR_RESPONSE_TO_STARVATION,-3.056880342,0,BRD-K26619122
EUKARYOTIC_TRANSLATION_INITIATION,-3.032628526,0,BRD-K26619122
TRANSLATION,-2.79328028,0,BRD-K26619122
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.666140557,0.000297381,BRD-K26619122
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.613074617,0.000374701,BRD-K26619122
SELENOAMINO_ACID_METABOLISM,3.22134693,0,canertinib
TRANSLATION,2.598086983,0,canertinib
RRNA_PROCESSING,2.614629318,0,canertinib
SIGNALING_BY_ROBO_RECEPTORS,2.728778885,0,canertinib
INFLUENZA_INFECTION,2.749007967,0,canertinib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.815039995,0,canertinib
SARS_COV_1_HOST_INTERACTIONS,2.638659166,0,canertinib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.093255625,0,canertinib
NONSENSE_MEDIATED_DECAY_NMD,3.093896922,0,canertinib
EUKARYOTIC_TRANSLATION_ELONGATION,3.151265729,0,canertinib
EUKARYOTIC_TRANSLATION_INITIATION,4.104232674,0,amsacrine
INFECTIOUS_DISEASE,2.642264321,0,amsacrine
CELLULAR_RESPONSES_TO_STIMULI,2.698371058,0,amsacrine
VIRAL_INFECTION_PATHWAYS,2.861974158,0,amsacrine
SARS_COV_2_HOST_INTERACTIONS,2.927932336,0,amsacrine
NERVOUS_SYSTEM_DEVELOPMENT,3.048010266,0,amsacrine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.300900846,0,amsacrine
SARS_COV_1_INFECTION,3.308589871,0,amsacrine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.417483623,0,amsacrine
SARS_COV_1_HOST_INTERACTIONS,3.460853774,0,amsacrine
EUKARYOTIC_TRANSLATION_ELONGATION,4.114443872,0,orphenadrine
SARS_COV_1_HOST_INTERACTIONS,2.791958501,0,orphenadrine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.865668402,0,orphenadrine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.865668402,0,orphenadrine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.94584983,0,orphenadrine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.478705511,0,orphenadrine
TRANSLATION,3.528352389,0,orphenadrine
RRNA_PROCESSING,3.606630313,0,orphenadrine
NERVOUS_SYSTEM_DEVELOPMENT,2.778435962,0,orphenadrine
SIGNALING_BY_ROBO_RECEPTORS,3.660232632,0,orphenadrine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.160215879,0,indacaterol
METABOLISM_OF_RNA,2.552325876,0,indacaterol
CELLULAR_RESPONSES_TO_STIMULI,2.6663507,0,indacaterol
INFECTIOUS_DISEASE,2.678936084,0,indacaterol
SARS_COV_2_INFECTION,2.83698162,0,indacaterol
VIRAL_INFECTION_PATHWAYS,2.84565982,0,indacaterol
NERVOUS_SYSTEM_DEVELOPMENT,2.939448982,0,indacaterol
SARS_COV_1_HOST_INTERACTIONS,3.175882856,0,indacaterol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.204361385,0,indacaterol
SARS_COV_1_INFECTION,3.260308155,0,indacaterol
SELENOAMINO_ACID_METABOLISM,4.636699346,0,tiapride
NERVOUS_SYSTEM_DEVELOPMENT,2.866686456,0,tiapride
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.866694866,0,tiapride
SARS_COV_1_INFECTION,2.870497835,0,tiapride
SARS_COV_1_HOST_INTERACTIONS,2.968214134,0,tiapride
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.872399094,0,tiapride
TRANSLATION,3.980877214,0,tiapride
INFLUENZA_INFECTION,4.080672033,0,tiapride
RRNA_PROCESSING,4.080917254,0,tiapride
METABOLISM_OF_RNA,3.011223883,0,tiapride
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.552703467,0,amantadine
SARS_COV_1_INFECTION,2.451957391,0,amantadine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.504035029,0,amantadine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.741535691,0,amantadine
SARS_COV_1_HOST_INTERACTIONS,2.803727491,0,amantadine
RRNA_PROCESSING,2.904898742,0,amantadine
INFLUENZA_INFECTION,3.087441849,0,amantadine
CELLULAR_RESPONSE_TO_STARVATION,3.095760442,0,amantadine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.125027951,0,amantadine
SIGNALING_BY_ROBO_RECEPTORS,3.106657428,0,amantadine
SELENOAMINO_ACID_METABOLISM,-2.815700342,0,ropinirole
SARS_COV_1_INFECTION,-2.372328451,0,ropinirole
INFLUENZA_INFECTION,-2.416775565,0,ropinirole
SARS_COV_1_HOST_INTERACTIONS,-2.503249747,0,ropinirole
RRNA_PROCESSING,-2.53638429,0,ropinirole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.540008364,0,ropinirole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.573952671,0,ropinirole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.616556517,0,ropinirole
CELLULAR_RESPONSE_TO_STARVATION,-2.594761915,0,ropinirole
EUKARYOTIC_TRANSLATION_INITIATION,-2.702863757,0,ropinirole
EUKARYOTIC_TRANSLATION_ELONGATION,-2.352780185,0,sufentanil
SELENOAMINO_ACID_METABOLISM,-2.305507234,0.00047381,sufentanil
EUKARYOTIC_TRANSLATION_INITIATION,-2.293205301,0.000631746,sufentanil
NONSENSE_MEDIATED_DECAY_NMD,-2.26460763,0.00047381,sufentanil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.222822042,0.000568572,sufentanil
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.208605572,0.000789683,sufentanil
INFLUENZA_INFECTION,-2.10254272,0.002165988,sufentanil
RRNA_PROCESSING,-2.099877809,0.001895239,sufentanil
TRANSLATION,-2.098787437,0.001684657,sufentanil
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.108699636,0.045131634,sufentanil
EUKARYOTIC_TRANSLATION_ELONGATION,3.920140652,0,gliquidone
VIRAL_INFECTION_PATHWAYS,2.518605429,0,gliquidone
SARS_COV_2_HOST_INTERACTIONS,2.58163665,0,gliquidone
NERVOUS_SYSTEM_DEVELOPMENT,3.002465629,0,gliquidone
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.294907849,0,gliquidone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.34008195,0,gliquidone
SARS_COV_1_HOST_INTERACTIONS,3.404573753,0,gliquidone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.407510806,0,gliquidone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.582838623,0,gliquidone
SIGNALING_BY_ROBO_RECEPTORS,3.614271309,0,gliquidone
FORMATION_OF_THE_CORNIFIED_ENVELOPE,1.848475893,0.097800603,lofexidine
KERATINIZATION,1.848475893,0.097800603,lofexidine
SENSORY_PERCEPTION,1.660184565,0.182538796,lofexidine
GLYCOSAMINOGLYCAN_METABOLISM,1.633175029,0.157753712,lofexidine
RAB_REGULATION_OF_TRAFFICKING,1.622022609,0.132499721,lofexidine
METABOLISM_OF_STEROIDS,1.600196961,0.123423021,lofexidine
ECM_PROTEOGLYCANS,1.503555313,0.169332844,lofexidine
SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT,1.48212902,0.162861449,lofexidine
DISEASES_OF_SIGNAL_TRANSDUCTION_BY_GROWTH_FACTOR_RECEPTORS_AND_SECOND_MESSENGERS,-2.391225424,1,lofexidine
CHROMATIN_ORGANIZATION,1.368875127,0.245580738,lofexidine
RAB_REGULATION_OF_TRAFFICKING,1.991042005,0.036334092,pentobarbital
INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING,-2.039749038,0.062556708,pentobarbital
EUKARYOTIC_TRANSLATION_ELONGATION,-1.915847111,0.15639177,pentobarbital
EUKARYOTIC_TRANSLATION_INITIATION,-1.824151626,0.270742742,pentobarbital
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.797858315,0.260821113,pentobarbital
NONSENSE_MEDIATED_DECAY_NMD,-1.783897919,0.234890349,pentobarbital
CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL,-1.779288299,0.205327259,pentobarbital
G_ALPHA_Q_SIGNALLING_EVENTS,-1.777896301,0.178156892,pentobarbital
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.771923466,0.146974631,pentobarbital
GPCR_LIGAND_BINDING,-1.772705541,0.164463603,pentobarbital
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.322585146,0,carisoprodol
SARS_COV_2_HOST_INTERACTIONS,2.484968612,0,carisoprodol
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.527659117,0,carisoprodol
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,2.57364233,0,carisoprodol
VIRAL_INFECTION_PATHWAYS,2.613751584,0,carisoprodol
CELLULAR_RESPONSES_TO_STIMULI,2.75738963,0,carisoprodol
SARS_COV_1_INFECTION,3.168377225,0,carisoprodol
RRNA_PROCESSING,3.370875127,0,carisoprodol
SARS_COV_1_HOST_INTERACTIONS,3.395190686,0,carisoprodol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.44448288,0,carisoprodol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.364016091,0,imexon
EUKARYOTIC_TRANSLATION_INITIATION,3.241012225,0,imexon
SELENOAMINO_ACID_METABOLISM,3.046726594,0,imexon
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.944582049,0,imexon
NONSENSE_MEDIATED_DECAY_NMD,2.838502376,0,imexon
TRANSLATION,2.829214266,0,imexon
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.816747797,0,imexon
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.714964744,0,imexon
CELLULAR_RESPONSE_TO_STARVATION,2.610394866,0,imexon
RESPIRATORY_ELECTRON_TRANSPORT,2.344292588,0.001552559,imexon
MRNA_SPLICING,-3.274411766,0,phentermine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.048382259,0,phentermine
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.417763743,0.005147563,phentermine
METABOLISM_OF_RNA,-2.345203192,0.005404942,phentermine
SUMOYLATION,-2.247693619,0.007412491,phentermine
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.19983159,0.007206589,phentermine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.154648039,0.025395103,phentermine
SIGNALING_BY_NTRKS,-2.014513621,0.017648789,phentermine
DNA_REPAIR,-1.987189687,0.018917296,phentermine
GPCR_LIGAND_BINDING,2.090088221,0.024601506,phentermine
EUKARYOTIC_TRANSLATION_ELONGATION,3.922627582,0,mocetinostat
NERVOUS_SYSTEM_DEVELOPMENT,2.556818605,0,mocetinostat
SARS_COV_1_INFECTION,2.708394346,0,mocetinostat
SARS_COV_1_HOST_INTERACTIONS,2.774530098,0,mocetinostat
CHROMATIN_ORGANIZATION,-2.792165776,0,mocetinostat
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.842463225,0,mocetinostat
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.942490357,0,mocetinostat
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.028093088,0,mocetinostat
TRANSLATION,3.299004415,0,mocetinostat
SIGNALING_BY_ROBO_RECEPTORS,3.417278092,0,mocetinostat
EUKARYOTIC_TRANSLATION_ELONGATION,3.539554972,0,terbinafine
SARS_COV_2_HOST_INTERACTIONS,2.602959734,0,terbinafine
SARS_COV_1_INFECTION,2.786126706,0,terbinafine
SARS_COV_1_HOST_INTERACTIONS,2.892864203,0,terbinafine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.893756387,0,terbinafine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.006759657,0,terbinafine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.047830321,0,terbinafine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.074145001,0,terbinafine
TRANSLATION,3.145971532,0,terbinafine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.581184237,0,terbinafine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.712606314,0,resorcinol
GPCR_LIGAND_BINDING,2.614737406,0,resorcinol
SIGNALING_BY_GPCR,2.396568935,0,resorcinol
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.522634779,0.003059886,resorcinol
G_ALPHA_Q_SIGNALLING_EVENTS,2.355539412,0.000188858,resorcinol
SENSORY_PERCEPTION,2.299029439,0.000604345,resorcinol
EUKARYOTIC_TRANSLATION_ELONGATION,2.298985581,0.00050362,resorcinol
SUMOYLATION,-2.414870444,0.010709602,resorcinol
EUKARYOTIC_TRANSLATION_INITIATION,2.249391596,0.000863349,resorcinol
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.13356037,0.028558939,resorcinol
EUKARYOTIC_TRANSLATION_ELONGATION,3.32794669,0,risperidone
RRNA_PROCESSING,2.809932136,0,risperidone
INFLUENZA_INFECTION,2.81816552,0,risperidone
SIGNALING_BY_ROBO_RECEPTORS,2.878015797,0,risperidone
CELLULAR_RESPONSE_TO_STARVATION,2.957087494,0,risperidone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.02633331,0,risperidone
TRANSLATION,2.729609874,0,risperidone
NONSENSE_MEDIATED_DECAY_NMD,3.215265015,0,risperidone
EUKARYOTIC_TRANSLATION_INITIATION,3.237939421,0,risperidone
SELENOAMINO_ACID_METABOLISM,3.27025614,0,risperidone
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,2.113141097,0.015481208,perampanel
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.57042558,0.048100266,perampanel
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,1.725108042,0.137610734,perampanel
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.47881266,0.105820586,perampanel
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.394444616,0.510306471,perampanel
INTERFERON_ALPHA_BETA_SIGNALING,1.386515688,0.403371463,perampanel
DISORDERS_OF_TRANSMEMBRANE_TRANSPORTERS,1.362314408,0.364324417,perampanel
GPCR_LIGAND_BINDING,-2.343961785,0.476192637,perampanel
GLYCOSAMINOGLYCAN_METABOLISM,1.316856466,0.383016542,perampanel
COPI_DEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC,1.315540029,0.329774294,perampanel
GPCR_LIGAND_BINDING,2.664030796,0,suvorexant
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.629540576,0,suvorexant
SIGNALING_BY_GPCR,2.31753511,0.000730785,suvorexant
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.309106186,0.000548089,suvorexant
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.407913755,0.011175369,suvorexant
SUMOYLATION,-2.187061668,0.042466404,suvorexant
KERATINIZATION,2.100379368,0.008623262,suvorexant
AMINE_LIGAND_BINDING_RECEPTORS,2.067889911,0.009987394,suvorexant
MHC_CLASS_II_ANTIGEN_PRESENTATION,-1.940332315,0.128144237,suvorexant
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,1.950156173,0.028396214,suvorexant
INNATE_IMMUNE_SYSTEM,3.840368228,0,irinotecan
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.783550593,0,irinotecan
SARS_COV_1_HOST_INTERACTIONS,-2.867632699,0,irinotecan
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.881252314,0,irinotecan
TRANSLATION,-2.691231508,0,irinotecan
INFLUENZA_INFECTION,-2.953034861,0,irinotecan
SIGNALING_BY_ROBO_RECEPTORS,-2.961456757,0,irinotecan
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.972464975,0,irinotecan
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.757563998,0,irinotecan
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.983425243,0,irinotecan
EUKARYOTIC_TRANSLATION_ELONGATION,3.956356048,0,mirtazapine
VIRAL_INFECTION_PATHWAYS,2.438817811,0,mirtazapine
METABOLISM_OF_RNA,2.4829733,0,mirtazapine
NERVOUS_SYSTEM_DEVELOPMENT,3.126990174,0,mirtazapine
SARS_COV_1_INFECTION,3.19141587,0,mirtazapine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.20058644,0,mirtazapine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.258602407,0,mirtazapine
SARS_COV_1_HOST_INTERACTIONS,3.35366459,0,mirtazapine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.434973625,0,mirtazapine
RRNA_PROCESSING,3.505083106,0,mirtazapine
EUKARYOTIC_TRANSLATION_ELONGATION,3.246032444,0,econazole
EUKARYOTIC_TRANSLATION_INITIATION,3.214362295,0,econazole
SELENOAMINO_ACID_METABOLISM,3.211482473,0,econazole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.160602712,0,econazole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.096691906,0,econazole
NONSENSE_MEDIATED_DECAY_NMD,3.088497708,0,econazole
TRANSLATION,3.000457428,0,econazole
CELLULAR_RESPONSE_TO_STARVATION,2.978487541,0,econazole
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.803221195,0,econazole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.781633262,0,econazole
EUKARYOTIC_TRANSLATION_ELONGATION,-3.364877524,0,tolcapone
SARS_COV_2_HOST_INTERACTIONS,-2.426681924,0,tolcapone
SARS_COV_1_INFECTION,-2.730280366,0,tolcapone
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.739267266,0,tolcapone
SARS_COV_1_HOST_INTERACTIONS,-2.773716833,0,tolcapone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.880155874,0,tolcapone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.899547325,0,tolcapone
TRANSLATION,-2.922914414,0,tolcapone
INFLUENZA_INFECTION,-2.95606785,0,tolcapone
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,-2.805214826,0,tolcapone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.158540967,0,KD-025
CELLULAR_RESPONSES_TO_STIMULI,2.967267104,0,KD-025
SARS_COV_1_INFECTION,3.181376046,0,KD-025
NERVOUS_SYSTEM_DEVELOPMENT,3.198713228,0,KD-025
SARS_COV_1_HOST_INTERACTIONS,3.278351076,0,KD-025
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.320293044,0,KD-025
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.385257526,0,KD-025
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.44374434,0,KD-025
INFLUENZA_INFECTION,3.554837612,0,KD-025
RRNA_PROCESSING,3.670070505,0,KD-025
MRNA_SPLICING,1.819789156,0.153226483,sitagliptin
RAB_REGULATION_OF_TRAFFICKING,1.695190916,0.159687841,sitagliptin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.666426295,0.126765685,sitagliptin
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.512274015,0.218301586,sitagliptin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.426553976,0.835154354,sitagliptin
GLYCOSAMINOGLYCAN_METABOLISM,1.465022659,0.22559369,sitagliptin
SELENOAMINO_ACID_METABOLISM,-2.362481686,0.706891618,sitagliptin
NONSENSE_MEDIATED_DECAY_NMD,-2.34890513,0.519480152,sitagliptin
EUKARYOTIC_TRANSLATION_INITIATION,-2.305831468,0.48194964,sitagliptin
REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC,1.364509752,0.343682694,sitagliptin
EUKARYOTIC_TRANSLATION_ELONGATION,4.775799105,0,loperamide
METABOLISM_OF_RNA,2.738096712,0,loperamide
NERVOUS_SYSTEM_DEVELOPMENT,2.807838754,0,loperamide
SARS_COV_1_INFECTION,3.014037024,0,loperamide
SARS_COV_1_HOST_INTERACTIONS,3.136203965,0,loperamide
RRNA_PROCESSING,3.902549177,0,loperamide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.910919938,0,loperamide
TRANSLATION,4.140060255,0,loperamide
SIGNALING_BY_ROBO_RECEPTORS,4.404337115,0,loperamide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.12956114,0,loperamide
PROTEASOME_ASSEMBLY,3.083355522,0,yohimbine
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,2.893249175,0,yohimbine
C_TYPE_LECTIN_RECEPTORS_CLRS,2.871439395,0,yohimbine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.608384463,0,yohimbine
NONSENSE_MEDIATED_DECAY_NMD,-2.584715727,0,yohimbine
SELENOAMINO_ACID_METABOLISM,-2.355149051,0,yohimbine
DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR,2.819239843,0.000848488,yohimbine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.327086324,0.000136229,yohimbine
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,2.746718814,0.00135758,yohimbine
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,2.718816634,0.001131317,yohimbine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.399730913,0,milrinone
NERVOUS_SYSTEM_DEVELOPMENT,2.672790089,0,milrinone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.733085484,0,milrinone
RRNA_PROCESSING,2.833657344,0,milrinone
TRANSLATION,2.925935732,0,milrinone
INFLUENZA_INFECTION,3.094480179,0,milrinone
SARS_COV_1_HOST_INTERACTIONS,3.120989264,0,milrinone
CELLULAR_RESPONSE_TO_STARVATION,3.136630716,0,milrinone
SARS_COV_1_INFECTION,2.882850211,0,milrinone
SIGNALING_BY_ROBO_RECEPTORS,3.218391364,0,milrinone
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.74923073,0.394179894,nefazodone
DISEASES_OF_METABOLISM,1.741759621,0.202380952,nefazodone
DISORDERS_OF_TRANSMEMBRANE_TRANSPORTERS,1.477425424,0.557319224,nefazodone
ASPARAGINE_N_LINKED_GLYCOSYLATION,1.462965359,0.44973545,nefazodone
RAB_REGULATION_OF_TRAFFICKING,1.41419736,0.457142857,nefazodone
UCH_PROTEINASES,1.341591114,0.555555556,nefazodone
NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH,1.298579167,0.583522298,nefazodone
ABC_TRANSPORTER_DISORDERS,1.255794335,0.628968254,nefazodone
HEDGEHOG_ON_STATE,1.243716477,0.583186361,nefazodone
TP53_REGULATES_METABOLIC_GENES,1.189135798,0.652910053,nefazodone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.008078689,0,ibutilide
EUKARYOTIC_TRANSLATION_INITIATION,2.862666226,0,ibutilide
NONSENSE_MEDIATED_DECAY_NMD,2.800059571,0,ibutilide
SELENOAMINO_ACID_METABOLISM,2.680578437,0,ibutilide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.607099837,0,ibutilide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.571759215,0.000391274,ibutilide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.50386438,0.000503067,ibutilide
MUSCLE_CONTRACTION,2.443742399,0.000880367,ibutilide
TRANSLATION,2.432685656,0.000912973,ibutilide
CELLULAR_RESPONSE_TO_STARVATION,2.410750499,0.000821676,ibutilide
EUKARYOTIC_TRANSLATION_ELONGATION,2.450909066,0.000812831,raclopride
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,-2.378825797,0.012281969,raclopride
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.25776801,0.004876987,raclopride
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.220516282,0.005960762,raclopride
SELENOAMINO_ACID_METABOLISM,2.203618275,0.006096234,raclopride
NONSENSE_MEDIATED_DECAY_NMD,2.193059603,0.005689818,raclopride
TOLL_LIKE_RECEPTOR_9_TLR9_CASCADE,-2.116706818,0.052637011,raclopride
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.129547448,0.0086702,raclopride
MHC_CLASS_II_ANTIGEN_PRESENTATION,-2.081736342,0.04327932,raclopride
ION_CHANNEL_TRANSPORT,2.102340883,0.010102331,raclopride
EUKARYOTIC_TRANSLATION_ELONGATION,3.268799591,0,dofequidar
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.591937033,0,dofequidar
TRANSLATION,2.595257751,0,dofequidar
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.747886996,0,dofequidar
SIGNALING_BY_ROBO_RECEPTORS,2.803024334,0,dofequidar
GPCR_LIGAND_BINDING,-2.811310936,0,dofequidar
EUKARYOTIC_TRANSLATION_INITIATION,2.894744182,0,dofequidar
RRNA_PROCESSING,2.607300524,0,dofequidar
CELLULAR_RESPONSE_TO_STARVATION,3.059893747,0,dofequidar
SELENOAMINO_ACID_METABOLISM,3.145740066,0,dofequidar
EUKARYOTIC_TRANSLATION_ELONGATION,3.396310328,0,ketanserin
TRANSLATION,2.479140635,0,ketanserin
RRNA_PROCESSING,2.779330157,0,ketanserin
SIGNALING_BY_ROBO_RECEPTORS,2.808259641,0,ketanserin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.94658179,0,ketanserin
CELLULAR_RESPONSE_TO_STARVATION,3.004299393,0,ketanserin
EUKARYOTIC_TRANSLATION_INITIATION,2.828947746,0,ketanserin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.152480784,0,ketanserin
SELENOAMINO_ACID_METABOLISM,3.154687782,0,ketanserin
NONSENSE_MEDIATED_DECAY_NMD,3.172850944,0,ketanserin
EUKARYOTIC_TRANSLATION_ELONGATION,3.938925406,0,vilazodone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.939540878,0,vilazodone
SIGNALING_BY_ROBO_RECEPTORS,3.255304557,0,vilazodone
RRNA_PROCESSING,3.273900774,0,vilazodone
TRANSLATION,3.557729714,0,vilazodone
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.748901693,0,vilazodone
CELLULAR_RESPONSE_TO_STARVATION,3.366297395,0,vilazodone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.769045854,0,vilazodone
SELENOAMINO_ACID_METABOLISM,3.845945568,0,vilazodone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.883481027,0,vilazodone
EUKARYOTIC_TRANSLATION_ELONGATION,3.778351228,0,loratadine
SARS_COV_2_HOST_INTERACTIONS,2.500974378,0,loratadine
METABOLISM_OF_RNA,2.628715649,0,loratadine
NERVOUS_SYSTEM_DEVELOPMENT,2.863860459,0,loratadine
SARS_COV_1_INFECTION,2.958481638,0,loratadine
SARS_COV_1_HOST_INTERACTIONS,3.253859042,0,loratadine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.330846526,0,loratadine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.338582296,0,loratadine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.408459491,0,loratadine
TRANSLATION,3.524169986,0,loratadine
EUKARYOTIC_TRANSLATION_ELONGATION,3.872339933,0,epinephrine
METABOLISM_OF_RNA,2.547582486,0,epinephrine
INFECTIOUS_DISEASE,2.62982789,0,epinephrine
SARS_COV_INFECTIONS,2.698160131,0,epinephrine
SARS_COV_2_HOST_INTERACTIONS,2.765239051,0,epinephrine
VIRAL_INFECTION_PATHWAYS,2.775333912,0,epinephrine
SARS_COV_2_INFECTION,2.788548679,0,epinephrine
NERVOUS_SYSTEM_DEVELOPMENT,2.955052602,0,epinephrine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.139916051,0,epinephrine
SARS_COV_1_INFECTION,3.175951621,0,epinephrine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.807353845,0,colchicine
EUKARYOTIC_TRANSLATION_INITIATION,-2.668231465,0,colchicine
NONSENSE_MEDIATED_DECAY_NMD,-2.658342138,0,colchicine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.64991079,0,colchicine
SELENOAMINO_ACID_METABOLISM,-2.596200572,0,colchicine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.528291591,0.000184084,colchicine
SARS_COV_1_INFECTION,-2.504145885,0.000157786,colchicine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.501182555,0.000138063,colchicine
INFLUENZA_INFECTION,-2.392174894,0.000773151,colchicine
TRANSLATION,-2.39428388,0.000859056,colchicine
EUKARYOTIC_TRANSLATION_ELONGATION,3.816274553,0,GDC-0199
NERVOUS_SYSTEM_DEVELOPMENT,2.611563035,0,GDC-0199
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.944671397,0,GDC-0199
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.1257387,0,GDC-0199
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.219256834,0,GDC-0199
RRNA_PROCESSING,3.35726281,0,GDC-0199
SARS_COV_1_INFECTION,3.382640302,0,GDC-0199
INFLUENZA_INFECTION,3.444993304,0,GDC-0199
SIGNALING_BY_ROBO_RECEPTORS,3.456792304,0,GDC-0199
TRANSLATION,3.301854087,0,GDC-0199
EUKARYOTIC_TRANSLATION_ELONGATION,-2.168467487,0.008452696,aliskiren
DISEASES_OF_METABOLISM,2.078161477,0.118847875,aliskiren
DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA,-2.120298534,0.006339522,aliskiren
SELENOAMINO_ACID_METABOLISM,-2.120130971,0.004226348,aliskiren
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.034546876,0.061800895,aliskiren
EUKARYOTIC_TRANSLATION_INITIATION,-2.107360446,0.004437665,aliskiren
NONSENSE_MEDIATED_DECAY_NMD,-2.097501925,0.004226348,aliskiren
RRNA_PROCESSING,-2.09013136,0.004226348,aliskiren
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.047013324,0.00603764,aliskiren
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.039038876,0.005811228,aliskiren
NONSENSE_MEDIATED_DECAY_NMD,3.397391048,0,paricalcitol
NERVOUS_SYSTEM_DEVELOPMENT,2.482708079,0,paricalcitol
SARS_COV_1_INFECTION,2.483534318,0,paricalcitol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.509867418,0,paricalcitol
SARS_COV_1_HOST_INTERACTIONS,2.667828075,0,paricalcitol
RRNA_PROCESSING,2.690937016,0,paricalcitol
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.751071586,0,paricalcitol
INFLUENZA_INFECTION,2.861183039,0,paricalcitol
TRANSLATION,3.004598036,0,paricalcitol
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.626795974,0,paricalcitol
GPCR_LIGAND_BINDING,2.731369006,0,melperone
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.682705627,0,melperone
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.456495325,0,melperone
SIGNALING_BY_GPCR,2.393457573,0,melperone
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.432434267,0.00208892,melperone
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.113760697,0.050134086,melperone
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.052501358,0.055008233,melperone
KERATINIZATION,2.053907155,0.011847466,melperone
M_PHASE,-2.016322895,0.052745236,melperone
NERVOUS_SYSTEM_DEVELOPMENT,1.978929987,0.021939753,melperone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.845751096,0,telmisartan
RRNA_PROCESSING,2.608601476,0,telmisartan
SIGNALING_BY_ROBO_RECEPTORS,2.922557423,0,telmisartan
CELLULAR_RESPONSE_TO_STARVATION,2.936142292,0,telmisartan
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.109358235,0,telmisartan
TRANSLATION,3.184123047,0,telmisartan
INFLUENZA_INFECTION,2.701988877,0,telmisartan
NONSENSE_MEDIATED_DECAY_NMD,3.310454604,0,telmisartan
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.401195088,0,telmisartan
EUKARYOTIC_TRANSLATION_INITIATION,3.535285763,0,telmisartan
CELL_CYCLE_MITOTIC,-2.983336729,0,tosedostat
MITOTIC_PROMETAPHASE,-2.807095532,0,tosedostat
M_PHASE,-2.76716539,0,tosedostat
CELL_CYCLE,-2.756375366,0,tosedostat
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.701257703,0,tosedostat
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.656458522,0,tosedostat
CELL_CYCLE_CHECKPOINTS,-2.52837852,0.000179399,tosedostat
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.450858782,0.000298999,tosedostat
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.514201299,0.001169046,tosedostat
MITOTIC_G2_G2_M_PHASES,-2.42018964,0.000384427,tosedostat
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.145768125,0.068157389,vicriviroc
SEPARATION_OF_SISTER_CHROMATIDS,-2.132700783,0.04232354,vicriviroc
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.119670431,0.031513631,vicriviroc
GPCR_LIGAND_BINDING,-2.082992275,0.035452835,vicriviroc
LATE_SARS_COV_2_INFECTION_EVENTS,2.027411729,0.268417214,vicriviroc
RHO_GTPASES_ACTIVATE_FORMINS,-1.966825702,0.083327905,vicriviroc
HIV_INFECTION,-1.927908515,0.09215905,vicriviroc
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,-1.923916062,0.08197732,vicriviroc
SIGNALING_BY_TGFB_FAMILY_MEMBERS,1.936959744,0.252524089,vicriviroc
CHROMATIN_ORGANIZATION,1.884327326,0.242517307,vicriviroc
SELENOAMINO_ACID_METABOLISM,3.653488359,0,moxisylyte
VIRAL_INFECTION_PATHWAYS,2.436573985,0,moxisylyte
NERVOUS_SYSTEM_DEVELOPMENT,2.473483793,0,moxisylyte
METABOLISM_OF_RNA,2.488592107,0,moxisylyte
SARS_COV_2_HOST_INTERACTIONS,2.581776935,0,moxisylyte
MRNA_SPLICING,-2.692903607,0,moxisylyte
SARS_COV_1_INFECTION,2.979843299,0,moxisylyte
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.124223145,0,moxisylyte
SARS_COV_1_HOST_INTERACTIONS,3.15750278,0,moxisylyte
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.192561734,0,moxisylyte
RRNA_PROCESSING,-2.56565646,0,procainamide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.541444854,0,procainamide
SIGNALING_BY_GPCR,2.482852956,0,procainamide
GPCR_LIGAND_BINDING,2.466942842,0,procainamide
METABOLISM_OF_RNA,-2.474070916,0.004350428,procainamide
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.209394328,0.002976227,procainamide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.238670843,0.020301998,procainamide
G_ALPHA_I_SIGNALLING_EVENTS,2.156246843,0.004910775,procainamide
G_ALPHA_Q_SIGNALLING_EVENTS,2.153794645,0.004216322,procainamide
SENSORY_PERCEPTION,2.04640139,0.012330085,procainamide
MITOTIC_METAPHASE_AND_ANAPHASE,-4.027753738,0,pralatrexate
GPCR_LIGAND_BINDING,2.709509945,0,pralatrexate
REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF,-2.763517326,0,pralatrexate
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.82189664,0,pralatrexate
ACTIVATION_OF_APC_C_AND_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS,-3.023993386,0,pralatrexate
RHO_GTPASES_ACTIVATE_FORMINS,-3.086631275,0,pralatrexate
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-3.18631809,0,pralatrexate
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,-3.190583686,0,pralatrexate
MITOTIC_PROMETAPHASE,-2.896286621,0,pralatrexate
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-3.361378273,0,pralatrexate
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.003891206,0,theophylline
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.415455434,0.006470186,theophylline
EUKARYOTIC_TRANSLATION_INITIATION,2.390752257,0.005032367,theophylline
TRANSLATION,2.200919814,0.021297696,theophylline
SIGNALING_BY_ROBO_RECEPTORS,2.189690784,0.018332194,theophylline
TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES,2.167589155,0.017433557,theophylline
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.121907623,0.020488923,theophylline
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.114613145,0.018736581,theophylline
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,2.112131448,0.016654738,theophylline
CELLULAR_RESPONSE_TO_STARVATION,2.036274715,0.0266356,theophylline
GPCR_LIGAND_BINDING,-2.556642256,0,lorazepam
ADAPTIVE_IMMUNE_SYSTEM,-2.350072596,0.001287093,lorazepam
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.312300429,0.000858062,lorazepam
SIGNALING_BY_GPCR,-2.224910794,0.00579192,lorazepam
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.196571972,0.006950304,lorazepam
SELECTIVE_AUTOPHAGY,-2.089861736,0.01737576,lorazepam
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.07166951,0.017651565,lorazepam
INTEGRIN_CELL_SURFACE_INTERACTIONS,2.103580853,0.08890069,lorazepam
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.028683014,0.02606364,lorazepam
G_ALPHA_Q_SIGNALLING_EVENTS,-2.0079026,0.027744011,lorazepam
RESPIRATORY_ELECTRON_TRANSPORT,1.543579791,0.601392734,glibenclamide
CLATHRIN_MEDIATED_ENDOCYTOSIS,1.32656927,0.824565819,glibenclamide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.22628049,1,glibenclamide
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.208675913,1,glibenclamide
SIGNALING_BY_NOTCH,-2.16764333,1,glibenclamide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.165535388,1,glibenclamide
SELENOAMINO_ACID_METABOLISM,-2.157959605,0.899742772,glibenclamide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.128338227,0.778884271,glibenclamide
G_ALPHA_Q_SIGNALLING_EVENTS,-2.118147057,0.676401363,glibenclamide
EUKARYOTIC_TRANSLATION_INITIATION,-2.07300483,0.629175142,glibenclamide
MRNA_SPLICING,2.109732269,0.012096774,moracizine
RAB_REGULATION_OF_TRAFFICKING,2.022813257,0.011424731,moracizine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.903137303,0.018369176,moracizine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.173966456,1,moracizine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.312075777,0.46202957,moracizine
SELENOAMINO_ACID_METABOLISM,-2.112634834,1,moracizine
NONSENSE_MEDIATED_DECAY_NMD,-2.105841169,0.821190675,moracizine
EUKARYOTIC_TRANSLATION_INITIATION,-2.066577488,0.65560417,moracizine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.051843185,0.532968205,moracizine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.036279841,0.452197508,moracizine
EUKARYOTIC_TRANSLATION_ELONGATION,2.549622276,0,tamsulosin
GPCR_LIGAND_BINDING,2.51291143,0,tamsulosin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.481368211,0,tamsulosin
NONSENSE_MEDIATED_DECAY_NMD,2.478551357,0,tamsulosin
SIGNALING_BY_GPCR,2.326825501,8.43E-05,tamsulosin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.334851408,9.37E-05,tamsulosin
MRNA_SPLICING,-2.336443199,0.001191692,tamsulosin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.381994766,0.000105406,tamsulosin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.448318999,0.000140542,tamsulosin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.450887379,0.00016865,tamsulosin
RAB_REGULATION_OF_TRAFFICKING,2.356098305,0.006459627,ritonavir
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.117199114,0.013995859,ritonavir
MRNA_SPLICING,2.029505303,0.017943409,ritonavir
S_PHASE,1.908873177,0.026915114,ritonavir
VISUAL_PHOTOTRANSDUCTION,-1.985673725,0.186799293,ritonavir
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.965823356,0.114260482,ritonavir
C_TYPE_LECTIN_RECEPTORS_CLRS,1.678647648,0.10163147,ritonavir
SWITCHING_OF_ORIGINS_TO_A_POST_REPLICATIVE_STATE,1.654441061,0.097253278,ritonavir
SYNTHESIS_OF_DNA,1.626649522,0.096279207,ritonavir
DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX,1.615413736,0.089627329,ritonavir
EUKARYOTIC_TRANSLATION_ELONGATION,3.071747136,0,semaxanib
SIGNALING_BY_ROBO_RECEPTORS,2.568954828,0,semaxanib
EUKARYOTIC_TRANSLATION_INITIATION,2.714013865,0,semaxanib
RRNA_PROCESSING,2.751434251,0,semaxanib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.755613514,0,semaxanib
INFLUENZA_INFECTION,2.606505257,0,semaxanib
NONSENSE_MEDIATED_DECAY_NMD,2.912241215,0,semaxanib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.931876562,0,semaxanib
SELENOAMINO_ACID_METABOLISM,2.95701648,0,semaxanib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.980094997,0,semaxanib
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.68942174,0.166637585,hydroflumethiazide
GLYCOSAMINOGLYCAN_METABOLISM,1.466921346,0.298813471,hydroflumethiazide
BIOLOGICAL_OXIDATIONS,1.237199371,0.565927994,hydroflumethiazide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.203597966,1,hydroflumethiazide
SELENOAMINO_ACID_METABOLISM,-2.142785985,1,hydroflumethiazide
EUKARYOTIC_TRANSLATION_INITIATION,-2.134837509,1,hydroflumethiazide
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.129532726,1,hydroflumethiazide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.117033845,1,hydroflumethiazide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.094907597,0.904590569,hydroflumethiazide
NONSENSE_MEDIATED_DECAY_NMD,-2.073765283,0.79661798,hydroflumethiazide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.822900798,0,phenylephrine
CELLULAR_RESPONSE_TO_STARVATION,2.612199146,0.000420894,phenylephrine
MUSCLE_CONTRACTION,2.29416257,0.010101462,phenylephrine
TRANSLATION,2.264733545,0.00883878,phenylephrine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.213482312,0.009091316,phenylephrine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.13793,0.013889511,phenylephrine
ION_CHANNEL_TRANSPORT,2.133069611,0.01202555,phenylephrine
DISEASES_OF_METABOLISM,2.108660261,0.013258169,phenylephrine
SIGNALING_BY_ROBO_RECEPTORS,2.10377115,0.012346232,phenylephrine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.096329681,0.011953397,phenylephrine
MRNA_SPLICING,2.694901149,0,amlexanox
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.331690071,0.003928987,amlexanox
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,2.034323999,0.047147846,amlexanox
RAB_REGULATION_OF_TRAFFICKING,1.784789067,0.178768917,amlexanox
GLUCOSE_METABOLISM,1.777932848,0.149301513,amlexanox
VESICLE_MEDIATED_TRANSPORT,1.635522104,0.299912689,amlexanox
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,1.562456206,0.336770331,amlexanox
S_PHASE,1.562267848,0.29467404,amlexanox
DNA_REPLICATION,1.5499716,0.280267753,amlexanox
SYNTHESIS_OF_DNA,1.548183362,0.253419674,amlexanox
EUKARYOTIC_TRANSLATION_ELONGATION,-2.293841956,0,armodafinil
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.27454485,0,armodafinil
EUKARYOTIC_TRANSLATION_INITIATION,-2.234416027,0.000311456,armodafinil
SELENOAMINO_ACID_METABOLISM,-2.204335391,0.000233592,armodafinil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.182432385,0.00056062,armodafinil
CELLULAR_RESPONSE_TO_STARVATION,-2.075519736,0.00498329,armodafinil
NONSENSE_MEDIATED_DECAY_NMD,-2.070117841,0.004404872,armodafinil
INFLUENZA_INFECTION,-2.013627185,0.008759689,armodafinil
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-1.994570112,0.009447487,armodafinil
G_ALPHA_Q_SIGNALLING_EVENTS,-1.868124804,0.039804027,armodafinil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.665872529,0,lonidamine
EUKARYOTIC_TRANSLATION_ELONGATION,2.637178838,0,lonidamine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.600403514,0,lonidamine
EUKARYOTIC_TRANSLATION_INITIATION,2.559241004,0,lonidamine
NONSENSE_MEDIATED_DECAY_NMD,2.503703033,0,lonidamine
SELENOAMINO_ACID_METABOLISM,2.500710261,0,lonidamine
CELLULAR_RESPONSE_TO_STARVATION,2.465573601,0,lonidamine
SARS_COV_1_HOST_INTERACTIONS,2.365385927,0,lonidamine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.337371308,0.01011972,lonidamine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.304128716,0.000550211,lonidamine
CELL_CYCLE_MITOTIC,-2.850482503,0,AT-7519
CELL_CYCLE,-2.364517297,0.008805065,AT-7519
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.247431233,0.017023126,AT-7519
COPI_MEDIATED_ANTEROGRADE_TRANSPORT,-2.24391705,0.013207598,AT-7519
SYNTHESIS_OF_DNA,-2.22819703,0.012327091,AT-7519
M_PHASE,-2.226404273,0.01085958,AT-7519
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,-2.174795624,0.014591251,AT-7519
S_PHASE,-2.106737054,0.022673043,AT-7519
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,-2.105356704,0.020153816,AT-7519
RHO_GTPASES_ACTIVATE_FORMINS,-2.094945261,0.019899447,AT-7519
EUKARYOTIC_TRANSLATION_ELONGATION,4.215347884,0,azelastine
SARS_COV_INFECTIONS,2.486586971,0,azelastine
METABOLISM_OF_RNA,2.724327838,0,azelastine
INFECTIOUS_DISEASE,2.813053079,0,azelastine
SARS_COV_2_HOST_INTERACTIONS,2.899410523,0,azelastine
VIRAL_INFECTION_PATHWAYS,2.945712642,0,azelastine
NERVOUS_SYSTEM_DEVELOPMENT,3.248267816,0,azelastine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.322611214,0,azelastine
SARS_COV_1_INFECTION,3.37920767,0,azelastine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.380381307,0,azelastine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.901124907,0,topiroxostat
NONSENSE_MEDIATED_DECAY_NMD,2.379850751,0.002756123,topiroxostat
SELENOAMINO_ACID_METABOLISM,2.305411327,0.004777279,topiroxostat
CELLULAR_RESPONSE_TO_STARVATION,2.206586437,0.011851327,topiroxostat
ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION,-2.194181107,0.055896727,topiroxostat
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.190444236,0.011906449,topiroxostat
TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES,2.147454464,0.015434286,topiroxostat
RESPIRATORY_ELECTRON_TRANSPORT,2.064909964,0.028506182,topiroxostat
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,2.050897559,0.027423419,topiroxostat
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,-2.011591055,0.136534628,topiroxostat
METABOLISM_OF_RNA,-3.921367518,0,rizatriptan
RRNA_PROCESSING,-3.465264044,0,rizatriptan
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.067680238,0,rizatriptan
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.701301041,0,rizatriptan
SUMOYLATION,-2.680117146,0,rizatriptan
SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS,-2.624945885,0,rizatriptan
GPCR_LIGAND_BINDING,2.563988348,0,rizatriptan
SIGNALING_BY_GPCR,2.436508967,0,rizatriptan
G_ALPHA_Q_SIGNALLING_EVENTS,2.426752447,0,rizatriptan
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.370898855,0.000360347,rizatriptan
RAB_REGULATION_OF_TRAFFICKING,2.298719394,0.00543913,rufinamide
MRNA_SPLICING,1.969080244,0.025155975,rufinamide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.90495569,0.02810217,rufinamide
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,1.861114572,0.026855703,rufinamide
PEPTIDE_HORMONE_METABOLISM,1.584495381,0.115853463,rufinamide
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.428968314,0.201927692,rufinamide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.187405221,1,rufinamide
SELENOAMINO_ACID_METABOLISM,-2.133534895,1,rufinamide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.126173509,0.884095588,rufinamide
NONSENSE_MEDIATED_DECAY_NMD,-2.112504931,0.677347176,rufinamide
EUKARYOTIC_TRANSLATION_ELONGATION,3.323116851,0,ilomastat
SIGNALING_BY_ROBO_RECEPTORS,2.614063137,0,ilomastat
TRANSLATION,2.621481256,0,ilomastat
INFLUENZA_INFECTION,2.651662217,0,ilomastat
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.811751663,0,ilomastat
EUKARYOTIC_TRANSLATION_INITIATION,2.886524084,0,ilomastat
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.686498284,0,ilomastat
SELENOAMINO_ACID_METABOLISM,3.135663414,0,ilomastat
NONSENSE_MEDIATED_DECAY_NMD,2.978222137,0,ilomastat
CELLULAR_RESPONSE_TO_STARVATION,2.912862943,0,ilomastat
EUKARYOTIC_TRANSLATION_ELONGATION,3.259833913,0,BRD-K41170226
RRNA_PROCESSING,2.602680763,0,BRD-K41170226
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.608049252,0,BRD-K41170226
GPCR_LIGAND_BINDING,2.668200256,0,BRD-K41170226
INFLUENZA_INFECTION,2.682832934,0,BRD-K41170226
TRANSLATION,2.815279634,0,BRD-K41170226
CELLULAR_RESPONSE_TO_STARVATION,2.823259441,0,BRD-K41170226
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.864633372,0,BRD-K41170226
NERVOUS_SYSTEM_DEVELOPMENT,2.634881739,0,BRD-K41170226
SIGNALING_BY_ROBO_RECEPTORS,3.04922715,0,BRD-K41170226
NONSENSE_MEDIATED_DECAY_NMD,3.207568405,0,ubenimex
RRNA_PROCESSING,2.621682725,0,ubenimex
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.644710416,0,ubenimex
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.658605432,0,ubenimex
SARS_COV_1_HOST_INTERACTIONS,2.773067628,0,ubenimex
INFLUENZA_INFECTION,2.800938246,0,ubenimex
TRANSLATION,2.816857737,0,ubenimex
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.595599748,0,ubenimex
CELLULAR_RESPONSE_TO_STARVATION,2.877482858,0,ubenimex
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.088246474,0,ubenimex
EUKARYOTIC_TRANSLATION_ELONGATION,4.030830562,0,methimazole
SARS_COV_1_INFECTION,2.705383369,0,methimazole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.28147239,0,methimazole
TRANSLATION,3.345257511,0,methimazole
RRNA_PROCESSING,3.487133919,0,methimazole
INFLUENZA_INFECTION,3.521157186,0,methimazole
SIGNALING_BY_ROBO_RECEPTORS,3.554610036,0,methimazole
SARS_COV_1_HOST_INTERACTIONS,2.8583104,0,methimazole
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.752957583,0,methimazole
CELLULAR_RESPONSE_TO_STARVATION,3.733012138,0,methimazole
EUKARYOTIC_TRANSLATION_ELONGATION,4.08668472,0,escitalopram
INFECTIOUS_DISEASE,2.617917067,0,escitalopram
SARS_COV_2_HOST_INTERACTIONS,2.632199293,0,escitalopram
VIRAL_INFECTION_PATHWAYS,2.777202257,0,escitalopram
NERVOUS_SYSTEM_DEVELOPMENT,2.996177121,0,escitalopram
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.097495345,0,escitalopram
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.226599767,0,escitalopram
SARS_COV_1_INFECTION,3.313611835,0,escitalopram
SARS_COV_1_HOST_INTERACTIONS,3.424670713,0,escitalopram
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.553053621,0,escitalopram
METABOLISM_OF_RNA,-5.200632764,0,cladribine
RRNA_PROCESSING,-4.303673812,0,cladribine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-4.056231676,0,cladribine
MRNA_SPLICING,-3.902235548,0,cladribine
CELL_CYCLE,-3.117577041,0,cladribine
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.936395366,0,cladribine
M_PHASE,-2.616796669,0.000343702,cladribine
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.488273774,0.000611025,cladribine
CELL_CYCLE_CHECKPOINTS,-2.695956197,0.000392802,cladribine
DNA_REPAIR,-2.416499225,0.001099845,cladribine
EUKARYOTIC_TRANSLATION_ELONGATION,4.314078556,0,atorvastatin
CELLULAR_RESPONSES_TO_STIMULI,2.532482939,0,atorvastatin
SARS_COV_2_HOST_INTERACTIONS,2.668575916,0,atorvastatin
METABOLISM_OF_RNA,2.715941226,0,atorvastatin
VIRAL_INFECTION_PATHWAYS,2.755012331,0,atorvastatin
NERVOUS_SYSTEM_DEVELOPMENT,3.186175379,0,atorvastatin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.214848251,0,atorvastatin
SARS_COV_1_INFECTION,3.29824315,0,atorvastatin
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.432354244,0,atorvastatin
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.452710615,0,atorvastatin
SEPARATION_OF_SISTER_CHROMATIDS,-2.316265979,0.0220372,nelarabine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.311059526,0.0110186,nelarabine
MITOTIC_METAPHASE_AND_ANAPHASE,-2.218971296,0.019012487,nelarabine
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.210072078,0.014583441,nelarabine
INTERFERON_SIGNALING,-2.193856283,0.013481581,nelarabine
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.17587358,0.013395161,nelarabine
M_PHASE,-2.119382906,0.017963096,nelarabine
CELL_CYCLE_CHECKPOINTS,-2.101984253,0.017662168,nelarabine
RHO_GTPASES_ACTIVATE_FORMINS,-2.09303909,0.017140045,nelarabine
CELL_CYCLE_MITOTIC,-2.073150961,0.018018652,nelarabine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.024856531,0,pyrimethamine
RESPIRATORY_ELECTRON_TRANSPORT,2.592159875,0,pyrimethamine
METABOLISM_OF_RNA,2.649591687,0,pyrimethamine
VIRAL_INFECTION_PATHWAYS,2.696669879,0,pyrimethamine
CELLULAR_RESPONSES_TO_STIMULI,2.875723904,0,pyrimethamine
SARS_COV_1_HOST_INTERACTIONS,2.961667845,0,pyrimethamine
SARS_COV_1_INFECTION,2.987252623,0,pyrimethamine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.163203719,0,pyrimethamine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.344547434,0,pyrimethamine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.376107668,0,pyrimethamine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.412098776,0,thalidomide
MRNA_SPLICING,-3.321835939,0,thalidomide
KERATINIZATION,2.500672178,0,thalidomide
RRNA_PROCESSING,-2.712784119,0.000953772,thalidomide
METABOLISM_OF_RNA,-2.490884006,0.000715329,thalidomide
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.347055492,0.000399145,thalidomide
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.315173644,0.004005844,thalidomide
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.22820567,0.006199521,thalidomide
INTERFERON_ALPHA_BETA_SIGNALING,-2.103844858,0.012262789,thalidomide
DNA_REPAIR,-2.069044483,0.012160599,thalidomide
GPCR_LIGAND_BINDING,-2.740131431,0,TG-100801
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.678419283,0,TG-100801
SIGNALING_BY_GPCR,-2.540628926,0,TG-100801
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.277168438,0.000540884,TG-100801
RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY,-2.218693131,0.001730829,TG-100801
G_ALPHA_I_SIGNALLING_EVENTS,-2.215780866,0.001442358,TG-100801
G_ALPHA_Q_SIGNALLING_EVENTS,-2.182155635,0.002008998,TG-100801
SIGNALING_BY_NTRKS,-2.034103479,0.01433343,TG-100801
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.031802598,0.012740827,TG-100801
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-1.985009179,0.019039122,TG-100801
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.684411482,0,VX-661
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.620926291,0,VX-661
GPCR_LIGAND_BINDING,2.416531448,0.000385271,VX-661
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.22911939,0.00179793,VX-661
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.346157028,0.012558807,VX-661
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.318562127,0.009568615,VX-661
MITOTIC_METAPHASE_AND_ANAPHASE,-2.285667811,0.008073519,VX-661
SIGNALING_BY_GPCR,2.171105699,0.00288953,VX-661
METABOLISM_OF_RNA,-2.173770598,0.012199984,VX-661
M_PHASE,-2.159005184,0.010764692,VX-661
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.310332259,0,BRD-K45330754
SARS_COV_1_INFECTION,2.375047514,0,BRD-K45330754
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.446342565,0,BRD-K45330754
SARS_COV_1_HOST_INTERACTIONS,2.599178048,0,BRD-K45330754
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.692393677,0,BRD-K45330754
TRANSLATION,2.735630527,0,BRD-K45330754
SIGNALING_BY_ROBO_RECEPTORS,2.840207843,0,BRD-K45330754
INFLUENZA_INFECTION,2.894166433,0,BRD-K45330754
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.802826966,0,BRD-K45330754
EUKARYOTIC_TRANSLATION_INITIATION,3.104161607,0,BRD-K45330754
EUKARYOTIC_TRANSLATION_ELONGATION,-2.229264125,0.001986548,felbamate
EUKARYOTIC_TRANSLATION_INITIATION,-2.194227409,0.001489911,felbamate
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.175034229,0.001324365,felbamate
SELENOAMINO_ACID_METABOLISM,-2.155608858,0.001738229,felbamate
TRANSLATION,-2.13850302,0.001589238,felbamate
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.118992724,0.002152093,felbamate
NONSENSE_MEDIATED_DECAY_NMD,-2.061858868,0.004540681,felbamate
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.058032504,0.004221414,felbamate
CELLULAR_RESPONSE_TO_STARVATION,-2.045537429,0.004745642,felbamate
SARS_COV_1_INFECTION,-2.026381667,0.004867042,felbamate
EUKARYOTIC_TRANSLATION_ELONGATION,-2.452034736,0,adapalene
SELENOAMINO_ACID_METABOLISM,-2.392090179,0.000478673,adapalene
NONSENSE_MEDIATED_DECAY_NMD,-2.377576215,0.000319115,adapalene
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.333262002,0.000478673,adapalene
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.278660595,0.000765877,adapalene
EUKARYOTIC_TRANSLATION_INITIATION,-2.271052571,0.000638231,adapalene
CELLULAR_RESPONSE_TO_STARVATION,-2.234627156,0.000820582,adapalene
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.111848652,0.005265403,adapalene
RRNA_PROCESSING,-2.090949508,0.006701422,adapalene
TRANSLATION,-2.0701976,0.007084361,adapalene
EUKARYOTIC_TRANSLATION_ELONGATION,-2.784078569,0,LY-215490
SARS_COV_1_HOST_INTERACTIONS,-2.322092451,0,LY-215490
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-2.357203848,0,LY-215490
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,-2.37617262,0,LY-215490
TRANSLATION,-2.43013385,0,LY-215490
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.437398224,0,LY-215490
INFLUENZA_INFECTION,-2.495596207,0,LY-215490
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.510306955,0,LY-215490
SIGNALING_BY_ROBO_RECEPTORS,-2.317571164,0,LY-215490
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.58814696,0,LY-215490
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.713028333,0,bisoprolol
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.386789671,0.005212982,bisoprolol
EUKARYOTIC_TRANSLATION_INITIATION,2.383955049,0.003861468,bisoprolol
SELENOAMINO_ACID_METABOLISM,2.308361205,0.005212982,bisoprolol
NONSENSE_MEDIATED_DECAY_NMD,2.218996618,0.0097309,bisoprolol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.20086533,0.009653671,bisoprolol
RESPIRATORY_ELECTRON_TRANSPORT,2.095175072,0.021844877,bisoprolol
CELLULAR_RESPONSE_TO_STARVATION,2.038429987,0.032291528,bisoprolol
TRANSLATION,2.021218865,0.032951196,bisoprolol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.010880404,0.032436333,bisoprolol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.194031249,0,E-2012
CELLULAR_RESPONSES_TO_STIMULI,2.395165578,0,E-2012
VIRAL_INFECTION_PATHWAYS,2.484105679,0,E-2012
SARS_COV_INFECTIONS,2.494760268,0,E-2012
METABOLISM_OF_RNA,2.612277515,0,E-2012
SARS_COV_2_INFECTION,2.727244367,0,E-2012
SARS_COV_2_HOST_INTERACTIONS,2.764946732,0,E-2012
SARS_COV_1_INFECTION,3.079364079,0,E-2012
NERVOUS_SYSTEM_DEVELOPMENT,3.187586606,0,E-2012
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.325131714,0,E-2012
EUKARYOTIC_TRANSLATION_ELONGATION,-2.202617935,0.001998913,asymmetrical-dimethylarginine
SELENOAMINO_ACID_METABOLISM,-2.125687774,0.00549701,asymmetrical-dimethylarginine
EUKARYOTIC_TRANSLATION_INITIATION,-2.077499317,0.006996195,asymmetrical-dimethylarginine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.064999248,0.005996739,asymmetrical-dimethylarginine
RAB_REGULATION_OF_TRAFFICKING,1.988520015,0.038497256,asymmetrical-dimethylarginine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.016901299,0.009994564,asymmetrical-dimethylarginine
NONSENSE_MEDIATED_DECAY_NMD,-1.987588072,0.011826901,asymmetrical-dimethylarginine
G_ALPHA_Q_SIGNALLING_EVENTS,-1.950805368,0.014991847,asymmetrical-dimethylarginine
CELLULAR_RESPONSE_TO_STARVATION,-1.951700782,0.017133539,asymmetrical-dimethylarginine
INFLUENZA_INFECTION,-1.945169084,0.014658694,asymmetrical-dimethylarginine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.71861558,0,fluspirilene
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.381500569,0,fluspirilene
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.364722256,0,fluspirilene
EUKARYOTIC_TRANSLATION_ELONGATION,2.364722256,0,fluspirilene
NONSENSE_MEDIATED_DECAY_NMD,2.321013196,0,fluspirilene
SELENOAMINO_ACID_METABOLISM,2.271465014,0.000462513,fluspirilene
MITOTIC_METAPHASE_AND_ANAPHASE,-2.296364646,0.007549205,fluspirilene
GPCR_LIGAND_BINDING,2.250870479,0.000642379,fluspirilene
SIGNALING_BY_GPCR,2.224650339,0.000867211,fluspirilene
EUKARYOTIC_TRANSLATION_INITIATION,2.225015505,0.000991098,fluspirilene
GPCR_LIGAND_BINDING,-2.732175093,0,milnacipran
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.6363206,0,milnacipran
SIGNALING_BY_GPCR,-2.528514896,0.000424297,milnacipran
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-2.306987129,0.001272891,milnacipran
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.255065543,0.003309516,milnacipran
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,-2.09314119,0.019941954,milnacipran
ADAPTIVE_IMMUNE_SYSTEM,-2.082502169,0.019275202,milnacipran
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.069387066,0.018456915,milnacipran
DISEASES_OF_MITOTIC_CELL_CYCLE,-2.051616042,0.019093361,milnacipran
G_ALPHA_I_SIGNALLING_EVENTS,-2.006208498,0.025075947,milnacipran
METABOLISM_OF_RNA,-2.697326939,0,gemcitabine
RRNA_PROCESSING,-2.218035433,0.012334199,gemcitabine
INFLUENZA_INFECTION,-2.177771416,0.010278499,gemcitabine
ADAPTIVE_IMMUNE_SYSTEM,-2.161760291,0.010175714,gemcitabine
CELL_CYCLE_MITOTIC,-2.131084673,0.010114043,gemcitabine
M_PHASE,-2.12649831,0.008839509,gemcitabine
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.152211303,0.046723776,gemcitabine
TRNA_PROCESSING,-2.066627686,0.015153444,gemcitabine
HOST_INTERACTIONS_OF_HIV_FACTORS,-2.023115666,0.02143067,gemcitabine
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,-2.021303776,0.019597671,gemcitabine
GPCR_LIGAND_BINDING,2.603877886,0,pranlukast
SIGNALING_BY_GPCR,2.560676431,0,pranlukast
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.52376364,0,pranlukast
POTASSIUM_CHANNELS,2.352839068,0.000932215,pranlukast
NEURONAL_SYSTEM,2.350189298,0.000745772,pranlukast
REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA,-2.412453957,0.027295956,pranlukast
HATS_ACETYLATE_HISTONES,-2.352558219,0.019851604,pranlukast
MITOTIC_PROMETAPHASE,-2.21730768,0.042184659,pranlukast
METABOLISM_OF_RNA,-2.206720972,0.033499582,pranlukast
G_ALPHA_I_SIGNALLING_EVENTS,2.133669428,0.00569687,pranlukast
EUKARYOTIC_TRANSLATION_ELONGATION,-2.392303845,0.004758573,KX-2391
NONSENSE_MEDIATED_DECAY_NMD,-2.379237345,0.002379286,KX-2391
EUKARYOTIC_TRANSLATION_INITIATION,-2.32893558,0.002855144,KX-2391
SELENOAMINO_ACID_METABOLISM,-2.32111611,0.002141358,KX-2391
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.27732461,0.004187544,KX-2391
RRNA_PROCESSING,-2.254839621,0.004758573,KX-2391
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.237635528,0.00530241,KX-2391
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.196555965,0.007494752,KX-2391
CELLULAR_RESPONSE_TO_STARVATION,-2.141267114,0.009728638,KX-2391
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.125127059,0.009326803,KX-2391
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.749913442,0,crizotinib
EUKARYOTIC_TRANSLATION_ELONGATION,2.670731742,0,crizotinib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.549561778,0,crizotinib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.542374154,0,crizotinib
EUKARYOTIC_TRANSLATION_INITIATION,2.531037476,0,crizotinib
NONSENSE_MEDIATED_DECAY_NMD,2.505792249,0,crizotinib
SELENOAMINO_ACID_METABOLISM,2.465287882,0,crizotinib
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.607106516,0.001339662,crizotinib
GPCR_LIGAND_BINDING,2.330461065,0.00021641,crizotinib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.323494491,0.000189358,crizotinib
RESPIRATORY_ELECTRON_TRANSPORT,2.954765425,0,fasudil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.534201926,0.000629745,fasudil
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.500967702,0.001679319,fasudil
TRANSLATION,2.186859572,0.022985683,fasudil
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.143243755,0.026197382,fasudil
MUSCLE_CONTRACTION,2.116204033,0.02518979,fasudil
CELLULAR_RESPONSE_TO_STARVATION,2.024478241,0.042462789,fasudil
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,1.975674025,0.052898559,fasudil
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,1.971006164,0.048840204,fasudil
PROTEIN_LOCALIZATION,1.921343621,0.061085241,fasudil
EUKARYOTIC_TRANSLATION_ELONGATION,-2.491639445,0,eugenol
SELENOAMINO_ACID_METABOLISM,-2.424673488,0,eugenol
NONSENSE_MEDIATED_DECAY_NMD,-2.420425032,0,eugenol
EUKARYOTIC_TRANSLATION_INITIATION,-2.39614343,0,eugenol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.361037999,0.000185431,eugenol
CELLULAR_RESPONSE_TO_STARVATION,-2.280101483,0.001081683,eugenol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.239032614,0.000927157,eugenol
RRNA_PROCESSING,-2.216859163,0.000927157,eugenol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.215259843,0.00082414,eugenol
RAB_REGULATION_OF_TRAFFICKING,2.10732138,0.016007417,eugenol
PROTEIN_LOCALIZATION,1.604293616,0.447460415,paracetamol
G_ALPHA_Q_SIGNALLING_EVENTS,-1.84183182,0.571772914,paracetamol
ANCHORING_OF_THE_BASAL_BODY_TO_THE_PLASMA_MEMBRANE,-1.790644021,0.500674195,paracetamol
GPCR_LIGAND_BINDING,-1.774690318,0.391125819,paracetamol
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.753099245,0.353256222,paracetamol
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,-1.747446755,0.298117425,paracetamol
CILIUM_ASSEMBLY,-1.742201554,0.263678465,paracetamol
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,1.349625585,0.864761121,paracetamol
INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING,-1.727228572,0.257404353,paracetamol
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.332358308,0.637557977,paracetamol
MRNA_SPLICING,-2.965104946,0,ketoprofen
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.735034295,0,ketoprofen
METABOLISM_OF_RNA,-2.723691161,0,ketoprofen
M_PHASE,-2.437060891,0.001511368,ketoprofen
MITOTIC_METAPHASE_AND_ANAPHASE,-2.169730777,0.007859114,ketoprofen
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.110052697,0.009068209,ketoprofen
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.110101793,0.010579577,ketoprofen
FATTY_ACID_METABOLISM,-2.088498912,0.010201735,ketoprofen
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.113574683,0.038664919,ketoprofen
CELL_CYCLE_MITOTIC,-1.978357191,0.019479856,ketoprofen
EUKARYOTIC_TRANSLATION_ELONGATION,2.638176385,0,BRD-A20239487
GPCR_LIGAND_BINDING,2.528371364,0,BRD-A20239487
NONSENSE_MEDIATED_DECAY_NMD,2.519090451,0,BRD-A20239487
SIGNALING_BY_GPCR,2.463286959,0,BRD-A20239487
SELENOAMINO_ACID_METABOLISM,2.445506054,0,BRD-A20239487
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.431110063,0,BRD-A20239487
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.429472773,0,BRD-A20239487
EUKARYOTIC_TRANSLATION_INITIATION,2.424913223,0,BRD-A20239487
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.372765601,0,BRD-A20239487
G_ALPHA_Q_SIGNALLING_EVENTS,2.307121864,0.000270318,BRD-A20239487
RAB_REGULATION_OF_TRAFFICKING,2.418468537,0,dosulepin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.412416538,0,dosulepin
SELENOAMINO_ACID_METABOLISM,-2.366900915,0,dosulepin
NONSENSE_MEDIATED_DECAY_NMD,-2.337356989,0,dosulepin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.304400618,0.000244553,dosulepin
EUKARYOTIC_TRANSLATION_INITIATION,-2.246381113,0.000391284,dosulepin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.202798942,0.001304281,dosulepin
CELLULAR_RESPONSE_TO_STARVATION,-2.201861001,0.001117955,dosulepin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.201130274,0.001100487,dosulepin
DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA,-2.137115924,0.001956421,dosulepin
EUKARYOTIC_TRANSLATION_ELONGATION,3.619363693,0,nilotinib
METABOLISM_OF_RNA,2.423718121,0,nilotinib
SARS_COV_INFECTIONS,2.441379584,0,nilotinib
SARS_COV_2_INFECTION,2.524114246,0,nilotinib
SARS_COV_2_HOST_INTERACTIONS,2.92639773,0,nilotinib
NERVOUS_SYSTEM_DEVELOPMENT,2.983908917,0,nilotinib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.195034758,0,nilotinib
SARS_COV_1_INFECTION,3.204836929,0,nilotinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.255100421,0,nilotinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.320976975,0,nilotinib
METABOLISM_OF_RNA,-3.274010077,0,losartan
RRNA_PROCESSING,-2.919453833,0,losartan
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.786958644,0,losartan
SIGNALING_BY_GPCR,2.530413745,0,losartan
GPCR_LIGAND_BINDING,2.467337826,0.000361305,losartan
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.388532671,0.00024087,losartan
G_ALPHA_I_SIGNALLING_EVENTS,2.33723626,0.000541957,losartan
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.375096623,0.003865691,losartan
SUMOYLATION,-2.277170495,0.00566968,losartan
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.217583915,0.002167829,losartan
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.453026644,0.004110823,nepafenac
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,2.287478724,0.012332468,nepafenac
GPCR_LIGAND_BINDING,-2.098281917,0.101435294,nepafenac
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.044167732,0.082114285,nepafenac
SIGNALING_BY_INTERLEUKINS,-2.036487765,0.061183193,nepafenac
PEPTIDE_LIGAND_BINDING_RECEPTORS,-1.956644493,0.097208823,nepafenac
TOLL_LIKE_RECEPTOR_9_TLR9_CASCADE,-1.953812022,0.081389748,nepafenac
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,-1.886537964,0.11612731,nepafenac
PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION,1.921811929,0.139572213,nepafenac
TOLL_LIKE_RECEPTOR_CASCADES,-1.864758338,0.122653901,nepafenac
ADAPTIVE_IMMUNE_SYSTEM,-2.422529714,0.001344819,tipiracil
INNATE_IMMUNE_SYSTEM,-2.374340471,0.002017228,tipiracil
FC_EPSILON_RECEPTOR_FCERI_SIGNALING,-2.350284505,0.001344819,tipiracil
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,-2.331854637,0.001008614,tipiracil
CELLULAR_SENESCENCE,-2.319383435,0.001075855,tipiracil
TRANSCRIPTIONAL_REGULATION_BY_TP53,-2.294958289,0.001344819,tipiracil
MAPK_FAMILY_SIGNALING_CASCADES,-2.278460669,0.001152702,tipiracil
CLEC7A_DECTIN_1_SIGNALING,-2.276205775,0.001008614,tipiracil
MITOTIC_METAPHASE_AND_ANAPHASE,-2.229098161,0.002241365,tipiracil
ANTIGEN_PROCESSING_CROSS_PRESENTATION,-2.227910355,0.00215171,tipiracil
GPCR_LIGAND_BINDING,2.528196943,0,BRD-K63750851
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.396240214,0.000729526,BRD-K63750851
METABOLISM_OF_RNA,-2.698453352,0.009842308,BRD-K63750851
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-2.527259854,0.006151442,BRD-K63750851
TRNA_PROCESSING_IN_THE_NUCLEUS,-2.5018886,0.004921154,BRD-K63750851
TRANSPORT_OF_MATURE_MRNAS_DERIVED_FROM_INTRONLESS_TRANSCRIPTS,-2.499062417,0.003690865,BRD-K63750851
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.468010173,0.003936923,BRD-K63750851
SIGNALING_BY_GPCR,2.321215432,0.001296935,BRD-K63750851
ISG15_ANTIVIRAL_MECHANISM,-2.422650198,0.004921154,BRD-K63750851
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.41192448,0.004218132,BRD-K63750851
RAB_REGULATION_OF_TRAFFICKING,2.688656509,0,sorafenib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.534003606,0,sorafenib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.466106145,0,sorafenib
SELENOAMINO_ACID_METABOLISM,-2.460169812,0,sorafenib
NONSENSE_MEDIATED_DECAY_NMD,-2.394680862,0,sorafenib
EUKARYOTIC_TRANSLATION_INITIATION,-2.334429337,0,sorafenib
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,2.416596235,0.001528935,sorafenib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.30389824,0.000488108,sorafenib
CELLULAR_RESPONSE_TO_STARVATION,-2.288148683,0.000418379,sorafenib
RRNA_PROCESSING,-2.283335286,0.000366081,sorafenib
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.343167473,0.008601468,minoxidil
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-2.148497223,0.100195503,minoxidil
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.126571687,0.060888037,minoxidil
L1CAM_INTERACTIONS,-2.113687305,0.048813194,minoxidil
ADAPTIVE_IMMUNE_SYSTEM,-2.029047957,0.080156403,minoxidil
CELL_CYCLE_MITOTIC,-2.011969437,0.073065644,minoxidil
MHC_CLASS_II_ANTIGEN_PRESENTATION,-2.002176395,0.066026268,minoxidil
ANTI_INFLAMMATORY_RESPONSE_FAVOURING_LEISHMANIA_PARASITE_INFECTION,-1.993692783,0.060117302,minoxidil
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,-1.981018776,0.058575833,minoxidil
NUCLEAR_ENVELOPE_NE_REASSEMBLY,-1.960570082,0.063028966,minoxidil
CELL_CYCLE,-2.541438041,0,dexloxiglumide
CELL_CYCLE_MITOTIC,-2.523292819,0,dexloxiglumide
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-2.302146512,0.00275939,dexloxiglumide
KERATINIZATION,2.392041183,0.00396557,dexloxiglumide
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.237979111,0.003794161,dexloxiglumide
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,-2.213998549,0.003311268,dexloxiglumide
S_PHASE,-2.212098875,0.002989339,dexloxiglumide
CELL_CYCLE_CHECKPOINTS,-2.206565391,0.003153589,dexloxiglumide
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.287418869,0.004163848,dexloxiglumide
SIGNALING_BY_NTRKS,-2.116315957,0.011210022,dexloxiglumide
GPCR_LIGAND_BINDING,-2.645317633,0,emedastine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.577775845,0,emedastine
SIGNALING_BY_GPCR,-2.56021751,0,emedastine
ADAPTIVE_IMMUNE_SYSTEM,-2.480985012,0,emedastine
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.403383763,0.000248321,emedastine
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.231756288,0.003310952,emedastine
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,-2.231200821,0.002837959,emedastine
G_ALPHA_Q_SIGNALLING_EVENTS,-2.199620054,0.004035223,emedastine
G_ALPHA_I_SIGNALLING_EVENTS,-2.155779099,0.006070079,emedastine
RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY,-2.039733692,0.018251623,emedastine
EUKARYOTIC_TRANSLATION_ELONGATION,4.73277344,0,carglumic-acid
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,2.621484839,0,carglumic-acid
SARS_COV_1_INFECTION,2.668577002,0,carglumic-acid
METABOLISM_OF_RNA,2.73008127,0,carglumic-acid
SARS_COV_1_HOST_INTERACTIONS,2.775181385,0,carglumic-acid
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.952309695,0,carglumic-acid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.46751768,0,carglumic-acid
RRNA_PROCESSING,3.994761192,0,carglumic-acid
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.142806129,0,carglumic-acid
SIGNALING_BY_ROBO_RECEPTORS,3.953864787,0,carglumic-acid
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.541516929,0,ciglitazone
GPCR_LIGAND_BINDING,2.539424547,0,ciglitazone
CELL_CYCLE_CHECKPOINTS,-2.829049857,0.002760345,ciglitazone
ISG15_ANTIVIRAL_MECHANISM,-2.623425903,0.001380172,ciglitazone
CHROMATIN_ORGANIZATION,-2.589740158,0.000920115,ciglitazone
M_PHASE,-2.550175092,0.001380172,ciglitazone
SIGNALING_BY_GPCR,2.331936293,0.000515763,ciglitazone
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.486382768,0.002760345,ciglitazone
DNA_REPLICATION,-2.432151571,0.002415302,ciglitazone
METABOLISM_OF_RNA,-2.437647604,0.003220402,ciglitazone
EUKARYOTIC_TRANSLATION_INITIATION,3.590322561,0,menadione
INFLUENZA_INFECTION,2.865005347,0,menadione
RRNA_PROCESSING,3.050281309,0,menadione
CELLULAR_RESPONSE_TO_STARVATION,3.354745936,0,menadione
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.375954024,0,menadione
TRANSLATION,3.382034443,0,menadione
SIGNALING_BY_ROBO_RECEPTORS,2.966862273,0,menadione
SELENOAMINO_ACID_METABOLISM,3.396116931,0,menadione
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.467491858,0,menadione
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.498921828,0,menadione
EUKARYOTIC_TRANSLATION_INITIATION,-2.373953179,0.000931898,flutamide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.360965001,0.000465949,flutamide
SELENOAMINO_ACID_METABOLISM,-2.309030376,0.000310633,flutamide
NONSENSE_MEDIATED_DECAY_NMD,-2.283753649,0.000232974,flutamide
RRNA_PROCESSING,-2.27102111,0.000372759,flutamide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.265229114,0.000310633,flutamide
SARS_COV_1_INFECTION,-2.189388563,0.000665641,flutamide
CELLULAR_RESPONSE_TO_STARVATION,-2.181976307,0.000698923,flutamide
TRANSLATION,-2.169040837,0.000724809,flutamide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.165833965,0.000652328,flutamide
EUKARYOTIC_TRANSLATION_INITIATION,3.31804611,0,doxorubicin
SARS_COV_1_INFECTION,2.621218719,0,doxorubicin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.623703981,0,doxorubicin
SIGNALING_BY_ROBO_RECEPTORS,2.767428903,0,doxorubicin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.912559784,0,doxorubicin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.967946116,0,doxorubicin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.669081708,0,doxorubicin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.065166665,0,doxorubicin
SELENOAMINO_ACID_METABOLISM,3.099911399,0,doxorubicin
NONSENSE_MEDIATED_DECAY_NMD,3.160430937,0,doxorubicin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.89951926,0,midodrine
EUKARYOTIC_TRANSLATION_INITIATION,2.70471654,0,midodrine
CELLULAR_RESPONSE_TO_STARVATION,2.622719142,0.000343267,midodrine
SELENOAMINO_ACID_METABOLISM,2.579453445,0.00025745,midodrine
RESPIRATORY_ELECTRON_TRANSPORT,2.553123172,0.00020596,midodrine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.519779775,0.000171634,midodrine
NONSENSE_MEDIATED_DECAY_NMD,2.503430869,0.000147115,midodrine
TRANSLATION,2.356282268,0.001673428,midodrine
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,2.326163026,0.002402871,midodrine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.303074813,0.002574505,midodrine
MRNA_SPLICING,3.016448761,0,vernakalant
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.635032561,0,vernakalant
RAB_REGULATION_OF_TRAFFICKING,2.396042313,0.00414951,vernakalant
EUKARYOTIC_TRANSLATION_ELONGATION,-2.097699569,0.020753432,vernakalant
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,1.982845631,0.017427942,vernakalant
SELENOAMINO_ACID_METABOLISM,-2.052615111,0.022168439,vernakalant
NONSENSE_MEDIATED_DECAY_NMD,-2.011654736,0.022954553,vernakalant
EUKARYOTIC_TRANSLATION_INITIATION,-1.987648422,0.023347611,vernakalant
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.974062021,0.023017443,vernakalant
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-1.962168575,0.022168439,vernakalant
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.255252927,0.02291989,labetalol
GPCR_LIGAND_BINDING,-2.223165901,0.014734215,labetalol
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.014262046,0.072033939,labetalol
REGULATION_OF_INSULIN_SECRETION,-1.995798641,0.06275684,labetalol
SARS_COV_1_HOST_INTERACTIONS,1.970097094,0.477457693,labetalol
G_ALPHA_I_SIGNALLING_EVENTS,-1.853055471,0.149961563,labetalol
CELLULAR_RESPONSE_TO_HEAT_STRESS,-1.835893068,0.140247895,labetalol
DEVELOPMENTAL_CELL_LINEAGES_OF_THE_EXOCRINE_PANCREAS,-1.821693952,0.134400985,labetalol
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,-1.817836997,0.121557271,labetalol
EUKARYOTIC_TRANSLATION_INITIATION,1.875557473,0.456659346,labetalol
CLATHRIN_MEDIATED_ENDOCYTOSIS,1.794300236,0.090978496,clozapine
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,1.675304838,0.085570683,clozapine
CARGO_RECOGNITION_FOR_CLATHRIN_MEDIATED_ENDOCYTOSIS,1.514530119,0.144208339,clozapine
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.521976163,1,clozapine
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.46049908,0.962759117,clozapine
BIOLOGICAL_OXIDATIONS,1.380952884,0.231899733,clozapine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.138784261,1,clozapine
G_ALPHA_I_SIGNALLING_EVENTS,-2.135383949,0.781922057,clozapine
SIGNALING_BY_INSULIN_RECEPTOR,-2.023054834,0.672192072,clozapine
GPCR_LIGAND_BINDING,-1.870222838,0.672362593,clozapine
GLYCOSAMINOGLYCAN_METABOLISM,1.709940339,0.296794209,bupivacaine
CHROMATIN_ORGANIZATION,1.617578378,0.236814891,bupivacaine
METABOLISM_OF_STEROIDS,1.564556266,0.208893485,bupivacaine
INTERLEUKIN_12_FAMILY_SIGNALING,-2.147160911,1,bupivacaine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.467018271,0.265641158,bupivacaine
INTERLEUKIN_12_SIGNALING,-2.147160911,1,bupivacaine
GPCR_LIGAND_BINDING,-1.981101564,1,bupivacaine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.968125733,1,bupivacaine
CELLULAR_RESPONSE_TO_HYPOXIA,-1.899357075,1,bupivacaine
TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES,-1.894099978,0.863608471,bupivacaine
CELL_CYCLE,-2.767421569,0,carfilzomib
CELL_CYCLE_MITOTIC,-2.736908257,0,carfilzomib
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.658845822,0,carfilzomib
MITOTIC_SPINDLE_CHECKPOINT,-2.576361055,0,carfilzomib
RHO_GTPASES_ACTIVATE_FORMINS,-2.456371266,0.000501831,carfilzomib
CELL_CYCLE_CHECKPOINTS,-2.394954443,0.000627289,carfilzomib
SEPARATION_OF_SISTER_CHROMATIDS,-2.360033129,0.000896127,carfilzomib
MITOTIC_METAPHASE_AND_ANAPHASE,-2.352716905,0.000784111,carfilzomib
CYCLIN_D_ASSOCIATED_EVENTS_IN_G1,-2.322004174,0.00111518,carfilzomib
MITOTIC_PROMETAPHASE,-2.317586638,0.001254578,carfilzomib
EUKARYOTIC_TRANSLATION_ELONGATION,3.861589747,0,duloxetine
SARS_COV_INFECTIONS,2.605976329,0,duloxetine
INFECTIOUS_DISEASE,2.631368184,0,duloxetine
SARS_COV_2_INFECTION,2.708327477,0,duloxetine
NERVOUS_SYSTEM_DEVELOPMENT,3.041193195,0,duloxetine
SARS_COV_2_HOST_INTERACTIONS,3.073621281,0,duloxetine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.28860325,0,duloxetine
SARS_COV_1_INFECTION,3.313984897,0,duloxetine
RRNA_PROCESSING,3.367501143,0,duloxetine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.387965085,0,duloxetine
RAB_REGULATION_OF_TRAFFICKING,2.250092118,0.008864555,mestinon
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.690557151,0.165102333,mestinon
INTEGRIN_CELL_SURFACE_INTERACTIONS,1.515653939,0.25707209,mestinon
REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA,1.488974174,0.211087212,mestinon
DISEASES_OF_METABOLISM,-2.35534935,0.692270166,mestinon
TOLL_LIKE_RECEPTOR_CASCADES,-2.347103348,0.38759416,mestinon
MRNA_SPLICING,1.343126663,0.336409855,mestinon
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.266270655,0.394472689,mestinon
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,1.26141726,0.346667412,mestinon
SIGNALING_BY_VEGF,1.209023433,0.393918655,mestinon
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-1.828323315,1,dopamine
APOPTOSIS,-1.75694175,1,dopamine
DEVELOPMENTAL_CELL_LINEAGES_OF_THE_EXOCRINE_PANCREAS,-1.738599009,1,dopamine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.226730467,1,dopamine
RNA_POLYMERASE_II_TRANSCRIPTION_TERMINATION,1.195648556,1,dopamine
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,-1.708386494,1,dopamine
GPCR_LIGAND_BINDING,-1.70590947,0.885497427,dopamine
GLYCOSAMINOGLYCAN_METABOLISM,1.113795424,1,dopamine
DEVELOPMENTAL_CELL_LINEAGES,-1.664858886,0.854172756,dopamine
DISEASES_OF_METABOLISM,1.096903092,0.977993102,dopamine
GPCR_LIGAND_BINDING,2.515587165,0.000832996,enoxacin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.500356657,0.000416498,enoxacin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.489464944,0.002034071,enoxacin
SIGNALING_BY_GPCR,2.487517888,0.000277665,enoxacin
REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF,-2.458795165,0.001017035,enoxacin
METABOLISM_OF_RNA,-2.13053676,0.023052801,enoxacin
G_ALPHA_I_SIGNALLING_EVENTS,2.127185651,0.009787703,enoxacin
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-1.927061565,0.064581744,enoxacin
PROGRAMMED_CELL_DEATH,2.024565835,0.021657897,enoxacin
TRNA_PROCESSING,-1.895615002,0.064276634,enoxacin
ADAPTIVE_IMMUNE_SYSTEM,-2.579646035,0,valdecoxib
NEURONAL_SYSTEM,-2.389633219,0.008115607,valdecoxib
G_ALPHA_I_SIGNALLING_EVENTS,-2.324958486,0.011804519,valdecoxib
SIGNALING_BY_GPCR,-2.300118986,0.010697845,valdecoxib
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,-2.215256116,0.016821439,valdecoxib
GPCR_LIGAND_BINDING,-2.131776569,0.024838675,valdecoxib
CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION,-2.118431351,0.024030627,valdecoxib
ANTIGEN_PROCESSING_CROSS_PRESENTATION,-2.093979139,0.024900156,valdecoxib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.060692282,0.029183393,valdecoxib
TCR_SIGNALING,-2.060440702,0.026265054,valdecoxib
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.45151009,0.011091505,droperidol
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.255518068,0.00329728,droperidol
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.425642965,0.006932191,droperidol
GPCR_LIGAND_BINDING,2.21106979,0.00288512,droperidol
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.405466705,0.007394337,droperidol
KERATINIZATION,2.189741155,0.002198186,droperidol
SIGNALING_BY_GPCR,2.183671609,0.00226688,droperidol
SENSORY_PERCEPTION,2.04880432,0.013518847,droperidol
PEPTIDE_LIGAND_BINDING_RECEPTORS,2.04651787,0.011952639,droperidol
G_ALPHA_Q_SIGNALLING_EVENTS,2.031398033,0.012011519,droperidol
RAB_REGULATION_OF_TRAFFICKING,2.504448557,0.006848729,VP-20629
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,2.284417256,0.00770482,VP-20629
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.951932712,0.025682733,VP-20629
MRNA_SPLICING,1.757719087,0.052221556,VP-20629
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.412943117,0.303398682,VP-20629
EUKARYOTIC_TRANSLATION_ELONGATION,-2.318812249,1,VP-20629
SELENOAMINO_ACID_METABOLISM,-2.26080268,1,VP-20629
NONSENSE_MEDIATED_DECAY_NMD,-2.219736878,0.783543911,VP-20629
EUKARYOTIC_TRANSLATION_INITIATION,-2.211290016,0.593723766,VP-20629
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.149814645,0.509724106,VP-20629
EUKARYOTIC_TRANSLATION_ELONGATION,-2.25704938,0.001984747,diphenylpyraline
SELENOAMINO_ACID_METABOLISM,-2.194781621,0.003473308,diphenylpyraline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.15753307,0.00529266,diphenylpyraline
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.131032923,0.005458055,diphenylpyraline
EUKARYOTIC_TRANSLATION_INITIATION,-2.129151595,0.004564919,diphenylpyraline
NONSENSE_MEDIATED_DECAY_NMD,-2.126780314,0.003969495,diphenylpyraline
RAB_REGULATION_OF_TRAFFICKING,2.210008049,0.012086277,diphenylpyraline
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,2.087386136,0.010273336,diphenylpyraline
RRNA_PROCESSING,-2.099141206,0.005245404,diphenylpyraline
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.989315176,0.011683402,diphenylpyraline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.111905216,0,TG-100115
INFECTIOUS_DISEASE,2.524300005,0,TG-100115
SARS_COV_2_INFECTION,2.682841817,0,TG-100115
VIRAL_INFECTION_PATHWAYS,2.73725864,0,TG-100115
SARS_COV_2_HOST_INTERACTIONS,2.883040421,0,TG-100115
NERVOUS_SYSTEM_DEVELOPMENT,3.111909913,0,TG-100115
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.336690959,0,TG-100115
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.355863586,0,TG-100115
SARS_COV_1_HOST_INTERACTIONS,3.436584466,0,TG-100115
TRANSLATION,3.527187336,0,TG-100115
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.381877689,0.017502524,fenoterol
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.329331501,0.008751262,fenoterol
RRNA_PROCESSING,-2.319626572,0.005834175,fenoterol
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.335840699,0.005268241,fenoterol
GPCR_LIGAND_BINDING,2.177158381,0.008654967,fenoterol
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.141980162,0.017502524,fenoterol
KERATINIZATION,2.112173032,0.010536481,fenoterol
G_ALPHA_S_SIGNALLING_EVENTS,2.101038511,0.008843118,fenoterol
DNA_REPAIR,-2.034566396,0.032204645,fenoterol
METABOLISM_OF_RNA,-2.000899731,0.035588466,fenoterol
EUKARYOTIC_TRANSLATION_INITIATION,-1.988612816,0.138026061,conivaptan
RNA_POLYMERASE_II_TRANSCRIPTION_TERMINATION,1.704177706,0.247808234,conivaptan
G_ALPHA_Q_SIGNALLING_EVENTS,-1.876536187,0.251694583,conivaptan
NONSENSE_MEDIATED_DECAY_NMD,-1.860244754,0.198919912,conivaptan
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-1.809715842,0.250425961,conivaptan
POTASSIUM_CHANNELS,-1.785792773,0.254942255,conivaptan
CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE,-1.771271426,0.241038159,conivaptan
P75_NTR_RECEPTOR_MEDIATED_SIGNALLING,-1.743434522,0.264163323,conivaptan
PROGRAMMED_CELL_DEATH,-1.741563146,0.23532936,conivaptan
INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING,-1.740909706,0.210873149,conivaptan
EUKARYOTIC_TRANSLATION_ELONGATION,3.005180779,0,roscovitine
SELENOAMINO_ACID_METABOLISM,2.936342134,0,roscovitine
NONSENSE_MEDIATED_DECAY_NMD,2.922012768,0,roscovitine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.868046291,0,roscovitine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.847241418,0,roscovitine
SIGNALING_BY_ROBO_RECEPTORS,2.846653518,0,roscovitine
CELLULAR_RESPONSE_TO_STARVATION,2.818224826,0,roscovitine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.800403471,0,roscovitine
EUKARYOTIC_TRANSLATION_INITIATION,2.753184227,0,roscovitine
RRNA_PROCESSING,2.496655077,0,roscovitine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.406217687,0.0018983,ampalex
NONSENSE_MEDIATED_DECAY_NMD,-2.343301381,0.00094915,ampalex
SELENOAMINO_ACID_METABOLISM,-2.276557935,0.0018983,ampalex
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.25465414,0.001423725,ampalex
EUKARYOTIC_TRANSLATION_INITIATION,-2.224628673,0.00170847,ampalex
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.218219746,0.001423725,ampalex
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.128315343,0.004203379,ampalex
RRNA_PROCESSING,-2.116039467,0.004389819,ampalex
CELLULAR_RESPONSE_TO_STARVATION,-2.109954308,0.004323906,ampalex
MRNA_SPLICING,2.016367069,0.08883167,ampalex
EUKARYOTIC_TRANSLATION_ELONGATION,3.751464025,0,TTNPB
SARS_COV_2_HOST_INTERACTIONS,2.450093208,0,TTNPB
SARS_COV_1_INFECTION,2.681927181,0,TTNPB
SARS_COV_1_HOST_INTERACTIONS,2.941713201,0,TTNPB
NERVOUS_SYSTEM_DEVELOPMENT,3.007108131,0,TTNPB
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.205470599,0,TTNPB
TRANSLATION,3.220620794,0,TTNPB
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.325337332,0,TTNPB
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.389032289,0,TTNPB
INFLUENZA_INFECTION,3.518385053,0,TTNPB
RAB_REGULATION_OF_TRAFFICKING,2.33574633,0.00532561,clomipramine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.946499144,0.040829674,clomipramine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.759852476,0.071008129,clomipramine
MRNA_SPLICING,1.585099368,0.152667476,clomipramine
GLYCOSAMINOGLYCAN_METABOLISM,1.535803611,0.162963655,clomipramine
SYNTHESIS_OF_DNA,1.376657034,0.291725062,clomipramine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.240572324,1,clomipramine
INTERLEUKIN_1_SIGNALING,1.354170415,0.278199704,clomipramine
SELENOAMINO_ACID_METABOLISM,-2.17981978,1,clomipramine
NONSENSE_MEDIATED_DECAY_NMD,-2.147882108,0.827245712,clomipramine
INTERFERON_SIGNALING,-2.532846092,0.005723032,EMD-1214063
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.486631122,0.004292274,EMD-1214063
INTERFERON_ALPHA_BETA_SIGNALING,-2.265915949,0.01430758,EMD-1214063
G_ALPHA_S_SIGNALLING_EVENTS,2.20342738,0.013476769,EMD-1214063
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.160112343,0.009513014,EMD-1214063
SENSORY_PERCEPTION,2.149245507,0.00713476,EMD-1214063
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.098267846,0.022176749,EMD-1214063
GPCR_LIGAND_BINDING,2.142953356,0.005747446,EMD-1214063
SIGNALING_BY_GPCR,2.085443664,0.008561712,EMD-1214063
METABOLISM_OF_RNA,-1.982572472,0.033193585,EMD-1214063
TRANSCRIPTION_COUPLED_NUCLEOTIDE_EXCISION_REPAIR_TC_NER,1.57260515,0.70240145,AMD-11070
DISEASES_OF_METABOLISM,1.570507906,0.354327141,AMD-11070
PROTEIN_LOCALIZATION,1.454618022,0.43978251,AMD-11070
INFLUENZA_INFECTION,1.444279904,0.352763933,AMD-11070
MRNA_SPLICING,1.367553248,0.428527413,AMD-11070
DISEASES_OF_GLYCOSYLATION,1.262487625,0.599577103,AMD-11070
INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING,-1.795492454,1,AMD-11070
GLYCOSAMINOGLYCAN_METABOLISM,1.225110793,0.614564049,AMD-11070
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.146030273,0.77170367,AMD-11070
G_ALPHA_Q_SIGNALLING_EVENTS,-1.67768471,1,AMD-11070
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.695487696,0,ramipril
RESPIRATORY_ELECTRON_TRANSPORT,2.564258375,0,ramipril
CELLULAR_RESPONSES_TO_STIMULI,2.70157029,0,ramipril
SARS_COV_1_HOST_INTERACTIONS,2.817642165,0,ramipril
RRNA_PROCESSING,2.834424297,0,ramipril
SARS_COV_1_INFECTION,2.858977517,0,ramipril
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.887833491,0,ramipril
NERVOUS_SYSTEM_DEVELOPMENT,2.943662021,0,ramipril
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.985505271,0,ramipril
INFLUENZA_INFECTION,3.086651235,0,ramipril
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.475135998,0.011344126,imatinib
KERATINIZATION,2.220220001,0.015544656,imatinib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.096215825,0.030657517,imatinib
GPCR_LIGAND_BINDING,2.073676166,0.026483488,imatinib
EUKARYOTIC_TRANSLATION_ELONGATION,2.066213633,0.022021596,imatinib
AMINE_LIGAND_BINDING_RECEPTORS,2.063786445,0.017962714,imatinib
SIGNALING_BY_ROBO_RECEPTORS,2.026339928,0.020294412,imatinib
SIGNALING_BY_GPCR,2.00692834,0.0215898,imatinib
DNA_REPAIR,-1.834122237,0.192850135,imatinib
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-1.78560895,0.164111683,imatinib
EUKARYOTIC_TRANSLATION_INITIATION,4.424141929,0,hexachlorophene
COMPLEX_IV_ASSEMBLY,2.644642152,0,hexachlorophene
RESPIRATORY_ELECTRON_TRANSPORT,2.682781143,0,hexachlorophene
SARS_COV_2_HOST_INTERACTIONS,2.730641011,0,hexachlorophene
TP53_REGULATES_METABOLIC_GENES,2.843750004,0,hexachlorophene
CELLULAR_RESPONSES_TO_STIMULI,2.876624718,0,hexachlorophene
METABOLISM_OF_RNA,2.922623483,0,hexachlorophene
SARS_COV_1_INFECTION,3.299786303,0,hexachlorophene
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.405758613,0,hexachlorophene
SARS_COV_1_HOST_INTERACTIONS,3.465241855,0,hexachlorophene
EUKARYOTIC_TRANSLATION_INITIATION,2.781944926,0,tamoxifen
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.595304728,0,tamoxifen
NONSENSE_MEDIATED_DECAY_NMD,2.56971561,0,tamoxifen
GPCR_LIGAND_BINDING,2.512391122,0,tamoxifen
SELENOAMINO_ACID_METABOLISM,2.492774585,0,tamoxifen
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.484206285,0,tamoxifen
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.463089011,0,tamoxifen
KERATINIZATION,2.448792036,0,tamoxifen
CELLULAR_RESPONSE_TO_STARVATION,2.275057005,0.000418577,tamoxifen
TRANSLATION,2.208508593,0.00097947,tamoxifen
EUKARYOTIC_TRANSLATION_ELONGATION,-2.456823568,0,moxonidine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.412527045,0,moxonidine
SELENOAMINO_ACID_METABOLISM,-2.37110871,0,moxonidine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.293564439,0.000454927,moxonidine
INFLUENZA_INFECTION,-2.245026676,0.000909854,moxonidine
EUKARYOTIC_TRANSLATION_INITIATION,-2.2444168,0.000758212,moxonidine
NONSENSE_MEDIATED_DECAY_NMD,-2.20368202,0.000779875,moxonidine
CELLULAR_RESPONSE_TO_STARVATION,-2.152532325,0.001137317,moxonidine
G_ALPHA_Q_SIGNALLING_EVENTS,-2.071575942,0.002931751,moxonidine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,-1.985620748,0.009189524,moxonidine
G_ALPHA_Q_SIGNALLING_EVENTS,-2.25501043,0.000998587,lesinurad
EUKARYOTIC_TRANSLATION_ELONGATION,-2.144445431,0.000998587,lesinurad
SELENOAMINO_ACID_METABOLISM,-2.066126015,0.005658661,lesinurad
EUKARYOTIC_TRANSLATION_INITIATION,-2.035614429,0.007739051,lesinurad
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.018323066,0.00778898,lesinurad
NONSENSE_MEDIATED_DECAY_NMD,-1.990408729,0.01115089,lesinurad
PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION,-1.933953087,0.023823437,lesinurad
SARS_COV_1_INFECTION,-1.876893582,0.042065485,lesinurad
CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL,-1.869507017,0.040720166,lesinurad
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-1.859470648,0.041041933,lesinurad
GPCR_LIGAND_BINDING,-2.347858489,0.003455208,pimavanserin
SIGNALING_BY_GPCR,-2.150940882,0.023322657,pimavanserin
G_ALPHA_I_SIGNALLING_EVENTS,-2.122072838,0.023322657,pimavanserin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.048475246,0.033472332,pimavanserin
CELLULAR_RESPONSE_TO_STARVATION,2.09326696,0.23632147,pimavanserin
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.038924408,0.029023751,pimavanserin
METABOLISM_OF_VITAMINS_AND_COFACTORS,1.987731472,0.240013993,pimavanserin
SARS_COV_2_INFECTION,1.96276064,0.188728952,pimavanserin
SARS_COV_1_INFECTION,1.956005269,0.150162601,pimavanserin
SARS_COV_INFECTIONS,1.858839382,0.210966145,pimavanserin
EUKARYOTIC_TRANSLATION_ELONGATION,3.734674932,0,clomethiazole
SARS_COV_2_HOST_INTERACTIONS,2.71622872,0,clomethiazole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.789893165,0,clomethiazole
NERVOUS_SYSTEM_DEVELOPMENT,2.88405583,0,clomethiazole
SARS_COV_1_INFECTION,2.979534914,0,clomethiazole
TRANSLATION,2.981604466,0,clomethiazole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.06551711,0,clomethiazole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.200323831,0,clomethiazole
SARS_COV_1_HOST_INTERACTIONS,3.202065611,0,clomethiazole
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.239861808,0,clomethiazole
NONSENSE_MEDIATED_DECAY_NMD,2.968277366,0,fluticasone-propionate
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.868988942,0,fluticasone-propionate
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.814850204,0,fluticasone-propionate
EUKARYOTIC_TRANSLATION_ELONGATION,2.781337185,0,fluticasone-propionate
EUKARYOTIC_TRANSLATION_INITIATION,2.737716564,0,fluticasone-propionate
CELLULAR_RESPONSE_TO_STARVATION,2.725532817,0,fluticasone-propionate
SELENOAMINO_ACID_METABOLISM,2.699435837,0,fluticasone-propionate
SARS_COV_1_HOST_INTERACTIONS,2.404153183,0,fluticasone-propionate
INFLUENZA_INFECTION,2.377006268,0.000276968,fluticasone-propionate
NUCLEAR_EVENTS_MEDIATED_BY_NFE2L2,-2.462355283,0.007603992,fluticasone-propionate
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.241591876,0,capsaicin
INFECTIOUS_DISEASE,2.555047728,0,capsaicin
SARS_COV_INFECTIONS,2.613197751,0,capsaicin
METABOLISM_OF_RNA,2.657515212,0,capsaicin
SARS_COV_2_INFECTION,2.701702656,0,capsaicin
VIRAL_INFECTION_PATHWAYS,2.705701826,0,capsaicin
CELLULAR_RESPONSES_TO_STIMULI,2.880803577,0,capsaicin
SARS_COV_2_HOST_INTERACTIONS,2.943507066,0,capsaicin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.40262368,0,capsaicin
NERVOUS_SYSTEM_DEVELOPMENT,3.480013655,0,capsaicin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.422189185,0.000919908,nicotinamide
NONSENSE_MEDIATED_DECAY_NMD,-2.386390775,0.000919908,nicotinamide
SELENOAMINO_ACID_METABOLISM,-2.328192904,0.000919908,nicotinamide
EUKARYOTIC_TRANSLATION_INITIATION,-2.305388061,0.000919908,nicotinamide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.214917984,0.002207778,nicotinamide
RAB_REGULATION_OF_TRAFFICKING,2.132978274,0.03556231,nicotinamide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.177006332,0.003679631,nicotinamide
RRNA_PROCESSING,-2.151524083,0.004468123,nicotinamide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.911871113,0.079422492,nicotinamide
MRNA_SPLICING,1.861286942,0.075075988,nicotinamide
EUKARYOTIC_TRANSLATION_ELONGATION,4.959253474,0,retigabine
BETA_CATENIN_INDEPENDENT_WNT_SIGNALING,2.565797603,0,retigabine
RESPIRATORY_ELECTRON_TRANSPORT,2.767075392,0,retigabine
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.784318404,0,retigabine
SARS_COV_2_INFECTION,2.843509352,0,retigabine
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.887335219,0,retigabine
INFECTIOUS_DISEASE,3.146932469,0,retigabine
VIRAL_INFECTION_PATHWAYS,3.462906729,0,retigabine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.699713488,0,retigabine
SARS_COV_1_INFECTION,3.725202548,0,retigabine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.332867548,0,clofibrate
NERVOUS_SYSTEM_DEVELOPMENT,2.565310909,0,clofibrate
RRNA_PROCESSING,2.999466981,0,clofibrate
CELLULAR_RESPONSE_TO_STARVATION,3.067332886,0,clofibrate
EUKARYOTIC_TRANSLATION_INITIATION,3.106532388,0,clofibrate
SIGNALING_BY_ROBO_RECEPTORS,3.15276278,0,clofibrate
INFLUENZA_INFECTION,2.999498479,0,clofibrate
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.231865976,0,clofibrate
EUKARYOTIC_TRANSLATION_ELONGATION,3.286049734,0,clofibrate
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.287514508,0,clofibrate
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,-2.617294644,0.001904762,zolpidem
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.272104329,0.025714286,zolpidem
MITOCHONDRIAL_TRANSLATION,-2.179839744,0.033015873,zolpidem
APC_C_MEDIATED_DEGRADATION_OF_CELL_CYCLE_PROTEINS,-2.141957542,0.035238095,zolpidem
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.061997572,0.056380952,zolpidem
TNFR2_NON_CANONICAL_NF_KB_PATHWAY,-2.032416532,0.056190476,zolpidem
ESTROGEN_DEPENDENT_GENE_EXPRESSION,2.043553497,0.166779661,zolpidem
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-1.971082929,0.071836735,zolpidem
HOST_INTERACTIONS_OF_HIV_FACTORS,-1.97016706,0.063095238,zolpidem
SEPARATION_OF_SISTER_CHROMATIDS,-1.95939958,0.059259259,zolpidem
EUKARYOTIC_TRANSLATION_ELONGATION,3.717551198,0,sasapyrine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.867562927,0,sasapyrine
SIGNALING_BY_GPCR,-2.94957981,0,sasapyrine
INFLUENZA_INFECTION,3.144100946,0,sasapyrine
SIGNALING_BY_ROBO_RECEPTORS,3.15193258,0,sasapyrine
GPCR_LIGAND_BINDING,-3.271104012,0,sasapyrine
RRNA_PROCESSING,3.278939262,0,sasapyrine
CELLULAR_RESPONSE_TO_STARVATION,3.300315761,0,sasapyrine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.470082298,0,sasapyrine
TRANSLATION,3.474404357,0,sasapyrine
NONSENSE_MEDIATED_DECAY_NMD,4.43446189,0,acenocoumarol
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.48185701,0,acenocoumarol
SARS_COV_INFECTIONS,2.567376259,0,acenocoumarol
SARS_COV_2_INFECTION,2.678921853,0,acenocoumarol
INFECTIOUS_DISEASE,2.890730593,0,acenocoumarol
METABOLISM_OF_RNA,2.894517776,0,acenocoumarol
CELLULAR_RESPONSES_TO_STIMULI,2.989545977,0,acenocoumarol
VIRAL_INFECTION_PATHWAYS,3.131197553,0,acenocoumarol
NERVOUS_SYSTEM_DEVELOPMENT,3.431212498,0,acenocoumarol
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.495041078,0,acenocoumarol
EUKARYOTIC_TRANSLATION_INITIATION,4.14929158,0,rotigotine
NERVOUS_SYSTEM_DEVELOPMENT,2.854052969,0,rotigotine
CELLULAR_RESPONSES_TO_STIMULI,2.867600662,0,rotigotine
SARS_COV_1_INFECTION,2.998454014,0,rotigotine
SARS_COV_1_HOST_INTERACTIONS,3.061435625,0,rotigotine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.236590976,0,rotigotine
INFLUENZA_INFECTION,3.509992109,0,rotigotine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.568922806,0,rotigotine
TRANSLATION,3.606410374,0,rotigotine
SIGNALING_BY_ROBO_RECEPTORS,3.709142018,0,rotigotine
SELENOAMINO_ACID_METABOLISM,3.800517419,0,nicotine
CELLULAR_RESPONSES_TO_STIMULI,2.497779514,0,nicotine
SARS_COV_2_HOST_INTERACTIONS,2.763041584,0,nicotine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.973622373,0,nicotine
SARS_COV_1_INFECTION,3.025609974,0,nicotine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.03746035,0,nicotine
NERVOUS_SYSTEM_DEVELOPMENT,3.126494581,0,nicotine
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.198377427,0,nicotine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.204827438,0,nicotine
RRNA_PROCESSING,3.296780167,0,nicotine
ADAPTIVE_IMMUNE_SYSTEM,-2.505056935,0.002973926,rilmenidine
RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY,-2.378245514,0.002230445,rilmenidine
HCMV_EARLY_EVENTS,-2.295335726,0.004956544,rilmenidine
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.138943284,0.030482744,rilmenidine
HCMV_INFECTION,-2.137039654,0.024386195,rilmenidine
MHC_CLASS_II_ANTIGEN_PRESENTATION,-2.126475335,0.022552274,rilmenidine
CELL_CYCLE_MITOTIC,-2.122936585,0.019967791,rilmenidine
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.114218288,0.018587039,rilmenidine
MITOTIC_PROMETAPHASE,-2.108821475,0.017513121,rilmenidine
FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS,-2.105886621,0.015910506,rilmenidine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.267993975,0,trimetazidine
SARS_COV_2_INFECTION,2.633926043,0,trimetazidine
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.7397596,0,trimetazidine
INFECTIOUS_DISEASE,2.855679254,0,trimetazidine
CELLULAR_RESPONSES_TO_STIMULI,3.014021576,0,trimetazidine
VIRAL_INFECTION_PATHWAYS,3.034951566,0,trimetazidine
SARS_COV_1_INFECTION,3.143146108,0,trimetazidine
SARS_COV_1_HOST_INTERACTIONS,3.240297985,0,trimetazidine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.345569025,0,trimetazidine
NERVOUS_SYSTEM_DEVELOPMENT,3.356470151,0,trimetazidine
MITOTIC_PROMETAPHASE,-3.273311037,0,triclosan
RRNA_PROCESSING,2.724126011,0,triclosan
TRANSLATION,2.745912809,0,triclosan
GPCR_LIGAND_BINDING,2.408864694,0,triclosan
INFLUENZA_INFECTION,2.831455887,0,triclosan
SIGNALING_BY_ROBO_RECEPTORS,2.894569659,0,triclosan
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.98777241,0,triclosan
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.594373919,0,triclosan
CELLULAR_RESPONSE_TO_STARVATION,3.044508986,0,triclosan
SELENOAMINO_ACID_METABOLISM,3.083181737,0,triclosan
FATTY_ACID_METABOLISM,2.37330876,0.020628883,pilaralisib
GPCR_LIGAND_BINDING,-2.069488039,0.17010682,pilaralisib
INTERFERON_SIGNALING,-1.997427119,0.152365618,pilaralisib
PKR_MEDIATED_SIGNALING,-1.939381748,0.160714419,pilaralisib
CHROMATIN_ORGANIZATION,1.974782943,0.259267547,pilaralisib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.9136369,0.151061118,pilaralisib
PEPTIDE_LIGAND_BINDING_RECEPTORS,-1.879145381,0.159044659,pilaralisib
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-1.831617584,0.186108688,pilaralisib
SIGNALING_BY_GPCR,-1.826992027,0.162801619,pilaralisib
G_ALPHA_Q_SIGNALLING_EVENTS,-1.798181218,0.176237971,pilaralisib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.473867944,0,theobromine
NONSENSE_MEDIATED_DECAY_NMD,-2.401405321,0,theobromine
SELENOAMINO_ACID_METABOLISM,-2.395625472,0,theobromine
EUKARYOTIC_TRANSLATION_INITIATION,-2.373207381,0.000243444,theobromine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.32561713,0.000194755,theobromine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.28464931,0.000324591,theobromine
CELLULAR_RESPONSE_TO_STARVATION,-2.201191396,0.001391106,theobromine
SARS_COV_2_HOST_INTERACTIONS,-2.163353878,0.002190992,theobromine
RRNA_PROCESSING,-2.16061848,0.002055746,theobromine
TRANSLATION,-2.151349255,0.002142304,theobromine
EUKARYOTIC_TRANSLATION_ELONGATION,4.157488112,0,flavoxate
VIRAL_INFECTION_PATHWAYS,2.613601858,0,flavoxate
SARS_COV_2_INFECTION,2.652824983,0,flavoxate
CELLULAR_RESPONSES_TO_STIMULI,2.738877393,0,flavoxate
SARS_COV_2_HOST_INTERACTIONS,2.888191102,0,flavoxate
NERVOUS_SYSTEM_DEVELOPMENT,3.262018243,0,flavoxate
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.486540319,0,flavoxate
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.525853857,0,flavoxate
SARS_COV_1_INFECTION,3.527671851,0,flavoxate
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.569126634,0,flavoxate
EUKARYOTIC_TRANSLATION_ELONGATION,3.673102113,0,zofenopril-calcium
NERVOUS_SYSTEM_DEVELOPMENT,2.532981859,0,zofenopril-calcium
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.680698365,0,zofenopril-calcium
TRANSLATION,2.750269945,0,zofenopril-calcium
SARS_COV_1_INFECTION,2.795071047,0,zofenopril-calcium
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.829479066,0,zofenopril-calcium
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.959438105,0,zofenopril-calcium
SARS_COV_1_HOST_INTERACTIONS,3.003861409,0,zofenopril-calcium
RRNA_PROCESSING,3.151128266,0,zofenopril-calcium
EUKARYOTIC_TRANSLATION_INITIATION,3.193012015,0,zofenopril-calcium
GPCR_LIGAND_BINDING,-3.005235067,0,bezafibrate
SIGNALING_BY_GPCR,-2.751769142,0,bezafibrate
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.74535318,0,bezafibrate
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.602340068,0.001622107,bezafibrate
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.583738769,0.001622107,bezafibrate
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.409193082,0.000726316,bezafibrate
RESPIRATORY_ELECTRON_TRANSPORT,2.464405062,0.00486632,bezafibrate
NONSENSE_MEDIATED_DECAY_NMD,2.267117326,0.020276333,bezafibrate
CHROMATIN_ORGANIZATION,2.254736829,0.018167595,bezafibrate
TRANSCRIPTIONAL_REGULATION_BY_RUNX3,2.248561382,0.015410013,bezafibrate
MRNA_SPLICING,-2.758657416,0,mepyramine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.706396926,0,mepyramine
SARS_COV_2_HOST_INTERACTIONS,2.303940062,0.001693758,mepyramine
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.014996372,0.030208049,mepyramine
GOLGI_TO_ER_RETROGRADE_TRANSPORT,-2.00658291,0.024597983,mepyramine
EUKARYOTIC_TRANSLATION_INITIATION,2.044468096,0.044461149,mepyramine
NONSENSE_MEDIATED_DECAY_NMD,2.014347794,0.03754497,mepyramine
GPCR_LIGAND_BINDING,2.005585586,0.031334524,mepyramine
SARS_COV_2_ACTIVATES_MODULATES_INNATE_AND_ADAPTIVE_IMMUNE_RESPONSES,1.991556782,0.027947008,mepyramine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,1.983142457,0.024700638,mepyramine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.718887536,0,felodipine
MRNA_SPLICING,2.515853578,0.00155554,felodipine
AMYLOID_FIBER_FORMATION,-2.534848471,0.162260662,felodipine
PEPTIDE_HORMONE_METABOLISM,1.879378535,0.065332673,felodipine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.646841321,0.141165241,felodipine
S_PHASE,1.603284093,0.142176342,felodipine
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,1.545837224,0.159183577,felodipine
UNFOLDED_PROTEIN_RESPONSE_UPR,1.463530561,0.2024424,felodipine
DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX,1.455298611,0.186859224,felodipine
DNA_REPLICATION,1.413839415,0.1991091,felodipine
EUKARYOTIC_TRANSLATION_ELONGATION,3.245290025,0,valsartan
SARS_COV_1_INFECTION,2.432994777,0,valsartan
NERVOUS_SYSTEM_DEVELOPMENT,2.483616648,0,valsartan
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.590296657,0,valsartan
SARS_COV_1_HOST_INTERACTIONS,2.600755327,0,valsartan
TRANSLATION,2.65721146,0,valsartan
SIGNALING_BY_ROBO_RECEPTORS,2.816009031,0,valsartan
EUKARYOTIC_TRANSLATION_INITIATION,2.87119743,0,valsartan
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.713312399,0,valsartan
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.931641017,0,valsartan
MRNA_SPLICING,-3.176584901,0,amiloride
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.141535801,0,amiloride
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.568770324,0.00248825,amiloride
NONSENSE_MEDIATED_DECAY_NMD,2.240996595,0.008316918,amiloride
DNA_REPAIR,-1.940861148,0.042300249,amiloride
EUKARYOTIC_TRANSLATION_INITIATION,2.088595424,0.03160429,amiloride
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.05479611,0.029386445,amiloride
SIGNALING_BY_ROBO_RECEPTORS,2.053701669,0.022247757,amiloride
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.044780955,0.019960604,amiloride
GPCR_LIGAND_BINDING,2.043264163,0.016772452,amiloride
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.052217129,0,darifenacin
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.148216718,0.034376008,darifenacin
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-1.834940791,0.12868967,darifenacin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,1.979688147,0.16165504,darifenacin
AMINE_LIGAND_BINDING_RECEPTORS,1.968170463,0.089487611,darifenacin
GPCR_LIGAND_BINDING,1.915583802,0.095948314,darifenacin
SIGNALING_BY_ROBO_RECEPTORS,1.900535092,0.081858483,darifenacin
KERATINIZATION,1.889004986,0.073404584,darifenacin
PROTEIN_LOCALIZATION,-1.619511821,0.282940987,darifenacin
FORMATION_OF_THE_CORNIFIED_ENVELOPE,1.867846915,0.074091893,darifenacin
SELENOAMINO_ACID_METABOLISM,4.184663304,0,moxifloxacin
METABOLISM_OF_RNA,2.632138319,0,moxifloxacin
INFECTIOUS_DISEASE,2.745237297,0,moxifloxacin
SARS_COV_INFECTIONS,2.7701948,0,moxifloxacin
VIRAL_INFECTION_PATHWAYS,2.911567792,0,moxifloxacin
SARS_COV_2_INFECTION,3.032314861,0,moxifloxacin
SARS_COV_2_HOST_INTERACTIONS,3.304615351,0,moxifloxacin
SARS_COV_1_INFECTION,3.380626738,0,moxifloxacin
NERVOUS_SYSTEM_DEVELOPMENT,3.50156523,0,moxifloxacin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.557006434,0,moxifloxacin
EUKARYOTIC_TRANSLATION_ELONGATION,-2.490596631,0,levothyroxine
SELENOAMINO_ACID_METABOLISM,-2.447030681,0,levothyroxine
NONSENSE_MEDIATED_DECAY_NMD,-2.420986092,0.000913132,levothyroxine
EUKARYOTIC_TRANSLATION_INITIATION,-2.41809029,0.000684849,levothyroxine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.392062815,0.000547879,levothyroxine
CELLULAR_RESPONSE_TO_STARVATION,-2.321475518,0.000456566,levothyroxine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.286793588,0.00052179,levothyroxine
RRNA_PROCESSING,-2.283123458,0.000456566,levothyroxine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.273958826,0.000507296,levothyroxine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.266403233,0.000547879,levothyroxine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.412449644,0,cytarabine
SELENOAMINO_ACID_METABOLISM,-2.331778594,0,cytarabine
NONSENSE_MEDIATED_DECAY_NMD,-2.267172914,0.000643597,cytarabine
EUKARYOTIC_TRANSLATION_INITIATION,-2.251669839,0.000724047,cytarabine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.235352005,0.000579237,cytarabine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.206205394,0.000643597,cytarabine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.167398681,0.00151705,cytarabine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.145851661,0.001810116,cytarabine
RRNA_PROCESSING,-2.137534477,0.001930791,cytarabine
MRNA_SPLICING,2.156860617,0.037616119,cytarabine
S_PHASE,-2.999620487,0,ixabepilone
MITOTIC_G1_PHASE_AND_G1_S_TRANSITION,-2.988904196,0,ixabepilone
CELL_CYCLE_MITOTIC,-2.976436302,0,ixabepilone
DNA_STRAND_ELONGATION,-2.972893532,0,ixabepilone
SYNTHESIS_OF_DNA,-2.935348585,0,ixabepilone
CELL_CYCLE,-2.755051546,0,ixabepilone
DNA_REPLICATION,-2.677221727,0,ixabepilone
CHROMOSOME_MAINTENANCE,-2.649003936,0,ixabepilone
ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX,-2.340903514,0.004041847,ixabepilone
ACTIVATION_OF_ANTERIOR_HOX_GENES_IN_HINDBRAIN_DEVELOPMENT_DURING_EARLY_EMBRYOGENESIS,-2.33831466,0.003810885,ixabepilone
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.894070218,0,thiomersal
MRNA_SPLICING,-2.513557067,0,thiomersal
SIGNALING_BY_ROBO_RECEPTORS,2.288510808,0.003383603,thiomersal
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.260461936,0.002114752,thiomersal
NONSENSE_MEDIATED_DECAY_NMD,2.217055598,0.004229503,thiomersal
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.214245837,0.003172128,thiomersal
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.144394059,0.018028553,thiomersal
CELLULAR_RESPONSE_TO_STARVATION,2.186732009,0.003552783,thiomersal
EUKARYOTIC_TRANSLATION_ELONGATION,2.133119815,0.005498354,thiomersal
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.117736438,0.005558776,thiomersal
INTEGRIN_CELL_SURFACE_INTERACTIONS,-2.106376966,0.077045394,CTS-1027
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.053554685,0.067273492,CTS-1027
GPCR_LIGAND_BINDING,2.044099483,0.042578159,CTS-1027
EUKARYOTIC_TRANSLATION_ELONGATION,1.992596768,0.045416703,CTS-1027
SIGNALING_BY_GPCR,1.926551931,0.063654348,CTS-1027
GASTRULATION,-1.727790885,0.393556203,CTS-1027
S_PHASE,-1.697175847,0.307487475,CTS-1027
SELENOAMINO_ACID_METABOLISM,1.863009795,0.094864139,CTS-1027
G_ALPHA_I_SIGNALLING_EVENTS,1.844826803,0.097078204,CTS-1027
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,1.842356282,0.085156319,CTS-1027
EUKARYOTIC_TRANSLATION_ELONGATION,3.205157539,0,bopindolol
INFLUENZA_INFECTION,2.588423125,0,bopindolol
TRANSLATION,2.598570634,0,bopindolol
SARS_COV_1_HOST_INTERACTIONS,2.606591559,0,bopindolol
RRNA_PROCESSING,2.879321903,0,bopindolol
CELLULAR_RESPONSE_TO_STARVATION,2.974343915,0,bopindolol
EUKARYOTIC_TRANSLATION_INITIATION,2.905050085,0,bopindolol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.020076017,0,bopindolol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.08007949,0,bopindolol
SIGNALING_BY_ROBO_RECEPTORS,3.105437043,0,bopindolol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.437397799,0,perindopril
SELENOAMINO_ACID_METABOLISM,-2.34639308,0.000497356,perindopril
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.320667665,0.00033157,perindopril
NONSENSE_MEDIATED_DECAY_NMD,-2.31071382,0.000248678,perindopril
EUKARYOTIC_TRANSLATION_INITIATION,-2.197975001,0.001193654,perindopril
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.169575891,0.001160497,perindopril
CELLULAR_RESPONSE_TO_STARVATION,-2.109335169,0.001847321,perindopril
INFLUENZA_INFECTION,-2.103546587,0.001740745,perindopril
SARS_COV_1_HOST_INTERACTIONS,-2.060031807,0.003315704,perindopril
SARS_COV_1_INFECTION,-2.021376347,0.006067739,perindopril
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.502032026,0,triamterene
INFLUENZA_INFECTION,2.708280716,0,triamterene
RESPIRATORY_ELECTRON_TRANSPORT,2.728768425,0,triamterene
SIGNALING_BY_ROBO_RECEPTORS,2.885211502,0,triamterene
CELLULAR_RESPONSE_TO_STARVATION,2.965518064,0,triamterene
NONSENSE_MEDIATED_DECAY_NMD,3.11723746,0,triamterene
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.113496243,0,triamterene
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.157413939,0,triamterene
SELENOAMINO_ACID_METABOLISM,3.242759774,0,triamterene
EUKARYOTIC_TRANSLATION_ELONGATION,3.259624172,0,triamterene
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.002853952,0.198024695,ciprofloxacin
EUKARYOTIC_TRANSLATION_ELONGATION,1.994807744,0.108963337,ciprofloxacin
KERATINIZATION,1.975896502,0.085578511,ciprofloxacin
ION_CHANNEL_TRANSPORT,1.929347105,0.099509897,ciprofloxacin
SELENOAMINO_ACID_METABOLISM,1.910194083,0.095728521,ciprofloxacin
NONSENSE_MEDIATED_DECAY_NMD,1.869195358,0.114104682,ciprofloxacin
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,1.839940706,0.124387371,ciprofloxacin
EUKARYOTIC_TRANSLATION_INITIATION,1.826809779,0.119785038,ciprofloxacin
CELL_CYCLE_MITOTIC,-1.628447905,1,ciprofloxacin
CELLULAR_RESPONSE_TO_HEAT_STRESS,-1.608442767,0.73841039,ciprofloxacin
EUKARYOTIC_TRANSLATION_INITIATION,5.127103839,0,mercaptopurine
INTERFERON_ALPHA_BETA_SIGNALING,-2.548720966,0,mercaptopurine
SARS_COV_INFECTIONS,2.689054581,0,mercaptopurine
SARS_COV_2_INFECTION,2.982326098,0,mercaptopurine
SARS_COV_2_HOST_INTERACTIONS,3.339420354,0,mercaptopurine
INFECTIOUS_DISEASE,3.343235276,0,mercaptopurine
VIRAL_INFECTION_PATHWAYS,3.634880117,0,mercaptopurine
CELLULAR_RESPONSES_TO_STIMULI,3.775807993,0,mercaptopurine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.848579945,0,mercaptopurine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.949491567,0,mercaptopurine
EUKARYOTIC_TRANSLATION_ELONGATION,4.424013607,0,donepezil
CELLULAR_RESPONSES_TO_STIMULI,2.38404517,0,donepezil
METABOLISM_OF_RNA,2.483054055,0,donepezil
VIRAL_INFECTION_PATHWAYS,2.505999679,0,donepezil
SARS_COV_2_INFECTION,2.626647262,0,donepezil
SARS_COV_2_HOST_INTERACTIONS,2.92609214,0,donepezil
SARS_COV_1_INFECTION,3.352308974,0,donepezil
NERVOUS_SYSTEM_DEVELOPMENT,3.469427325,0,donepezil
TRANSLATION,3.625314793,0,donepezil
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.630242971,0,donepezil
GPCR_LIGAND_BINDING,-2.700834704,0,troglitazone
PI3K_AKT_SIGNALING_IN_CANCER,-2.616457194,0,troglitazone
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.609128301,0,troglitazone
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.467682103,0.000973183,troglitazone
CONSTITUTIVE_SIGNALING_BY_ABERRANT_PI3K_IN_CANCER,-2.433218678,0.001038062,troglitazone
SIGNALING_BY_GPCR,-2.416577769,0.000865052,troglitazone
MAPK_FAMILY_SIGNALING_CASCADES,-2.263840545,0.002409787,troglitazone
TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES,-2.21731458,0.003406142,troglitazone
G_ALPHA_I_SIGNALLING_EVENTS,-2.180143528,0.005478662,troglitazone
NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION,-2.120703311,0.009083045,troglitazone
SARS_COV_2_HOST_INTERACTIONS,2.311455327,0.001655597,goserelin-acetate
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.532768353,0.00532016,goserelin-acetate
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.333873847,0.00532016,goserelin-acetate
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.237944567,0.007093546,goserelin-acetate
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.186290821,0.00496679,goserelin-acetate
SARS_COV_2_ACTIVATES_MODULATES_INNATE_AND_ADAPTIVE_IMMUNE_RESPONSES,2.165439576,0.004414924,goserelin-acetate
INTERFERON_ALPHA_BETA_SIGNALING,-2.104231509,0.015960479,goserelin-acetate
MHC_CLASS_II_ANTIGEN_PRESENTATION,-1.999050808,0.023408702,goserelin-acetate
KERATINIZATION,2.061135233,0.015521217,goserelin-acetate
METABOLISM_OF_RNA,-1.896710259,0.034137691,goserelin-acetate
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.567128468,0,BRD-K89997465
INFECTIOUS_DISEASE,2.670926645,0,BRD-K89997465
SARS_COV_2_HOST_INTERACTIONS,2.798651793,0,BRD-K89997465
VIRAL_INFECTION_PATHWAYS,2.853543291,0,BRD-K89997465
CELLULAR_RESPONSES_TO_STIMULI,2.965256184,0,BRD-K89997465
NERVOUS_SYSTEM_DEVELOPMENT,3.332375337,0,BRD-K89997465
SARS_COV_1_INFECTION,3.56586721,0,BRD-K89997465
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.581487929,0,BRD-K89997465
SARS_COV_1_HOST_INTERACTIONS,3.606799468,0,BRD-K89997465
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.713269664,0,BRD-K89997465
SELENOAMINO_ACID_METABOLISM,3.777688211,0,pramipexole
SARS_COV_2_INFECTION,2.529612435,0,pramipexole
VIRAL_INFECTION_PATHWAYS,2.558826745,0,pramipexole
NERVOUS_SYSTEM_DEVELOPMENT,2.91920951,0,pramipexole
SARS_COV_2_HOST_INTERACTIONS,2.921069842,0,pramipexole
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.085821301,0,pramipexole
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.098011218,0,pramipexole
SARS_COV_1_INFECTION,3.140710803,0,pramipexole
TRANSLATION,3.154644992,0,pramipexole
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.174273915,0,pramipexole
EUKARYOTIC_TRANSLATION_ELONGATION,2.686869405,0.000998731,nafamostat
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.623992251,0.00100344,nafamostat
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.525491753,0.000499366,nafamostat
SELENOAMINO_ACID_METABOLISM,2.521310905,0.00033291,nafamostat
EUKARYOTIC_TRANSLATION_INITIATION,2.488845493,0.000249683,nafamostat
NONSENSE_MEDIATED_DECAY_NMD,2.487051535,0.000199746,nafamostat
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.429490158,0.000166455,nafamostat
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.477177686,0.00100344,nafamostat
CELLULAR_RESPONSE_TO_STARVATION,2.316317546,0.001854786,nafamostat
RRNA_PROCESSING,2.301216228,0.001997462,nafamostat
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.67367596,0,epinastine
CYTOPROTECTION_BY_HMOX1,2.543237635,0,epinastine
SARS_COV_2_INFECTION,2.660968699,0,epinastine
SARS_COV_2_HOST_INTERACTIONS,2.819706314,0,epinastine
INFECTIOUS_DISEASE,3.053871264,0,epinastine
METABOLISM_OF_RNA,3.253243292,0,epinastine
VIRAL_INFECTION_PATHWAYS,3.280240746,0,epinastine
SARS_COV_1_INFECTION,3.382518395,0,epinastine
CELLULAR_RESPONSES_TO_STIMULI,3.384251303,0,epinastine
NERVOUS_SYSTEM_DEVELOPMENT,3.427503919,0,epinastine
EUKARYOTIC_TRANSLATION_ELONGATION,2.578404279,0.00149645,piribedil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.492783,0.002244675,piribedil
SELENOAMINO_ACID_METABOLISM,2.393071701,0.005985799,piribedil
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.241374838,0.020576185,piribedil
EUKARYOTIC_TRANSLATION_INITIATION,2.231992235,0.017059528,piribedil
RRNA_PROCESSING,2.223674613,0.01471509,piribedil
NONSENSE_MEDIATED_DECAY_NMD,2.17200906,0.019667626,piribedil
SARS_COV_1_HOST_INTERACTIONS,2.141742802,0.022633803,piribedil
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,-2.031692719,0.203179129,piribedil
INTERFERON_SIGNALING,-2.006916943,0.12809119,piribedil
EUKARYOTIC_TRANSLATION_INITIATION,3.394302054,0,R-547
TRANSLATION,3.037074271,0,R-547
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.04715315,0,R-547
RRNA_PROCESSING,3.057030805,0,R-547
CELLULAR_RESPONSE_TO_STARVATION,2.891817769,0,R-547
NONSENSE_MEDIATED_DECAY_NMD,3.174931742,0,R-547
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.211626651,0,R-547
EUKARYOTIC_TRANSLATION_ELONGATION,3.300248782,0,R-547
SELENOAMINO_ACID_METABOLISM,3.128736419,0,R-547
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.648716035,7.55E-05,R-547
NUCLEOTIDE_EXCISION_REPAIR,1.618254994,0.376605996,SN-38
DISEASES_OF_METABOLISM,1.608132593,0.207976445,SN-38
CARGO_RECOGNITION_FOR_CLATHRIN_MEDIATED_ENDOCYTOSIS,1.566500747,0.132093148,SN-38
CLATHRIN_MEDIATED_ENDOCYTOSIS,1.566500747,0.132093148,SN-38
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.510900182,0.131156317,SN-38
DNA_REPAIR,1.277287803,0.353809779,SN-38
EUKARYOTIC_TRANSLATION_ELONGATION,-2.021118541,1,SN-38
EUKARYOTIC_TRANSLATION_INITIATION,-1.953719213,1,SN-38
G_ALPHA_Q_SIGNALLING_EVENTS,-1.916847819,0.743229513,SN-38
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.892266027,0.581425959,SN-38
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.959749142,0,darapladib
RAB_REGULATION_OF_TRAFFICKING,2.398902045,0.00093433,darapladib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.290344003,0.005799933,darapladib
RAB_GEFS_EXCHANGE_GTP_FOR_GDP_ON_RABS,2.147291612,0.004983093,darapladib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.246515104,0.009666555,darapladib
SELENOAMINO_ACID_METABOLISM,-2.238332341,0.007411026,darapladib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.237533895,0.005799933,darapladib
EUKARYOTIC_TRANSLATION_INITIATION,-2.215256101,0.005799933,darapladib
NONSENSE_MEDIATED_DECAY_NMD,-2.209935867,0.004994387,darapladib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.167838886,0.00759515,darapladib
EUKARYOTIC_TRANSLATION_ELONGATION,4.345493102,0,febuxostat
METABOLISM_OF_RNA,2.547419847,0,febuxostat
INFECTIOUS_DISEASE,2.548898939,0,febuxostat
SARS_COV_INFECTIONS,2.63790754,0,febuxostat
VIRAL_INFECTION_PATHWAYS,2.753229534,0,febuxostat
SARS_COV_2_INFECTION,2.80222913,0,febuxostat
SARS_COV_2_HOST_INTERACTIONS,3.219310079,0,febuxostat
NERVOUS_SYSTEM_DEVELOPMENT,3.35876287,0,febuxostat
TRANSLATION,3.640976904,0,febuxostat
SARS_COV_1_INFECTION,3.646581709,0,febuxostat
EUKARYOTIC_TRANSLATION_ELONGATION,4.187916843,0,triptorelin
SARS_COV_INFECTIONS,2.718188455,0,triptorelin
METABOLISM_OF_RNA,2.72366329,0,triptorelin
INFECTIOUS_DISEASE,2.784093172,0,triptorelin
SARS_COV_2_INFECTION,2.786489888,0,triptorelin
CELLULAR_RESPONSES_TO_STIMULI,2.866308197,0,triptorelin
VIRAL_INFECTION_PATHWAYS,2.870167177,0,triptorelin
SARS_COV_2_HOST_INTERACTIONS,3.025170138,0,triptorelin
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.393070787,0,triptorelin
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.519080473,0,triptorelin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.387912559,0,oxybuprocaine
SARS_COV_1_INFECTION,2.604094303,0,oxybuprocaine
SARS_COV_2_HOST_INTERACTIONS,2.632457271,0,oxybuprocaine
TRANSLATION,2.714716374,0,oxybuprocaine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.885193593,0,oxybuprocaine
SARS_COV_1_HOST_INTERACTIONS,2.924482737,0,oxybuprocaine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.949003529,0,oxybuprocaine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.955377302,0,oxybuprocaine
RRNA_PROCESSING,2.988148496,0,oxybuprocaine
INFLUENZA_INFECTION,2.993309457,0,oxybuprocaine
EUKARYOTIC_TRANSLATION_ELONGATION,2.74519424,0,moclobemide
SELENOAMINO_ACID_METABOLISM,2.611600631,0,moclobemide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.541930832,0,moclobemide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.500160034,0.000202838,moclobemide
EUKARYOTIC_TRANSLATION_INITIATION,2.496231743,0.00016227,moclobemide
NONSENSE_MEDIATED_DECAY_NMD,2.493503407,0.000135225,moclobemide
CELLULAR_RESPONSE_TO_STARVATION,2.446670874,0.000115907,moclobemide
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.384511358,0.000202838,moclobemide
GPCR_LIGAND_BINDING,-2.413502138,0.010940108,moclobemide
TRANSLATION,2.231188124,0.003515857,moclobemide
EUKARYOTIC_TRANSLATION_ELONGATION,4.682105682,0,betahistine
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.513690321,0,betahistine
SARS_COV_INFECTIONS,2.762727959,0,betahistine
SARS_COV_2_INFECTION,3.030781975,0,betahistine
INFECTIOUS_DISEASE,3.130898847,0,betahistine
METABOLISM_OF_RNA,3.332230423,0,betahistine
CELLULAR_RESPONSES_TO_STIMULI,3.478792203,0,betahistine
VIRAL_INFECTION_PATHWAYS,3.501314745,0,betahistine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.720094528,0,betahistine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.781253999,0,betahistine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-3.213227188,0,trapidil
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.718950214,0.001552347,trapidil
METABOLISM_OF_RNA,-2.664185179,0.001034898,trapidil
KERATINIZATION,2.37535551,0.00160648,trapidil
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.366483971,0.00232852,trapidil
RAB_REGULATION_OF_TRAFFICKING,-2.290375579,0.00434657,trapidil
MITOTIC_METAPHASE_AND_ANAPHASE,-2.134676051,0.010866426,trapidil
M_PHASE,-2.067235533,0.013749355,trapidil
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,-1.967962826,0.020956679,trapidil
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.066188657,0.024900439,trapidil
GPCR_LIGAND_BINDING,2.501924426,0,safinamide
NONSENSE_MEDIATED_DECAY_NMD,2.452366058,0,safinamide
SIGNALING_BY_GPCR,2.438718752,0,safinamide
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.420828802,0,safinamide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.399296345,0,safinamide
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.342202338,0,safinamide
EUKARYOTIC_TRANSLATION_ELONGATION,2.277742732,0.000330733,safinamide
EUKARYOTIC_TRANSLATION_INITIATION,2.272763918,0.000289392,safinamide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.266380456,0.000428728,safinamide
SELENOAMINO_ACID_METABOLISM,2.260885471,0.000463026,safinamide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.391747954,0.597878404,amodiaquine
MRNA_SPLICING,1.44489196,1,amodiaquine
EPIGENETIC_REGULATION_BY_WDR5_CONTAINING_HISTONE_MODIFYING_COMPLEXES,1.418380795,0.836698718,amodiaquine
SELENOAMINO_ACID_METABOLISM,-2.311876668,0.609703531,amodiaquine
NONSENSE_MEDIATED_DECAY_NMD,-2.301239041,0.433587978,amodiaquine
SIGNALING_BY_VEGF,1.349601787,0.759294872,amodiaquine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.274039121,0.380296073,amodiaquine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.232432345,0.361943477,amodiaquine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.300900356,0.720592949,amodiaquine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.293225855,0.598589744,amodiaquine
GPCR_LIGAND_BINDING,-2.419391692,0.005039468,tetracaine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.362574225,0.003779601,tetracaine
CIRCADIAN_CLOCK,2.402843654,0.017794776,tetracaine
EUKARYOTIC_TRANSLATION_INITIATION,2.303655277,0.019574254,tetracaine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.28072475,0.016608458,tetracaine
INTERFERON_SIGNALING,-2.15416298,0.01959793,tetracaine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.237231646,0.021353732,tetracaine
SIGNALING_BY_ROBO_RECEPTORS,2.194566486,0.022777314,tetracaine
CELLULAR_RESPONSE_TO_STARVATION,2.186294333,0.019771974,tetracaine
SIGNALING_BY_GPCR,-2.118794291,0.018898004,tetracaine
EUKARYOTIC_TRANSLATION_ELONGATION,4.148371483,0,avanafil
INFECTIOUS_DISEASE,2.628241655,0,avanafil
CELLULAR_RESPONSES_TO_STIMULI,2.664997805,0,avanafil
SARS_COV_INFECTIONS,2.701731091,0,avanafil
VIRAL_INFECTION_PATHWAYS,2.782333038,0,avanafil
SARS_COV_2_INFECTION,3.044308784,0,avanafil
NERVOUS_SYSTEM_DEVELOPMENT,3.212943957,0,avanafil
SARS_COV_2_HOST_INTERACTIONS,3.264767044,0,avanafil
SARS_COV_1_INFECTION,3.327577005,0,avanafil
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.40202476,0,avanafil
DNA_REPAIR,1.604661801,0.584068407,andarine
GLOBAL_GENOME_NUCLEOTIDE_EXCISION_REPAIR_GG_NER,1.409520849,0.780648065,andarine
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.403080252,0.533663366,andarine
DISEASES_OF_METABOLISM,1.362869587,0.494284428,andarine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.40052614,1,andarine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.35085017,0.41659766,andarine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.380001251,0.837273432,andarine
SELENOAMINO_ACID_METABOLISM,-2.338191687,0.760194175,andarine
MRNA_SPLICING,1.276234281,0.511926193,andarine
EUKARYOTIC_TRANSLATION_INITIATION,-2.327005154,0.617356676,andarine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,4.294026802,0,apixaban
METABOLISM_OF_RNA,2.661961059,0,apixaban
SARS_COV_INFECTIONS,2.707888673,0,apixaban
SARS_COV_2_INFECTION,2.75147904,0,apixaban
CELLULAR_RESPONSES_TO_STIMULI,2.764833024,0,apixaban
INFECTIOUS_DISEASE,2.784138578,0,apixaban
VIRAL_INFECTION_PATHWAYS,2.96989641,0,apixaban
SARS_COV_2_HOST_INTERACTIONS,3.000860304,0,apixaban
SARS_COV_1_INFECTION,3.353684508,0,apixaban
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.593205336,0,apixaban
EUKARYOTIC_TRANSLATION_INITIATION,4.035877637,0,ifosfamide
METABOLISM_OF_RNA,2.516124288,0,ifosfamide
INFECTIOUS_DISEASE,2.565138935,0,ifosfamide
SARS_COV_INFECTIONS,2.578112916,0,ifosfamide
CELLULAR_RESPONSES_TO_STIMULI,2.619876438,0,ifosfamide
SARS_COV_2_INFECTION,2.953756808,0,ifosfamide
SARS_COV_2_HOST_INTERACTIONS,3.115569789,0,ifosfamide
NERVOUS_SYSTEM_DEVELOPMENT,3.252001216,0,ifosfamide
SARS_COV_1_INFECTION,3.25870718,0,ifosfamide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.262457934,0,ifosfamide
SELENOAMINO_ACID_METABOLISM,4.106543728,0,nintedanib
CELLULAR_RESPONSES_TO_STIMULI,2.552024412,0,nintedanib
NERVOUS_SYSTEM_DEVELOPMENT,2.965433215,0,nintedanib
SARS_COV_1_INFECTION,2.966729905,0,nintedanib
SARS_COV_2_HOST_INTERACTIONS,2.970409477,0,nintedanib
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.209434921,0,nintedanib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.240508995,0,nintedanib
SARS_COV_1_HOST_INTERACTIONS,3.352331286,0,nintedanib
TRANSLATION,3.380952119,0,nintedanib
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.522575492,0,nintedanib
EUKARYOTIC_TRANSLATION_ELONGATION,3.49084892,0,cinnarizine
SARS_COV_1_HOST_INTERACTIONS,2.721958839,0,cinnarizine
TRANSLATION,2.788134579,0,cinnarizine
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.789168537,0,cinnarizine
SARS_COV_1_INFECTION,2.802402879,0,cinnarizine
RRNA_PROCESSING,2.864300783,0,cinnarizine
INFLUENZA_INFECTION,2.889170079,0,cinnarizine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.715826476,0,cinnarizine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.1377421,0,cinnarizine
NONSENSE_MEDIATED_DECAY_NMD,3.161336123,0,cinnarizine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.571647901,0.001661504,oxandrolone
MRNA_SPLICING,-2.46923947,0.000830752,oxandrolone
GPCR_LIGAND_BINDING,2.429239813,0.001727636,oxandrolone
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.38284472,0.001295727,oxandrolone
SIGNALING_BY_GPCR,2.293333705,0.001439697,oxandrolone
REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF,-2.004339393,0.047629776,oxandrolone
MITOTIC_SPINDLE_CHECKPOINT,-1.986003642,0.040706843,oxandrolone
AMINE_LIGAND_BINDING_RECEPTORS,2.006150794,0.034336773,oxandrolone
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-1.892347285,0.059814137,oxandrolone
KERATINIZATION,1.964718596,0.044573019,oxandrolone
EUKARYOTIC_TRANSLATION_ELONGATION,3.759803916,0,piclamilast
SARS_COV_1_INFECTION,2.83102981,0,piclamilast
SARS_COV_2_HOST_INTERACTIONS,2.890867808,0,piclamilast
NERVOUS_SYSTEM_DEVELOPMENT,2.995619103,0,piclamilast
SARS_COV_1_HOST_INTERACTIONS,3.095781217,0,piclamilast
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.129349448,0,piclamilast
TRANSLATION,3.20802773,0,piclamilast
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.326551504,0,piclamilast
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.360459322,0,piclamilast
SIGNALING_BY_ROBO_RECEPTORS,3.404746223,0,piclamilast
EUKARYOTIC_TRANSLATION_ELONGATION,4.595865411,0,nalbuphine
SARS_COV_INFECTIONS,2.701339979,0,nalbuphine
SARS_COV_2_INFECTION,2.843117697,0,nalbuphine
INFECTIOUS_DISEASE,2.897662591,0,nalbuphine
METABOLISM_OF_RNA,2.997763601,0,nalbuphine
VIRAL_INFECTION_PATHWAYS,2.998532183,0,nalbuphine
CELLULAR_RESPONSES_TO_STIMULI,3.112650701,0,nalbuphine
SARS_COV_2_HOST_INTERACTIONS,3.206126256,0,nalbuphine
SARS_COV_1_INFECTION,3.598010087,0,nalbuphine
NERVOUS_SYSTEM_DEVELOPMENT,3.69290015,0,nalbuphine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.983034949,0,bazedoxifene
RESPIRATORY_ELECTRON_TRANSPORT,2.730032489,0,bazedoxifene
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.738902933,0,bazedoxifene
CELLULAR_RESPONSES_TO_STIMULI,2.770880665,0,bazedoxifene
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.794357038,0,bazedoxifene
RRNA_PROCESSING,3.235140869,0,bazedoxifene
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.296889001,0,bazedoxifene
INFLUENZA_INFECTION,3.308369186,0,bazedoxifene
VIRAL_INFECTION_PATHWAYS,2.641741373,0,bazedoxifene
SIGNALING_BY_ROBO_RECEPTORS,3.518630211,0,bazedoxifene
RHO_GTPASE_EFFECTORS,-2.990259356,0,anagrelide
RRNA_PROCESSING,2.785424901,0,anagrelide
RHO_GTPASES_ACTIVATE_FORMINS,-2.782180416,0,anagrelide
RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL,2.578502734,0,anagrelide
METABOLISM_OF_RNA,2.603093788,0,anagrelide
GLYCOSAMINOGLYCAN_METABOLISM,-2.759587951,0.000661337,anagrelide
MITOTIC_PROMETAPHASE,-2.737026901,0.000496003,anagrelide
CELL_CYCLE_MITOTIC,-2.697810138,0.000396802,anagrelide
SEPARATION_OF_SISTER_CHROMATIDS,-2.644557892,0.000661337,anagrelide
M_PHASE,-2.61662614,0.000992006,anagrelide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.749625059,0.205769899,piretanide
MRNA_SPLICING,1.702361524,0.126984127,piretanide
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,1.559054543,0.180434867,piretanide
ONCOGENIC_MAPK_SIGNALING,-2.4120757,0.472401839,piretanide
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.39433767,0.329973352,piretanide
NON_INTEGRIN_MEMBRANE_ECM_INTERACTIONS,1.353895475,0.320704437,piretanide
DISEASES_OF_METABOLISM,1.283379372,0.377244815,piretanide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.252626852,1,piretanide
SELENOAMINO_ACID_METABOLISM,-2.186869483,1,piretanide
NONSENSE_MEDIATED_DECAY_NMD,-2.180496731,0.885267438,piretanide
EUKARYOTIC_TRANSLATION_ELONGATION,4.072913597,0,orlistat
CELLULAR_RESPONSES_TO_STIMULI,2.511695291,0,orlistat
METABOLISM_OF_RNA,2.514054959,0,orlistat
VIRAL_INFECTION_PATHWAYS,2.678176899,0,orlistat
SARS_COV_2_HOST_INTERACTIONS,2.744992994,0,orlistat
SARS_COV_1_INFECTION,3.196052924,0,orlistat
NERVOUS_SYSTEM_DEVELOPMENT,3.202957492,0,orlistat
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.204150821,0,orlistat
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.459869955,0,orlistat
SARS_COV_1_HOST_INTERACTIONS,3.47324437,0,orlistat
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.705160562,0,trimebutine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.588617442,0,trimebutine
GPCR_LIGAND_BINDING,2.345211401,0.002807374,trimebutine
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.258360304,0.012282116,trimebutine
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.191622309,0.010917437,trimebutine
SIGNALING_BY_GPCR,2.282025614,0.003743165,trimebutine
METABOLISM_OF_RNA,-2.180243019,0.008870417,trimebutine
DNA_REPAIR,-2.103249472,0.012009181,trimebutine
AMINE_LIGAND_BINDING_RECEPTORS,2.144442519,0.008021068,trimebutine
CELL_CYCLE,-2.031167716,0.019105515,trimebutine
EUKARYOTIC_TRANSLATION_ELONGATION,3.890295374,0,ivacaftor
SARS_COV_1_INFECTION,2.581651459,0,ivacaftor
SARS_COV_1_HOST_INTERACTIONS,2.600428104,0,ivacaftor
C_TYPE_LECTIN_RECEPTORS_CLRS,-2.715150423,0,ivacaftor
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.190871561,0,ivacaftor
INFLUENZA_INFECTION,3.37563757,0,ivacaftor
RRNA_PROCESSING,3.376264701,0,ivacaftor
TRANSLATION,3.383050165,0,ivacaftor
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.656007554,0,ivacaftor
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.529345244,0,ivacaftor
EUKARYOTIC_TRANSLATION_ELONGATION,4.92064132,0,chloroquine
SARS_COV_INFECTIONS,2.78427089,0,chloroquine
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.960975368,0,chloroquine
RESPIRATORY_ELECTRON_TRANSPORT,3.023120384,0,chloroquine
INFECTIOUS_DISEASE,3.151130649,0,chloroquine
SARS_COV_2_HOST_INTERACTIONS,3.154730299,0,chloroquine
METABOLISM_OF_RNA,3.312153263,0,chloroquine
VIRAL_INFECTION_PATHWAYS,3.428779634,0,chloroquine
CELLULAR_RESPONSES_TO_STIMULI,3.455570173,0,chloroquine
NERVOUS_SYSTEM_DEVELOPMENT,3.65144619,0,chloroquine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.352178469,0,seocalcitol
NONSENSE_MEDIATED_DECAY_NMD,-2.349129199,0,seocalcitol
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.336212788,0.00033912,seocalcitol
SELENOAMINO_ACID_METABOLISM,-2.323368323,0.00025434,seocalcitol
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.287978033,0.000203472,seocalcitol
SIGNALING_BY_ROBO_RECEPTORS,-2.286032571,0.00016956,seocalcitol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.263707745,0.000145337,seocalcitol
EUKARYOTIC_TRANSLATION_INITIATION,-2.208594672,0.000890189,seocalcitol
CELLULAR_RESPONSE_TO_STARVATION,-2.199081213,0.000904319,seocalcitol
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.166832228,0.001119095,seocalcitol
EUKARYOTIC_TRANSLATION_ELONGATION,-2.780984769,0,tioconazole
SELENOAMINO_ACID_METABOLISM,-2.726729565,0,tioconazole
EUKARYOTIC_TRANSLATION_INITIATION,-2.696150774,0,tioconazole
NONSENSE_MEDIATED_DECAY_NMD,-2.695414266,0,tioconazole
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.657609035,0,tioconazole
CELLULAR_RESPONSE_TO_STARVATION,-2.573907652,0,tioconazole
RRNA_PROCESSING,-2.565646459,0,tioconazole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.550375288,0,tioconazole
INFLUENZA_INFECTION,-2.541221608,0,tioconazole
TRANSLATION,-2.366285549,0,tioconazole
EUKARYOTIC_TRANSLATION_ELONGATION,2.462578412,0.000708254,metoprolol
CELL_CYCLE_MITOTIC,-2.554442702,0.004469712,metoprolol
SELENOAMINO_ACID_METABOLISM,2.356436666,0.002833016,metoprolol
CELL_CYCLE,-2.358609022,0.008939424,metoprolol
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,2.330827729,0.002833016,metoprolol
NONSENSE_MEDIATED_DECAY_NMD,2.276158525,0.003187142,metoprolol
EUKARYOTIC_TRANSLATION_INITIATION,2.270714538,0.002691365,metoprolol
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.243644374,0.003187142,metoprolol
RHO_GTPASES_ACTIVATE_FORMINS,-2.232279808,0.016885578,metoprolol
RESOLUTION_OF_SISTER_CHROMATID_COHESION,-2.223910995,0.013409135,metoprolol
TRANSPORT_TO_THE_GOLGI_AND_SUBSEQUENT_MODIFICATION,2.320481726,0.022006458,dicoumarol
METABOLISM_OF_VITAMINS_AND_COFACTORS,2.208126248,0.034009981,dicoumarol
GPCR_LIGAND_BINDING,-2.138761435,0.078981616,dicoumarol
FATTY_ACID_METABOLISM,2.147673241,0.039678311,dicoumarol
INTERFERON_SIGNALING,-2.092092714,0.067484292,dicoumarol
ASPARAGINE_N_LINKED_GLYCOSYLATION,2.125535798,0.036510715,dicoumarol
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.020578557,0.083647197,dicoumarol
ER_TO_GOLGI_ANTEROGRADE_TRANSPORT,2.038718142,0.053215618,dicoumarol
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,-1.957945635,0.09597766,dicoumarol
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,1.856770525,0.152211337,dicoumarol
NONSENSE_MEDIATED_DECAY_NMD,3.615923592,0,raloxifene
VIRAL_INFECTION_PATHWAYS,2.526410277,0,raloxifene
NERVOUS_SYSTEM_DEVELOPMENT,2.644500104,0,raloxifene
SARS_COV_INFECTIONS,2.670563894,0,raloxifene
SARS_COV_2_INFECTION,2.81036893,0,raloxifene
SARS_COV_2_HOST_INTERACTIONS,2.843317129,0,raloxifene
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,2.903051914,0,raloxifene
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.918188387,0,raloxifene
TRANSLATION,2.920885683,0,raloxifene
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.986110408,0,raloxifene
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.250209798,0,tolfenamic-acid
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.702277051,0,tolfenamic-acid
VIRAL_INFECTION_PATHWAYS,2.829749094,0,tolfenamic-acid
SARS_COV_1_INFECTION,2.896148997,0,tolfenamic-acid
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.926750057,0,tolfenamic-acid
CELLULAR_RESPONSES_TO_STIMULI,2.9276447,0,tolfenamic-acid
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.933060565,0,tolfenamic-acid
SARS_COV_1_HOST_INTERACTIONS,3.230662424,0,tolfenamic-acid
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.27525937,0,tolfenamic-acid
METABOLISM_OF_RNA,3.279305875,0,tolfenamic-acid
EUKARYOTIC_TRANSLATION_ELONGATION,-2.051427077,0.041511889,fingolimod
INTEGRIN_CELL_SURFACE_INTERACTIONS,1.805961919,0.292538916,fingolimod
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.975363565,0.064112807,fingolimod
SELENOAMINO_ACID_METABOLISM,-1.921930844,0.074413905,fingolimod
NONSENSE_MEDIATED_DECAY_NMD,-1.90813917,0.064804672,fingolimod
SARS_COV_2_HOST_INTERACTIONS,-1.907645334,0.052028235,fingolimod
REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA,1.540579168,0.621309716,fingolimod
DISEASES_OF_METABOLISM,1.500900441,0.508140991,fingolimod
EUKARYOTIC_TRANSLATION_INITIATION,-1.798559004,0.142216658,fingolimod
PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION,-1.767374093,0.163543666,fingolimod
EUKARYOTIC_TRANSLATION_ELONGATION,4.099438166,0,amrinone
INFECTIOUS_DISEASE,2.694875922,0,amrinone
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.757967013,0,amrinone
VIRAL_INFECTION_PATHWAYS,2.782788026,0,amrinone
CELLULAR_RESPONSES_TO_STIMULI,2.788938759,0,amrinone
SARS_COV_1_INFECTION,2.800791638,0,amrinone
SARS_COV_1_HOST_INTERACTIONS,2.826367673,0,amrinone
SIGNALING_BY_GPCR,-3.01720029,0,amrinone
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-3.037977146,0,amrinone
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.059564476,0,amrinone
EUKARYOTIC_TRANSLATION_ELONGATION,4.074914574,0,dipraglurant
SARS_COV_2_HOST_INTERACTIONS,2.639475187,0,dipraglurant
SARS_COV_1_INFECTION,3.008613835,0,dipraglurant
NERVOUS_SYSTEM_DEVELOPMENT,3.077042431,0,dipraglurant
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.130749911,0,dipraglurant
SARS_COV_1_HOST_INTERACTIONS,3.283686671,0,dipraglurant
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.302641959,0,dipraglurant
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.393444598,0,dipraglurant
TRANSLATION,3.47947527,0,dipraglurant
INFLUENZA_INFECTION,3.721482895,0,dipraglurant
GPCR_LIGAND_BINDING,-2.60712557,0,midostaurin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.335914448,0.007909605,midostaurin
SIGNALING_BY_GPCR,-2.170843963,0.02259887,midostaurin
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,2.075345394,0.154128004,midostaurin
CELLULAR_RESPONSE_TO_HEAT_STRESS,-2.002839881,0.059887006,midostaurin
MHC_CLASS_II_ANTIGEN_PRESENTATION,-1.84924406,0.138757062,midostaurin
G_ALPHA_I_SIGNALLING_EVENTS,-1.829816991,0.129001883,midostaurin
EPH_EPHRIN_SIGNALING,-1.828582309,0.111380145,midostaurin
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-1.773342651,0.13940678,midostaurin
PEPTIDE_LIGAND_BINDING_RECEPTORS,-1.772310731,0.124670433,midostaurin
EUKARYOTIC_TRANSLATION_ELONGATION,4.637484155,0,desvenlafaxine
NUCLEAR_EVENTS_MEDIATED_BY_NFE2L2,2.605419608,0,desvenlafaxine
SARS_COV_INFECTIONS,2.774479008,0,desvenlafaxine
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.853542513,0,desvenlafaxine
INFECTIOUS_DISEASE,3.132349058,0,desvenlafaxine
SARS_COV_2_INFECTION,3.150845966,0,desvenlafaxine
METABOLISM_OF_RNA,3.267805361,0,desvenlafaxine
SARS_COV_2_HOST_INTERACTIONS,3.290823134,0,desvenlafaxine
VIRAL_INFECTION_PATHWAYS,3.450850933,0,desvenlafaxine
CELLULAR_RESPONSES_TO_STIMULI,3.503712478,0,desvenlafaxine
G_ALPHA_Q_SIGNALLING_EVENTS,-1.976426134,0.14746698,fenoldopam
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.89526626,0.197785105,fenoldopam
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.475818919,0.74205592,fenoldopam
EUKARYOTIC_TRANSLATION_ELONGATION,-1.823732945,0.262052809,fenoldopam
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.457796993,0.406620758,fenoldopam
DISEASES_OF_METABOLISM,1.42256088,0.318178047,fenoldopam
EUKARYOTIC_TRANSLATION_INITIATION,-1.748283771,0.401797701,fenoldopam
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.742290223,0.339572613,fenoldopam
EPIGENETIC_REGULATION_BY_WDR5_CONTAINING_HISTONE_MODIFYING_COMPLEXES,1.28381864,0.448415332,fenoldopam
GPCR_LIGAND_BINDING,-1.728209936,0.320674255,fenoldopam
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.18671966,0.014088,mitoxantrone
EUKARYOTIC_TRANSLATION_ELONGATION,-2.173194392,0.0075136,mitoxantrone
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.122902018,0.009078934,mitoxantrone
SELENOAMINO_ACID_METABOLISM,-2.115051514,0.0086876,mitoxantrone
GPCR_LIGAND_BINDING,-2.08087644,0.01014336,mitoxantrone
NONSENSE_MEDIATED_DECAY_NMD,-2.071159676,0.009548534,mitoxantrone
EUKARYOTIC_TRANSLATION_INITIATION,-2.053137,0.0103312,mitoxantrone
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.050798477,0.0090398,mitoxantrone
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.85403132,0.226080063,mitoxantrone
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.035798672,0.010539911,mitoxantrone
SELENOAMINO_ACID_METABOLISM,3.783033327,0,tizanidine
CELLULAR_RESPONSES_TO_STIMULI,2.38250503,0,tizanidine
METABOLISM_OF_RNA,2.414178358,0,tizanidine
VIRAL_INFECTION_PATHWAYS,2.462061429,0,tizanidine
SARS_COV_2_HOST_INTERACTIONS,2.55426977,0,tizanidine
SARS_COV_2_INFECTION,2.562147425,0,tizanidine
NERVOUS_SYSTEM_DEVELOPMENT,3.087562274,0,tizanidine
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.180088576,0,tizanidine
SARS_COV_1_INFECTION,3.209109716,0,tizanidine
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.253748894,0,tizanidine
EUKARYOTIC_TRANSLATION_ELONGATION,-2.389234798,0.004665774,ketotifen
SELENOAMINO_ACID_METABOLISM,-2.310887888,0.012131012,ketotifen
EUKARYOTIC_TRANSLATION_INITIATION,-2.299982982,0.010886806,ketotifen
NONSENSE_MEDIATED_DECAY_NMD,-2.297598514,0.008398393,ketotifen
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.216777706,0.015117107,ketotifen
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.183020152,0.016485734,ketotifen
TRANSLATION,-2.130126012,0.021195944,ketotifen
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.103020661,0.022395715,ketotifen
RAB_REGULATION_OF_TRAFFICKING,1.789258319,0.30713422,ketotifen
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.779705326,0.164449819,ketotifen
EUKARYOTIC_TRANSLATION_INITIATION,4.065111955,0,aniracetam
THE_ROLE_OF_GTSE1_IN_G2_M_PROGRESSION_AFTER_G2_CHECKPOINT,2.49822933,0,aniracetam
METABOLISM_OF_RNA,2.502931952,0,aniracetam
SARS_COV_2_HOST_INTERACTIONS,2.617924854,0,aniracetam
VIRAL_INFECTION_PATHWAYS,2.698981321,0,aniracetam
CELLULAR_RESPONSES_TO_STIMULI,2.771902664,0,aniracetam
SARS_COV_1_HOST_INTERACTIONS,3.124334431,0,aniracetam
NERVOUS_SYSTEM_DEVELOPMENT,3.137522959,0,aniracetam
SARS_COV_1_INFECTION,3.153733227,0,aniracetam
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.289163211,0,aniracetam
GPCR_LIGAND_BINDING,-2.846979829,0,varenicline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.774754851,0,varenicline
SIGNALING_BY_GPCR,-2.663147449,0,varenicline
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.717497766,0.000695503,varenicline
NONSENSE_MEDIATED_DECAY_NMD,2.715879918,0.000463669,varenicline
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.468219204,0.000931601,varenicline
EUKARYOTIC_TRANSLATION_INITIATION,2.675538718,0.001043255,varenicline
RRNA_PROCESSING,2.477369434,0.003338417,varenicline
TRANSLATION,2.460550554,0.002782014,varenicline
SIGNALING_BY_ROBO_RECEPTORS,2.438336111,0.002384583,varenicline
EUKARYOTIC_TRANSLATION_ELONGATION,3.220199367,0,romidepsin
CELLULAR_RESPONSE_TO_STARVATION,3.194154069,0,romidepsin
EUKARYOTIC_TRANSLATION_INITIATION,3.122329284,0,romidepsin
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,3.009280183,0,romidepsin
MITOTIC_SPINDLE_CHECKPOINT,-2.91733135,0,romidepsin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.785649713,0,romidepsin
SELENOAMINO_ACID_METABOLISM,2.746232301,0,romidepsin
CELL_CYCLE_MITOTIC,-2.703175051,0,romidepsin
CELL_CYCLE,-2.600694287,0,romidepsin
SEPARATION_OF_SISTER_CHROMATIDS,-2.565314878,0,romidepsin
EUKARYOTIC_TRANSLATION_ELONGATION,2.987618981,0,berberine
SELENOAMINO_ACID_METABOLISM,2.649637985,0,berberine
RRNA_PROCESSING,2.65768117,0,berberine
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.783773346,0,berberine
CELLULAR_RESPONSE_TO_STARVATION,2.820745507,0,berberine
SIGNALING_BY_ROBO_RECEPTORS,2.753648534,0,berberine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.883810573,0,berberine
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.93101493,0,berberine
NONSENSE_MEDIATED_DECAY_NMD,2.956225263,0,berberine
EUKARYOTIC_TRANSLATION_INITIATION,2.876514683,0,berberine
EUKARYOTIC_TRANSLATION_ELONGATION,4.985263273,0,tandutinib
RESPIRATORY_ELECTRON_TRANSPORT,2.614419758,0,tandutinib
SARS_COV_INFECTIONS,2.661289016,0,tandutinib
SARS_COV_2_INFECTION,2.801317462,0,tandutinib
SARS_COV_2_HOST_INTERACTIONS,2.937964927,0,tandutinib
INFECTIOUS_DISEASE,3.238961198,0,tandutinib
VIRAL_INFECTION_PATHWAYS,3.50139611,0,tandutinib
METABOLISM_OF_RNA,3.528780437,0,tandutinib
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.687020887,0,tandutinib
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.782426163,0,tandutinib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.326675381,0.022632884,methyldopa
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.04402549,0.187847877,methyldopa
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,2.003081638,0.217990406,methyldopa
MITOCHONDRIAL_PROTEIN_DEGRADATION,1.94916553,0.212431452,methyldopa
GPCR_LIGAND_BINDING,-1.909374197,0.258075409,methyldopa
INTERFERON_SIGNALING,-1.89437487,0.191869086,methyldopa
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,1.890625206,0.238538682,methyldopa
BIOLOGICAL_OXIDATIONS,-1.873858421,0.170829549,methyldopa
PKR_MEDIATED_SIGNALING,-1.836403178,0.171648152,methyldopa
SIGNALING_BY_GPCR,-1.82073338,0.161710023,methyldopa
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.438170271,0,telcagepant
RESPIRATORY_ELECTRON_TRANSPORT,2.745488673,0,telcagepant
INFECTIOUS_DISEASE,2.775027215,0,telcagepant
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.882409401,0,telcagepant
VIRAL_INFECTION_PATHWAYS,2.978351264,0,telcagepant
METABOLISM_OF_RNA,3.105270204,0,telcagepant
NERVOUS_SYSTEM_DEVELOPMENT,3.254238418,0,telcagepant
CELLULAR_RESPONSES_TO_STIMULI,3.268715571,0,telcagepant
SARS_COV_1_INFECTION,3.400717909,0,telcagepant
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.467584083,0,telcagepant
NONSENSE_MEDIATED_DECAY_NMD,3.138000776,0,alvocidib
SIGNALING_BY_ROBO_RECEPTORS,2.60745439,0,alvocidib
INFLUENZA_INFECTION,2.607843908,0,alvocidib
RRNA_PROCESSING,2.624140909,0,alvocidib
TRANSLATION,2.74838534,0,alvocidib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.783655019,0,alvocidib
CELLULAR_RESPONSE_TO_STARVATION,2.639697803,0,alvocidib
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.912667761,0,alvocidib
EUKARYOTIC_TRANSLATION_INITIATION,3.020745957,0,alvocidib
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.075571948,0,alvocidib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,4.261815196,0,PS-178990
RESPIRATORY_ELECTRON_TRANSPORT,2.556664453,0,PS-178990
SARS_COV_INFECTIONS,2.602947863,0,PS-178990
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.763696651,0,PS-178990
METABOLISM_OF_RNA,2.865165847,0,PS-178990
SARS_COV_2_INFECTION,2.87648472,0,PS-178990
SARS_COV_2_HOST_INTERACTIONS,3.024575913,0,PS-178990
VIRAL_INFECTION_PATHWAYS,3.12505797,0,PS-178990
CELLULAR_RESPONSES_TO_STIMULI,3.132147802,0,PS-178990
SARS_COV_1_INFECTION,3.42551482,0,PS-178990
GPCR_LIGAND_BINDING,-2.286041318,0.012293571,levetiracetam
LATE_SARS_COV_2_INFECTION_EVENTS,2.323456879,0.055636346,levetiracetam
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.23059663,0.011323026,levetiracetam
DISEASES_OF_METABOLISM,2.127679636,0.139822921,levetiracetam
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.032039853,0.045076427,levetiracetam
SIGNALING_BY_WNT,2.096918818,0.120057377,levetiracetam
SARS_COV_2_INFECTION,2.096543128,0.090043033,levetiracetam
G_ALPHA_I_SIGNALLING_EVENTS,-2.025436913,0.036071926,levetiracetam
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,-2.01286687,0.032351503,levetiracetam
TCF_DEPENDENT_SIGNALING_IN_RESPONSE_TO_WNT,2.077529307,0.083454518,levetiracetam
CELL_CYCLE_MITOTIC,-2.39852158,0.003568532,pilocarpine
CELL_CYCLE,-2.340490293,0.003568532,pilocarpine
HIV_INFECTION,-2.243164295,0.007930071,pilocarpine
HIV_LIFE_CYCLE,-2.212186659,0.008623952,pilocarpine
METABOLISM_OF_RNA,-2.200004374,0.008088673,pilocarpine
MITOTIC_G2_G2_M_PHASES,-2.18564227,0.007335316,pilocarpine
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.139305654,0.011045456,pilocarpine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.13845424,0.009813463,pilocarpine
RHO_GTPASE_EFFECTORS,-2.10274116,0.011895107,pilocarpine
INFLUENZA_INFECTION,-2.075592224,0.01451203,pilocarpine
ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES,1.437577026,0.459042922,dexniguldipine
COLLAGEN_FORMATION,1.437577026,0.459042922,dexniguldipine
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.344150425,1,dexniguldipine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.257288952,1,dexniguldipine
G_ALPHA_I_SIGNALLING_EVENTS,-2.177197878,0.882807215,dexniguldipine
GPCR_LIGAND_BINDING,-1.996442281,0.758185369,dexniguldipine
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-1.95038154,0.632235994,dexniguldipine
COLLAGEN_DEGRADATION,1.336074059,0.524312245,dexniguldipine
SIGNALING_BY_GPCR,-1.875914884,0.573824689,dexniguldipine
CYCLIN_D_ASSOCIATED_EVENTS_IN_G1,-1.82704595,0.532955741,dexniguldipine
METABOLISM_OF_RNA,-3.059223048,0,diosmin
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.560819743,0.001483799,diosmin
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,2.339351888,0.004101603,diosmin
RRNA_PROCESSING,-2.358756316,0.006924393,diosmin
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,-2.333695418,0.005193295,diosmin
GPCR_LIGAND_BINDING,2.199322152,0.006562564,diosmin
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.18673262,0.010683349,diosmin
INTERFERON_ALPHA_BETA_SIGNALING,-2.164530671,0.00989199,diosmin
INTERFERON_SIGNALING,-2.157746342,0.008478849,diosmin
SIGNALING_BY_GPCR,2.071108349,0.017226731,diosmin
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.648598695,0,carbimazole
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.569155035,0,carbimazole
TP53_REGULATES_METABOLIC_GENES,2.577845868,0,carbimazole
RESPIRATORY_ELECTRON_TRANSPORT,2.58915773,0,carbimazole
SARS_COV_INFECTIONS,2.70062061,0,carbimazole
SARS_COV_2_INFECTION,2.742683881,0,carbimazole
SARS_COV_2_HOST_INTERACTIONS,2.904557195,0,carbimazole
METABOLISM_OF_RNA,3.186435188,0,carbimazole
VIRAL_INFECTION_PATHWAYS,3.400515083,0,carbimazole
CELLULAR_RESPONSES_TO_STIMULI,3.473124319,0,carbimazole
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,4.853429094,0,flumazenil
RESPIRATORY_ELECTRON_TRANSPORT,2.499345585,0,flumazenil
TP53_REGULATES_METABOLIC_GENES,2.535391613,0,flumazenil
SARS_COV_INFECTIONS,2.599672123,0,flumazenil
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.742854356,0,flumazenil
SARS_COV_2_INFECTION,2.807580268,0,flumazenil
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,2.837612244,0,flumazenil
INFECTIOUS_DISEASE,3.306716896,0,flumazenil
METABOLISM_OF_RNA,3.591194824,0,flumazenil
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.669168845,0,flumazenil
EUKARYOTIC_TRANSLATION_ELONGATION,-2.508097424,0,bicalutamide
SELENOAMINO_ACID_METABOLISM,-2.440214859,0,bicalutamide
NONSENSE_MEDIATED_DECAY_NMD,-2.412632821,0,bicalutamide
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.391507732,0,bicalutamide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.377069867,0,bicalutamide
EUKARYOTIC_TRANSLATION_INITIATION,-2.346536523,0.000329397,bicalutamide
CELLULAR_RESPONSE_TO_STARVATION,-2.30604399,0.00028234,bicalutamide
MRNA_SPLICING,2.45039502,0.00641574,bicalutamide
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,2.349530783,0.004491018,bicalutamide
RRNA_PROCESSING,-2.292129893,0.000370572,bicalutamide
EUKARYOTIC_TRANSLATION_ELONGATION,-2.065481658,0.0104222,enprofylline
G_ALPHA_Q_SIGNALLING_EVENTS,-2.02503891,0.015159564,enprofylline
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-1.977513469,0.022423522,enprofylline
MRNA_SPLICING,1.792627034,0.160744186,enprofylline
SELENOAMINO_ACID_METABOLISM,-1.936610584,0.03789891,enprofylline
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.93311196,0.031266601,enprofylline
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.633360819,0.197581395,enprofylline
EUKARYOTIC_TRANSLATION_INITIATION,-1.890892298,0.045162868,enprofylline
NONSENSE_MEDIATED_DECAY_NMD,-1.866159785,0.052517061,enprofylline
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-1.845427363,0.058388008,enprofylline
EUKARYOTIC_TRANSLATION_ELONGATION,2.651483869,0,rilpivirine
KERATINIZATION,2.492251862,0,rilpivirine
NONSENSE_MEDIATED_DECAY_NMD,2.41855686,0.001268001,rilpivirine
FORMATION_OF_THE_CORNIFIED_ENVELOPE,2.377502155,0.001268001,rilpivirine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.355319425,0.001394801,rilpivirine
CELL_CYCLE_MITOTIC,-2.403186009,0.013676373,rilpivirine
SELENOAMINO_ACID_METABOLISM,2.274232883,0.003275669,rilpivirine
EUKARYOTIC_TRANSLATION_INITIATION,2.201780934,0.005887148,rilpivirine
TRANSLATION,2.179725065,0.006102255,rilpivirine
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.162061386,0.062303475,rilpivirine
EUKARYOTIC_TRANSLATION_ELONGATION,2.887569627,0,vardenafil
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.518049322,0,vardenafil
SELENOAMINO_ACID_METABOLISM,2.744471563,0.000395342,vardenafil
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.680502307,0.000263561,vardenafil
CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM,-2.48325738,0.000407914,vardenafil
GPCR_LIGAND_BINDING,-2.499092564,0.000611871,vardenafil
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.415093266,0.000611871,vardenafil
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.588440824,0.000593012,vardenafil
NONSENSE_MEDIATED_DECAY_NMD,2.544073299,0.00047441,vardenafil
EUKARYOTIC_TRANSLATION_INITIATION,2.443553591,0.000527122,vardenafil
EUKARYOTIC_TRANSLATION_ELONGATION,2.731268275,0.000906329,meclofenamic-acid
SELENOAMINO_ACID_METABOLISM,2.693677866,0.000453165,meclofenamic-acid
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.668571626,0.00030211,meclofenamic-acid
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.577347629,0.000226582,meclofenamic-acid
CELLULAR_RESPONSE_TO_STARVATION,2.529454403,0.000181266,meclofenamic-acid
NONSENSE_MEDIATED_DECAY_NMD,2.524077883,0.000151055,meclofenamic-acid
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.441790774,0.000129476,meclofenamic-acid
SARS_COV_1_HOST_INTERACTIONS,2.431184569,0.000113291,meclofenamic-acid
SIGNALING_BY_ROBO_RECEPTORS,2.413309638,0.000201407,meclofenamic-acid
INFLUENZA_INFECTION,2.334050831,0.000271899,meclofenamic-acid
EUKARYOTIC_TRANSLATION_ELONGATION,3.85807327,0,rimonabant
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,2.686507589,0,rimonabant
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,2.755588406,0,rimonabant
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,2.810699058,0,rimonabant
NERVOUS_SYSTEM_DEVELOPMENT,2.872718539,0,rimonabant
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.108852958,0,rimonabant
TRANSLATION,3.167796061,0,rimonabant
INFLUENZA_INFECTION,3.569941984,0,rimonabant
RRNA_PROCESSING,3.439473132,0,rimonabant
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,3.668093708,0,rimonabant
DISEASES_OF_METABOLISM,1.588627763,0.365495984,loxoprofen
ONCOGENIC_MAPK_SIGNALING,-2.442135898,0.877277896,loxoprofen
PROTEIN_LOCALIZATION,1.411661029,0.478423314,loxoprofen
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.381969122,0.371567345,loxoprofen
GLYCOSAMINOGLYCAN_METABOLISM,1.376649558,0.286264711,loxoprofen
MRNA_SPLICING,1.324921098,0.294825332,loxoprofen
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,1.268112135,0.320163148,loxoprofen
EPH_EPHRIN_SIGNALING,1.262555611,0.282058125,loxoprofen
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.359677281,1,loxoprofen
DISEASES_OF_GLYCOSYLATION,1.16748636,0.388718943,loxoprofen
EUKARYOTIC_TRANSLATION_ELONGATION,4.170398815,0,zonisamide
SARS_COV_2_HOST_INTERACTIONS,2.815423926,0,zonisamide
SARS_COV_1_INFECTION,3.088733312,0,zonisamide
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.312424324,0,zonisamide
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.423982989,0,zonisamide
NERVOUS_SYSTEM_DEVELOPMENT,3.431300209,0,zonisamide
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.438010831,0,zonisamide
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.472387411,0,zonisamide
SARS_COV_1_HOST_INTERACTIONS,3.536825406,0,zonisamide
TRANSLATION,3.570003461,0,zonisamide
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.95955466,0,linsitinib
NONSENSE_MEDIATED_DECAY_NMD,2.809589189,0,linsitinib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.782845839,0,linsitinib
EUKARYOTIC_TRANSLATION_INITIATION,2.758237529,0,linsitinib
GPCR_LIGAND_BINDING,-2.757362749,0,linsitinib
EUKARYOTIC_TRANSLATION_ELONGATION,2.716074844,0,linsitinib
SELENOAMINO_ACID_METABOLISM,2.69594103,0,linsitinib
SIGNALING_BY_GPCR,-2.511306548,0.000218276,linsitinib
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.444161028,0.000327414,linsitinib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.585144651,0.00024801,linsitinib
EUKARYOTIC_TRANSLATION_INITIATION,4.384282693,0,clinofibrate
CELLULAR_RESPONSES_TO_STIMULI,2.764545087,0,clinofibrate
METABOLISM_OF_RNA,2.800314198,0,clinofibrate
SARS_COV_1_HOST_INTERACTIONS,3.085799808,0,clinofibrate
SARS_COV_2_MODULATES_HOST_TRANSLATION_MACHINERY,3.097099065,0,clinofibrate
NERVOUS_SYSTEM_DEVELOPMENT,3.114668989,0,clinofibrate
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,3.210602011,0,clinofibrate
SARS_COV_1_INFECTION,3.250839156,0,clinofibrate
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.395122147,0,clinofibrate
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.70039254,0,clinofibrate
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.112801308,0.023049281,valproic-acid
PEPTIDE_LIGAND_BINDING_RECEPTORS,-1.986694972,0.058625345,valproic-acid
GPCR_LIGAND_BINDING,-1.985919852,0.040085706,valproic-acid
G_ALPHA_Q_SIGNALLING_EVENTS,-1.981998034,0.031818029,valproic-acid
MRNA_SPLICING,1.711308658,0.202114628,valproic-acid
INSULIN_RECEPTOR_SIGNALLING_CASCADE,-1.937225732,0.046298991,valproic-acid
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-1.919663046,0.046098562,valproic-acid
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.510772187,0.319128361,valproic-acid
SIGNALING_BY_GPCR,-1.840585847,0.091194982,valproic-acid
COPI_DEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC,1.442541765,0.313648379,valproic-acid
GPCR_LIGAND_BINDING,-2.534065111,0,cediranib
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.391381509,0.001641861,cediranib
NONSENSE_MEDIATED_DECAY_NMD,2.525076059,0.011707025,cediranib
SIGNALING_BY_GPCR,-2.269401164,0.00459721,cediranib
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.276721919,0.036584454,cediranib
AEROBIC_RESPIRATION_AND_RESPIRATORY_ELECTRON_TRANSPORT,2.21704495,0.03951121,cediranib
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.069211,0.026926516,cediranib
TRANSLATION,2.11625582,0.065120328,cediranib
SARS_COV_1_INFECTION,2.104754327,0.056193721,cediranib
SEMAPHORIN_INTERACTIONS,-1.937251942,0.066462522,cediranib
EUKARYOTIC_TRANSLATION_ELONGATION,-2.261958512,0.002978873,FK-866
SELENOAMINO_ACID_METABOLISM,-2.222950647,0.001985915,FK-866
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.205131016,0.001323944,FK-866
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,-2.181836732,0.001985915,FK-866
NONSENSE_MEDIATED_DECAY_NMD,-2.1764405,0.001588732,FK-866
EUKARYOTIC_TRANSLATION_INITIATION,-2.172938752,0.001323944,FK-866
SARS_COV_1_MODULATES_HOST_TRANSLATION_MACHINERY,-2.033379094,0.005815895,FK-866
SARS_COV_1_INFECTION,-2.033289739,0.005088908,FK-866
INFLUENZA_INFECTION,-2.033179584,0.004523474,FK-866
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,-2.025845765,0.0040621,FK-866
EUKARYOTIC_TRANSLATION_INITIATION,3.605548849,0,nortriptyline
SARS_COV_1_INFECTION,2.640385492,0,nortriptyline
SARS_COV_1_HOST_INTERACTIONS,2.777550383,0,nortriptyline
RRNA_PROCESSING,2.959111966,0,nortriptyline
INFLUENZA_INFECTION,2.979782563,0,nortriptyline
SIGNALING_BY_ROBO_RECEPTORS,3.128749165,0,nortriptyline
CELLULAR_RESPONSE_TO_STARVATION,3.16369136,0,nortriptyline
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S,3.196175295,0,nortriptyline
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,3.221654201,0,nortriptyline
TRANSLATION,3.251053463,0,nortriptyline
GPCR_LIGAND_BINDING,-2.420988015,0.003445771,thioridazine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.228983728,0.015505971,thioridazine
SIGNALING_BY_GPCR,-2.21900824,0.010911609,thioridazine
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,-2.179911646,0.011629478,thioridazine
LATE_SARS_COV_2_INFECTION_EVENTS,2.04461108,0.32405457,thioridazine
ASPARAGINE_N_LINKED_GLYCOSYLATION,2.03565202,0.178868831,thioridazine
CIRCADIAN_CLOCK,2.02486704,0.128924937,thioridazine
ADIPOGENESIS,1.884903364,0.250590586,thioridazine
METABOLISM_OF_VITAMINS_AND_COFACTORS,1.88429474,0.20116936,thioridazine
ESTROGEN_DEPENDENT_GENE_EXPRESSION,1.847855598,0.210616113,thioridazine
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,3.130242554,0,umeclidinium
RRNA_PROCESSING,2.602359673,0,umeclidinium
SIGNALING_BY_ROBO_RECEPTORS,2.654727062,0,umeclidinium
DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX,-2.74014592,0,umeclidinium
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.80728705,0,umeclidinium
CELLULAR_RESPONSE_TO_STARVATION,2.928403736,0,umeclidinium
INFLUENZA_INFECTION,2.753012508,0,umeclidinium
EUKARYOTIC_TRANSLATION_INITIATION,2.957174851,0,umeclidinium
REGULATION_OF_HSF1_MEDIATED_HEAT_SHOCK_RESPONSE,-2.967074954,0,umeclidinium
SELENOAMINO_ACID_METABOLISM,3.01913428,0,umeclidinium
METABOLISM_OF_RNA,3.169770142,0,BRD-K76674262
RRNA_PROCESSING,3.058933445,0,BRD-K76674262
NONSENSE_MEDIATED_DECAY_NMD,2.7005304,0.000353283,BRD-K76674262
EUKARYOTIC_TRANSLATION_INITIATION,2.503630336,0.000264962,BRD-K76674262
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE,2.394812227,0.002331665,BRD-K76674262
INFLUENZA_INFECTION,2.326112352,0.00423939,BRD-K76674262
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.245854255,0.00802456,BRD-K76674262
SIGNALING_BY_RHO_GTPASES_MIRO_GTPASES_AND_RHOBTB3,-2.123559423,0.11333651,BRD-K76674262
GLYCOSAMINOGLYCAN_METABOLISM,-2.096265283,0.077318551,BRD-K76674262
SELENOAMINO_ACID_METABOLISM,2.062088406,0.026761151,BRD-K76674262
TNFR2_NON_CANONICAL_NF_KB_PATHWAY,3.04836191,0,bortezomib
REGULATION_OF_RAS_BY_GAPS,2.751025466,0,bortezomib
METABOLISM_OF_POLYAMINES,2.763670646,0,bortezomib
SOMITOGENESIS,2.76716189,0,bortezomib
CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES,2.76716189,0,bortezomib
TRANSCRIPTIONAL_REGULATION_BY_RUNX3,2.779266696,0,bortezomib
INTERLEUKIN_1_FAMILY_SIGNALING,2.781758989,0,bortezomib
ANTIGEN_PROCESSING_CROSS_PRESENTATION,2.785264848,0,bortezomib
HH_MUTANTS_ABROGATE_LIGAND_SECRETION,2.792476384,0,bortezomib
REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC,2.804092887,0,bortezomib
MRNA_SPLICING,-3.140843982,0,istaroxime
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,-2.72469183,0,istaroxime
EUKARYOTIC_TRANSLATION_INITIATION,2.470558799,0.00081367,istaroxime
EUKARYOTIC_TRANSLATION_ELONGATION,2.453250851,0.000271223,istaroxime
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,2.453250851,0.000271223,istaroxime
NONSENSE_MEDIATED_DECAY_NMD,2.437548703,0.000406835,istaroxime
SELENOAMINO_ACID_METABOLISM,2.378042272,0.000325468,istaroxime
REGULATION_OF_EXPRESSION_OF_SLITS_AND_ROBOS,2.205370258,0.001627339,istaroxime
EPIGENETIC_REGULATION_OF_GENE_EXPRESSION,-2.088088613,0.034787299,istaroxime
SIGNALING_BY_ROBO_RECEPTORS,2.137359679,0.004184587,istaroxime
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.754743015,0.154372252,ketorolac
MRNA_SPLICING,1.667133714,0.144601856,ketorolac
COPI_DEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC,1.239528941,0.68099658,ketorolac
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.2396112,0.906692721,ketorolac
G_ALPHA_Q_SIGNALLING_EVENTS,-1.788047737,1,ketorolac
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.198513906,0.669858329,ketorolac
INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING,-1.727642463,1,ketorolac
GPCR_LIGAND_BINDING,-1.723266567,1,ketorolac
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.701079356,0.906712238,ketorolac
ASPARAGINE_N_LINKED_GLYCOSYLATION,1.109264833,0.84123107,ketorolac
RAC3_GTPASE_CYCLE,1.633713389,0.446952596,clonazepam
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,1.47140473,0.509255079,clonazepam
MRNA_SPLICING,1.44579421,0.395936795,clonazepam
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.549703627,1,clonazepam
TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM,1.359171097,0.455756208,clonazepam
PROTEIN_LOCALIZATION,1.280309145,0.556930023,clonazepam
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.398248309,1,clonazepam
SIGNALING_BY_NOTCH,-2.369957677,1,clonazepam
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.32015504,1,clonazepam
GPCR_LIGAND_BINDING,-2.290584658,0.906566098,clonazepam
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.953206125,0.130077022,acetazolamide
INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING,-1.832321896,0.2553718,acetazolamide
IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL,1.447579482,1,acetazolamide
MRNA_SPLICING,1.387229938,0.801298929,acetazolamide
GPCR_LIGAND_BINDING,-1.770147967,0.315628068,acetazolamide
ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES,1.339989669,0.698028202,acetazolamide
CLATHRIN_MEDIATED_ENDOCYTOSIS,1.331180324,0.547217834,acetazolamide
G_ALPHA_Q_SIGNALLING_EVENTS,-1.698501392,0.451682894,acetazolamide
ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES,1.235087518,0.719325961,acetazolamide
CARGO_RECOGNITION_FOR_CLATHRIN_MEDIATED_ENDOCYTOSIS,1.230229649,0.612895676,acetazolamide
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.58533758,0.469457014,phenprocoumon
DISEASES_OF_METABOLISM,1.489081253,0.371182127,phenprocoumon
GLYCOSAMINOGLYCAN_METABOLISM,1.387668077,0.42515083,phenprocoumon
EUKARYOTIC_TRANSLATION_ELONGATION,-2.334895908,1,phenprocoumon
RESPONSE_OF_EIF2AK4_GCN2_TO_AMINO_ACID_DEFICIENCY,-2.290511584,1,phenprocoumon
DISORDERS_OF_TRANSMEMBRANE_TRANSPORTERS,1.209308959,0.743778281,phenprocoumon
SELENOAMINO_ACID_METABOLISM,-2.278239928,1,phenprocoumon
BIOLOGICAL_OXIDATIONS,1.190561923,0.646776018,phenprocoumon
PHASE_I_FUNCTIONALIZATION_OF_COMPOUNDS,1.176168779,0.577394419,phenprocoumon
EUKARYOTIC_TRANSLATION_INITIATION,-2.204899531,1,phenprocoumon
COPI_DEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC,1.748505592,0.258522942,paroxetine
MRNA_SPLICING,1.664064542,0.206364805,paroxetine
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.638598392,0.156222441,paroxetine
CELLULAR_RESPONSE_TO_CHEMICAL_STRESS,-2.317713354,1,paroxetine
SUMOYLATION_OF_DNA_DAMAGE_RESPONSE_AND_REPAIR_PROTEINS,1.398205611,0.410461864,paroxetine
G_ALPHA_Q_SIGNALLING_EVENTS,-2.034458873,1,paroxetine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.350903629,0.420893492,paroxetine
NUCLEOTIDE_EXCISION_REPAIR,1.318364744,0.413485524,paroxetine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.790844643,1,paroxetine
SUMOYLATION_OF_CHROMATIN_ORGANIZATION_PROTEINS,1.248815511,0.481625865,paroxetine
SARS_COV_1_HOST_INTERACTIONS,-1.930325133,0.44935448,adenosine
G_ALPHA_Q_SIGNALLING_EVENTS,-1.928100226,0.229795173,adenosine
INTEGRIN_CELL_SURFACE_INTERACTIONS,1.76381464,0.305582928,adenosine
DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA,-1.877539932,0.251802283,adenosine
SIGNALING_BY_NTRKS,-1.875065792,0.193201955,adenosine
TRANSPORT_OF_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS,1.667613593,0.279401271,adenosine
PROGRAMMED_CELL_DEATH,-1.862714248,0.172986121,adenosine
SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR,-1.829562227,0.200111164,adenosine
GPCR_LIGAND_BINDING,-1.822278014,0.180297453,adenosine
METABOLISM_OF_STEROIDS,1.568049859,0.317566573,adenosine
GOLGI_TO_ER_RETROGRADE_TRANSPORT,1.762398401,0.427245646,elacridar
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.460141499,1,elacridar
DISEASES_OF_METABOLISM,1.423020805,0.828024748,elacridar
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.33900024,0.898917278,elacridar
MRNA_SPLICING,1.239559766,1,elacridar
MEMBRANE_TRAFFICKING,1.233580562,0.97548121,elacridar
DISORDERS_OF_TRANSMEMBRANE_TRANSPORTERS,1.230458708,0.84963009,elacridar
PHOSPHOLIPID_METABOLISM,-1.945986881,1,elacridar
TOLL_LIKE_RECEPTOR_TLR1_TLR2_CASCADE,1.220873029,0.779345211,elacridar
INTERFERON_ALPHA_BETA_SIGNALING,-1.932506457,0.966505724,elacridar
TRNA_PROCESSING,1.882994628,0.120183136,efaproxiral
COLLAGEN_FORMATION,1.661246613,0.226344907,efaproxiral
DISEASES_OF_GLYCOSYLATION,1.642664069,0.16491797,efaproxiral
ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES,1.58638582,0.177270126,efaproxiral
GLYCOSAMINOGLYCAN_METABOLISM,1.553545452,0.169458222,efaproxiral
RHOB_GTPASE_CYCLE,1.482843664,0.206147463,efaproxiral
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.314051162,1,efaproxiral
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.120785684,1,efaproxiral
G_ALPHA_I_SIGNALLING_EVENTS,-2.109506162,0.916877238,efaproxiral
GPCR_LIGAND_BINDING,-2.07195641,0.706655385,efaproxiral
G_ALPHA_Q_SIGNALLING_EVENTS,-2.055311685,0.029638889,tirofiban
MRNA_SPLICING,1.720507114,0.191698243,tirofiban
PROTEIN_LOCALIZATION,1.636126874,0.163968309,tirofiban
DISEASES_OF_METABOLISM,1.524548091,0.20295097,tirofiban
GPCR_LIGAND_BINDING,-1.785769526,0.381353711,tirofiban
COLLAGEN_FORMATION,1.409271741,0.278806407,tirofiban
DISEASES_OF_GLYCOSYLATION,1.39420582,0.245711333,tirofiban
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.750313908,0.361923772,tirofiban
SENSORY_PERCEPTION,-1.714542159,0.375425933,tirofiban
INTERFERON_ALPHA_BETA_SIGNALING,-1.705517645,0.326027784,tirofiban
RNA_POLYMERASE_II_TRANSCRIPTION_TERMINATION,2.415844112,0.004369582,cholic-acid
CLATHRIN_MEDIATED_ENDOCYTOSIS,1.773725797,0.150750581,cholic-acid
G_ALPHA_Q_SIGNALLING_EVENTS,-2.009484396,0.173175123,cholic-acid
DISEASES_OF_METABOLISM,1.713412265,0.134728781,cholic-acid
INSULIN_RECEPTOR_SIGNALLING_CASCADE,-1.906458483,0.225779395,cholic-acid
CARGO_RECOGNITION_FOR_CLATHRIN_MEDIATED_ENDOCYTOSIS,1.562982966,0.256166749,cholic-acid
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-1.877949484,0.193968552,cholic-acid
SIGNALING_BY_INSULIN_RECEPTOR,-1.845848444,0.202735931,cholic-acid
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.4752028,0.328592572,cholic-acid
TRNA_PROCESSING,1.468250755,0.282930439,cholic-acid
SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT,1.663679675,0.250803859,ambrisentan
RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2,-2.541743284,0.273898112,ambrisentan
SLC_TRANSPORTER_DISORDERS,1.648051899,0.137620579,ambrisentan
MRNA_SPLICING,1.599615683,0.119185423,ambrisentan
METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES,1.565244163,0.112861736,ambrisentan
INFLUENZA_INFECTION,1.50849479,0.122700965,ambrisentan
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.271134603,0.333333333,ambrisentan
SIGNALING_BY_NOTCH1,-2.384136941,1,ambrisentan
INTERLEUKIN_4_AND_INTERLEUKIN_13_SIGNALING,-2.363024162,1,ambrisentan
DISEASES_OF_GLYCOSYLATION,1.17399953,0.447588424,ambrisentan
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.531991226,0.170299368,butorphanol-(+)-tartrate
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.394417025,0.294598331,butorphanol-(+)-tartrate
COLLAGEN_FORMATION,1.457191273,1,butorphanol-(+)-tartrate
REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_TRANSPORT_AND_UPTAKE_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS,1.455383208,0.526023711,butorphanol-(+)-tartrate
DISEASES_OF_GLYCOSYLATION,1.349709061,0.57849155,butorphanol-(+)-tartrate
ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES,1.267811394,0.620869419,butorphanol-(+)-tartrate
NUCLEOTIDE_EXCISION_REPAIR,1.202823996,0.66378542,butorphanol-(+)-tartrate
PROTEIN_LOCALIZATION,1.194494975,0.574455562,butorphanol-(+)-tartrate
METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES,1.117166074,0.672280213,butorphanol-(+)-tartrate
GPCR_LIGAND_BINDING,-2.209608274,1,butorphanol-(+)-tartrate
RRNA_PROCESSING,4.131878634,0,zardaverine
RRNA_MODIFICATION_IN_THE_NUCLEUS_AND_CYTOSOL,2.809763768,0.000427673,zardaverine
METABOLISM_OF_RNA,2.101919458,0.007983229,zardaverine
COLLAGEN_FORMATION,1.863195531,0.026943396,zardaverine
COLLAGEN_BIOSYNTHESIS_AND_MODIFYING_ENZYMES,1.723100844,0.044820126,zardaverine
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.438257626,1,zardaverine
GPCR_LIGAND_BINDING,-2.300058674,1,zardaverine
CYCLIN_A_CDK2_ASSOCIATED_EVENTS_AT_S_PHASE_ENTRY,-2.28859108,0.87892905,zardaverine
CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS,-2.243643991,0.706426595,zardaverine
TCR_SIGNALING,-2.160296621,0.632020705,zardaverine
MRNA_SPLICING,1.637200431,0.347537502,imipramine
PEPTIDE_LIGAND_BINDING_RECEPTORS,-2.327048394,1,imipramine
COPI_DEPENDENT_GOLGI_TO_ER_RETROGRADE_TRAFFIC,1.240434494,1,imipramine
PROTEIN_LOCALIZATION,1.129019487,1,imipramine
INTRA_GOLGI_AND_RETROGRADE_GOLGI_TO_ER_TRAFFIC,1.125030312,0.982676225,imipramine
CHEMOKINE_RECEPTORS_BIND_CHEMOKINES,-2.257123102,1,imipramine
METABOLISM_OF_WATER_SOLUBLE_VITAMINS_AND_COFACTORS,1.102985332,0.858993761,imipramine
SPHINGOLIPID_METABOLISM,1.037343402,0.903225806,imipramine
GOLGI_TO_ER_RETROGRADE_TRANSPORT,1.005498763,0.858622063,imipramine
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA,1.005043296,0.753152794,imipramine
